0001144204-15-023064.txt : 20150415 0001144204-15-023064.hdr.sgml : 20150415 20150415172524 ACCESSION NUMBER: 0001144204-15-023064 CONFORMED SUBMISSION TYPE: 10-Q/A PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20140331 FILED AS OF DATE: 20150415 DATE AS OF CHANGE: 20150415 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AmpliPhi Biosciences Corp CENTRAL INDEX KEY: 0000921114 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 911549568 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-23930 FILM NUMBER: 15772642 BUSINESS ADDRESS: STREET 1: 4870 SADLER ROAD STREET 2: SUITE 300 CITY: GLEN ALLEN STATE: VA ZIP: 23060 BUSINESS PHONE: 650-888-2422 MAIL ADDRESS: STREET 1: 4870 SADLER ROAD STREET 2: SUITE 300 CITY: GLEN ALLEN STATE: VA ZIP: 23060 FORMER COMPANY: FORMER CONFORMED NAME: TARGETED GENETICS CORP /WA/ DATE OF NAME CHANGE: 19940331 10-Q/A 1 v407150_10qa.htm FORM 10-Q/A

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q/A

(Amendment No. 2)

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934		  

  

For the quarterly period ended March 31, 2014

 

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934		  

  

For the transition period from _________________ to _______________________

 

Commission file number: 000-23930

 

AMPLIPHI BIOSCIENCES CORPORATION
(Exact name of registrant as specified in its charter)

 

Washington

(State or other jurisdiction of

incorporation or organization)

91-1549568
I.R.S. Employer Identification Number)

 

   

4870 Sadler Road, Suite 300

Glen Allen, Virginia

23060

(Zip Code)

   
(Address of principal executive offices)  

 

Registrant’s telephone number, including area code: (804) 205-5069

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes  ¨     No    x 

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

 

Yes   x    No    ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company as defined in Rule 12b-2 of the Exchange Act. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  ¨ Accelerated filer  ¨
Non-accelerated filer ¨ (Do not check if a small reporting company) Smaller reporting company  x

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 

Yes ¨    No x

The number of shares of the Registrant’s Public Common Stock outstanding at May 5, 2014 was 182,535,562.

 

 
 

 

EXPLANATORY NOTE

 

Previously Amended Financial Statements

 

The Company’s previously issued March 31, 2014 financial statements have been restated to remove deemed dividends which were accrued on its preferred shares and to recognize an increase in derivative expense due to adding several features to the valuation model used to measure the compound derivatives and changing from a Black-Scholes valuation model to a Monte Carlo valuation model. Additional paid in capital and accumulated deficit have been reduced by $8,464,000 to reflect the elimination of deemed dividends. Loss on derivative liabilities increased by $1,870,000 to $9,428,000 due to the change in the valuation model.

 

The Company also contracted a valuation team to review the purchase price allocation of Biocontrol. As a result, in process research and development (IPR&D) was restated and a new intangible asset, patents, was recognized. For the Biocontrol acquisition, $493,000 of IPR&D was reclassified to patents. In addition, amortization expense for patents was recognized in the three month period ending March 31, 2014 and the three month period ending March 31, 2013.

 

As a result of these corrections, the Company’s net loss for the period ending March 31, 2014 decreased by $726,000 to $11,303,000. The net loss per share decreased by $0.01 per share to $(0.06) per share which reflected both the increased net loss and the removal of the deemed dividends.

 

Amended Financial Statements

 

The Company’s financial statements for the quarter ended March 31, 2014 have been further amended to:

 

·reclassify its Series B Redeemable Convertible Preferred Stock from Stockholders’ Equity (Deficit) to temporary equity due to the stock’s redemption features. This adjustment resulted in a reclassification at March 31, 2014 of $1,021,000 of Stockholders’ Equity (Deficit) to Series B Redeemable Convertible Preferred Stock, including the par value of these shares of $89,000 and the accretion of the stock’s redemption value of $932,000.
·recognize deferred revenue and deferred costs related to certain sub-licensing agreements. This change resulted in an increase in revenue of $104,000 and an increase in G&A expense of $33,000 in the first quarter of 2014.
·reclassify certain warrants issued in 2011 as liability instruments. These warrants were previously recorded in error as equity instruments. This adjustment resulted in the in the recording of a liability of $646,000 as of March 31, 2014.
·adjust goodwill for the acquisitions of Biocontrol and SPH for acquired deferred tax liabilities and errors in previous reporting. This change resulted in an increase of $1,685,000 in goodwill related to the Biocontrol acquisition and $1,548,000 in goodwill related to the acquisition of SPH.
·modify the key assumptions employed to value the compound derivative associated with the Series B Redeemable Convertible Preferred Stock and the Company’s 2013 warrants, under a Monte Carlo valuation model. The change in assumptions resulted in a $4,969,000 increase in the compound derivative liability and a $285,000 reduction in the warrant liability related to 2013 warrants. Loss on derivative liabilities declined by $655,000 in the first quarter of 2014.

 

As a result of these corrections, the Company’s net loss attributable to common stockholders in the first quarter of 2014, as amended, was reduced by $408,000 to $11,621,000. The net loss per share attributable to common stockholders increased by $0.01 per share to $(0.06) per share. The Company’s net loss in the first quarter of 2013, as amended, was reduced by $26,000 to $1,645,000. The net loss per share in the attributable to common stockholders increased ($0.01) per share to $(0.03) per share.

 

 
 

 

TABLE OF CONTENTS

 

    Page
     
PART I - FINANCIAL INFORMATION  
     
Consolidated Balance Sheets 2
   
Consolidated Statements of Operations 3
   
Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) 4
   
Consolidated Statements of Cash Flows 5
   
Condensed Notes to Consolidated Financial Statements 6
     
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 15
     
PART II.  OTHER INFORMATION 18
     
Item 1. Legal Proceedings 18
     
Item 1A. Risk Factors 18
     
Item 1A. Unregistered Sales of Equity Securities and Use of Proceeds 18
     
Item 3. Defaults upon Senior Securities 19
     
Item 4. Mine Safety Disclosures 19
     
Item 5. Other Information 19
     
Item 6. Exhibits 19
     
Signatures   20

 

 
 

 

AmpliPhi Biosciences Corporation

Consolidated Balance Sheets

 

   March 31, 2014   December 31, 2013 
   (Unaudited)     
   (Restated)   (Restated) 
Assets          
Current assets          
Cash and cash equivalents  $16,435,000   $20,355,000 
Accounts receivable   12,000    8,000 
Prepaid expenses and other current assets   345,000    297,000 
Total current assets   16,792,000    20,660,000 
Property and equipment, net of accumulated depreciation of $491,000 and $473,000 as of March 31, 2014 and December 31, 2013, respectively   356,000    145,000 
Intangible Assets          
In process research and development   12,446,000    12,446,000 
Patents, net of accumulated amortization of $101,000 and $93,000 as of March 31, 2014 and December 31, 2013, respectively   392,000    400,000 
Goodwill   7,562,000    7,562,000 
Total intangible assets   20,400,000    20,408,000 
Total assets  $37,548,000   $41,213,000 
Liabilities, Series B Redeemable Convertible Preferred Stock and Stockholders’ Equity (deficit)          
Current liabilities          
Accounts payable and accrued expenses  $886,000   $2,147,000 
Deferred revenue   140,000    244,000 
Total current liabilities   1,026,000    2,391,000 
Long term liabilities          
Derivative preferred shares conversion liability   46,325,000    40,791,000 
Derivative warrants liability   20,110,000    16,871,000 
Deferred tax liability   3,078,000    3,078,000 
Total long term liabilities   69,513,000    60,740,000 
Total liabilities   70,539,000    63,131,000 
           
Series B redeemable convertible preferred stock          
$0.01 par value, 10,000,000 shares authorized, 8,859,978 shares issued and outstanding at March 31, 2014 and December 31, 2013 (liquidation preference of $13,336,000 and $13,022,000 at March 31, 2014 and December 31, 2013, respectively)   1,021,000    707,000 
           
Stockholders’ equity (deficit)          
Common stock, $0.01 par value, 445,000,000 shares authorized, 182,535,562 shares issued and outstanding at March 31, 2014 and  December 31, 2013   1,825,000    1,825,000 
Additional paid-in capital   358,748,000    358,828,000 
Paid-in-capital – contingent shares   1,837,000    1,837,000 
Accumulated deficit   (396,422,000)   (385,115,000)
Total stockholders’ equity (deficit)   (34,012,000)   (22,625,000)
Total liabilities, Series B redeemable preferred stock and stockholders’ equity (deficit)  $37,548,000   $41,213,000 

 

See accompanying condensed notes to consolidated financial statements.

 

2
 

 

AmpliPhi Biosciences Corporation

Consolidated Statements of Operations

 

   Three Months Ended March 31,   Year Ended 
   2014   2013   December 31, 2013 
   (Unaudited)   (Unaudited)     
   (Restated)   (Restated)   (Restated) 
Revenue               
Licensing revenue  $104,000   $22,000   $81,000 
Total revenue   104,000    22,000    81,000 
Operating expenses               
Research and development   1,011,000    641,000    6,469,000 
General and administrative   1,627,000    714,000    5,996,000 
Total operating expenses   2,638,000    1,355,000    12,465,000 
Loss from operations   (2,534,000)   (1,333,000)   (12,384,000)
Other income (expenses)               
Gain (loss) on derivative liabilities   (8,773,000)   87,000    (49,330,000)
Amortization of note discount   —    (303,000)   (2,636,000)
Interest expense, net   —    (96,000)   (233,000)
Total other expense   (8,773,000)   (312,000)   (52,199,000)
Net loss   (11,307,000)   (1,645,000)   (64,583,000)
Accretion of Series B redeemable convertible preferred stock   (314,000)   —    (618,000)
Net loss attributable to common stockholders  $(11,621,000)  $(1,645,000)  $(65,201,000)
Per share information:               
Net loss per share – basic & diluted  $(0.06)  $(0.03)  $(0.64)
Weighted average number of shares of common stock outstanding – basic & diluted   182,535,562    66,908,810    101,201,753 

 

 

See accompanying condensed notes to consolidated financial statements.

 

3
 

 

AmpliPhi Biosciences Corporation

Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)

 

   Redeemable Convertible
Preferred Stock		   Stockholders' Equity ( Deficit) 
   Series B   Common Stock             
   Shares   Amount   Shares   Amount   Additional
Paid-in Capital		   Accumulated
Deficit		   Total
Stockholders'
Equity (Deficit)		 
Balances, December 31, 2012 (Restated)   —   $—    66,908,810   $669,000   $332,806,000   $(320,532,000)  $12,943,000 
Net loss   —    —    —    —    —    (64,583,000)   (64,583,000)
Stock-based compensation   —    —    —    —    1,437,000    —    1,437,000 
Beneficial conversion feature and warrants associated with issuance of convertible loan notes   —    —    —    —    2,635,000    —    2,635,000 
Shares issued for Intrexon   —    —    24,000,000    240,000    2,760,000    —    3,000,000 
Accretion of Series B convertible preferred stock to its redemption value   —    618,000    —    —    (618,000)   —    (618,000)
Issuance of preferred stock from conversion of convertible loan notes   5,016,081    50,000    —    —    —    —    — 
Issuance of preferred stock   4,999,999    50,000    —    —    —    —    — 
Preferred shares converted to common stock   (1,156,102)   (11,000)   11,561,020    115,000    6,969,000    —    7,084,000 
Stock options exercised   —    —    61,018    1,000    12,000    —    13,000 
Shares released from escrow   —    —    8,000,000    80,000    (80,000)   —    — 
Issuance of common stock for December financing   —    —    72,007,000    720,000    14,744,000    —    15,464,000 
Escheat shares   —    —    (2,286)   —    —    —    — 
Balances, December 31, 2013 (Restated)   8,859,978   707,000    182,535,562   1,825,000   360,665,000   (385,115,000)  (22,625,000)
Net loss   —    —    —    —    —    (11,307,000)   (11,307,000)
Stock-based compensation   —    —    —    —    234,000    —    234,000 
Accretion of Series B convertible preferred stock to its redemption value   —    314,000    —    —    (314,000)   —    (314,000)
Balances, March 31, 2014 (Unaudited) (Restated)   8,859,978   $1,021,000    182,535,562   $1,825,000   $360,585,000   $(396,422,000)  $(34,012,000)

 

See accompanying condensed notes to consolidated financial statements.

 

4
 

 

AmpliPhi Biosciences Corporation

Consolidated Statement of Cash Flows

 

   Three Months Ended March 31,   Year Ended
December 31,		 
   2014   2013   2013 
   (Unaudited)   (Unaudited)     
   (Restated)   (Restated)   (Restated) 
Cash flows from operating activities               
Net loss from operations  $(11,307,000)  $(1,645,000)  $(64,583,000)
Adjustments required to reconcile net loss from operations to net cash used in operating activities:               
Loss on derivative liabilities   8,773,000    (87,000)   49,330,000 
Shares issued for technology access fee   —    —    3,000,000 
Amortization of note discount and patents   8,000    311,000    2,667,000 
Warrants issued as investment fees   —    —    759,000 
Depreciation   18,000    21,000    82,000 
Stock-based compensation   234,000    154,000    1,437,000 
Changes in operating assets and liabilities net of acquisitions:               
Accounts receivable   (4,000)   12,000    15,000 
Tax refund   —    618,000    618,000 
Accounts payable and accrued expenses   (1,365,000)   (380,000)   454,000 
Prepaid expenses and other current assets   (48,000)   (219,000)   (149,000)
Interest on loan notes   —    96,000    233,000 
Other   —    —    (155,000)
Net cash used in operating activities   (3,691,000)   (1,119,000)   (6,292,000)
Cash flows from investing activities               
Purchases of property and equipment   (229,000)   —    (102,000)
Net cash used in investing activities   (229,000)   —    (102,000)
Cash flows from financing activities               
Proceeds from December financings   —    —    16,887,000 
Proceeds from Series B redeemable convertible preferred stock   —    —    7,000,000 
Proceeds from convertible loan notes   —    976,000    2,000,000 
Net cash provided by financing activities   —    976,000    25,887,000 
Net increase (decrease) in cash and cash equivalents   (3,920,000)   (143,000)   19,493,000 
Cash and cash equivalents, beginning of period   20,355,000    862,000    862,000 
Cash and cash equivalents, end of period  $16,435,000   $719,000   $20,355,000 
Supplemental schedule of non-cash financing activities:               
Conversion of convertible loan notes and accrued interest to Series B redeemable convertible preferred stock  $—   $—   $6,316,000 
Accretion of Series B redeemable convertible preferred stock   314,000    —    618,000 

 

See accompanying condensed notes to consolidated financial statements.

 

5
 

 

AmpliPhi Biosciences Corporation

Condensed Notes to Consolidated Financial Statements

March 31, 2014
(Unaudited) (Restated)

 

1. Nature of Business and Significant Accounting Policies

 

Nature of Business

 

AmpliPhi Biosciences Corporation (the “Company”) was incorporated in the state of Washington in 1989 under the name Targeted Genetics Corporation. In February 2011, Targeted Genetics Corporation changed its name to AmpliPhi Biosciences Corporation. The Company, headquartered in Richmond, Virginia, is dedicated to developing novel antibacterial solutions called bacteriophage (phage). Phages are naturally occurring viruses that preferentially target and kill their bacterial targets.

 

Basis of Presentation

 

The interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries Biocontrol, Ampliphi d.o.o., and AmpliPhi Australia. All significant intercompany accounts and transactions have been eliminated. All numbers on the financial statements and disclosures have been rounded to the nearest 1,000 except share and per share data.

 

The interim consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) necessary to present fairly our results of operations for the three months ended March 31, 2014 and 2013, our cash flows for the three months ended March 31, 2014 and 2013 and our financial position as of March 31, 2014 have been made. The results of operations for such interim periods are not necessarily indicative of the operating results to be expected for the full year.

 

Certain information and disclosures normally included in the notes to the annual financial statements have been condensed or omitted from these interim consolidated financial statements. Accordingly, these interim consolidated financial statements should be read in conjunction with the 2013 audited consolidated financial statements and notes.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

The Company considers cash equivalents to be short-term investments that have a maturity at the time of purchase of three months or less, are readily convertible into cash and have an insignificant level of valuation risk attributable to potential changes in interest rates. Cash equivalents are recorded at cost, which approximates fair market value, and consist primarily of money market accounts.

 

Accounts Receivable

 

Accounts receivable amounts are stated at their face amounts less any allowance. Provisions for doubtful accounts are estimated based on assessment of the probable collection from specific customer accounts and other known factors. If an account was determined to be uncollectible (payment has not been made in accordance with contract terms), it would be written off against the allowance. As of March 31, 2014 and December 31, 2013, management determined no allowance for doubtful accounts was required.

 

6
 

 

Property and Equipment

 

Property and equipment are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, generally three to seven years.

 

Prepaid Expenses and Other Current Assets

 

Prepaid and other current assets as of March 31, 2014 and December 31, 2013 consist primarily of prepaid insurance and deposits.

 

Goodwill

 

Costs of investments in purchased companies in excess of the underlying fair value of net assets at the date of acquisition are recorded as goodwill and assessed annually for impairment. If considered impaired, goodwill will be written down to fair value and a corresponding impairment loss recognized.

 

During the year ended December 31, 2012, the rights to SPH Holdings Pty Ltd’s know-how and phage libraries were acquired by a business combination. At December 31, 2012, goodwill in the amount of $3,929,000 has been recorded. In management’s opinion, no goodwill has been impaired as of March 31, 2014 and December 31, 2013.

 

During the year ended December 31, 2011, the rights to Biocontrol Limited’s patents and phage libraries were acquired by a business combination. At December 31, 2011, goodwill in the amount of $3,633,000 has been recorded. In management’s opinion, no goodwill has been impaired as of March 31, 2014 and December 31, 2013.

 

Patents

 

Patents are recorded at cost and are amortized using the straight-line method over the estimated useful lives of the patents.

 

During the year ended December 31, 2011, the rights to Biocontrol Limited’s patents were acquired by a business combination. At December 31, 2011, patents in the amount of $493,000 have been recorded. These patents are amortized over their useful life through December 2026.

 

Stock-Based Compensation

 

The Company accounts for stock-based payments under the guidance of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 718, Stock Compensation, which requires measurement of compensation cost for all share-based payment awards at fair value on the date of grant and recognition of compensation cost over the requisite service period (typically the vesting period) for awards expected to vest.

 

Warrant and Preferred Shares Conversion Feature Liability

 

The Company accounts for warrants and preferred shares conversion feature with anti-dilution (“down-round”) provisions under the guidance of ASC 815, Derivatives, and Hedging and Emerging Issue Task Force Statement 07-5: Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity’s Own Stock, which require the warrants and the preferred shares conversion feature to be recorded as a liability and adjusted to fair value in each reporting period.

 

Fair Value of Financial Assets and Liabilities — Derivative Instruments

 

The Company measures the fair value of financial assets and liabilities in accordance with GAAP, which defines fair value, establishes a framework for measuring fair value, and requires certain disclosures about fair value measurements.

 

7
 

 

GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes as fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. GAAP describes three levels of inputs that may be used to measure fair value:

 

Level 1 — quoted prices in active markets for identical assets or liabilities.

 

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable.

 

Level 3 — inputs that are unobservable.

 

The Company does not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, the Company has entered into certain financial instruments and contracts, such as convertible loan notes with detachable common stock warrants and the issuance of preferred stock with detachable common stock warrants with features that are either i) not afforded equity classification, ii) embody risks not clearly and closely related to host contracts, or iii) may be net-cash settled by the counterparty. These instruments are required to be carried as derivative liabilities, at fair value.

 

The Company estimates fair values of these derivatives (and related embedded beneficial conversion features) utilizing Level 3 inputs. The Company uses the Monte Carlo valuation technique for derivatives as it embodies all of the requisite assumptions (including trading volatility, remaining term to maturity, market price, strike price, risk free rates) necessary to fair value these instruments.

 

Estimating fair values of derivative financial instruments, including Level 3 instruments, require the use of significant and subjective inputs that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are volatile and sensitive to changes in our trading market price, the trading market price of various peer companies and other key assumptions. Since derivative financial instruments are initially and subsequently carried at fair value, our income will reflect this sensitivity of internal and external factors.

 

Revenue Recognition

 

The Company generates revenue from technology licenses, collaborative research arrangements, and agreements to provide research and development services. Revenue under technology licenses typically consists of nonrefundable, up-front license fees, technology access fees and various other payments. The Company recognizes revenue associated with performance milestones as earned, typically based upon the achievement of the specific milestones defined in the applicable agreements.

 

The Company recognizes revenue under research and development contracts as the related costs are incurred. When contracts include multiple elements, the Company follows ASC 605-25, Multiple Element Arrangements, which requires the Company to satisfy the following before revenue can be recognized:

 

  • The delivered items have value to the customer on a stand-alone basis;

 

  • Any undelivered items have objective and reliable evidence of fair value; and

 

  • Delivery or performance is probable and within the Company’s control for any delivered items that have a right of return.

 

The Company classifies advance payments received in excess of amounts earned as deferred revenue.
   

    Based upon the terms specified in its collaboration agreements, the Company receives advance payments from some of its collaboration partners before the project has been performed. These payments are deferred and recognized as revenue when the costs are incurred.

 

8
 

 

In Process Research and Development

 

In Process Research & Development (IPR&D) assets represent capitalized incomplete research projects that the Company acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The fair value of the research projects is recorded as intangible assets on the consolidated balance sheet rather than expensed regardless of whether these assets have an alternative future use. The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company will make a determination as to the then remaining useful life of the intangible asset and begin amortization. The Company tests its indefinite-lived intangibles, including IPR&D assets, for impairment at least quarterly.

 

During the year ended December 31, 2012, the rights to SPH Holdings Pty Ltd’s IPR&D were acquired by the business combination. At December 31, 2012, IPR&D in the amount of $5,161,000 has been recorded. In management’s opinion, this IPR&D has not been impaired as of March 31, 2014 and December 31, 2013.

 

During the year ended December 31, 2011, the rights to Biocontrol - IPR&D and patents were acquired by the business combination. At December 31, 2011, IPR&D in the amount of $7,285,000 has been recorded. In management’s opinion, this IPR&D has not been impaired as of March 31, 2014 and December 31, 2013.

 

Research and development costs include salaries, costs of outside collaborators and outside services, royalty and license costs and allocated facility, occupancy and utility expenses. The Company expenses research and development costs as incurred.

 

Net Loss per Common Share

 

Net loss per common share is based on net loss divided by the weighted average number of common shares outstanding during the period. For each fiscal year reported, the diluted net loss per share is the same as the basic net loss per share because all stock options, warrants, contingent shares, and Series B redeemable convertible preferred stock shares are antidilutive with respect to computing the net loss per share and therefore are excluded from the calculation of diluted net loss per share. The total number of shares that the Company excluded from the calculations of net loss per share were 148,692,651 shares for the three month period ending March 31, 2014, 20,000,000 shares for the three month period ending March 31, 2013, and 77,490,242 shares for the year ending December 31, 2013.

 

Recent Accounting Pronouncements

 

On February 5, 2013, the FASB issued ASU no. 2013-02 which adds new disclosure requirements for items reclassified out of accumulated other comprehensive income (AOCI). The ASU is intended to help entities improve the transparency of changes in other comprehensive income (OCI) and items reclassified out of AOCI in their financial statements. It does not amend any existing requirements for reporting net income or OCI in the financial statements. For public entities, the new disclosure requirements are effective for fiscal years, and interim periods within those years, beginning after December 15, 2012. For nonpublic entities, the ASU is effective for fiscal years beginning after December 15, 2013, and interim and annual periods thereafter. The Company elected to early adopt this standard which did not result in any changes to the consolidated financial statements.

 

9
 

 

2. Preferred Shares

 

On June 13, 2013, the Company’s Board of Directors approved a resolution designating 10,016,080 shares of Preferred Stock as Series B redeemable convertible preferred stock with an initial stated value of $1.40 and par value of $0.01. Each Series B redeemable convertible preferred stock is convertible into 10 shares of common stock and is entitled to the number of votes equal to the number of shares of common stock. These Series B redeemable convertible preferred stock shares may be converted to common stock by the holder of the shares at any time. The Series B redeemable convertible preferred stock shares shall be automatically converted into common shares upon the closing of an underwritten initial public offering with aggregate proceeds to the Company of at least $7 million and a price per share to the public of at least the Series B redeemable convertible preferred stock stated value upon the closing of which the shares of common stock of the Company shall be listed for trading on the New York Stock Exchange. The Series B redeemable convertible preferred stock shares are also convertible into common shares upon the election of the holders of two-thirds of the outstanding Series B redeemable convertible preferred stock shares. Until conversion, the holders of Series B redeemable convertible preferred stock shares shall be entitled to receive dividends of 10% of the Series B redeemable convertible preferred stock stated value per annum.

 

In connection with the private placement of Series B redeemable convertible preferred stock, the Company recorded a liability for a complex embedded derivative that required bifurcation under ASC Section 815. The embedded derivative includes a redemption feature, multiple dividend features, as well as multiple conversion features with a down-round ratchet provision. The Company estimates the fair values of the conversion feature using a Monte Carlo valuation model. The Company measured the fair value of the conversion feature on June 26, 2013 and July 15, 2013 (dates of issuance) and recorded the initial liability as part of the private placement proceeds.

 

On June 26, 2013, the Company issued 4,999,999 shares of the Company’s newly-created Series B redeemable convertible preferred stock and warrants to purchase 12,499,996 shares of common stock at an exercise price of $0.14 per share for an aggregate purchase price of $7.0 million. The value of the derivative liability related to the warrants was $1,886,000 and the value of the derivative liability related to the preferred shares was $5,064,000. As part of the same transaction, the Company converted $5,491,000 in outstanding convertible loan notes (principal and interest) into 4,357,936 shares of Series B redeemable convertible preferred stock and warrants to purchase 10,894,839 shares of common stock at an exercise price of $0.14 per share. The value of the derivative liability related to the warrants was $1,644,000 and the value of the derivative liability related to the preferred shares was $3,804,000. As part of this issuance, the Company issued warrants to purchase 4,999,999 shares of common stock at an exercise price of $0.14 per share with an initial fair value of $759,000 and paid $350,000 to the placement agents. As a result of this financing, all outstanding convertible notes were converted into shares of Series B redeemable convertible preferred stock and warrants to purchase common stock. On July 15, 2013, the remaining outstanding convertible loan notes, totaling $829,277 in principal and interest, were converted into 658,145 shares of Series B redeemable convertible preferred stock and warrants to purchase 1,645,361 shares of common stock at an exercise price of $0.14 per share. The value of the derivative liability related to the warrants was $674,000 and the value of the derivative liability related to the preferred shares was $155,000.

 

On July 25, 2013, 1,132,875 preferred shares were converted into 11,328,750 shares of common stock. In connection with the conversion, a loss on derivative of $5,035,000 was recorded in relation to the conversion. $6,518,000 was reclassified from the derivative liability to equity due to conversion.

 

10
 

 

On October 17, 2013, 23,227 preferred shares were converted into 232,270 shares of common stock. In connection with the conversion, a gain on the derivative liability was recorded in the amount of $5,000. Due to this conversion, $97,000 was reclassified out of the derivative liability account and into equity.

 

The Company re-measured the fair value of the conversion feature and recorded $11,882,000 in total charges to record the liabilities associated with the conversion feature at their estimated fair value totaling $46,323,000 as of March 31, 2014.

 

3. Stock Options and Warrants

 

The Company follows ASC 815-40, Contracts in an Entity’s Own Equity, as it relates to outstanding warrants. No warrants were exercised through March 31, 2014.

 

In connection with the December 2013 private placement of 72,007,000 shares of the Company's common stock at a price per share of $0.25, the Company issued an aggregate of warrants to purchase 4,320,420 shares of common stock at an exercise price of $0.25 per share to the placement agents. These warrants expire December 2018. These warrants contain provisions that protect holders from a decline in the issue price of the Company’s common stock (“down-round” provision) and contain net settlement provisions. Due to these provisions, the Company accounted for these warrants as liabilities instead of equity.

 

In connection with the private placement of Series B redeemable convertible preferred stock, which occurred through two closings on June 26, 2013 and July 15, 2013, respectively, the Company issued an aggregate of warrants to purchase 30,040,195 shares of common stock at an exercise price of $0.14 per share. These warrants expire June 2018. These warrants contain provisions that protect holders from a decline in the issue price of the Company’s common stock (“down-round” provision) and contain net settlement provisions. Due to these provisions, the Company accounted for these warrants as liabilities instead of equity. The Company measured the fair value of these warrants on June 26, 2013 and July 15, 2013 and recorded the initial liability as part of the private placement proceeds and expensed $759,000 for the warrants issued to the placement agent.

 

We estimate the fair values of these securities using a Monte Carlo valuation model. The following warrants were issued in 2013 using the Monte Carlo valuation method with the key inputs as follows:

 

   June 26, 2013   July 15, 2013   December 23, 2013 
Warrants Issued   28,394,834    1,645,361    4,320,420 
Risk free interest rate   0.0109    0.0109    0.0167 
Volatility   160.94%   163.08%   155.24%
Expected term   5 years    5 years    5 years 
Exercise price  $0.14   $0.14   $0.25 

 

The Company re-measured the fair value of these warrants and recorded $9,929,000 in charges to record the liabilities associated with these warrants at their estimated fair values totaling $16,311,000 as of December 31, 2013.

 

From February through May 2013, in connection with the issuance of new convertible promissory notes, the Company issued warrants to purchase up to 7,030,387 shares of its common stock. These warrants expire February through May 2018 and are exercisable at a price of $0.14 per share. These warrants are considered to be equity.

 

On December 22, 2011, in connection with the Biocontrol business combination, the Company issued warrants to purchase up to 1,355,164 shares of its common stock. These warrants expire in December 2016 and are exercisable at a price of $0.46 per share. These warrants are considered to be equity. The Company re-measured the fair value of these warrants and recorded a gain of $87,000 to adjust the liability associated with these warrants to their estimated fair value totaling $646,000 as of March 31, 2014.

 

The Company’s warrant liability is adjusted to fair value each reporting period and is influenced by several factors including the price of the Company’s common stock as of the balance sheet date. On March 31, 2014, the price per share of the Company’s common stock was $0.58 per share compared to $0.50 per share at December 31, 2013. There were no warrant liabilities as of March 31, 2013.

 

11
 

 

The Company re-measured the fair value of the warrants liability and recorded a loss of $3,149,000 to adjust the liabilities associated with the warrants at their estimated fair value totaling $19,460,000 as of March 31, 2014.

 

4. Stock-Based Compensation

 

The Company’s Stock Incentive Plan provides for the issuance of long-term incentive awards, or Awards, in the form of non-qualified and incentive stock options, or Options, stock appreciation rights, stock grants and restricted stock units. The awards may be granted by the Company’s Board of Directors to its employees, directors and officers and to consultants, agents, advisors and independent contractors who provide services to the Company. The exercise price for Options must not be less than the fair market value of the underlying shares on the date of grant. Options expire no later than ten years from the date of grant and generally vest and become exercisable over a four-year period following the date of grant. Every non-employee member of the Company’s Board of Directors receives an annual non-qualified Option or restricted stock unit grant. Upon the exercise of Options, the Company issues the resulting shares from shares reserved for issuance under the Company’s Incentive Plan.

 

Under ASC 718 Stock Compensation, the Company is required to expense the fair value of share-based payments granted over the vesting period. The Company values Awards granted at their grant date fair value in accordance with the provisions of ASC 718 and recognizes stock-based compensation expense on a straight-line basis over the service period of each award.

 

Stock-based compensation expense is reduced by an estimated forfeiture rate derived from historical employee termination behavior. If the actual number of forfeitures differs from the Company’s estimates, the Company may record adjustments to increase or decrease compensation expense in future periods. There were no significant adjustments related to changes in the Company’s estimates for the three months-ended March 31, 2014 and year ended December 31, 2013.

 

Following is a summary of the amount included as stock-based compensation expense in the accompanying consolidated statements of operations and comprehensive loss:

 

   Three Months Ended March 31,   Year Ended 
   2014   2013   December 31, 
   (Unaudited)   (Unaudited)   2013 
Stock options:               
General and administrative expense  $196,000   $112,000   $191,000 
Research and development expense   38,000    42,000    1,246,000 
Total stock-based compensation expense  $234,000   $154,000   $1,437,000 

 

The following table summarizes Option activity:

  

   Shares   Weighted Average Exercise
Price		   Average Remaining
Contractual Term
(Years)		   Intrinsic Value 
Outstanding at December 31, 2013   25,721,000   $0.19    9.15   $6,451,441 
Granted   —    —           
Exercised   —    —           
Forfeited   —    —           
Expired   —    —           
Outstanding at March 31, 2014   25,721,000   $0.19    8.88   $8,416,233 
Exercisable at March 31, 2014   10,089,662   $0.19    8.89   $4,049,376 

 

12
 

 

The aggregate intrinsic value is determined using the closing price of the Company’s common stock of $0.58 on March 31, 2014.

 

As of March 31, 2014, the Company had unrecognized compensation cost related to unvested Options of approximately $2,072,890 net of estimated forfeitures, which the Company expects to recognize over a weighted average period of approximately two and a half years

 

As of March 31, 2013, the Company had reserved shares of its common stock for future issuance as follows:

 

   Shares Reserved 
Stock options outstanding   25,721,000 
Available for future grants under the Stock Incentive Plan   40,000,000 
Warrants   38,425,745 
Total Shares reserved   104,146,745 

 

5. Correction of Errors

 

The Company’s previously issued March 31, 2014 financial statements were restated to remove deemed dividends which were accrued on its preferred shares and to recognize an increase in derivative expense due to adding several features to the valuation model used to measure the compound derivatives and changing from a Black-Scholes valuation model to a Monte Carlo valuation model. Additional paid in capital and accumulated deficit were reduced by $8,464,000 to reflect the elimination of deemed dividends. Loss on derivative liabilities increased by $1,870,000 to $9,428,000 due to the change in the valuation model.

 

The Company also contracted a valuation team to review the purchase price allocation of Biocontrol. As a result, in process research and development (IPR&D) was restated and a new intangible asset, patents, was recognized. For the Biocontrol acquisition, $493,000 of IPR&D was reclassified to patents. In addition, amortization expense for patents was recognized in the three month period ending March 31, 2014 and the three month period ending March 31, 2013.

 

As a result of these corrections, the Company’s net loss for the period ending March 31, 2014 increased by $1,885,000 to $12,029,000. The net loss per share decreased by $0.03 per share to $(0.07) per share which reflected both the increased net loss and the removal of the deemed dividends. The Company’s net loss for the period ending March 31, 2013 increased $7,000 to $1,619,000. The net loss per share remained the same.

 

Amended Financial Statements

 

The Company’s financial statements for the quarter ended March 31, 2014 have been further amended to:

 

·reclassify its Series B Redeemable Convertible Preferred Stock from Stockholders’ Equity (Deficit) to temporary equity due to the stock’s redemption features. This adjustment resulted in a reclassification at March 31, 2014 of $1,021,000 of Stockholders’ Equity (Deficit) to Series B Redeemable Convertible Preferred Stock, including the par value of these shares of $89,000 and the accretion of the stock’s redemption value of $932,000.
·recognize deferred revenue and deferred costs related to certain sub-licensing agreements. This change resulted in an increase in revenue of $104,000 and an increase in G&A expense of $33,000 in the first quarter of 2014.
·reclassify certain warrants issued in 2011 as liability instruments. These warrants were previously recorded in error as equity instruments. This adjustment resulted in the in the recording of a liability of $646,000 as of March 31, 2014.
·adjust goodwill for the acquisitions of Biocontrol and SPH for acquired deferred tax liabilities and errors in previous reporting. This change resulted in an increase of $1,685,000 in goodwill related to the Biocontrol acquisition and $1,548,000 in goodwill related to the acquisition of SPH.

 

13
 

 

·modify the key assumptions employed to value the compound derivative associated with the Series B Redeemable Convertible Preferred Stock and the Company’s 2013 warrants, under a Monte Carlo valuation model. The change in assumptions resulted in a $4,969,000 increase in the compound derivative liability and a $285,000 reduction in the warrant liability related to 2013 warrants. Loss on derivative liabilities declined by $655,000 in the first quarter of 2014.

 

As a result of these corrections, the Company’s net loss attributable to common stockholders in the first quarter of 2014, as amended, was reduced by $408,000 to $11,621,000. The net loss per share attributable to common stockholders increased by $(0.01) per share to $(0.06) per share. The Company’s net loss attributable to common stockholders in the first quarter of 2013, as amended, was reduced by $26,000 to $1,645,000. The net loss per share in the attributable to common stockholders increased by $(0.01) to $(0.03) per share.

 

14
 

 

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with “Selected Consolidated Financial Data” and the Unaudited Condensed Consolidated Financial Statements and related Notes included in Part I Item 1 of this Form 10-Q.

 

This discussion contains forward-looking statements that involve risks and uncertainties. Such statements, which include statements concerning product development plans, the use of bacteriophages to kill bacterial pathogens, future revenue sources, selling and marketing expenses, general and administrative expenses, clinical trial and other research and development expenses, capital resources, capital expenditures, tax credits and carry-forwards, and additional financings or borrowings, are subject to risks and uncertainties, including, but not limited to, those discussed below and elsewhere in this Form 10-Q, particularly in Part II Item 1A. “Risk Factors,” that could cause actual results to differ materially from those projected. The forward-looking statements set forth in this Form 10-Q are as of the close of business on May 4, 2014, and we do not intend to update this forward-looking information.

 

Overview

 

AmpliPhi Biosciences is a biotechnology company focused on the discovery, development and commercialization of novel phage therapeutics. Our proprietary pipeline is based on the use of bacteriophages, a family of viruses that infect only bacteria. Phages have powerful and highly selective mechanisms of action that permit them to target and kill specific bacterial pathogens, including the so-called multi-drug-resistant (MDR) or “Superbug” strains.

 

We are combining our proprietary approach and expertise in identifying, characterizing and developing naturally occurring bacteriophages with that of our collaboration partners in bacteriophage biology, drug engineering, development and manufacturing, to develop second-generation bacteriophage products. We believe that phages represent a promising means to treat bacterial infections, especially those that have developed resistance to current medicines.

 

Our lead program is AmpliPhage-002, for the treatment of methicillin-resistant S. aureus (MRSA) infections. We have two other product candidates in development: AmpliPhage-001 for the treatment of P. aeruginosa lung infections in CF patients and AmpliPhage-004 for the treatment of C. difficile infections.

 

We have incurred net losses since our inception. Our operations to date have been limited to research and development and raising capital. Since November 2010, we have raised approximately $5.6 million through the sale and issuance of convertible notes and warrants to purchase common stock. In June and July of 2013, we completed a private placement of shares of our Series B redeemable convertible preferred stock and warrants to purchase common stock, which raised approximately $7.0 million in addition to converting approximately $6.3 million in outstanding convertible notes. In December 2013, we completed a private placement of shares of our common stock, which raised approximately $18 million, prior to commissions.

 

To date, we have not generated any revenue and have primarily financed our operations through the sale and issuance of convertible notes and the private placement of our equity securities. As of March 31, 2014, we had a deficit accumulated of $396.4 million. We recorded annual net losses of $64.6 million in 2013 and $1.1 million in 2012. Net loss in 2013 included $49.3 million in non-cash expense related to the change in derivative liability associated with the outstanding warrants and the conversion feature of the outstanding shares of Series B redeemable convertible preferred stock. We anticipate that a substantial portion of our capital resources and efforts in the foreseeable future will be focused on completing the development and obtaining regulatory approval of our product candidates.

 

We expect our research and development expenses to increase as we pursue regulatory approval for our product candidates. We also expect to incur additional expenses associated with operating as a public company. As a result, we expect to continue to incur significant and increasing operating losses at least for the next several years. We do not expect to generate product revenue unless and until we successfully complete development and obtain marketing approval for at least one of our product candidates.

 

15
 

 

We currently expect to use our existing cash and cash equivalents for the continued research and development of our product candidates and for working capital and other general corporate purposes. 

  

We may also use a portion for the potential acquisition of, or investment in, product candidates, technologies, formulations or companies that complement our business, although we have no current understandings, commitments or agreements to do so. We expect that these funds will not be sufficient to enable us to complete all necessary development of any potential product candidates. Accordingly, we will be required to obtain further funding through other public offerings, debt financing, collaboration and licensing arrangements or other sources. Adequate additional funding may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs.

 

Results of Operations

 

Revenue

 

For the quarter ended March 31, 2014, we recognized $104,000 in revenue related to sublicensing agreements involving our former gene therapy program. For the quarter ended March 31, 2013 we recognized $22,000 in grant revenue.

 

Research and Development

 

Research and development expenses were $1.0 million for the quarter ended March 31, 2014, compared to $0.6 million for the quarter ended March 31, 2013. The $0.4 million increase in expenses is due to an increase in discovery, laboratory, nonclinical testing, research and development collaborations, consulting and clinical development planning expenses for all of our product candidates.

 

Research and development expenses are expected to increase in 2014 compared to 2013 as we plan to continue devoting substantial resources to research and development in future periods as we prepare to start clinical trials and continue our discovery efforts.

 

General and Administrative

 

General and administrative expenses were $1.6 million for the quarter ended March 31, 2014 compared to $0.7 million for the quarter ended March 31, 2013. The $0.9 million increase is due to higher legal expenses due to preparation to become a public company and staffing expenses.

 

We currently expect our general and administrative expenses to increase in 2014 compared to 2013 due to the costs associated with being a public company.

 

Derivative Liabilities

 

During the quarter ended March 31, 2014, we recognized a loss on derivative liabilities of $8,773,000 for warrants issued in June, July, and December 2013 and the conversion feature of the shares of Series B Preferred Stock issued in June and July 2013.

 

Income Taxes

 

We incurred net operating losses for the years ended December 31, 2013 and 2012 and, accordingly, we did not pay any federal or state income taxes. As of December 31, 2013, we had accumulated approximately $176.3 million in U.S., Australian and UK operating loss carry-forwards and research tax credit carry-forwards of approximately $3.7 million. The carry-forwards began to expire in 2012. Our net operating loss carry-forwards are subject to certain limitations on annual utilization as a result of changes in ownership of the Company, as defined by federal and state tax laws.

 

16
 

 

Net Operating Losses

 

We have not recorded a benefit from our net operating loss or research credit carry-forwards because we believe that it is uncertain that we will have sufficient income from future operations to realize the carry-forwards prior to their expiration. Accordingly, we have established a 100% valuation allowance against the deferred tax asset arising from the carry-forwards.

 

Liquidity and Capital Resources

 

We have incurred net losses since inception through March 31, 2014 of $396.4 million, of which $315.5 million was incurred in the Company’s prior focus of gene therapy in 2010 and years earlier. We have not generated any product revenues and do not expect to generate revenue from the sale of product candidates in the near term.

 

We had cash of $16.4 million and $20.4 million at March 31, 2014 and December 31, 2013, respectively. Net cash used in operating activities for the quarters ended March 31, 2014 and 2013 was $3.7 million and $1.0 million, respectively. For the quarter ended March 31, 2014, cash used in operations was attributable to the net loss for the year after adding back non-cash charges for loss on derivative liabilities, amortization of patents, stock-based compensation expense, and depreciation expenses offset by a decrease in accrued liabilities and increases in prepaid expenses and receivables. For the quarter ended March 31, 2013, cash used in operations was attributable to the net loss for the year after adding back non-cash charges for amortization of loan discount and patents, stock-based compensation expense, depreciation expenses and loss on disposal of equipment, offset by decreases in accrued liabilities and receivables. Net cash used in investing activities for the quarter ended March 31, 2014 was $0.2 million due to purchases of equipment. There were no cash flows provided by financing activities for the quarter ended March 31, 2014. Net cash provided by financing activities for the quarter ended March 31, 2013 was $1.0 million due to convertible loan notes. We expect 2014 cash requirements to be in the range of $15.0 million to $17.0 million. We believe that our cash as of March 31, 2014, will be sufficient to fund our projected operating requirements into the first quarter of 2015.

 

We expect to need to raise additional capital or incur indebtedness to continue to fund our future operations. We may seek to raise capital through a variety of sources, including:

 

·the public equity market;
·private equity financing;
·collaborative arrangements;
·licensing arrangements; and/or
·public or private debt.

 

Our ability to raise additional funds will depend on our clinical and regulatory developments, our product development activities, our ability to identify promising in-licensing opportunities and factors related to financial, economic and market conditions, many of which are beyond our control. We cannot be certain that sufficient funds will be available to us when required or on satisfactory terms. If adequate funds are not available, we may be required to significantly reduce or refocus our operations or to obtain funds through arrangements that may require us to relinquish rights to certain of our products, technologies or potential markets, any of which could delay or require that we curtail our development programs or otherwise have a material adverse effect on our business, financial condition and results of operations. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of such securities would result in ownership dilution to our existing stockholders.

 

If we are unable to secure additional financing on a timely basis or on terms favorable to us, we may be required to cease or reduce certain research and development projects, to sell some or all of our technology or assets or to merge all or a portion of our business with another entity. Insufficient funds may require us to delay, scale back or eliminate some or all of our activities, and if we are unable to obtain additional funding, there is uncertainty regarding our continued existence.

 

17
 

 

Off-Balance Sheet Arrangements

 

As of March 31, 2014, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not engage in trading activities involving non-exchange traded contracts. Therefore, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in these relationships. 

 

Recent Accounting Pronouncements

 

None.

 

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

 

Item 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our Principal Executive Officer and Principal Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of the end of the period covered by this report. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is accumulated and communicated to management, including our Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our Principal Executive Officer and Principal Financial Officer, have concluded that our financial disclosure controls and procedures were effective during the period covered by this report.  

 

Changes in Internal Controls Over Financial Reporting.

 

There were no changes in our internal control over financial reporting during the first quarter of 2014 that has materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

  

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings

 

From time to time we are involved in legal proceedings or subject to claims arising in the ordinary course of our business. Although the results of litigation and claims cannot be predicted with certainty, we do not believe we are a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, operating results, financial condition or cash flows. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

 

Item 1A. Risk Factors

 

There have been no material changes from the risk factors disclosed in Part I, Item 1A, of our Annual Report on Form 10-K/A for the fiscal year ended December 31, 2013 as amended and filed with the SEC on September 12, 2014.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

18
 

 

Item 3. Defaults upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

None.

  

Item 6. Exhibits

 

(a)Exhibits

 

Number   Description
  3.1   Amended and Restated Articles of Incorporation, effective May 21, 2009 (incorporated by reference to Exhibit 3.1 to the Registration Statement on Form 10 filed December 16, 2013).
  3.2   Articles of Amendment to Amended and Restated Articles of Incorporation, effective June 26, 2013 (incorporated by reference to Exhibit 3.2 to the Registration Statement on Form 10 filed December 16, 2013).
  3.3   Articles of Correction to Amended and Restated Articles of Incorporation, effective June 26, 2013 (incorporated by reference to Exhibit 3.3 to the Registration Statement on Form 10 filed December 16, 2013).
  3.4   Amended and Restated Bylaws (incorporated by reference to Exhibit 3.4 to the Registration Statement on Form 10 filed December 16, 2013).
  4.1   Specimen stock certificate evidencing shares of common stock (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form 10 filed December 16, 2013).
  4.2   Form of Warrant to Purchase Shares of Common Stock (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form 10 filed December 16, 2013).
  4.3   Subscription Agreement to Purchase Series B Preferred Stock and Warrants, dated June 26, 2013 (incorporated by reference to Exhibit 4.3 to the Registration Statement on Form 10 filed December 16, 2013).
  4.4   Registration Rights Agreement, dated December 16, 2013 (incorporated by reference to Exhibit 4.4 to the Registration Statement on Form 10 filed December 16, 2013).
  4.5   Subscription Agreement, dated December 16, 2013 (incorporated by reference to Exhibit 4.5 to the Registration Statement on Form 10 filed December 16, 2013).
  10.1   Agreement of Lease of Business Premises, dated as of February 21, 2014, by and between Avotehna d.d. and Ampliphi, Biotehnološke Raziskave in Razvoj, d.o.o. (incorporated by reference to Exhibit 10.22 to Amendment No. 2 to the Registration Statement on Form 10 filed April 15, 2014).
  31.1*   Certification of the Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a).
  31.2*   Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a).
  32.1*   Certification of the Chief Executive Officer Required by Rule 13a-14(b)  or Rule 15d-14(b) and 18 U.S.C. 1350.
  32.2*   Certification of the Chief Financial Officer Required by Rule 13a-14(b)  or Rule 15d-14(b) and 18 U.S.C. 1350.
  101.INS   XBRL Instance Document.
  101.SCH   XBRL Taxonomy Extension Schema Document.
  101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document.
  101.DEF   XBRL Taxonomy Extension Definition Linkbase Document.
  101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document.
  101.LAB   XBRL Taxonomy Extension Label Linkbase Document.

 

* Furnished electronically with this report.

 

19
 

 

AMPLIPHI BIOSCIENCES CORPORATION

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  AMPLIPHI BIOSCIENCES CORPORATION
   
Date:  April 15, 2015   By /s/ Jeremy Curnock Cook
     

Name: Jeremy Curnock Cook

Title: Chief Executive Officer

(Principal Executive Officer)

 

20

 EX-31.1 2 v407150_ex31-1.htm EXHIBIT 31.1

 

Exhibit 31.1

 

AMPLIPHI BIOSCIENCES CORPORATION

 

CERTIFICATION

 

I, Jeremy Curnock Cook, certify that:

 

1.I have reviewed this quarterly report on Form 10-Q of AmpliPhi Biosciences Corporation;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: April 15, 2015

 

  /s/ Jeremy Curnock Cook
  Jeremy Curnock Cook
  Chief Executive Officer

 

 

 

 EX-31.2 3 v407150_ex31-2.htm EXHIBIT 31.2

 

Exhibit 31.2

 

AMPLIPHI BIOSCIENCES CORPORATION

 

CERTIFICATION

 

I, David E. Bosher, certify that:

 

1.I have reviewed this quarterly report on Form 10-Q of AmpliPhi Biosciences Corporation;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

 

a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: April 15, 2015

 

  /s/ David E. Bosher
  David E. Bosher
  Chief Financial Officer

 

 

 

 EX-32.1 4 v407150_ex32-1.htm EXHIBIT 32.1

 

Exhibit 32.1

 

AMPLIPHI BIOSCIENCES CORPORATION

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the quarterly report of AmpliPhi Biosciences Corporation (the “Company”) on Form 10-Q for the period ended March 31, 2014 as filed with the Securities and Exchange Commission (the “Report”), I, Jeremy Curnock Cook, Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:

 

(1)the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and

 

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

This Certification has not been, and shall not be deemed, “filed” with the Securities and Exchange Commission.

 

Date: April 15, 2015

 

  /s/ Jeremy Curnock Cook
  Jeremy Curnock Cook
  Chief Executive Officer

 

 

 

 EX-32.2 5 v407150_ex32-2.htm EXHIBIT 32.2

 

Exhibit 32.2

 

AMPLIPHI BIOSCIENCES CORPORATION

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the quarterly report of AmpliPhi Biosciences Corporation (the “Company”) on Form 10-Q for the period ended March 31, 2014 as filed with the Securities and Exchange Commission (the “Report”), I, David E. Bosher, Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:

 

(1)the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and

 

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

This Certification has not been, and shall not be deemed, “filed” with the Securities and Exchange Commission.

 

Date: April 15, 2015

 

  /s/ David E. Bosher
  David E. Bosher
  Chief Financial Officer

 

 

 EX-101.INS 6 aphb-20140331.xml XBRL INSTANCE DOCUMENT 0000921114 2013-01-01 2013-03-31 0000921114 2013-01-01 2013-12-31 0000921114 2014-01-01 2014-03-31 0000921114 2014-03-31 0000921114 2014-05-05 0000921114 2013-07-01 2013-07-25 0000921114 2013-10-02 2013-10-17 0000921114 2013-10-17 0000921114 2013-12-31 0000921114 2012-12-31 0000921114 2013-03-31 0000921114 aphb:SeriesBRedeemableConvertiblePreferredStockMember 2014-03-31 0000921114 aphb:SeriesBRedeemableConvertiblePreferredStockMember 2013-12-31 0000921114 us-gaap:RedeemableConvertiblePreferredStockMember 2012-12-31 0000921114 us-gaap:CommonStockMember 2012-12-31 0000921114 us-gaap:AdditionalPaidInCapitalMember 2012-12-31 0000921114 us-gaap:RetainedEarningsMember 2012-12-31 0000921114 us-gaap:RedeemableConvertiblePreferredStockMember 2013-01-01 2013-12-31 0000921114 us-gaap:CommonStockMember 2013-01-01 2013-12-31 0000921114 us-gaap:AdditionalPaidInCapitalMember 2013-01-01 2013-12-31 0000921114 us-gaap:RetainedEarningsMember 2013-01-01 2013-12-31 0000921114 us-gaap:RetainedEarningsMember 2014-01-01 2014-03-31 0000921114 us-gaap:RedeemableConvertiblePreferredStockMember 2014-01-01 2014-03-31 0000921114 us-gaap:CommonStockMember 2014-01-01 2014-03-31 0000921114 us-gaap:AdditionalPaidInCapitalMember 2014-01-01 2014-03-31 0000921114 us-gaap:RedeemableConvertiblePreferredStockMember 2013-12-31 0000921114 us-gaap:CommonStockMember 2013-12-31 0000921114 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0000921114 us-gaap:RetainedEarningsMember 2013-12-31 0000921114 us-gaap:RedeemableConvertiblePreferredStockMember 2014-03-31 0000921114 us-gaap:CommonStockMember 2014-03-31 0000921114 us-gaap:AdditionalPaidInCapitalMember 2014-03-31 0000921114 us-gaap:RetainedEarningsMember 2014-03-31 0000921114 aphb:BiocontrolLimitedMember 2011-12-31 0000921114 aphb:SphHoldingsPtyLtdMember 2012-12-31 0000921114 aphb:BiocontrolLimitedMember 2013-01-01 2013-03-31 0000921114 aphb:SphHoldingsPtyLtdMember 2013-01-01 2013-03-31 0000921114 aphb:BiocontrolLimitedMember 2014-01-01 2014-03-31 0000921114 aphb:SphHoldingsPtyLtdMember 2014-01-01 2014-03-31 0000921114 aphb:WarrantsIssuedOnJune262013MemberMember 2013-01-01 2013-12-31 0000921114 aphb:WarrantsIssuedOnJuly152013MemberMember 2013-01-01 2013-12-31 0000921114 aphb:WarrantsIssuedOnDecember232013MemberMember 2013-01-01 2013-12-31 0000921114 aphb:WarrantsIssuedOnDecember232013MemberMember 2013-12-31 0000921114 aphb:WarrantsIssuedOnJuly152013MemberMember 2013-12-31 0000921114 aphb:WarrantsIssuedOnJune262013MemberMember 2013-12-31 0000921114 us-gaap:PrivatePlacementMember us-gaap:CommonStockMember 2013-01-01 2013-12-31 0000921114 aphb:BiocontrolLimitedMember 2011-01-01 2011-12-31 0000921114 aphb:SeriesBRedeemableConvertiblePreferredStockMember us-gaap:PrivatePlacementMember 2013-01-01 2013-12-31 0000921114 us-gaap:ConvertibleNotesPayableMember 2013-01-01 2013-12-31 0000921114 us-gaap:WarrantMember 2014-03-31 0000921114 aphb:BiocontrolLimitedMember 2014-03-31 0000921114 us-gaap:WarrantMember 2013-12-31 0000921114 aphb:SeriesBRedeemableConvertiblePreferredStockMember 2013-01-01 2013-12-31 0000921114 aphb:ConvertibleNotesPayableTwoMember 2013-01-01 2013-12-31 0000921114 aphb:ConvertibleNotesPayableOneMember aphb:SeriesBRedeemableConvertiblePreferredStockMember 2013-01-01 2013-12-31 0000921114 aphb:ConvertibleNotesPayableOneMember 2013-01-01 2013-12-31 0000921114 aphb:SeriesBRedeemableConvertiblePreferredStockMember aphb:ConvertibleNotesPayableTwoMember 2013-01-01 2013-12-31 0000921114 us-gaap:GeneralAndAdministrativeExpenseMember 2013-01-01 2013-03-31 0000921114 us-gaap:ResearchAndDevelopmentExpenseMember 2013-01-01 2013-03-31 0000921114 us-gaap:GeneralAndAdministrativeExpenseMember 2013-01-01 2013-12-31 0000921114 us-gaap:ResearchAndDevelopmentExpenseMember 2013-01-01 2013-12-31 0000921114 us-gaap:GeneralAndAdministrativeExpenseMember 2014-01-01 2014-03-31 0000921114 us-gaap:ResearchAndDevelopmentExpenseMember 2014-01-01 2014-03-31 0000921114 us-gaap:EmployeeStockOptionMember 2013-12-31 0000921114 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-03-31 0000921114 us-gaap:EmployeeStockOptionMember 2014-03-31 0000921114 us-gaap:EmployeeStockOptionMember 2013-01-01 2013-12-31 0000921114 us-gaap:PatentsMember 2011-12-31 0000921114 us-gaap:PreferredStockMember 2013-12-31 0000921114 us-gaap:WarrantMember aphb:ConvertibleNotesPayableOneMember 2013-12-31 0000921114 aphb:ConvertibleNotesPayableOneMember us-gaap:PreferredStockMember 2013-12-31 0000921114 us-gaap:WarrantMember aphb:ConvertibleNotesPayableTwoMember 2013-12-31 0000921114 us-gaap:PreferredStockMember aphb:ConvertibleNotesPayableTwoMember 2013-12-31 0000921114 us-gaap:PreferredStockMember 2013-01-01 2013-12-31 0000921114 us-gaap:PreferredStockMember 2013-10-02 2013-10-17 0000921114 us-gaap:CommonStockMember 2013-10-02 2013-10-17 0000921114 us-gaap:RestatementAdjustmentMember 2014-03-31 0000921114 us-gaap:DerivativeMember 2014-01-01 2014-03-31 0000921114 us-gaap:RestatementAdjustmentMember 2014-01-01 2014-03-31 0000921114 us-gaap:RestatementAdjustmentMember 2013-01-01 2013-03-31 0000921114 us-gaap:RestatementAdjustmentMember aphb:FirstAmendmentMember 2013-01-01 2013-03-31 0000921114 aphb:FirstAmendmentMember 2013-01-01 2013-03-31 0000921114 aphb:FirstAmendmentMember us-gaap:RestatementAdjustmentMember 2014-01-01 2014-03-31 0000921114 aphb:FirstAmendmentMember 2014-01-01 2014-03-31 0000921114 us-gaap:PatentsMember 2014-03-31 0000921114 us-gaap:PatentsMember 2013-12-31 0000921114 us-gaap:RestatementAdjustmentMember aphb:BiocontrolLimitedMember 2014-03-31 0000921114 us-gaap:RestatementAdjustmentMember aphb:SphHoldingsPtyLtdMember 2014-03-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure 10-Q/A true 2014-03-31 2014 Q1 APHB 182535562 AmpliPhi Biosciences Corp 0000921114 --12-31 Smaller Reporting Company 16435000 20355000 12000 8000 345000 297000 16792000 20660000 356000 145000 12446000 12446000 7562000 7562000 37548000 41213000 886000 2147000 1026000 2391000 46325000 40791000 20110000 16871000 69513000 60740000 70539000 63131000 1021000 707000 1825000 1825000 358748000 358828000 1837000 1837000 -396422000 -385115000 -34012000 -22625000 37548000 41213000 491000 473000 0.01 0.01 10000000 10000000 8859978 8859978 8859978 8859978 0.01 0.01 445000000 445000000 182535562 182535562 182535562 182535562 22000 81000 104000 641000 6469000 1011000 714000 5996000 1627000 1355000 12465000 2638000 -1333000 -12384000 -2534000 87000 -49330000 -8773000 303000 2636000 0 96000 233000 0 -1645000 -65201000 -11621000 -0.03 -0.64 -0.06 66908810 101201753 182535562 12943000 0 669000 332806000 -320532000 0 66908810 -64583000 0 0 0 -64583000 -11307000 -11307000 0 0 0 1437000 0 0 1437000 0 234000 0 0 234000 0 2635000 0 2635000 0 0 3000000 0 240000 2760000 0 0 24000000 0 50000 0 0 0 5016081 0 0 50000 0 0 0 4999999 0 7084000 -11000 115000 6969000 0 -1156102 11561020 13000 0 1000 12000 0 0 61018 0 0 80000 -80000 0 0 8000000 15464000 0 720000 14744000 0 0 72007000 0 2286 707000 1825000 360665000 -385115000 1021000 1825000 360585000 -396422000 8859978 182535562 8859978 182535562 -1645000 0 3000000 0 311000 2667000 8000 0 759000 0 21000 82000 18000 154000 1437000 234000 -12000 -15000 4000 -618000 -618000 0 -380000 454000 -1365000 219000 149000 48000 96000 233000 0 -1119000 -6292000 -3691000 0 102000 229000 0 -102000 -229000 0 16887000 0 0 7000000 0 976000 2000000 0 976000 25887000 0 -143000 19493000 -3920000 862000 719000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>1. Nature of Business and Significant Accounting Policies</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Nature of Business</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> AmpliPhi Biosciences Corporation (the &#8220;Company&#8221;) was incorporated in the state of Washington in 1989 under the name Targeted Genetics Corporation. In February 2011, Targeted Genetics Corporation changed its name to AmpliPhi Biosciences Corporation. The Company, headquartered in Richmond, Virginia, is dedicated to developing novel antibacterial solutions called bacteriophage (phage). Phages are naturally occurring viruses that preferentially target and kill their bacterial targets.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Basis of Presentation</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries Biocontrol, Ampliphi d.o.o., and AmpliPhi Australia. All significant intercompany accounts and transactions have been eliminated. All numbers on the financial statements and disclosures have been rounded to the nearest 1,000 except share and per share data.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The interim consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. In the opinion of the Company&#8217;s management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) necessary to present fairly our results of operations for the three months ended March 31, 2014 and 2013, our cash flows for the three months ended March 31, 2014 and 2013 and our financial position as of March 31, 2014 have been made. The results of operations for such interim periods are not necessarily indicative of the operating results to be expected for the full year.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Certain information and disclosures normally included in the notes to the annual financial statements have been condensed or omitted from these interim consolidated financial statements. Accordingly, these interim consolidated financial statements should be read in conjunction with the 2013 audited consolidated financial statements and notes.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Use of Estimates</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Cash and Cash Equivalents</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company considers cash equivalents to be short-term investments that have a maturity at the time of purchase of three months or less, are readily convertible into cash and have an insignificant level of valuation risk attributable to potential changes in interest rates. Cash equivalents are recorded at cost, which approximates fair market value, and consist primarily of money market accounts.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Accounts Receivable</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Accounts receivable amounts are stated at their face amounts less any allowance. Provisions for doubtful accounts are estimated based on assessment of the probable collection from specific customer accounts and other known factors. If an account was determined to be uncollectible (payment has not been made in accordance with contract terms), it would be written off against the allowance. As of March 31, 2014 and December 31, 2013, management determined no allowance for doubtful accounts was required.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Property and Equipment</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Property and equipment are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, generally three to seven years.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Prepaid Expenses and Other Current Assets</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Prepaid and other current assets as of March 31, 2014 and December 31, 2013 consist primarily of prepaid insurance and deposits.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Goodwill</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Costs of investments in purchased companies in excess of the underlying fair value of net assets at the date of acquisition are recorded as goodwill and assessed annually for impairment. If considered impaired, goodwill will be written down to fair value and a corresponding impairment loss recognized.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> During the year ended December 31, 2012, the rights to SPH Holdings Pty Ltd&#8217;s know-how and phage libraries were acquired by a business combination. At December 31, 2012, goodwill in the amount of $3,929,000 has been recorded. In management&#8217;s opinion, no goodwill has been impaired as of March 31, 2014 and December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> During the year ended December 31, 2011, the rights to Biocontrol Limited&#8217;s patents and phage libraries were acquired by a business combination. At December 31, 2011, goodwill in the amount of $3,633,000 has been recorded. In management&#8217;s opinion, no goodwill has been impaired as of March 31, 2014 and December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Patents</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Patents are recorded at cost and are amortized using the straight-line method over the estimated useful lives of the patents.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> During the year ended December 31, 2011, the rights to Biocontrol Limited&#8217;s patents were acquired by a business combination. At December 31, 2011, patents in the amount of $493,000 have been recorded. These patents are amortized over their useful life through December 2026.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Stock-Based Compensation</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company accounts for stock-based payments under the guidance of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 718, <i>Stock Compensation</i>, which requires measurement of compensation cost for all share-based payment awards at fair value on the date of grant and recognition of compensation cost over the requisite service period (typically the vesting period) for awards expected to vest.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Warrant and Preferred Shares Conversion Feature Liability</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company accounts for warrants and preferred shares conversion feature with anti-dilution (&#8220;down-round&#8221;) provisions under the guidance of ASC 815, <i>Derivatives</i>, <i>and Hedging</i> and Emerging Issue Task Force Statement 07-5: <i> Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity&#8217;s Own Stock</i>, which require the warrants and the preferred shares conversion feature to be recorded as a liability and adjusted to fair value in each reporting period.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Fair Value of Financial Assets and Liabilities&#160;&#151;&#160;Derivative Instruments</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company measures the fair value of financial assets and liabilities in accordance with GAAP, which defines fair value, establishes a framework for measuring fair value, and requires certain disclosures about fair value measurements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes as fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. GAAP describes three levels of inputs that may be used to measure fair value:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Level 1&#160;&#151;&#160;quoted prices in active markets for identical assets or liabilities.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Level 2&#160;&#151;&#160;quoted prices for similar assets and liabilities in active markets or inputs that are observable.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Level 3&#160;&#151;&#160;inputs that are unobservable.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company does not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, the Company has entered into certain financial instruments and contracts, such as convertible loan notes with detachable common stock warrants and the issuance of preferred stock with detachable common stock warrants with features that are either i) not afforded equity classification, ii) embody risks not clearly and closely related to host contracts, or iii) may be net-cash settled by the counterparty. These instruments are required to be carried as derivative liabilities, at fair value.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company estimates fair values of these derivatives (and related embedded beneficial conversion features) utilizing Level 3 inputs. The Company uses the Monte Carlo valuation technique for derivatives as it embodies all of the requisite assumptions (including trading volatility, remaining term to maturity, market price, strike price, risk free rates) necessary to fair value these instruments.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Estimating fair values of derivative financial instruments, including Level 3 instruments, require the use of significant and subjective inputs that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are volatile and sensitive to changes in our trading market price, the trading market price of various peer companies and other key assumptions. Since derivative financial instruments are initially and subsequently carried at fair value, our income will reflect this sensitivity of internal and external factors.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Revenue Recognition</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company generates revenue from technology licenses, collaborative research arrangements, and agreements to provide research and development services. Revenue under technology licenses typically consists of nonrefundable, up-front license fees, technology access fees and various other payments. The Company recognizes revenue associated with performance milestones as earned, typically based upon the achievement of the specific milestones defined in the applicable agreements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company recognizes revenue under research and development contracts as the related costs are incurred. When contracts include multiple elements, the Company follows ASC 605-25, <i>Multiple Element Arrangements</i>, which requires the Company to satisfy the following before revenue can be recognized:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 2%"> <div>&#160;</div> </td> <td style="WIDTH: 2%"> <div><font style="FONT-SIZE: 10pt">&#8226;</font></div> </td> <td style="WIDTH: 96%"> <div><font style="FONT-SIZE: 10pt">The delivered items have value to the customer on a stand-alone basis;</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="center">&#160;</div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 2%"> <div>&#160;</div> </td> <td style="WIDTH: 2%"> <div><font style="FONT-SIZE: 10pt">&#8226;</font></div> </td> <td style="WIDTH: 96%"> <div><font style="FONT-SIZE: 10pt">Any undelivered items have objective and reliable evidence of fair value; and</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="center">&#160;</div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 2%"> <div>&#160;</div> </td> <td style="WIDTH: 2%"> <div><font style="FONT-SIZE: 10pt">&#8226;</font></div> </td> <td style="WIDTH: 96%"> <div><font style="FONT-SIZE: 10pt">Delivery or performance is probable and within the Company&#8217;s control for any delivered items that have a right of return.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 2%"></td> <td style="TEXT-ALIGN: left; WIDTH: 2%"></td> <td style="TEXT-ALIGN: justify; WIDTH: 96%"> <div>The Company classifies advance payments received in excess of amounts earned as deferred revenue.</div> </td> </tr> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: justify"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;&#160;&#160;&#160;Based upon the terms specified in its collaboration agreements, the Company receives advance payments from some of its collaboration partners before the project has been performed. These payments are deferred and recognized as revenue when the costs are incurred.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>In Process Research and Development</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In Process Research &amp; Development (IPR&amp;D) assets represent capitalized incomplete research projects that the Company acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The fair value of the research projects is recorded as intangible assets on the consolidated balance sheet rather than expensed regardless of whether these assets have an alternative future use. The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company will make a determination as to the then remaining useful life of the intangible asset and begin amortization. The Company tests its indefinite-lived intangibles, including IPR&amp;D assets, for impairment at least quarterly.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> During the year ended December 31, 2012, the rights to SPH Holdings Pty Ltd&#8217;s IPR&amp;D were acquired by the business combination. At December 31, 2012, IPR&amp;D in the amount of $5,161,000 has been recorded. In management&#8217;s opinion, this IPR&amp;D has not been impaired as of March 31, 2014 and December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> During the year ended December 31, 2011, the rights to Biocontrol - IPR&amp;D and patents were acquired by the business combination. At December 31, 2011, IPR&amp;D in the amount of $7,285,000 has been recorded. In management&#8217;s opinion, this IPR&amp;D has not been impaired as of March 31, 2014 and December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Research and development costs include salaries, costs of outside collaborators and outside services, royalty and license costs and allocated facility, occupancy and utility expenses. The Company expenses research and development costs as incurred.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Net Loss per Common Share</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Net loss per common share is based on net loss divided by the weighted average number of common shares outstanding during the period. For each fiscal year reported, the diluted net loss per share is the same as the basic net loss per share because all stock options, warrants, contingent shares, and Series B redeemable convertible preferred stock shares are antidilutive with respect to computing the net loss per share and therefore are excluded from the calculation of diluted net loss per share. The total number of shares that the Company excluded from the calculations of net loss per share were 148,692,651 shares for the three month period ending March 31, 2014, 20,000,000 shares for the three month period ending March 31, 2013, and 77,490,242 shares for the year ending December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>&#160;</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Recent Accounting Pronouncements</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> On February 5, 2013, the FASB issued ASU no. 2013-02 which adds new disclosure requirements for items reclassified out of accumulated other comprehensive income (AOCI). The ASU is intended to help entities improve the transparency of changes in other comprehensive income (OCI) and items reclassified out of AOCI in their financial statements. It does not amend any existing requirements for reporting net income or OCI in the financial statements. For public entities, the new disclosure requirements are effective for fiscal years, and interim periods within those years, beginning after December 15, 2012. For nonpublic entities, the ASU is effective for fiscal years beginning after December 15, 2013, and interim and annual periods thereafter. The Company elected to early adopt this standard which did not result in any changes to the consolidated financial statements.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong>4. Stock-Based Compensation</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in"> The Company&#8217;s Stock Incentive Plan provides for the issuance of long-term incentive awards, or Awards, in the form of non-qualified and incentive stock options, or Options, stock appreciation rights, stock grants and restricted stock units. The awards may be granted by the Company&#8217;s Board of Directors to its employees, directors and officers and to consultants, agents, advisors and independent contractors who provide services to the Company. The exercise price for Options must not be less than the fair market value of the underlying shares on the date of grant. Options expire no later than ten years from the date of grant and generally vest and become exercisable over a four-year period following the date of grant. Every non-employee member of the Company&#8217;s Board of Directors receives an annual non-qualified Option or restricted stock unit grant. Upon the exercise of Options, the Company issues the resulting shares from shares reserved for issuance under the Company&#8217;s Incentive Plan.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> Under ASC 718 <i>Stock Compensation</i>, the Company is required to expense the fair value of share-based payments granted over the vesting period. The Company values Awards granted at their grant date fair value in accordance with the provisions of ASC 718 and recognizes stock-based compensation expense on a straight-line basis over the service period of each award.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> Stock-based compensation expense is reduced by an estimated forfeiture rate derived from historical employee termination behavior. If the actual number of forfeitures differs from the Company&#8217;s estimates, the Company may record adjustments to increase or decrease compensation expense in future periods. There were no significant adjustments related to changes in the Company&#8217;s estimates for the three months-ended March 31, 2014 and year ended December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Following is a summary of the amount included as stock-based compensation expense in the accompanying consolidated statements of operations and comprehensive loss:</div> </div> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="63%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Three&#160;Months&#160;Ended&#160;March&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Year&#160;Ended</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014<br/> (Unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013<br/> (Unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;31,<br/> 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Stock options:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>General and administrative expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>196,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>112,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>191,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Research and development expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>38,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>42,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,246,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Total stock-based compensation expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>234,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>154,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,437,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="center">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following table summarizes Option activity:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.25in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="46%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted&#160;Average&#160;Exercise<br/> Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average&#160;Remaining<br/> Contractual&#160;Term<br/> (Years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Intrinsic&#160;Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Outstanding at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>25,721,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>9.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6,451,441</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 8px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 8px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 8px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 8px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Outstanding at March 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>25,721,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>8.88</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>8,416,233</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Exercisable at March 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>10,089,662</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>8.89</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4,049,376</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> The aggregate intrinsic value is determined using the closing price of the Company&#8217;s common stock of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.58</font> on March 31, 2014.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> As of March 31, 2014, the Company had unrecognized compensation cost related to unvested Options of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,072,890</font> net of estimated forfeitures, which the Company expects to recognize over a weighted average period of approximately two and a half years</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>As of March 31, 2013, the Company had reserved shares of its common stock for future issuance as follows:</div> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Shares&#160;Reserved</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Stock options outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>25,721,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Available for future grants under the Stock Incentive Plan</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>40,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>38,425,745</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"> <div>Total Shares reserved</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>104,146,745</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><b><i> Basis of Presentation</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in; CLEAR: both"> The interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries Biocontrol, Ampliphi d.o.o., and AmpliPhi Australia. All significant intercompany accounts and transactions have been eliminated. All numbers on the financial statements and disclosures have been rounded to the nearest 1,000 except share and per share data.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in; CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in; CLEAR: both"> The interim consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. In the opinion of the Company&#8217;s management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) necessary to present fairly our results of operations for the three months ended March 31, 2014 and 2013, our cash flows for the three months ended March 31, 2014 and 2013 and our financial position as of March 31, 2014 have been made. The results of operations for such interim periods are not necessarily indicative of the operating results to be expected for the full year.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in; CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in; CLEAR: both"> Certain information and disclosures normally included in the notes to the annual financial statements have been condensed or omitted from these interim consolidated financial statements. Accordingly, these interim consolidated financial statements should be read in conjunction with the 2013 audited consolidated financial statements and notes.</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><b><i>Use of Estimates</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; CLEAR: both"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i><b><i>Cash and Cash Equivalents</i></b></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.3in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company considers cash equivalents to be short-term investments that have a maturity at the time of purchase of three months or less, are readily convertible into cash and have an insignificant level of valuation risk attributable to potential changes in interest rates. Cash equivalents are recorded at cost, which approximates fair market value, and consist primarily of money market accounts.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Accounts Receivable</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Accounts receivable amounts are stated at their face amounts less any allowance. Provisions for doubtful accounts are estimated based on assessment of the probable collection from specific customer accounts and other known factors. If an account was determined to be uncollectible (payment has not been made in accordance with contract terms), it would be written off against the allowance. As of March 31, 2014 and December 31, 2013, management determined no allowance for doubtful accounts was required.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i><b><i>Property and Equipment</i></b></i></b></div> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.3in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Property and equipment are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, generally three to seven years.&#160;</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><strong><i>Goodwill</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.3in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Costs of investments in purchased companies in excess of the underlying fair value of net assets at the date of acquisition are recorded as goodwill and assessed annually for impairment. If considered impaired, goodwill will be written down to fair value and a corresponding impairment loss recognized.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> During the year ended December 31, 2012, the rights to SPH Holdings Pty Ltd&#8217;s know-how and phage libraries were acquired by a business combination. At December 31, 2012, goodwill in the amount of $3,929,000 has been recorded. In management&#8217;s opinion, no goodwill has been impaired as of March 31, 2014 and December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> During the year ended December 31, 2011, the rights to Biocontrol Limited&#8217;s patents and phage libraries were acquired by a business combination. At December 31, 2011, goodwill in the amount of $3,633,000 has been recorded. In management&#8217;s opinion, no goodwill has been impaired as of March 31, 2014 and December 31, 2013.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><b><i> Stock-Based Compensation</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; CLEAR: both"> The Company accounts for stock-based payments under the guidance of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 718, <i>Stock Compensation</i>, which requires measurement of compensation cost for all share-based payment awards at fair value on the date of grant and recognition of compensation cost over the requisite service period (typically the vesting period) for awards expected to vest.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><b><i> Warrant and Preferred Shares Conversion Feature Liability</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; CLEAR: both"> The Company accounts for warrants and preferred shares conversion feature with anti-dilution (&#8220;down-round&#8221;) provisions under the guidance of ASC 815, <i>Derivatives</i>, <i>and Hedging</i> and Emerging Issue Task Force Statement 07-5: <i> Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity&#8217;s Own Stock</i>, which require the warrants and the preferred shares conversion feature to be recorded as a liability and adjusted to fair value in each reporting period.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><b><i> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Fair Value of Financial Assets and Liabilities&#160;&#151;&#160;Derivative Instruments</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in; CLEAR: both"> The Company measures the fair value of financial assets and liabilities in accordance with GAAP, which defines fair value, establishes a framework for measuring fair value, and requires certain disclosures about fair value measurements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in; CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in; CLEAR: both"> GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes as fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. GAAP describes three levels of inputs that may be used to measure fair value:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in; CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in; CLEAR: both"> Level 1&#160;&#151;&#160;quoted prices in active markets for identical assets or liabilities.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in; CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in; CLEAR: both"> Level 2&#160;&#151;&#160;quoted prices for similar assets and liabilities in active markets or inputs that are observable.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in; CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in; CLEAR: both"> Level 3&#160;&#151;&#160;inputs that are unobservable.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in; CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in; CLEAR: both"> The Company does not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, the Company has entered into certain financial instruments and contracts, such as convertible loan notes with detachable common stock warrants and the issuance of preferred stock with detachable common stock warrants with features that are either i) not afforded equity classification, ii) embody risks not clearly and closely related to host contracts, or iii) may be net-cash settled by the counterparty. These instruments are required to be carried as derivative liabilities, at fair value.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in; CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in; CLEAR: both"> The Company estimates fair values of these derivatives (and related embedded beneficial conversion features) utilizing Level 3 inputs. The Company uses the Monte Carlo valuation technique for derivatives&#160;as it embodies all of the requisite assumptions (including trading volatility, remaining term to maturity, market price, strike price,&#160;risk free rates) necessary to fair value these instruments.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in; CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in; CLEAR: both"> Estimating fair values of derivative financial instruments, including Level 3 instruments, require the use of significant and subjective inputs that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are volatile and sensitive to changes in our trading market price, the trading market price of various peer companies and other key assumptions. Since derivative financial instruments are initially and subsequently carried at fair value, our income will reflect this sensitivity of internal and external factors.</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> <b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Revenue Recognition</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; CLEAR: both"> The Company generates revenue from technology licenses, collaborative research arrangements, and agreements to provide research and development services. Revenue under technology licenses typically consists of nonrefundable, up-front license fees, technology access fees and various other payments. The Company recognizes revenue associated with performance milestones as earned, typically based upon the achievement of the specific milestones defined in the applicable agreements. <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> The Company recognizes revenue under research and development contracts as the related costs are incurred. When contracts include multiple elements, the Company follows ASC 605-25, <i>Multiple Element Arrangements</i>, which requires the Company to satisfy the following before revenue can be recognized:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 3%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="WIDTH: 3%"> <div style="CLEAR:both;CLEAR: both"><font style="FONT: 10pt Times New Roman, Times, Serif">&#8226;</font></div> </td> <td style="WIDTH: 94%"> <div style="CLEAR:both;CLEAR: both"><font style="FONT: 10pt Times New Roman, Times, Serif">The delivered items have value to the customer on a stand-alone basis;</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: center; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 3%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="WIDTH: 3%"> <div style="CLEAR:both;CLEAR: both"><font style="FONT: 10pt Times New Roman, Times, Serif">&#8226;</font></div> </td> <td style="WIDTH: 94%"> <div style="CLEAR:both;CLEAR: both"><font style="FONT: 10pt Times New Roman, Times, Serif">Any undelivered items have objective and reliable evidence of fair value; and</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: center; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 3%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="WIDTH: 3%"> <div style="CLEAR:both;CLEAR: both"><font style="FONT: 10pt Times New Roman, Times, Serif">&#8226;</font></div> </td> <td style="WIDTH: 94%"> <div style="CLEAR:both;CLEAR: both"><font style="FONT: 10pt Times New Roman, Times, Serif">Delivery or performance is probable and within the Company&#8217;s control for any delivered items that have a right of return.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0px 0in 0.9in; FONT: 10pt Times New Roman, Times, Serif"> The Company classifies advance payments received in excess of amounts earned as deferred revenue.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0px 0in 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0px 0in 0.6in; FONT: 10pt Times New Roman, Times, Serif"> Based upon the terms specified in its collaboration agreements, the Company receives advance payments from some of its collaboration partners before the project has been performed. These payments are deferred and recognized as revenue when the costs are incurred.</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><b><i> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>In Process Research and Development</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in; CLEAR: both"> In Process Research &amp; Development (IPR&amp;D) assets represent capitalized incomplete research projects that the Company acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The fair value of the research projects is recorded as intangible assets on the consolidated balance sheet rather than expensed regardless of whether these assets have an alternative future use. The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company will make a determination as to the then remaining useful life of the intangible asset and begin amortization. The Company tests its indefinite-lived intangibles, including IPR&amp;D assets, for impairment at least quarterly.&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in; CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in; CLEAR: both"> During the year ended December 31, 2012, the rights to SPH Holdings Pty Ltd&#8217;s IPR&amp;D were acquired by the business combination. At December 31, 2012, IPR&amp;D in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,161,000</font> has been recorded. In management&#8217;s opinion, this IPR&amp;D has not been impaired as of March 31, 2014 and December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in; CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in; CLEAR: both"> During the year ended December 31, 2011, the rights to Biocontrol - IPR&amp;D and patents&#160;were acquired by the business combination. At December 31, 2011, IPR&amp;D in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7,285,000</font> has been recorded. In management&#8217;s opinion, this IPR&amp;D has not been impaired as of March 31, 2014 and December 31, 2013.&#160;</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in; CLEAR: both"> <b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in; CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in; CLEAR: both"> Research and development costs include salaries, costs of outside collaborators and outside services, royalty and license costs and allocated facility, occupancy and utility expenses. The Company expenses research and development costs as incurred.<br/> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><b><i> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Net Loss per Common Share</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; CLEAR: both"> Net loss per common share is based on net loss divided by the weighted average number of common shares outstanding during the period. For each fiscal year reported, the diluted net loss per share is the same as the basic net loss per share because all stock options, warrants, contingent shares, and Series B redeemable convertible preferred stock shares are antidilutive with respect to computing the net loss per share and therefore are excluded from the calculation of diluted net loss per share. The total number of shares that the Company excluded from the calculations of net loss per share were <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 148,692,651</font> shares for the three month period ending March 31, 2014, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 20,000,000</font> shares for the three month period ending March 31, 2013, and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 77,490,242</font> <font style="BACKGROUND-COLOR: transparent"> shares for the year ending December 31, 2013.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> Following is a summary of the amount included as stock-based compensation expense in the accompanying consolidated statements of operations and comprehensive loss:</div> </div> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="63%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Three&#160;Months&#160;Ended&#160;March&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Year&#160;Ended</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014<br/> (Unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2013<br/> (Unaudited)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;31,<br/> 2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Stock options:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>General and administrative expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>196,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>112,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>191,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Research and development expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>38,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>42,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,246,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Total stock-based compensation expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>234,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>154,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,437,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="center"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table summarizes Option activity:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.25in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="46%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted&#160;Average&#160;Exercise<br/> Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average&#160;Remaining<br/> Contractual&#160;Term<br/> (Years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Intrinsic&#160;Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Outstanding at December 31, 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>25,721,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>9.15</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6,451,441</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 8px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 8px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 8px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 8px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Outstanding at March 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>25,721,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>8.88</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>8,416,233</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="46%"> <div>Exercisable at March 31, 2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>10,089,662</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.19</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>8.89</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4,049,376</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> As of March 31, 2013, the Company had reserved shares of its common stock for future issuance as follows:</div> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Shares&#160;Reserved</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Stock options outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>25,721,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Available for future grants under the Stock Incentive Plan</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>40,000,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="67%"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>38,425,745</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="67%"> <div>Total Shares reserved</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>104,146,745</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 3633000 3929000 7285000 5161000 20000000 77490242 148692651 0 0 0 0 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The following warrants were issued in 2013 using the Monte Carlo valuation method with the key inputs as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 88%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June&#160;26,&#160;2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>July&#160;15,&#160;2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;23,&#160;2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Warrants Issued</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>28,394,834</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,645,361</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4,320,420</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0109</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0109</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0167</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>160.94</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>163.08</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>155.24</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Expected term</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Exercise price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 28394834 1645361 4320420 0.000109 0.000109 0.000167 1.6094 1.6308 1.5524 P5Y P5Y P5Y 0.25 0.14 0.14 0.25 0.46 0.14 0.14 72007000 1355164 7030387 30040195 0.58 0.50 9929000 87000 -3149000 19460000 646000 16311000 759000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b>2. Preferred Shares</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> On June 13, 2013, the Company&#8217;s Board of Directors approved a resolution designating <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10,016,080</font> shares of Preferred Stock as Series B redeemable convertible preferred stock with an initial stated value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.40</font> and par value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.01</font>. Each Series B redeemable convertible preferred stock is convertible into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font> shares of common stock and is entitled to the number of votes equal to the number of shares of common stock. These Series B redeemable convertible preferred stock shares may be converted to common stock by the holder of the shares at any time. The Series B redeemable convertible preferred stock shares shall be automatically converted into common shares upon the closing of an underwritten initial public offering with aggregate proceeds to the Company of at least $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7</font> million and a price per share to the public of at least the Series B redeemable convertible preferred stock stated value upon the closing of which the shares of common stock of the Company shall be listed for trading on the New York Stock Exchange. The Series B redeemable convertible preferred stock shares are also convertible into common shares upon the election of the holders of two-thirds of the outstanding Series B redeemable convertible preferred stock shares. Until conversion, the holders of Series B redeemable convertible preferred stock shares shall be entitled to receive dividends of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% of the Series B redeemable convertible preferred stock stated value per annum.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> &#160;</div> In connection with the private placement of Series B redeemable convertible preferred stock, the Company recorded a liability for a complex embedded derivative that required bifurcation under ASC Section 815. The embedded derivative includes a redemption feature, multiple dividend features, as well as multiple conversion features with a down-round ratchet provision. The Company estimates the fair values of the conversion feature using a Monte Carlo valuation model. The Company measured the fair value of the conversion feature on June 26, 2013 and July 15, 2013 (dates of issuance) and recorded the initial liability as part of the private placement proceeds. <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> &#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> On June 26, 2013, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,999,999</font> shares of the Company&#8217;s newly-created Series B redeemable convertible preferred stock and warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12,499,996</font> shares of common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.14</font> per share for an aggregate purchase price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7.0</font> million. The value of the derivative liability related to the warrants was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,886,000</font> and the value of the derivative liability related to the preferred shares was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,064,000</font>. As part of the same transaction, the Company converted $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,491,000</font> in outstanding convertible loan notes (principal and interest)&#160;into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,357,936</font> shares of Series B redeemable convertible preferred stock and warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10,894,839</font> shares of common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.14</font> per share. The value of the derivative liability related to the warrants was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,644,000</font> and the value of the derivative liability related to the preferred shares was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,804,000</font>. As part of this issuance, the Company issued warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,999,999</font> shares of common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.14</font> per share with an initial fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">759,000</font> and paid $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">350,000</font> to the placement agents. As a result of this financing, all outstanding convertible notes were converted into shares of Series B redeemable convertible preferred stock and warrants to purchase common stock. On July 15, 2013, the remaining outstanding convertible loan notes, totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">829,277</font> in principal and interest,&#160;were converted into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 658,145</font> shares of Series B redeemable convertible preferred stock and warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,645,361</font> shares of common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.14</font> per share. The value of the derivative liability related to the warrants was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">674,000</font> and the value of the derivative liability related to the preferred shares was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">155,000</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> On July 25, 2013, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,132,875</font> preferred shares were converted into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11,328,750</font> shares of common stock. In connection with the conversion, a loss on derivative of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,035,000</font> was recorded in relation to the conversion. $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,518,000</font> was reclassified from the derivative liability to equity due to conversion.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> On October 17, 2013, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 23,227</font> preferred shares were converted into <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 232,270</font></font> shares of common stock. In connection with the conversion, a gain on the derivative liability was recorded in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,000</font>. Due to this conversion, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">97,000</font> was reclassified out of the derivative liability account and into equity.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> The Company re-measured the fair value of the conversion feature and recorded $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">11,882,000</font> in total charges to record the liabilities associated with the conversion feature at their estimated fair value totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">46,323,000</font> as of March 31, 2014.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 1.40 7000000 7000000 10016080 0.01 10 0.1 4999999 1645361 12499996 10894839 0.14 0.14 0.14 5491000 829277 4357936 658145 11882000 154000 112000 42000 1437000 191000 1246000 234000 196000 38000 25721000 0 0 0 0 25721000 10089662 0.19 0 0 0 0 0.19 0.19 P9Y1M24D P8Y10M17D P8Y10M20D 8416233 6451441 4049376 40000000 38425745 104146745 0.58 2072890 P2Y6M three to seven years December 2016 December 2018 June 2018 February through May 2018 392000 400000 20400000 20408000 22000 81000 104000 -312000 -52199000 -8773000 0 6316000 0 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><strong> <i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Patents</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in; CLEAR: both"> Patents are recorded at cost and are amortized using the straight-line method over the estimated useful lives of the patents.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in; CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0in; CLEAR: both"> During the year ended December 31, 2011, the rights to Biocontrol Limited&#8217;s patents were acquired by a business combination. At December 31, 2011, patents in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">493,000</font> have been recorded. These patents are amortized over their useful life through December 2026.</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 493000 1886000 5064000 1644000 3804000 674000 155000 4999999 0.14 759000 350000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>5. Correction of Errors</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px 0in 0in; FONT: 10pt Times New Roman, Times, Serif"> The Company&#8217;s previously issued March 31, 2014 financial statements were restated to remove deemed dividends which were accrued on its preferred shares and to recognize an increase in derivative expense due to adding several features to the valuation model used to measure the compound derivatives and changing from a Black-Scholes valuation model to a Monte Carlo valuation model. Additional paid in capital and accumulated deficit were reduced by $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8,464,000</font> to reflect the elimination of deemed dividends. Loss on derivative liabilities increased by $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,870,000</font> to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,428,000</font> due to the change in the valuation model.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px 0in 0in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px 0in 0in; FONT: 10pt Times New Roman, Times, Serif"> The Company also contracted a valuation team to review the purchase price allocation of Biocontrol. As a result, in process research and development (IPR&amp;D) was restated and a new intangible asset, patents, was recognized. For the Biocontrol acquisition, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">493,000</font> of IPR&amp;D was reclassified to patents. In addition, amortization expense for patents was recognized in the three month period ending March 31, 2014 and the three month period ending March 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px 0in 0in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px 0in 0in; FONT: 10pt Times New Roman, Times, Serif"> As a result of these corrections, the Company&#8217;s net loss for the period ending March 31, 2014 increased by $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,885,000</font> to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">12,029,000</font>. The net loss per share decreased by $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.03</font> per share to $(<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.07</font>) per share which reflected both the increased net loss and the removal of the deemed dividends. The Company&#8217;s net loss for the period ending March 31, 2013 increased $7,000 to $1,619,000. The net loss per share remained the same.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>Amended Financial Statements</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company&#8217;s financial statements for the quarter ended March 31, 2014 have been further amended to:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td> <div>reclassify its Series B Redeemable Convertible Preferred Stock from Stockholders&#8217; Equity (Deficit) to temporary equity due to the stock&#8217;s redemption features. This adjustment resulted in a reclassification at March 31, 2014 of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,021,000</font> of Stockholders&#8217; Equity (Deficit) to Series B Redeemable Convertible Preferred Stock, including the par value of these shares of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">89,000</font> and the accretion of the stock&#8217;s redemption value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">932,000</font>.</div> </td> </tr> </table> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td> <div>recognize deferred revenue and deferred costs related to certain sub-licensing agreements. This change resulted in an increase in revenue of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">104,000</font> and an increase in G&amp;A expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">33,000</font> in the first quarter of 2014.</div> </td> </tr> </table> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td> <div>reclassify certain warrants issued in 2011 as liability instruments. These warrants were previously recorded in error as equity instruments. This adjustment resulted in the in the recording of a liability of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">646,000</font> as of March 31, 2014.</div> </td> </tr> </table> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td> <div>adjust goodwill for the acquisitions of Biocontrol and SPH for acquired deferred tax liabilities and errors in previous reporting. This change resulted in an increase of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,685,000</font> in goodwill related to the Biocontrol acquisition and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,548,000</font> in goodwill related to the acquisition of SPH.</div> </td> </tr> </table> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td> <div>modify the key assumptions employed to value the compound derivative associated with the Series B Redeemable Convertible Preferred Stock and the Company&#8217;s 2013 warrants, under a Monte Carlo valuation model. The change in assumptions resulted in a $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,969,000</font> increase in the compound derivative liability and a $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">285,000</font> reduction in the warrant liability related to 2013 warrants. Loss on derivative liabilities declined by $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">655,000</font> in the first quarter of 2014.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> As a result of these corrections, the Company&#8217;s net loss attributable to common stockholders in the first quarter of 2014, as amended, was reduced by $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">408,000</font> to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">11,621,000</font>. The net loss per share attributable to common stockholders increased by $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">(0.01)</font> per share to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">(0.06)</font> per share. The Company&#8217;s net loss attributable to common stockholders in the first quarter of 2013, as amended, was reduced by $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">26,000</font> to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,645,000</font>. The net loss per share in the attributable to common stockholders increased by $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">(0.01)</font> to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">(0.03)</font> per share.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 1132875 23227 11328750 232270 8464000 9428000 1870000 -26000 7000 1619000 -1885000 -12029000 -0.01 0.07 0.03 -0.01 493000 97000 6518000 5035000 5000 Previously Amended Financial Statements - The Company&#8217;s previously issued March 31, 2014 financial statements have been restated to remove deemed dividends which were accrued on its preferred shares and to recognize an increase in derivative expense due to adding several features to the valuation model used to measure the compound derivatives and changing from a Black-Scholes valuation model to a Monte Carlo valuation model. Additional paid in capital and accumulated deficit have been reduced by $8,464,000 to reflect the elimination of deemed dividends. Loss on derivative liabilities increased by $1,870,000 to $9,428,000 due to the change in the valuation model. The Company also contracted a valuation team to review the purchase price allocation of Biocontrol. As a result, in process research and development (IPR&D) was restated and a new intangible asset, patents, was recognized. For the Biocontrol acquisition, $493,000 of IPR&D was reclassified to patents. In addition, amortization expense for patents was recognized in the three month period ending March 31, 2014 and the three month period ending March 31, 2013. As a result of these corrections, the Company&#8217;s net loss for the period ending March 31, 2014 decreased by $726,000 to $11,303,000. The net loss per share decreased by $0.01 per share to $(0.06) per share which reflected both the increased net loss and the removal of the deemed dividends. Amended Financial Statements - The Company&#8217;s financial statements for the quarter ended March 31, 2014 have been further amended to: reclassify its Series B Redeemable Convertible Preferred Stock from Stockholders&#8217; Equity (Deficit) to temporary equity due to the stock&#8217;s redemption features. This adjustment resulted in a reclassification at March 31, 2014 of $1,021,000 of Stockholders&#8217; Equity (Deficit) to Series B Redeemable Convertible Preferred Stock, including the par value of these shares of $89,000 and the accretion of the stock&#8217;s redemption value of $932,000. recognize deferred revenue and deferred costs related to certain sub-licensing agreements. This change resulted in an increase in revenue of $104,000 and an increase in G&A expense of $33,000 in the first quarter of 2014. reclassify certain warrants issued in 2011 as liability instruments. These warrants were previously recorded in error as equity instruments. This adjustment resulted in the in the recording of a liability of $646,000 as of March 31, 2014. adjust goodwill for the acquisitions of Biocontrol and SPH for acquired deferred tax liabilities and errors in previous reporting. This change resulted in an increase of $1,685,000 in goodwill related to the Biocontrol acquisition and $1,548,000 in goodwill related to the acquisition of SPH. modify the key assumptions employed to value the compound derivative associated with the Series B Redeemable Convertible Preferred Stock and the Company&#8217;s 2013 warrants, under a Monte Carlo valuation model. The change in assumptions resulted in a $4,969,000 increase in the compound derivative liability and a $285,000 reduction in the warrant liability related to 2013 warrants. Loss on derivative liabilities declined by $655,000 in the first quarter of 2014. As a result of these corrections, the Company&#8217;s net loss attributable to common stockholders in the first quarter of 2014, as amended, was reduced by $408,000 to $11,621,000. The net loss per share attributable to common stockholders increased by $0.01 per share to $(0.06) per share. The Company&#8217;s net loss in the first quarter of 2013, as amended, was reduced by $26,000 to $1,645,000. The net loss per share in the attributable to common stockholders increased ($0.01) per share to $(0.03) per share. <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong>3. Stock Options and Warrants</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> The Company follows ASC 815-40, <em>Contracts in an Entity&#8217;s Own Equity</em>, as it relates to outstanding warrants. No warrants were exercised through March 31, 2014.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> In connection with the December 2013 private placement of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 72,007,000</font> shares of the Company's common stock at a price per share of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.25</font>, the Company issued an aggregate of warrants to purchase 4,320,420 shares of common stock at an exercise price of $0.25 per share to the placement agents. These warrants expire <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 2018</font>. These warrants contain provisions that protect holders from a decline in the issue price of the Company&#8217;s common stock (&#8220;down-round&#8221; provision) and contain net settlement provisions. Due to these provisions, the Company accounted for these warrants as liabilities instead of equity.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> In connection with the private placement of Series B redeemable convertible preferred stock, which occurred through two closings on June 26, 2013 and July 15, 2013, respectively, the Company issued an aggregate of warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 30,040,195</font> shares of common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.14</font> per share. These warrants expire <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">June 2018</font>. These warrants contain provisions that protect holders from a decline in the issue price of the Company&#8217;s common stock (&#8220;down-round&#8221; provision) and contain net settlement provisions. Due to these provisions, the Company accounted for these warrants as liabilities instead of equity. The Company measured the fair value of these warrants on June 26, 2013 and July 15, 2013 and recorded the initial liability as part of the private placement proceeds and expensed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">759,000</font> for the warrants issued to the placement agent.</div> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> We estimate the fair values of these securities using a Monte Carlo valuation model. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following warrants were issued in 2013 using the Monte Carlo valuation method with the key inputs as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 15pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="clear:both;MARGIN: 0px:auto; WIDTH: 88%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June&#160;26,&#160;2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>July&#160;15,&#160;2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;23,&#160;2013</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Warrants Issued</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>28,394,834</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,645,361</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4,320,420</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0109</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0109</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.0167</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>160.94</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>163.08</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>155.24</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Expected term</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Exercise price</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.14</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> The Company re-measured the fair value of these warrants and recorded $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,929,000</font> in charges to record the liabilities associated with these warrants at their estimated fair values totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">16,311,000</font> as of December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> From February through May 2013, in connection with the issuance of new convertible promissory notes, the Company issued warrants to purchase up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7,030,387</font> shares of its common stock. These warrants expire <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">February through May 2018</font> and are exercisable at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.14</font> per share. These warrants are considered to be equity.&#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> On December 22, 2011, in connection with the Biocontrol business combination, the Company issued warrants to purchase up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,355,164</font> shares of its common stock. These warrants expire in <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">December 2016</font> and are exercisable at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.46</font> per share. These warrants are considered to be equity.&#160;The Company re-measured the fair value of these warrants and recorded a gain of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">87,000</font> to adjust the liability associated with these warrants to their estimated fair value totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">646,000</font> as of March 31, 2014.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> The Company&#8217;s warrant liability is adjusted to fair value each reporting period and is influenced by several factors including the price of the Company&#8217;s common stock as of the balance sheet date. On March 31, 2014, the price per share of the Company&#8217;s common stock was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.58</font> per share compared to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.50</font> per share at December 31, 2013. There were no warrant liabilities as of March 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in"> The Company re-measured the fair value of the warrants liability and recorded a loss of&#160;$3,149,000 to adjust the liabilities associated with the warrants at their estimated fair value totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">19,460,000</font> as of March 31, 2014.</div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 101000 93000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><b><i> Recent Accounting Pronouncements</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; CLEAR: both"> On February 5, 2013, the FASB issued ASU no. 2013-02 which adds new disclosure requirements for items reclassified out of accumulated other comprehensive income (AOCI). The ASU is intended to help entities improve the transparency of changes in other comprehensive income (OCI) and items reclassified out of AOCI in their financial statements. It does not amend any existing requirements for reporting net income or OCI in the financial statements. For public entities, the new disclosure requirements are effective for fiscal years, and interim periods within those years, beginning after December 15, 2012. For nonpublic entities, the ASU is effective for fiscal years beginning after December 15, 2013, and interim and annual periods thereafter. The Company elected to early adopt this standard which did not result in any changes to the consolidated financial statements.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 140000 244000 3078000 3078000 13336000 13022000 0 618000 314000 0 0 0 0 0 -618000 0 618000 0 -314000 0 314000 0 0 -155000 0 0 618000 314000 89000 932000 646000 104000 33000 1685000 1548000 4969000 285000 655000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></i></b> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <b><i>Prepaid Expenses and Other Current Assets</i></b></div> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.3in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Prepaid and other current assets as of March 31, 2014 and December 31, 2013 consist primarily of prepaid insurance and deposits.</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> -408000 EX-101.SCH 7 aphb-20140331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 103 - Statement - Consolidated Balance Sheets [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 104 - Statement - Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 105 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) link:presentationLink link:definitionLink link:calculationLink 106 - Statement - Consolidated Statement of Cash Flows link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - Nature of Business and Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Preferred Shares link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Stock Options and Warrants link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Stock-Based Compensation link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Correction of Errors link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Nature of Business and Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Stock Options and Warrants (Tables) link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Nature of Business and Significant Accounting Policies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Preferred Shares (Details Textual) link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Stock Options and Warrants (Details) link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Stock Options and Warrants (Details Textual) link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Stock-Based Compensation (Details 1) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Stock-Based Compensation (Details 2) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Stock-Based Compensation (Details Textual) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Correction of Errors (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 aphb-20140331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 aphb-20140331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 aphb-20140331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 11 aphb-20140331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0#X\2[1P@$``,X0```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F-]*PS`4QN\%WZ'D5M8L M];^L\V+JI0KJ`\3D;"U+DY!DNKV]IYT.D;DQ''AN&MKDG._7%+[R97`];TSV M!B'6SI9,Y'V6@55.UW92LI?GN]X%RV*25DOC+)1L`9%=#P\/!L\+#S'#:AM+ M5J7DKSB/JH)&QMQYL#@S=J&1"6_#A'NIIG("O.CWS[AR-H%-O=3V8,/!#8SE MS*3L=HZ/ER0!3&39:+FPU2J9]-[42B8DY6]6_U#I?2KD6-FMB57MXQ%B,+Y6 MH9WY7>"S[@&W)M0:LD<9TKUL$(//#7]W8?KJW#3?W&0-I1N/:P7:J5F#.Y!' M'T#J6`&DQN3=F#>RME_<&_2[Q9%W@]@S2/M^7>,=.0HB',=$.$Z(<)P2X3@C MPG%.A.."",YY;`0AU;"*V.NB MZDH1L_ON@C^R,K2G`QKT&FW>G48,/P```/__`P!02P,$%``&``@````A`+55 M,"/U````3`(```L`"`)?]=J>*V?5@^@8B)G:13'&HX< M85?=WFQ?>*24FV+7^ZBRBXL:NI3\(V(T'4\4"_'L)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]H MJ?B]SCSBIX3A363X8<'%#U1?````__\#`%!+`P04``8`"````"$`]6F^?;(! M``!]#P``&@`(`7AL+U]R96QS+W=O6 M.OM&ZW8`(>T*XP=$;=96:],J"1_[]T1CI$P"PR'R95)I1-=+Y/]FJ M[FWBLVB;LJE7;4]4K[)_O.M-+YHREY+_.#+!47:3KCYGL.MK[( MF6R+C)EMX>_?'7M_\]^YN_V^SM5]E[^T2KL?KN!OG3G82BGGDTI3*I>Q$++\ M]&0Q\HH9_UD,C(G5P!B50PT'4#IB%I..K:11Q9,SWHIVJ-=%&(-#72JT4@)B MH@F>';"$T-G&`C`VE8=VS\!`_3[_.,X:`N M#EZ;J!,F],S`(X3.;00SE(U_6Y*^G$2*R:&>,>B(H:X46B@@1X.R$9.8OG%^ MV5*#A4]'?OI%142=*Z%O!ATA=&ZE*6I=:C6`RA'4RX-`MP>@GC.`SYEE3/L& MG_QN'5ABWHG:3/]0,\'$4*-!R0`U&D#9"/)=`ETF1-1%+Y=-?E?)6@\V#J$O MP_"+C^;U!P```/__`P!02P,$%``&``@````A`)O(=!B]`@``,0@```\```!X M;"]W;W)K8F]O:RYX;6R4E5UOVC`4AN\G[3]$N5_S`:4?`JI!.ZTW'1JLO8S< MQ"%6'3NRG4'__8Z=$4X(H/8J.,&/W_.^YR3CNVW)O;]4:2;%Q(\N0M^C(I49 M$^N)_V?UX]NU[VE#1$:X%'3BOU/MWTV_?AEOI'I[E?+-`X#0$[\PIKH-`IT6 MM"3Z0E94P)-2[R)('89AY3QY%XSZ3$*%U_1$JBWQ/W3+XH1ZSR`K'E#F8*#G+"%B4S`@G M(J7)TF[5"!$C1/P)1+(@B#)`%.?U22%+`WILW#J1>?*KHH@R1)3A62U=RF^: M(0KXWIIR^3&*E3(GND"4$:*XGL`5/1%3*VIWS6K-!-4Z@:%*EFPM6,X0)<8E M71V*62B:4Z4@GF5!%,SB/MD85W%]N'%I9/H&YKE!<4>_$*4(F(H1N(2;HX@9 MT7#X7)8PW]J-'=Y_A2R(PD/`7(+RU"JP/CPH)57G='C5M#%$O>8\[R#TM;/; M]GA\@T&]%CUM1;(BKX@S@(G="^HUJ>/T_;`0WDEFT!FZ7IN>+PRFK2TLPA'# MXF!\#YLCN:>&,*Z3%=V:&G-PSE&O5\\8!$3,Z>3=:];S')Q8U(G^>/,><;JI M#POJ)/_1#O[O$Q9D7]9M]+`X-Y&#WM9_^`P``__\#`%!+`P04 M``8`"````"$`!='\IO\$``#"$@``&````'AL+W=OA=UD\MJ8[.Y:UNBRN0^KXX;^^^_GF>1 M;35M6NW30E9B8_\0C?UM^_-/ZXNL7YN3$*T%#%6SL4]M>UXY3I.=1)DVB41F;Z6H6B2I M19&VH+\YY>?FRE9F4^C*M'Y].\\R69Z!XB4O\O9'1VI;9;;Z?JQDG;X4$/<' M6Z39E;O[,Z(O\ZR6C3RT]&H*;G='=SUT%_JBM MO3BD;T7[I[S\*O+CJ85R^Q"1"FRU_Y&()H.,`LV<^XHIDP4(@$^KS%5K0$;2 MC^[[DN_;T\;V@KD?NAX#N/4BFO8Y5Y2VE;TUK2S_15`7T4#">Q(/U/?7^9=) M%CT)?%])@OF"^V$T08J#87592M(VW:YK>;&@]4!X$*H)B37``/F^LR^$> M!P(8HH`$ZU'<+^Y5K`(KL==Y=CB@S\.':3HE\1@1NA22C"'<&R!$+'3!=+$* MO+&A,D,.0B-O.X1@\ZJ\Q>9`H@T0)4`[78D"0_?K2HPT[1"R[!J`N0O7-9(4 MZP`..Z%Q/=&O1TR_3G3#RINN6X$-W;?"=.7=(21XK%L'W-.M7_]$=_`5W0IL M5'XQ-!3J1HA6>7,@T09(!L.O*%%@(X.^H00AUPPR4CI<0CHB6(P!"04$RX?5 M5]:L;5F?+W8%-K0'AG:$]-H#'NH3HW8=$;)Q7RT*;&@/ M#>T(0>T\\")]8M2N(YCG^R-$0A!\$1`(4<_`?J>GOD,;^D>NH!@W-@8PX[XW M3F[<\_08YGG>.`8#P[V($-$HE*],;B"&+@0[TVT'OKD0KL,>HRW$T4BBCU`Y MRCFFRT&?T;?AR-A%=PPQ?<*B,!PG+":8:-SS"0',%LLNZ[>9:`C*8*:'@'9$ M0C`]C2'&[[;DVZS8TOW%/C[/'8>74`BLC,=+DBG3F2X>+8J(-VVP8]S8#\0C M02^>;A5=>$E_>X_@M-UIWI7O3)>.+D6DFTZHCL:W]?B@=0@&#L)WEB.!^)PM M'V_G3'G4]"#0T4@0IBUVC,.FPICGCOL[-D#!@FQ[?25PLKX2`(E(J]%:*/_2 MPE`G:0]VM\_MB:'KD7!,;^TQUW:_XS]Q#[G;<0F]/V#$)&@,RL>^'@.Z'XG! M]%B&&#P:SA@+^/@$$!N@^R4A1('/74)$PU'.IH7S/Z5`']0W^LBT6X88?:,W M1Q(=0^1PPSVG=4AW%W71R'31'@,FJ!Z]9N[<-?(?CQ'&RD]&B."VK&@8AGVJ M,!:PWC_/+D<;)4UBVFB/P49G$9P&?#\P-M>8@`(X)D9PX*:G(O5"X;:+,1=V M*!;ZMX`Q''QE@`_#I:B/(A9%T5B9?%.O`SBD76'< M&2[`&X1S>A2_I_4QKQJK$`>@=.8)W10*> MXMPY@`]2MM<_:H+A[=/V/P```/__`P!02P,$%``&``@````A`!7'`:&P`@`` M60<``!D```!X;"]W;W)K&ULE)5=;]HP%(;O)^T_ M6+YOOC\``56AZE9IDZ9I']?&<8C5.(YL4]I_O^,86!(Z1KD@)+Q^\YSWG#CS MVQ=1HV>F-)?-`H=>@!%KJ"QXLUW@GS\>;B88:4.:@M2R80O\RC2^77[\,-]+ M]:0KQ@P"AT8O<&5,._-]32LFB/9DRQKXIY1*$`.G:NOK5C%2=(M$[4=!D/F" M\`8[AYFZQD.6):?L7M*=8(UQ)HK5Q`"_KGBKCVZ"7F,GB'K:M3=4BA8L-KSF MYK4SQ4C0V>.VD8IL:JC[)4P(/7IW)V?V@E,EM2R-!W:^`SVO>>I/?7!:S@L. M%=C8D6+E`M^%LW6._>6\R^<79WO=^XUT)?>?%"^^\(9!V-`FVX"-E$]6^EC8 M2[#8/UO]T#7@FT(%*\FN-M_E_C/CV\I`MU,HR-8U*U[OF:80*-AX46J=J*P! M`+Z1X'8R(!#RTAWWO##5`L>9E^9!'((<;9@V#]Q:8D1WVDCQVXG"@Y4SB0XF M<#R8A-&[3>*#"1S_FD23-$RS_Z/XKJPNI7MBR'*NY![!Y`&X;HF=XW`&SC:> M&$)^.Q[(Q:ZYLXNZI:#6T-+G91).YOXS]($>-*MS3314K-]0Q">)#WPG2,BM M#WD9SHJA"(Q.@2]"P,"L.D37*[=BH>U1_GXSDZ3=6V+TCP*@R`8PJTO2@9TD$6?[KKQ ML8O&E/D08>4TCC(!0OL92M9.TD4X8,J&3)<3L^(QRWB4G<:QQ),$0DM&`[5V MDG.6_#TL5CQFF0Z+7CF-8PF#)$RR7XO(/````__\# M`%!+`P04``8`"````"$`_O9OT$`$``!#$```&0```'AL+W=O]`>%^A`7$TZF9T,G>;["67S>[>,T*K M9(`V=#O.?/NK[@*$`CUF7T3@W\6OJZK_T,LO;WEFO?)2IJ)8V6SBVA8O8I&D MQ6%E__SQ_/G!MJ2*BB3*1,%7]CN7]I?U'Y^6%U&^R"/GRH((A5S91Z5."\>1 M\9'GD9R($R_@SEZ4>:3@M#PX\E3R*#&#\LSQ7#=T\B@M;(RP*,?$$/M]&O,G M$9]S7B@,4O(L4L`OC^E)UM'R>$RX/"I?SJ?/LQ>7/,DV^I06';$.==`5V0KQHZ==$7X+!3F_T MLZG`/Z65\'UTSM1WC@G)/849Z8HOD_8G+&#(*82;>5$>*108`\&OE MJ6X-R$CT9HZ7-%''E>V'D^G,]1G(K1V7ZCG5(6TK/DLE\G]1Q*I0&,2K@L"Q M"N(%HP?[U6`XUH.]"0O<\/\!')R,R3+T3?O)NG+!S7:NPPA5VF^RQ:3%D>N@_:H&9J M6"A$?4_;3KL]9Q^!T&(*<6U[;`K4#$/4]RB$?F^U5O;]3&AQ%R*@*=^@9ABB MODA6#0E.-38=04@QC$IA+=;='[FD[#,&U]HXME MU)3PZD_8,I4("6$!/;R(RB7+W70.6M+JZH"2.] MOJVB#$!I)VPE:204^B?\-N^=P*6FRU`T'USEU?,;P#U+3EPJ26;T"O[!M`M-V;$CD>6K._+@4M]V82^"73+F1FQYI%` M?8\.7-*W&Q,:/J-N-S9&&1)TS8`X]TC&`0MGY(6U82@:0L`/GTHPT.O$R4=" M#5@ZHY;.:M]NK5#6LZHAT=7S.@GTB-^/8S6CB'LQZEZ5"/K]ZB:,N,FV$=$7 MD?;^C$Q%;_YTG%;OX5X.]RLY+P]\R[-,6K$XZWT:`[=NKC9[R$>SA72: M&["%.T4'_G=4'M)"6AG?PU!W,H,2EK@)Q!,E3F8WM!,*-F_F[Q$VZQP^P=T) MB/="J/I$U[79_J__`P``__\#`%!+`P04``8`"````"$`X==$NTL#``!B"@`` M&0```'AL+W=O(>[7`+_Y24-4C`)3OXO&,8%7U34_M1$,S]!I'6 M50Q+]A8.6I8DQQG-CPUNA2)AN$8"]/.*='Q@:_*WT#6(W1^[JYPV'5#L24W$ M4T_J.DV^_')H*4/[&N9^#!.4#]S]Q82^(3FCG);"`SI?"9W.G/JI#TR;54%@ M`FF[PW"Y=F_#918&KK]9]0;])OC$M=\.K^CI$R/%5])B-)-,.:U! M`'PZ#9%+`QQ!C_WWB12B6KOQW)LM@C@$N+/'7-P12>DZ^9$+VOQ1H/!,I4BB M,TD,ZL__1^\F2ABI>?)JTMR$"V;`*=Y$:>6A*W"J&4L#=S9A4PK&)*`UY84PU[[MX^R M"?:#($LRD@,P!)O-`IC!G`PO?/()OL&:SPMPJC MV6H7,JU@2)I/)5U.6C9=2EIA-$EV(=,*AJ3%5-+EI&63[9*=M,+,^Z3#=*[' MU._FG0$(X1RTED)F`-)0!Q@CR+/9>F9='D$VV2,\[\]>X59A-%?M0J85#$GI M5-+EH&73I:`51I-D%S*M8$B"4_4_;.J[;)_LJ,\@M:OC:STH%;4!2%Z(V@"$ M46(L%S6&.M+58=5@=L`[7-?E1'M<1K+.Q.KY*W$;RH6[5M^$2CA:H^^,? M<,)WZ("_(78@+7=J7`)EX"U@'S/UCJ`N!.WZ(W)/!9SM_<\*WN4P/%L##\`E MI6*XD#<8WPXW?P$``/__`P!02P,$%``&``@````A`%9)%#RG`P``R`L``!@` M``!X;"]W;W)K&5"5KQ-0S*/PX"U.2^J]IR&7[\\SQ["0"K:%K3F+4O#=R;#3X>??]K?N'B1 M%\94`!9:F887I;I=%,G\PAHJY[QC+;PIN6BH@D=QCF0G&"WTIJ:.DCA>1PVM MVM!8V(DI-GA95CE[XOFU8:TR1@2KJ0)^>:DZ.5AK\BGF&BI>KMTLYTT')DY5 M7:EW;30,FGSW^=QR04\UG/N-+&D^V-8/=^:;*A=<\E+-P5QD0._/O(VV$5@Z M[(L*3H!A#P0KT_"1[#*R"J/#7@?H[XK=Y.AW("_\]HNHBM^JED&T(4^*GOYB M-7!B4CU7:#(,\JM4O/G'B`@"6B.+W@A\]T8(F9-EO/Y_ M&Y'AT4=]HHH>]H+?`KAHX%%V%*\MV8'=_SX/,*#V$<5I"(4`J!*"^GJ(]]$K MA"WO%4>C@$^K(*XB&Q08>6"P(!"9Z2`H1A",#I(=S<+8;^+Y-8I$4R_)9KVT M[QT,B,%T#!2GX7)TVH6U:KB,PMP(!,U&"XY?,#+=+XKA!HW\?C^-\6L4<+5L M'E8N638H_#S`GND@*'9!UJZ;HU&L=-BW"2'$(\T&@<^Q_@@'BEV.C<=A%,A1 M'F8SDLP6<#%+O,(SLG6UV:#UD38?04*QB_3@NCD:!9S?YL@'&10^"/X532Y: M%+L@Q*]:(QF3$+]L!XF/LG51L"\NH"7_N(_@)@_)*]>CD8P*QRRL]44B#\EJ ML5JMOV]R:HD`P/3X:+5'XY=QKW$BY%]DJ_%#1+#E34Z75GLX7NT>>XW!.9F0 MN)\U&<'AG3.QT6O\R) MT3B)\NHNLYJ[T'RH"9/[+NQWDF.O,>TOB>^:GWU_AP(G&$<&ZVH9;^>P_./2 MPJ'$JZW$+_=>,PY2XM>[U5@R,R>9X:%AXLPR5MK=I#K)RS[ M`D:BCI[9[U2$-#.X(=O````__\#`%!+`P04``8`"````"$`N)<4V*$"``!C!@``&0`` M`'AL+W=OGEVC`%K,4:V<_O[CNV$)'MIM\T#8#ASYIR9L3._VIX@??\76DG4@OZ32-Z>%"/)9@]U MIS1=M>![EXPI.W+[Q3-Z*9A61E4V`CH2A#[WG).<`--B7@IPX,J.-*\*?)O, M[C),%G-?GY^";\W9,S*-VG[4HOPL.@[%AC:Y!JR4>G30A]*]@F#R+'KI&_!5 MHY)7=-W:;VK[B8NZL=#M"1AROF;E_IX;!@4%FBB=.":F6A``5R2%FPPH"-WY M^U:4MBGP*(LFU_$H`3A:<6.7PE%BQ-;&*ODK@)(#52!)#R1P/Y`DDV@ZF8RS MZ?5?64A0Y`W>4TL7NA%,9L!\=!9T#%Y?LPH>'S6*'M.Y(,"=F1CEV<`?%`2,GX,+7Q!U[LLES&`4_^S/!<&X MG"4BKGU,;@/V!RKR:-K]-I?A)\ MH2#['P4NZ*F"4X>#@H`!'<.HC=/14+2@(6SVL!B,ZCE%83&D=N..IP286%5[W?:2EG8W?ZQ@<.< MP[Q"NS"JE++'A3N'AK^'Q6\```#__P,`4$L#!!0`!@`(````(0"@G8&MV`<` M`&DE```9````>&PO=V]R:W-H965T6Z)D^8(DB[5(M@NT0%'T\JS8?_[I_K6LOM;[/&]&$.%4/XSW37->3:?U9I\?LWI2GO,3?+,K MJV/6P,?J>5J?JSS;MH..AZD(@F1ZS(K3&".LJB$QRMVNV.2RW+P<\U.#0:K\ MD#60?[TOSO4EVG$S)-PQJ[Z^G.\VY?$,(9Z*0]'\:(..1\?-ZLOSJ:RRIP/H M_A[&V>82N_W`PA^+3576Y:Z90+@I)LHU+Z?+*41ZO-\6H,"4?53ENX?QYW"E M8S&>/MZW!?JGR%]K\O>HWI>OOU3%]K?BE$.UH4^F`T]E^=50OVP-!(.G;+1N M._!'-=KFN^SET/Q9OOZ:%\_[!MH]`T5&V&K[0^;U!BH*829B9B)MR@,D`#]' MQ\),#:A(]KW]_5ILF_W#.$HFLWD0A4`?/>5UHPL3?P72:$-A4&$ M#1)!]O9[<7.0V`:!WY<@R206L_GBEE0@Z59/TD41$[&8A;/D?4%3+$Y;:YDU MV>-]5;Z.8`*#_/J40KB#RI&*:7)JQ$`'Y>PR9+=XRZ4"YC-`&FH/$J%#I)A?;/ MHHL>0S9Z+E'7"-!,A)M(RAGSP*5(3A&12U&<$HG$Y>@^SNS*<43#M!TNVI!A MD9!J+_P>(F79=C@,HV`>!)[(U*$D\8PQ)&4`81$QBD(*KFHS$S0!'(&PI*A` M,WTCN-*\W5TSR!4*B_%:P';JK9$3!JW4NV`2>%U(&<%KI?0)B5=,A00BD@". M2%CY5.3;X@S9%^?EOD9.@FT,1,@:D"*CRTW2(?.>OBM_A":`HP:N,L/5&+*O MQNL44E","$(CQI^32"%JZ)@P6WT9LBLO\E;^&BFH;@[NS%)+D=&E)M\=HOPA MF@".&KAF?:!K[2A75RP\LUU;DNU;F`@^N5*7TVL`#B69P:)E%5*6TY5(4\05 M;"R?3-.W^Q?B!@$,Y;JIB"-O!:TMJ?O?4X9(ABB&:(JX.1L3'YXS6KZ;L[=[ M6H=(PN8L8[%@14TMI9,E&:(8HBGBBC"N/%P$>C@5$47>+FH=(JG+,&6(9(AB MB*:(F[,QV>$YHR6[.7O7LI#8=KMW2!DB&:(L@MV*EF+)NJ7I(%>#L=;A&M"( M70W>7F1M;JS@LD;K[B.2<11#-$7.%P# M.B;5$/,E2VS5BO`1&?J(8HBFB)NS<;KA.:,OTIS9;4R('*Q7*(*>U9+`DO&6'8WJ2*_/V%)=E%LS![=F_;E%H*%8&1 M.T0QCJ:(*^(FKQ; M^4'/[!HW3RB\AJ7O,J1E=.50#-$4<;49+QU\61;HO/2R'$?LNH4D;$:\=&P, MK<6&Z3*6#%$,T11Q-7B6/K`_W-KCR'_&(I!DUSPWC]02J!3?_!7C:(JX4HS% MDG8,E(+&[+;%?R`AD(12EE'/_:QE4"W,\1E'4\35)J M\%Q\V)2*>MQ<^`^`+`FUN/M57.B60*5@W`Y1C*,IXDKYD+E'?>;.I"`)I<3+ MI&>IVSA=ZI(ABB&:(JX88ZIDJ;\SM]""W27N/]F)D(0BX*42]W;+H!IP3()J\=Q\X%KOL(R1UF:8,D0Q1#-$4<7/W M7/R=]<#=F]V81]2\PUG<5W_?K*4=U.E4#-$4<35\R+ZC'OMFWF=)75XI0R1# M%$,T1=S<;[+KB-LUKS]RR[L[2!.YV*(9HBCH;8\^MA\[\=Y?EV M[-^Y6E*75\H0R1#%$$T1-W?/I]^>_S'W9W:?9#GV1>^BK_X.Y8Z_P9&6T,E6 M#-$4<25]R*_A.`J[C^5O=I%D;YS@OLGK5VJC=(E+ABB&F*,PUR>H*`5/MN!I MBV->/>=I?CC4HTWY8DZM"'@VCC3E\$X]F`!Y5Y;- MY0,<=IA>#TD]_@<``/__`P!02P,$%``&``@````A`/MBI6V4!@``IQL``!,` M``!X;"]T:&5M92]T:&5M93$N>&UL[%E/;]LV%+\/V'<@=&]M)[8;!W6*V+&; MK4T;Q&Z''FF9EEA3HD#227T;VN.``<.Z89UC1"SF67"72(6=L#/F-^-"0/E(<8E@HFVE[5_+S* MUM4*WDP7,;5B;6%=W_S2=>F"\73-\!3!*&=:Z]=;5W9R^@;`U#*NU^MU>[6< MG@%@WP=-K2Q%FO7^1JV3T2R`[.,R[6ZU4:V[^`+]]2696YU.I]%*9;%$#<@^ MUI?P&]5F?7O-P1N0Q3>6\/7.=K?;=/`&9/'-)7S_2JM9=_$&%#(:3Y?0VJ'] M?DH]ATPXVRV%;P!\HYK"%RB(ACRZ-(L)C]6J6(OP?2[Z`-!`AA6-D9HG9()] MB.(NCD:"8LT`;Q)_ M_/QY.1`R:"'1BR^?_/;LR8NO/OW]N\*1R5D1SBB!4-?A.K ML$S(P5SX15Q/*O!T0!A'O3&1LFS-;0'Z%IQ^`T.]*G7['IM'+E(H.BVC>1-S M7D3N\&DWQ%%2AAW0."QB/Y!3"%&,]KDJ@^]Q-T/T._@!QRO=?9<2Q]VG%X([ M-'!$6@2(GIF)$E]>)]R)W\&<33`Q509*NE.I(QK_7=EF%.JVY?"N;+>];=C$ MRI)G]T2Q7H7[#Y;H'3R+]PEDQ?(6]:Y"OZO0WEM?H5?E\L77Y44IABJM&Q+; M:YO..UK9>$\H8P,U9^2F-+VWA`UHW(=!O-29#`P<7""P68,$ M5Q]1%0Y"G$#?7O,TD4"FI`.)$B[AO&B&2VEK//3^RIXV&_H<8BN'Q&J/C^WP MNA[.CALY&2-58,ZT&:-U3>"LS-:OI$1!M]=A5M-"G9E;S8AFBJ+#+5=9F]B< MR\'DN6HPF%L3.AL$_1!8N0G'?LT:SCN8D;&VN_51YA;CA8MTD0SQF*0^TGHO M^ZAFG)3%RI(B6@\;#/KL>(K5"MQ:FNP;<#N+DXKLZBO89=Y[$R]E$;SP$E`[ MF8XL+B8GB]%1VVLUUAH>\G'2]B9P5(;'*`&O2]U,8A;`?9.OA`W[4Y/99/G" MFZU,,3<):G#[8>V^I+!3!Q(AU0Z6H0T-,Y6&`(LU)RO_6@/,>E$*E%2CLTFQ MO@'!\*])`79T74LF$^*KHK,+(]IV]C4MI7RFB!B$XR,T8C-Q@,'].E1!GS&5 M<.-A*H)^@>LY;6TSY1;G-.F*EV(&9\F_W4`BA;JI)6@8,[F3\N>]I!HT" MW>04\\VI9/G>:W/@G^Y\;#*#4FX=-@U-9O]2!=(.SB"QLD.VF#2I*QIT]9)6RW;K"^X MT\WYGC"VENPL_CZGL?/FS&7GY.)%&CNUL&-K.[;2U.#9DRD*0Y/L(&,<8[Z4 M%3]F\=%]KC.A@#1DA@EV=._ M[]CC!8\)A_0&%G@R?CWVS.OU[-M'M??>BJ8M93WWV2CTO:+.Y;JLMW/_[[^> M'L:^UW99O<[VLB[F_F?1^M\6/_\T>Y?-2[LKBLZ#"'4[]W===Y@&09OOBBIK M1_)0U/#+1C95UL''9ANTAZ;(UOJA:A_P,$R"*BMK'R-,FWMBR,VFS(M'F;]6 M1=UAD*;89QWH;W?EH?V*5N7WA*NRYN7U\)#+Z@`AGLM]V7WJH+Y7Y=,?VUHV MV?,>YOW!HBS_BJT_G(6ORKR1K=QT(P@7H-#S.4^"20"1%K-U"3-0:?>:8C/W MO[/I2C`_6,QT@OXIB_?6^MMK=_+]EZ9<_U;6!60;UDFMP+.4+PK]L59?P@7^:+QUL]]V?\OW7HMSN.ECN&&:D)C9=?SX6;0X9A3`C'JM(N=R# M`'CUJE)M#_EKV\GJ7X3TC(Y! MN`D"[R8(XX.#"!,$WD]!^#AF<7);2H#3TEEZS+IL,6ODNP=;#X2WATQM9#:% MR/UI@7PH]KN"]2,PXQ;6\FW!^2QX@_3G!EGV()18]1#BB`0@ZZ@-TG6_-@7/ M_+\X!3OB$CKR$I$$Q4%W#YW<&'T8Y\1<[FQ,M>:[][ZFG<5U[<`P.+A(XX@,;@2B M(2`3,IV?L-@!L;C MGD(E!&?1Y>;/!G5_33MKZ+9_PZ`ZIO<8[30K0O!((4>"IM#I_M>MB9VW?>&V M?<,8<2'ORYW=^;F8L,OR!O5^=M[\H].\3?^PFKW9[=8W-#=._[_O7,'.C2!R MC<`PIL`2P7O.%I0)TRM9XHX57%]$3=,=%KD68!@4R$.F5LC)Y(HP+!FGEY>1 M#[(!33L"71LP#`H48=K3Q:XB9*'Y(!O0M"//M0'#H+QD$M,.BON.,F%*ZY@* M'&0#'-LWO!Z[;.3:@&%08!K&8M*SP+8-)(*)*POLV(`J%:8VR(VMB'Y`E+I^ MP)%!I2SD1(3)I(VDX>56K/Y7O=].-4W/DI%K%(:QW,K^ABZBXP,J1RD(NI$B M/,B3%+E^P.W#/AOW=9.K")4YR!'XN2-$KB,8QM1J/$[[SAPN-.:DI*G$0:[` ML;_;&8R=7K8TC-ED8T&VD-ED&*8?H?(!VAA%?(2+5/\CWEX*F:<^+7<\PS)?(*(0&<&8:%.(Q:Y[&`8O12X<@@ESX1",-W]XIW7(ML7O6;,MZ];;%QO0&HY4>3=X M[X_B/P```/__`P!0 M2P,$%``&``@````A`*T[A+II`P``]`L``!@```!X;"]W;W)KV`"58!(^PV M[;_?,28)-@E);T*`UR^/S['/\>K^K2J-5]PR0NNUZ5J.:>`ZI1FI=VOSS^^G MNX5I,([J#)6TQFOS'3/S?O/YTVI/VV=68,P-<*C9VBPX;Y:VS=("5XA9M,$U MO,EI6R$.M^W.9DV+4=8-JDK;FP;&_QH'E.4OQ(TY<*UUR:M+A$ M'/A901IV<*O26^PJU#Z_-'@O MP7LV^&^P@NZ_M"3[3FH,T88\B0QL*7T6TF^9>`2#[='HIRX#/ULCPSEZ*?DO MNO^*R:[@D.X`9B0FMLS>'S%+(:)@8WF!<$II"0#P:U1$+`V("'KKKGN2\6)M M^J$5S!W?!;FQQ8P_$6%I&ND+X[3Z)T5N;R5-O-X$KKV)ZWW8Q.]-X'HR\1:! M&X3746PYK2Y*CXBCS:JE>P.6'H"S!HF%["[!683'AR"?#P_$18QY$(.ZH:!F MD-/733!;V:^0AK27Q&.)IRJ2,PK_*+$![\@(8=,99Q=3>&`4@V`NIG%B#([V MW31B*8FZ"=6B#6LN?K96$I"&;=9`&$91J:+;3*M4?`@E,)L8:WT/"D M1.*Y"R_P`]@AJB:9UBAXX4?PA%C#B]1/QU(RC3>M4?#F*MYM&U@,4C%#;>W' M4B)+HMCTR>"!`B`ZY87$&M8VLJ)I:1/ MGUSZ6NB228D"![-3@C=-UZDUO%/)E#6MUTB^Q2*(HKFV/Y))B8JG=8+*B M0U$ZEMQPU!:D9A)O2J+BG6D,U^NN.^X,H=X9>DV?9=_WPW&%TS2.!R>[TTI0 M046A'NR1*W&495V)H]X97*D9;,_A$_7C6OF_K4+`F6RT%?0^T&MD`W6=,PU4 M441G&J@\M\D328-V^`=J=Z1F1HES6$2.-8="W%&G`N/Y_7-?P```/__`P!02P,$%``&``@````A`&W@?1M> M/P``<-\``!0```!X;"]S:&%R9613=')I;F=S+GAM;.R=V6Y<29K?[PWX'0X$ MCD<"DBQN(JE>:D!14K7&JBJ.R.I"HS$7R.+%\^Q;?^=4_?7\]+MZ6\\5H M.OGU@YVM[0=%.1E,AZ/)FU\_^.;\Q>;1@V*Q[$^&_?%T4O[ZP?MR\>"?/O^/ M_^%7B\6RX-W)XM M]H>+J[)<7H\_V]W>/OCLNC^:/"@&T]5D^>L'AT\.'Q2KR>B/J_+$?]G?WW_P M^:\6H\]_M?S\V72PNBXGR^)X,BR>3Y:CY?OBY<3G9]N_^FSY^:\^TU`?OE=\ M.9TLKQ8,'9;#YM,O^_.M8F^G5^QN[^PW'Z:5LNF+W[\:3^SQZ_ZUV5SU/'U;#PZO1H53T?3Q6`$@,M%<3*=SYH#PW0G'';> M'W/(8?E]\9_+]\UQ)ZOYG#'%B]%BP+C?E?VY3EL\ZR];BXM:?M`:>S_NBC>+L_?7%=-SEO/15(34#:^T<`!N&/X"(EPT5_R7G>8OS;<--9WO5KM]5BX& M\]%LV4'+I_/R[6BZ6HS?%S:^'(+S27\R&('VLR78U'D7Q69Q?E5&G/WPYW]; M%'!MM?CEBF_!X!PJ_#5:E7^D,CN$6)E.+0EV5_N1+M M\&C)F=_VQRO>8]WKZ;`<%ZN%[_F:F1EG8P;0,F*%K:=5%FQ@6`RN^I,W(N?+ M^?2ZZ!=/Q_W!=YMG@ZOIF!6:4VLS)EN`='\^GC8';!7'[%5[89^S_FBH@PWZ ML]&2O[4<0%I=K\8&UF%Y.1J,ED4.\>%JP.8OWA<;1[W]@_W>]O:V`^UR7`Z6 M=I1R/+H&<7;@Z64+)5O%J^EB(2Q41RW&H_[%:,S&.%.$N2^STSLZW([+;#SI M[>\>V5\!](*O@]@32V7R*`%WH)P0?%"C8#J&/ M\71F[/_PY>GK_]2_GOWRV:/B7=\&.BT;$HH)&QA-4&IO1A=C%EXL2B:>@198 MJ1?>"'0ZW"I>3.>VWVI+(/*/J]'"4-TK-O:?[!G4P$=:.,XR9O;1YT7_6B+W3W[T2/QHM[BC.)4SCA&54+&\FI[RP5P-XP:%X&2P-IO#S0%L&1IHO:`B3-I-R68Q%>=JW'MZXHV'IC.]$ M>+A[D$AP9Z>WMVW0=-)*\S*?BQ(0G;^\O;6]H\7"0UATXR&_'3S*?G0QA402 M%XG!IH!,FZR8(:T3@64B#[;UXW?PV3W%<:>TC<#ZXZH_7W(&\,?V&NBK!,3E M:LZNYQ",#UQ.?P$/#)S$WIOQR MS_Z)R$-D+,!F\1SBQL1Z^,Q%U",3M24B=-Z?OR]*?YJ)B(5TNI$!`I]Q)IRB MG!8>1S#P\`^KQ=*XTSF9@\+*XNMP@%%@_OZR"0%PL+'3V][E_Q"(_'67#=\3 M$A(L@_'*^,?H%XM*\K^L&"!H,NWFZ(EM)1*+E%\91;+>[H1(FF[CR=ZNWM_2 MX8,Z1!VXOD1MEQ.6U=SIQ\%T@5*=EZXZ(/(!",6`+A:KB\TQTG.R$./WWR`2 MS"`(4`_"NP;QNMZ-RQF,MUWE:.F&>O["Q.EQTLT:ON=2CUWHR)>C.1Y!I&2> MR[ZV$T;ZC'M^UY_+4D87N5W"!(S=00XG304Q3["GS>I?F"1``*7WS."85?:- MH#@7YS`30$0",54@T\8\ZRE19PA'\?D$4([1SS:E4Q_LN[1B"?ZL\^I6(//B MS70Z?#<:8ZT$<9@I#'LOUR5`^^ST-S;4ALEJ2IA?]K]/&Q!G"S=V1JGR9.1! M&L%NOQOB=9"=WL'18R-C)DH;SFA,$,GW6>D\VP43/-YW<^&&";*#&^>>_F9+ MAMKH\KU1S7?E>^G?E0L-L(:G-'T/`*!QYQ?MHL-^TUM3K&#)\W>C(,_OR?-V M#,V?:S)(<2^16@^G%*D($:Z MCACM-D`DCBPV=@/"H)"5:>+X=F"-1"GO9>HLG/H)'B&3L7QWIB<=>'T7*KK.C] M;:=/6058%@>N04R>8`0&BZ4R'NZVF7M:'[Y:3F%IY2!NN@ZV=_/!:[B^VQF(Z'@V-+Y_VQWBJ)Z7=K')@>:Y?4%FPXA+@@) M&323X8Y_U`KGO*SWL=,&/^E2'^R)H MX>8&'6--#[!%-#ZL&^F1+J.(1C4W5TDT-^N_-_%F0CR$22*5-5_"Y*Z9@W)X%&-U.DV(3`SEYO;R\8GI(#_+V]:T[$7:>ORX%'+5C)APL:]__\Y8?_ M\K]_^*]_B3;T0ZQ1Q:I:+Z'5%-,UZ!$'<5^\`M^^*Z9U\-LYVNT]WGO<>WRP M^VD@V#Q3(QJWB2(,T;CFR%,D/X\W8[!NT\)8>``HD["WYBNP=S.6UQSB!)K; M,G>&;(NV"9E'USZCYB8%B[!^U'HWZ>W?GQ*K)\J$ATNRX5_7Z?$<(,]*=A:4 M6`]2GXW=/=;^CK-P5Z^(FI%_82P0AM,0!2!")`^<#:?C<7^^N(7Z$ML6#ZMW MJB#0+6^WV+N)RSJIA^'.\'<:F@F$YO@NQ-XDIG[_I6GX5B[J/(5H!+_E>T`* M+^*`6IY@6/S6PAFGV`9GBLG?$4[M6>WM17&<1&'S0&M?>6D._YV'WY`=:B_Q M*A.>IR;8)3R;:YVZ;5*L@V%.Q`U"#6]FU-5!4YGUFV5G,'2^QOXSR;[6#M[9 M-2?S+GG+O>:Q7GO0J/GSJQ09"F&>Y@`7,VL>ABVCB==9*Z_7!.";RWQ13BQW M(][N#\E?6+)4%FESI&](QC+`NF%ERW)8TB:,Q>]HSO6U&>\XVM-KB#V>H86T M+Q1'>ZC@]:/U>9/FW#EM2$%/ID0'AF1CE;UN#L;()D5&="SLP>S^YJ!PTJ0Y5UP#L^)6S[SYKD2+249<=@)?9/^Q9'[1')56 M`,EA^&9QT5^,!H4%&0'C>*6P3L9I-\CQ;\O1FRL-)W,Y[Q.!F:S,_P$I04KS M+T@@&2HUVVS]ROYRBUIJBK+.XJ\K*Y-1[*8[Y"XF.,NLK7]LQ]O7>,I&(DUP M!L5D,ZX7:U5>,I@Z9#`]+[E.$KXN%6`&KL_[\PFLN%@[^1W/G0ASW8HA7(#G MO91UG(("N\TCIX&BD("G6U\R`&U"9QP)BS-3FR2M:N?/K*!0K9#+-. MDJN#:U@+0,IT?0)$J(EHLX\.1X-2F$6IB.8/=G:'Q22:]"1PW+'"? M`V9DUWS-+0^@%X5/@#4_-**;/_[-FT[H8F!J*3BBZ=^7\\$(BF\NMF;8C3,[ MJ9(?4,G&T#.'*ER9OFO-OG[H32ODV*D);/%%)*@:$JUEOZ6!&6DU)=KZESS`D.1EJZIMW>PDK]:_=))'HS"$ZB%5HC2AFLR"_(T.J^XX)9(EI7!T MQ&SPEI)VE$61[Y[$R'YC)HW2,PL66YD0ZJ,R-:NMM4R6FVMJFB=IB^IE.;B: M3,?3-P2`!U:ZR[&(&&XL-VR9B?$_)2$$3@LAR?(L6[,Y)8.*.D4=KKI3,8H48UZI(L^*; MKXI8;D5C\Z4F53J0Y&54J&^^WZZHLQ$E7?FPXPHY,125M$S=J8<7T'PE/0? M)FI0/+LCQAN#U+DZ;6EH53:&5@ M>$@TH/CAS_\3'V]&+?8/?_Y?7L^HF,9^$!#5NHPE%[_A:B`A%+X,JC MG2='3T(1@T9-R)47Y_WYFU*O*BY#4-=KT<.B5ISXHKR84Y/VW@IS>C>_$"H? MV`A^@\T/R=UVM%I6O%=@;0U#Z9"?Z#6%Q7CL9%E^.YK#G*,^!5H+RF*&*A-C M#&N$BD\1W83RY#'HQN.&.&!@,=N4,`+4M4`R4-N.K/%'T]F5P@0/[3^/MHI3 M_0E)@_&)$,_@]\64Z/Y\KJG?CN;8"I0;7V%FS4)@< MS>,Z;,&?+UI9\J=$.TRCY$3?I(YST&5\'E/-!ZA&?:I%.?DB$P:V:;G8D*SL'=^+>)PW\+J]AC0K?(XUS27%MIK, M(SAL/U:6Q8+W[+R:3O$VXG;PZB*;;$F'%WCS-7'X_*&?!L#=X M5$$H$F_]%J9^%!*&T/.\A/FJTDT(AP2%B-#KG@)**%FA=HG<0-&G]%!%R*NY M'.MEW/T<;>'B=EZ^4>6X$31 M^(4**WR.U8B7*_#['L9HT?M)J"O-`KAVWIS5'/NV`Y,Y205-%.**E-N?3%;0 M2`6DC'DKOH"NN$JB>`)XF%Z/EI+M9L^"%&H^[RP`D1Q(FKGJ=\=DON[Y-I[^ M=#6&.TLHK6\'8F=_6$U,5E4%AE9*9ZS*-F\7RJ(Z`TH+SM]P-K#V')8B3-ZV MELXA2=@`F9$,HDY(R@">6K!=%=M6"!DDKEB5BQ6XQ-B?BX),ME(P8(WGB$#V M'PR';R8C_74F79)S5W(<4C"KJ$E`XD`2-),"Z=WP5)':B_2[HN,H2=W?M)V2];$,Q M.<2=(U/ZU3L&1O,(1&%+D71D+A0;)$,I*T4DD6:GX#6!J87UY$38/Y2E75.O M)O0'V6QDAJ\TEQU3KW(38J!8:'>^W,3JN0:ET>\/!HMQ6A_T8=B(0K!A=#:H MSB"7KN"8!$GW29!B\P*J60!!S"*QA"0.B$E9#1B3:DUM2`CT961PYH;`6%=R MA%&%D)V.YZ/%=VRBGEJ:(3=`.:!U!6;!!^-\*6Y9N8LMCSIE[EW86:C\YERJ MD4>?VI6T_@P/\WMG+5,C0&#^'4ZD!;.=+L2^J#0Q"0]U/G:*S4E%<3\@'-A16D#3`# M51B(/6`B5V6"\N@H9EPL29I2]QP/*B1[,>1W$^Q&;7VX2R'K,"E<4M5)9A(O.\.$ M2W\1"V9PM"'O5\P\%-FB%?!6!8W$\E;8TC3V:Z-$Y5[^XMQ7IW%C.#T8QB(; M("W'G(HY#B^S7!E1KH5P:_FZQ+P$=?"M/:T(!*=&Y#/&?C`8Z=U8_.]BMY/P*>N84[,=FB[-:=26)30/O<+G&[T>1;^))30'G<6F<87*RJ389DK@#NC MT<5EDZUG86>0"`Z>BNJT%`"4X=8^R(E=MX%=%K)X7FA!H56!9`;8@U%'>\2J(=.S-+KYIUAV"8/U&Q8IK&KJ5<<)LF,,]0[`QBL[W:2AP1%"QF&&@Z2K6& MW_-#K(7[B"V*?U;I4-F8P2!O,MRN7R*%L9L[[>'3!732!/UP^=N:3=]4O+F*4"B1=A+NR*&]+*M=JH]E" M`DLPAEP""Y4;>[TGNWY70Y+*I)0.K8M&YDY5XL)V&3PK:CNFU:SIS8@(,*C) M&QZ"`-Z$S]Z/A"N=#8R5$URS*SRON#N,K6?[# MA>)S\^KBNW4@1B6%S$S*Z=(\\^GJS57%(+O;NPY/`&MB0Y=Q=WC&G MG8BZEOQB,^O4#],*BG+\M'WS.QI+%G:P>"5DN#$KZ)YRGS(I=PI_RD>OC@^>_HHCYA7(TYT,DRRA\=G M)X^*PYVC7N'6`IO7_Y[R_T:?T>SD3U(M]&S9?L!?F%AL%LZ_YE@[^F7^`MO) MAYQC[B^*K[CV_GJ*V-+3R_ZU3%Z?03]\9A,O/S=`=H`P6_VOM'(TWD-6%Q?4 M6SA$VU4Z-Z+5K'V_,DDH8Z&"@SJ.BCYE.@`=`SO3;"&B&/7N&^O8(ND;U)G9 MPLCG]E*1.!F)KL%JP-*"9L6 MCT'M:E@@9B"<=;$)65T3-J?IHL*9EU:<5.F@%]X/HW@5[D&\KYN63'I?BF>3 M?C]7@(%#<&]E2QB0<4*KI6-1E(<=\.`VK71/_L1#LA:R+#8M&FN)"]R.Z,"8 MB61J*F3.=PEL6DC/VW#S&%"?5Z\EUX\1.`^I]9TB$58!#9\5+Q<,(:V3?P&>^,;/X5?L[U>]`K"I%Q MI[GFHU5A1/>!C4#S<"7G:<8HOC@^/HV`UDTI,N39K#T%90BWC.A^)JA=SDG! MOIO.OS.-X%L16*I]>'@J:<%!",E705*FN5#.J'HE5Y5M=U8;Q-EM[DQ8%`1P M7SUOY'UX+):;8BR@G/`5:)4MI$B/4*'PH'GZD(7E]!0!S0GB(2/+[XG5V)16 MI^&49O%H`GU,<(V3#=6\)=M%WHD>5S'LII4T.BT5X:^)\,QJJ4(8P8W(<+L\CYN:$+("MP@!C78MJ.,K15UR-B)O39(BD0NPC M8\XF2.",QMMB].L^X4;UM=+.,5_EY4TO9")8J&TTF7$CD%>&A:X_-$>N)NVQ M[ZX4%S,3J$X?8=]#ZQIV`5%Y<,:BK>9=AL4,D=?]]^)<=F3R*,`@(YU6JBU0W,*`-6@/3@,"(,_@TL'K5H,]7 MV.UZ`XR_D++F)P70-U4HV8O$SU$` M`7<:J`ZR&-B`7@X$S1=;!$?>@9JY^_=Q%W*C@;Y'>RPF'\1%)(>6\MB;<3,1;9[)1P:H466.\ M"Y`FS61!F'@[M9YI)D+,.,(\TV$`G+TTH&I9(L/.3\T`5^%1 M2>33G2VN)(LRN(B@-$_@'B)W7JN%[%M:*8EG\2T+4,XE;-Y;7A=*J$&;S>D8S&7DC_7/)?B,)RL6P]&'&SS$.62-*,O@Z>3RQHF!FM5S< M=-F!^U`4T(Q'?Y+X<9[="WSF2>Q(@S"`:Y(O.YND+%7]JM:>ID.J4R,.D2C< MBA*R%,O#=XI!U,K+0J2D-"/5T:E'4^A#^78*$M7<#OE,SRZ2`-HM_&#=YF+> M*[&7R3'HG@04"P\=XS4!;:AI#IWMX3( M&U!5P$X"1*0\4V->&."I M?^\\YN475] MP)"\7V.(I*#CXN9#A*"]B:**LB"OE<`U[J*T"`CREO0479MFFYR"\%?8.UU# MM7^CMF8=OEMED3R<%F*@KR[G0I#H3XBJ5#S0N`)&M`?M1(P-RL&(04"34#9! M!ZA(B;*'%"7RF.**#(OQ-$IVA'Z/T2[1#/`3AS20Z0*.M2A4K! MO2(=75C*J/,2BM-%$\6&#K8?;^[^S.&A+^/VGOOVBN.,UIVM_NH!HZ87[[". MRA?^TD7&16BHY@"3_KDH94@F2J5..[KPUH!W&`Q_MI]%'7_X\U^ZA`6-=>%X MRRA2-"=_YM,B//%3,XY$M"*+O/A!<\O>#/F+`$X+ MTQA=3[UYGUGZC5V:81HJ:RQ_J2UQ`WLUGS0X;UG+*T1+50)!?B]GB8*&UX.? MK8!)RB?'@A`7'FXTAG!LD$"M!3]^\/_Q5$B2+K*(4"Q>X8']R3(J!JI+%\_>NDOR"%9_)ZO7WP M75[QF^K92T7>LC\<@@),D:8!)\'ATELG?J"(F3 M;VFPKNPVBO-,9:-A71>\T2()+C]*V8H.B+#EY0:6"JG8B9G`0<9?PJOVT]XJ MS"2588TW9#8HAJ*?Y:Z86F2`MKB?&#"]#4J[K4:3>K,0"D[]2AY4SY[:Z!Q.SDNYOK MKH$+#=25,/>B^$7E=39J:-^G2%=MWJUO$(,`37/A1F8]^PB%2!B9_"6T.\4V M>8$\MU36I7]TQ6K;/*UE?AV"P-+?Z(ZT%6TX[523+73_3E)78L-ZWG2,O2@' M?02PQ<.L_"3$3""%&'054:!O\@9U[GF?L5OLRZ<@YBZW>F-67\#4]3D[@9Q[ M"\6BKU2I(!TA70-)!)AT;%KXYU1XX?(Z-!]FK*ZDH6)U/UDG)D4P")>8I%76 M@\N5R-(ZJ[;Z^9CYK>DJ8KQA(0\/1-JH$&*B9X<&U@=/=GL'CWY?"><^PYZ@X/>_M/MGN[^[O-O<0R2H'_]CK! MU[@2V)Q9#=(IL1`*UND,RX-6:O3K"=GK<-\3]]JO20F^JE2*3=J/S[XAD+YE M3S>W=V.=_7"H+@#O\AL<(4YI2[GN-I<1339&H_NW,)2]A`"PPE(/10^\B,SF M);;(0D1HIC(EX\=?G[SDIN8Y>](^X'J%Q#`H+*=U58YGGHD3Y:/P*#3Q/)PE M"/%!Z`1G@;0\B,@!/0[87DZKF53%&L1IZMJY=L0F1"D8U%6N!<!-FC$/MQHX@ M+8K-Y!J21OPL*',[(M`_Q;;17]8U%Q$EXZJ[\_U+1E?TJ4H>:&G7)2PC/>'6-8Z&LA.X!,@L]='=H7OMT7:4;$R0[<6VCE:\K_(R M)87O&,+O0IH2>AZ88HF-G:W];:-DA$#VLQK5;M'8#)?YODM"&FA>8F&>+(7J MIAPO.Q82S&P*/Y.8R!*T(\L;!D*I5-I;NS))LJ`_CIY8]=`L!]-?^:1&P_#? M?7<>9@LIS7`(EZ#Y]/&&LO<"CLY?>%D)6>A>U\>4-X2W MWD`A2-=@T(2PH@TZ=+O2@MC_?33<1QBKC#0]S$_W>$#8R(HH2XC2QH8JK MRFS9'S>QT.(TC8V5N!T9J?(I[*/XS3Q.LK/]#_%`]UXK)Q,9L[H(=-T*@+RT M5`N7ZJV@V:A?L(6$J77EOWSF+B6:[KF%>FB)\X4(8"K1\3M)??,8QGR^,A4; M#.'%\(D_,^&#`82C-N++5MXH(%36*]U#=P/;/27!3I%=$P5G&254R.&I?WN* MK'],WT3XI\\'8N#H\A`8X[]IF`L@:[.3RE!<=F#*Q6IFA2UIY*/BME#1[/N+ MG*=XH%=E".99;#4BO;T*-4024W?XS$Q<)$5UZVO8;C>Q]L\K MS)Y@J>T5#X=0AS%;K.5Q.SAA68M%&1MK5C";\,P)],>UVU06Y6V+3I6J:-H\ M7S?V62/>OV-G%3=/:!]G:4;BYUI>6Q-#WYHM!<<#W-,C?V;<@AHEP$\D,[%=Z*70; MRUXYW-J.>LBI+!DW.F[&4A4Z8A8V*+=T"%U3Y:--1T?5=P0TQ[TGG"6C-6@B MFYAOT/@7*XE\UNG!8A[FBJEV<#JI([32^1N/`:S'/[&O[TC_RA<`ZMRP4.Y7QV=@3\3T>6$Q&QP\5/C+H8XX#!@YN\05>@)]81)&XA M,M/"214M&P$&]F!+GXSL=N*=]2 MY7N^AX_7N:>65()F6W:BT[$WD**LO_U%87$9`I^/MXC/)/^3B0#UF`*221_8 MK9INB^\G]AYSI3%[K8H*ICAQIUIC,E5`$@X)GQ[-INVP(;XF.*'O8.T<1O#M M[O5V=P_O!KM=`+U[^!,!IY84\?)!YY&:@)/@KN4#`=-6\8S*68-DBCTX9C:> M'';#$;:/MECGLB'Y'95FA&N+`L\K@PJ<;M[?Y)0`3H2A+_`=\'!_ M@%.F[GN:#QAM&2L*[DB)5YB/]GQ5W!"M;SS>ZF9/)>3X>N<>A*!-0+70 M<3V:WX*!N\9?AX;:.M"WX7IDD^9L9'0C0^#N*W3##=&[]9/?&,C;H]S##,W; MMW6WTK^\R@YW:W-_^^>]CGA"+BN6!4J>/Y<'75V9F8[,V8]`$5E7,"K\2SBUV3 M/X29309L?W>=L+Q)1^^BRM)63,;EP8EHG"&'B'>FQ>%9G.IJ=)]-;)C M\ZXT6X)M#=UU4MH][;EX4\Z;J&*.1'98OB.1[-%;9&_#SS=U5(M'Z,Z#):") MH(6F?I&V[T6A>QC_B+2=)[F-VF*-.WCL+2H+I.AQE;^3H0K8;B%#2^(&`15O MK8I`\D!9,%YR\KZ=6(Q\DK&A"7]"H,HF"S4N?&TQ.I060V?F)(J"M]LMN5HL M]RTU$2$VV#AQ#'!SY$75U/7.0<&JZ#OMS!RUL#VL+=,B/I]`\R72$3U!TM,_ MLVV5>Z##FH6E<+$^SATOKNJFIY7BM^Z+BO@_?B"JR/]#5S7-(G'TQP^$&+L? M1SW'T[TU0[Z-_2A>6NRON MI_XU:%_SZ4;SAW.0$+G@5M,Z9X2Z24T8,O2H`L<_RI:N MS:W[AS5?&=$1B^FKPRW:?Z$:H%1F$A7"E]Q.%M&H M`%3N:\L3%05;H3R*3-4,C$E9)?2DVAQ/:1H\40RFKBT#[2>&R$V6U4P6#*83 MFF'OZ#"+7'@)>Z7=UTG\=2#6$GJ;A!YY-8W&/+N%R;5HQFFO$BKFCMG-UY;SVX9 MMQW@LU:LUNE25+?_LC.:J1KH/VEE)#I:VKZAX[25>DHC!C+9B1^%CEA.`B)**,K4&-S&!*TZFT]VO"U,,4 MK6!"NX-?AAQ,V]L"*DET9125!U1B9.[RXP>:%>[L>]"[FQC715+2&IP;.*Z1 M_1DQ[CSI[1]X,-WQ5T=22^X_2SWZ!1^A*;7P>AWNWY^HO)GO&RL_'ZX%GWJ/ MV)L^^/%3)[[A$R#[(;YR:SNYVO4NHSV/R[R$30AAD/?71XW=H:,>RFLPH-9< MJ^E3Y[%YY=Q27A>'(.A(=!!6(K.L4"O!4BUTE?1D)=3RBB``\.:"XL- M^35KWE0%H8>O=.]=16(JV(I?9RZ\`6=\9!W1$!!&9[HE;P5R_MJ*2\[XJB+B MT%PMU!+92RX7M,><%SO*Q2!0:5ER]>/I>[N6.ZQ*R5B7HAU"%*&NG<%2A:3Q MU(@KYYM628RTHRXR&/119M=FIS@.^2Z[:K(9$85[$#^LF@'0J+X#RQ"8 M"E]$2ORO?0J@3K-^>E&G3/86H44@V9TGK9=P!``3/6<;\8B`HCQV64V%'VBC M@`"_INAU9"RGEH]>$94XT9!F+^?D6V?DAG!;'UO]1A1@=Y9IW_BS=BUS^9.+ M6?<\?HZP:1T9H-7Z59B6#:ZTB[`J+`\J#4'UUHWT/%;_03"4.E/4FRDZTP8\ M>?T"-\1-4*97DSZSN0JC[LS409PJG):W&M?VJ]";^%152$)@]+GLWK1*@ZN. MH#!;I=#B*0E6Z`ITWH=;=SUP\F$J@T&01K([Q(FL9;:7B=5`9?4HL>$U@*ES M36;'HED%\PRFRWRXZ?R2%CHK+!@YQEXT(OJ72T:M,P:<-6]*C(X02C<$+THN M6XZF5$Z_=.F&P:=BU:I*%6D9IJ>EC7T,`447;WP$))F4B#M"C.>D(B7B<9M@ ME_K-`:F)B7_G34)B&+[Y9L9;,B$BQ$%GN/_I$'4UE9ELM4XIM2](2N8:C0ZJ M#B/9]NH[3QH\NQVRV)3J&382248T\=X&3]M&93,D\,+B*Q):LM"YYWF-!6 MZ.?\BJ8Y'S\HFG1%.[[G@@-_JBG(QP]8S\TC_HXR^S"L^>CA-Y/P7976)[!Y](L9MA8E>HQV\J0D@R"_GK1E_;G>4;D-% MX[3=S3`_?@BJHN[-5<$]M1$D0&B$P55R^DF:!8$DP]8D8=8Z_IEIO,;BG\$41[*$I8M##] M$MN-S,5H\/'#;]4%LCGOU]D-O2Y'K3G^"]4 MGUL6JC6^L<6Z=[1FU1@CNGGPN:1`*A4DUNF@"O5[R(QXM1MI4T5Z8[&\^\UP M>5.VP>;5?06>RR$^4G*FOIN&[;/\_+@C>UX7[%?DGU:TY4DM&R11DNC6_5#D M?A*_*P)[5J@>S6+V8C=+_#,NV+@;Y#O)>1X]V;8+ECR/&L5LN:B$8O8I.Z@Q MN[K.H%32?EP;]_'JU2H?H/6=&S*E7%]?V2L)QCXWK,>7W6'@#JCLM:&23-!@ MGG*49N#1-$W0:BOB\([JW_\(/DEZ[9):C4YF=>R-0<>O^W3?%&"1FY0 MV($947G;38@=8_N:T[-_F\IGS\.+>B` MIU6%75L-MJY%5U6E?9@J5C<(N5''IQ!P@+J!S2@^QH4:T&A) MZXSV*&9=6%3%XB22>QDL*1JPQHDB3=(M6B@5>K@*"9T#PCFK=$*MAM;B53A3 MUF='+-YI4N4M<[P4+E"U2UGE>U!S(@*)(VL'DKX[H:OP7G7HW:S\EJGV6VT) MPP@75#T$572^$;]+`7JJMA%AEJH($;S.8"VK"GZ)(Y?Z%F*!ZVL?CN+(!I*1 M87AC0Q$SF:<0-0O^@LBZP>W&A.S_CB^TH\OHGGH-,W"'NY(8K.DADT#I&K^. M8;AV?[1[@U$B)!(]\O)/(+;!I8AMST2ZB8-X7"0K`.U^?"<7W,IG&:X`PSVDE14 M48!QI!V^=T!8'/Y<>W8OR>8(VI/N0[08]!BO5U[DB_0-D3-)>/.%FWJO>82N MJ\;)4PV?52Y\^@;-59]HX086>^,^6=C'MQ],L-L_0SD65%EXM5_Q\)G+X$?23`!B1MM) MW&'/@^:"<*%PC)$S`1#&F0B.M[>$$;G3R>67P4%L$$@C_L4NL2M!N'^&6]&` M$92$/-[>]7PW?]UEP_>$A.1EZFP+B=2N*X,7&#FH:NWFJ+K>('J2=@\=IYSH M.R$B#6'1YXTGU#:+6#N0Z9_T@FN"?1`[K(F[TH_>V24SW0>AY33]L6B>11K" M+[.E9G(!":;/8W`V(*!N9\3E#.1^[\15E[7I)J8U);7.#Y/ZIK%@($5+3NY M&]8BC9FPN9"SJ*U`Q(UYUM.ICA1.YO-)?7"JO.6^@'"O3'%(6:>/=47YERE- M<_%R?0H9Z#-M&IH:TR6Z6/:_3VEFRS^UO%49@D M*Q3&]S=.G"Q$Y5OI,BN(T;+%A!!!'U<]X`_BU&;A`[T'!@N$4ZM+7OM M1+>:T!@8^N:EVQ<'?JLF;O)N`N$G6%#-;]H"E116B;7&XR&EB9IRY1MM MV\KMV-]VZC5K`VYP963"IZO9U-TVX\%U!Y=LKYW<]M)*^O$@^]'7RTDN&4]W M6W&M;-Z[^?@4%XIW@ZW%C;";;*T`Y;OMJ`,&\>1[^[T(1UJ>V!?<&OV7B+@/)!(?GH9_M4*?M&M%_B-VJHA$K[#1M'\)_[TA!/$- M.HB7GX?R4MC_[N_:QZC%I_8/F5_(+SE`]YGDG-82F"+,\C5RB>2GQV;R3R3? M9[K3\-5D5\_BGG[%CF[J1Z MEM4(20[%:'(OI4(`R\M4"2/:X5NRXKD[<5&(6!JM`/%@!-NB"U1M[!@2/_95 M?7/O/@!ZEH)I]V.P2MNGN#?AX)1,-^$!ZR$(JA#3W^9W/SY^0-?]#7SXX^.' M3_CEC]>$0"=X6*\]W^$QI[N3'O(?RR4U_EF2-"/#^_]]N^[7T'.*'>;MMDF_ M*7U['\9[V='Z^^]]O%5M4&E"N6I)#>`.E$1U"%K+U:A5#M0K=O_>Q]L[QQ=_ M[^.=PEA5B-W)Z"Y]O-MVS]TZ>7/=011:?4L^BP6L:3T=6EFD*`8U[9JBZTX$ MF8UV4?C_([VGVQ!]SG=H"+Y@%F&EFVES'QFJEG&5AZ)/*62-9>\SD0518R&G M&5S!^,)D.5?ZN5T=0N:/"C_$S">AU)JQ=_MB]3K MS>1C[_L=LG?!5M$7[*$&52):+?X=`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`_H.JZ"$:3*X M>V#K(5)^#QE\A3^PO66I6L0%F"6&_9G+6:Z2^K16V,>A::/09VJK,L`U5;6I MB)@P+F_F<_=QO`I_5/]=]LUC.A`M4[>6%`](DO24U.$EV=VJ=B(4,$@'6Z;H M[T:H.1(CE0XRGS'Y.OZ)PP;17`Z;$-FF0&=NZEN( M=BC<&L,%GL&@X?6$11X/+\M_NZC,$Z.;]8&=U%<(.U(M!%M8%HNOL)X(W,X: M%O5"ZP6Z9C'@T.:N:@@323MT)0J?VF,5WDY2\-$_Z[NTY#?@@3ZTK;GR1"RL MN@9?F+--9\3HPWMZ3T3OPCN]8>;Y.T@Q*4I@93(N"W.Y7`0D&O5A+N"0J0'Y M%Q>)@;SU2X&7JN4JM+T,?2B[>I=;F_2V,?7XR,>)Z1JK;+N;(4,ALFD*H>#K MB/N:-M5H4@4XIV9+T:HF5^:/#MAY!5LZ@#>KVGS2OPW=93*H1[10Q4=YE4%J M@;3^+D@A';14.L7S+6(YZX8('9X.X92PBME#2%<*0TA'/$.X17(;8ELD4)7C M5`])=AI75U"E-)V200H>"]E:O7@K#1_PG!#\G>03>OD&A>L/E8G\3@?&<6'] MJCEL"5F+UEL3BN:?+4+AO9,B13:*NZNOQBXB:;R[KH>[:^6\'2.ED$+/_+?P1K5`>T,@TA0YP-:/_*#LY*%+'+V61ZL MY:MY+5^7_;]5PD=5"//\N"U'.N7TW?#59?OM_HP[^`IN1L0N[,R'6ZUNB-=C M7')Q]^9/Q@[]C,P\"GIPK@DX'\6)8Q/^1P=[;NQLCBA20\<',M91,RCFD0,( ME+%J+96$PG.?VZ(2@+-$9HY-M5S\(:NI,BZ!V=$[3N?G$AGVUGM889QIT4S( M/,3>\*P@\)J2ZY`@HM$E2J]#G'-ZG5**42QAA368IZ?`3XR`"96_61`K;)I& MRC?@@W8%;\$HFJ9PD`H5W$CI2UMOX.F`XGS@@>)SR.]FQNMBB8;UAF=TD%H& M%LF%QO=9DW^GTZ_W M?P$``/__`P!02P,$%``&``@````A`(I@5/I(#```!'<```T```!X;"]S='EL M97,N>&ULY%U[;^/&$?^_0+\#P6N+!*A/+\J2',O!23;;`ZYND'/1`DU1T!)E M,^9#I:@[.T&_>V>6KUGQM10IKHU&R%FBM#._><\NN>3E]\^.K7PQ_9WEN7-U M\+ZO*J:[\M:6^S!7_W:GGTU591<8[MJP/=>_N=P%+[;Y^=$T M`P5(N+NY^A@$VXM>;[=Z-!UC]][;FBY\L_%\QPC@H__0VVU]TUCO<)!C]X;] M_GG/,2Q7#2E<."L1(H[A/^VW9RO/V1J!=6_95O#":*F*L[KX^.!ZOG%O`]3G M@6:L8MKL0X:\8ZU\;^=M@O=`KN=M-M;*S**<]68]H'1UZ>X=W0EVRLK;N\%< M'2:'E/";C^NY>JXJHWW_WS1W/]KY^^ MR7[WT[=J+V9#:((-RFF^[Y>2A:]#RKU(@JO+C><20310$VKKXLGUOKHZ?@?. M`.+ASZXN=[\H7PP;C@P0WLJS/5\)P,H@'SOB&HX9_F)IV-:];^'/-H9CV2_A MX2$>8(X1_,U MKN;51'\<+R9%N5RM\:.S!]5X'_?>3V6PV'9Q/I].9-AIH&E/R?>31EKLVGTV< M,;:FIBR",2"8C::S\R$`Z6M3QJI3!",`,!F/I^/!;*C!_ZS"G!Y!VSH=J[*M M2A!(LBI!(,FJ;(;2:R'S1Y$"BS628Y4@D&15@D"252%OZ]]X(`SNU<7:XMX\%S#1O>]N(1\=^2D7#V"TYTS=7@T5H]`3-N<274 M3AQ.VEE@[YMK:.UGI$MZY?@EJ1-U6"TYTZ"9, M(G=(%_AZ:(7(?((CF*F9I04'@$_$+B$XH@T9T\5N41G)"#$9R0!!&2(U4*A7KH1E($SB,0>JE2EW#*E25V4F MCZH[-`LKT[8_8_G^QR;I&&`1[NKR>4.NKH!+7O#R`[QX`]_"2G?T-NP.P@]@ MD:)!P\)!BK'=VB^W>^?>]'5V'0QCP8[BBGKZ:<':FO3S!]MZ=:BC",RK`,X@(B>!IPA\N)LE5(NA)6!]-^,,R52Y_T(M4_N!< MPOS;]`>\(BER:C`!=>HR/&TB@,6(&`$8008"O((JT@&XIPP$,,F+$8"#I@@` M3HE7-(F#`=Y4+J0.BB9-8/=X>#A["F>.8`LVER)3:=RS9L1K MI\JCYUN_P"03]ZZM8#'5]%7-P=KO6QV&:T0 MBV/DEUECK-TB!\55+VT?Z+90FZGFX"2"JE2JC3`7UYJ@?AI@05C14B"\Y5([ M[V2%BJB4'%>$*L\H'*@]WUV.QT"=5ECDMD&5=.@9J*BCU M8B$B&*V5`4.9HS*$XO,M,&^0IW!>W*HB\@)&JF4HH)_WN\#:O-#Z7+_*G%)C M>`%&(W3"2?CXG$_"J#FW)J[[?YM`I<1&?!3J%>,C>H`S>_,V]="';18+VY'8VI;ISD:!<^7%1]70'6";IF M`<;9^L1XF[KBB>$US*8G1G>$\HJS$?0T+4?*,?"*>@F\MJ`,WE')O&GU`4PE M*TM\VJY1O!M&+]:>-J?6M+MHJC&^='10KT5]D!3L&NFO?KT65:%.]\8'Q7\@JF]R#'@>!K[6;CUE7R4$$T]Y6U)4>0ZG+_C MY5=EE4*^ZU3`?2.N\[:D(*XSQ)!^M0624RN@%G=EH=)R3`&G"AN]*7S9O,PW M92WD@F,4.B!=[FM4*-=,\"6BJQ66ACTP60%\M2TG34DR\;;:"&7\XY55,Z+T M$B^OE7>/:MQ"I3?S10KGZL@`DHQXH>M6X=@MY,U7*@1X(WY?(47K MY5(PV1"O*9Z.=^`U;\W+F^+EB_T;C,H*`=Y(5%9(\0JBLJ3VG-YKCO%RTG)# M3*@Y0U9SEJ.IWS"P%-#D+L#-(74Z58QCE](]= M(@MOTO@:D86W>LT@PQ03*PW?YJ4A.,Y/&?(]LC"!5UY?P/;32KAHF.W,@+T8 MY,XV_'UMDIT;"M[Q'YY0U/^]> MLP@/1OL@RF@E"^FX`$AI06ZK2RMI"H:XTXK@@E-`=6D!^]#R(Y"6T(*;_M2F M!;O?(EJX#R[%I<$5XW5QP9"(%J_[L:#NM3P[LAVC*2X46007I97:$8L2H04B MUZ65VA$,1VF!R'5II78$A(26!DSJTDKM"%:@M,#=ZM)*[*B!X0BML:#NSW/M MR/LJ;N\2P45II7;D?74DZ*N45FI'WE=1Y+JX4CL"5:(O#;ZH2RNU(Y\G-,$\ M065,[`=T1&N3HOH**226HWW\I&@EX=44GOQ M_JT)^G=();44T",2:?"%N$2)C4:\=C5![2Z,=9QU>8?!.B,"`YYEM]K;\(Q! M#Y]0R+8O8K-+!,(%*"%*C^;J25G"W>@20GP\8!D5(73SO+4-UP@\_T7!+8L) M.=[H8T%R?_*\1$<\A2%\%`'T9WB>(SPJ4@&]A!KB?1CW_=4AD\0"KQ[LM^J0 M@=$A&M[_PT,` M*4+IUMP'OI'X'Q]20T'%W.(]#!,:?(H(GWX4WW`QZC]OX9:%L1)Q0R*)'6SD M18#_=1\0->(H0@2>)B)$Y,X*X,:T<1!S)!"6"(X[#[81)R0.,HH@C;\;OHO1 MPH7N@8\62)1NRH;N?_VVE#%,/M+R'=?-K!_9GAK[+WK;GZZ\UB,KN^ MT8=GT_YB>J:-S/'9;+RX/AMKR\7UM3[K#_O+_X+*\/&P%_!\T0:/7V6/B85M MV0/M8F?#0UK]2-@(_.?TV%PE'T+X[`:Z`!ON+!L+T=LECZ^]^A\```#__P,` M4$L#!!0`!@`(````(0`&$]5FY0,``'0.```9````>&PO=V]R:W-H965T0&(@V MB2/;++O_ON,/`G&`)CP`@9-S9L8SQ\[JVV==>1^4BY(U:Q\%D>_1)F=%V>S7 M_M]_O3W-?4_(K"FRBC5T[7]1X7_;_/C#ZL3XNSA0*CU@:,3:/TC9+L-0Y`=: M9R)@+6W@GQWC=2;ADN]#T7*:%?JFN@IQ%"5AG96-;QB6?`P'V^W*G+ZR_%C3 M1AH23JM,0OSB4+;BS%;G8^CJC+\?VZ>;2O( M^Q/%67[FUA<#^KK,.1-L)P.@"TV@PYP7X2($ILVJ*"$#57:/T]W:?T;+%TS\ M<+/2!?JGI"=Q]=T3!W;ZA9?%;V5#H=JP3FH%MHR]*^CW0OT$-X>#N]_T"OS! MO8+NLF,E_V2G7VFY/TA8[AEDI!);%E^O5.104:`)\$PQY:R"`.#=JTO5&E"1 M[%-_GLI"'M8^28)9&A$$<&]+A7PK%:7OY4X=)%ATDA'"ZF"".ZYAN5_DLK2V#NGKJ-P)],9C/743X*[2(.FLXS&+LC9D%GZ2`AT26Z?E-- M'3<+ZL8-7\YLQFC,X=^P1[('=K]U#QS/6CPW='W#F M;[,]_3WC^[(17D5W<&L4I)`T-T\-YD*R5I^\MTS":5]_/<#3'87C:Q0`>,>8 M/%^HYY+N>7'S'P```/__`P!02P,$%``&``@````A`")BWP%\!@``H!P``!D` M``!X;"]W;W)K&ULG)EO;^(X$,;?GW3?(7QKVJ_=KBQ[#S(N\A[?M=MH= MVS)?ZT'U?AH%03*M\^K@8X:'=DR.9K.IBE(VQ6M='GI,TI;[O`?^;E<=NU.V MNAB3KL[;KZ_'#T53'R'%2[6O^A\ZJ>_5QGI<5S`#57:O+3=+_SE\D&+A3Y\>=8'^KV6O]1'4JH-JR36H&7IOFJI)_7*@2#I\[H3WH%_FR]=;G)7_?] M7\W;[V6UW?6PW#.8D9K8P_J'++L"*@II)M%,92J:/0#`;Z^NU-:`BN3?]>M; MM>YW2U\DD]D\$"'(O9>RZS]5*J7O%:]=W]3_H2@TJ3!)9)+`JTD2SB9Q-)NG M]V01)@N\FBS1;!*ELW"6W,$2FRSP>F*)1F>98G5TL67>YT^/;?/FP0Z&^7?' M7)V'\`$RGZJ,-1GJ_K.R0[U5DF>59>G#T8.*=K!7OCV)^>)Q^@W6MS":%6K@ M]Z`)N2)SLR16$GF2J)T#,QBF`0M$IW%YDYQHE5C1JDVC\%<8H&B1A79!(;A$ MNA(1S08-HX6-,)Y6B9<^K,U0-S%/AKPX`=3@,5`SRNR`)`&&`GG'HR@QG".* MD@86"FK"0.^"`$[<@OU8Y)DMY]DD?JPGQK#A"(_'5F(+.[96;X6:A:;^(,)X M$036S#(J62PB5R%1X=(F]]`J,:>-K=VX0DFB8:,@#('5AJ62,$GG2F/5%B4N M[?P>6B7FM$+$_!^M4$-VIQV0),"669DYZ4[7C[42WSHHJ"$H=D"2`$-9_*2MP*%CY1K'J$=9D(FU5U9& M1"B=B#01W):AF,W"Y+P36"U#U<;)NHX$Q>;/VD]B5U.G7OH4%(>=(])H@%#REYLOL M])40-4B7Q,D%/%10/!+A>*IWC\?#3@_)SC:7VGTO)':@C2]S(I)&.(_JSN-Y ML)?#/SSS.+:KKD>AIN=J9$Y$T@CG4?V7\(P\!-BU>9V<0T!:NZG3*4*FDUH> M*,.3R+ZZ"E5_OA\5NSI#=1L+:?T&%2.X">%Z/1#IG!N*U#RF[KRFJGO?#XH] MGX,Z-27&8$`Q,K21,(;S0GZL##(D&3BU:O#W4Z,M4&JWNK:79*$=D33"L"++ M3JZW/ZV^9;]&1`Z,$Y$TPGG>Y1K1)=>P[HB]FP3>@-(.HJ3 M6L8Q[FA'%PS$\3B.MU%T`[B,F8IH@ MW'IR+Q4D'<5)51\G_>3&0F+79X3DBL@0$FO`[A?9$4DCG,>RCQL\V/]OK*1C M&Y$=D33">50C'E\?;-NT/LZ%4X0:TRT6^LK)ZC$9UR1"?VVSC,UH]';DR! MJHV(\CC6036T;RJAST1W+(9HL.#J.=(WJ.^*P_/%I_^!P``__\#`%!+`P04``8`"````"$`QUY)?00%``"[ M$P``&0```'AL+W=OQ2[Z=V19J75:F?VF>"VC6)H"TB<_/U6T8#[DDE('H(YG"[7J:Z+ MZ=77E_+L//.Z*42U=LG,=QU>Y6)?5,>U^^-?]N7.=9HVJ_;9651\[;[RQOVZ M^?VWU574C\V)\]8!"U6S=D]M>UEZ7I.?>)DU,W'A%3PYB+K,6KBMCUYSJ7FV M[Q:59R_P_=@KLZ)RI85E/<6&.!R*G%.1/Y6\:J61FI^S%OQO3L6E&:R5^11S M958_/EV^Y**\@(F'XERTKYU1URGSY;=C)>KLX0RZ7TB4Y8/M[L8R7Q9Y+1IQ M:&=@SI..VIH3+_'`TF:U+T`!AMVI^6'MWI,E"WS7VZRZ`/TL^+51/CO-25S_ MJ(O]]Z+B$&W8)]R!!R$>D?IMCQ`L]JS5K-N!OVMGSP_9T[G]1US_Y,7QU,)V MST$1"EON7REOM@))Y%P7QQ]QE!(+V+2GRS$DP6Y,D0=SM&LS;;K&IQ=:`,((C-)<.B M(DNPC%L5PH;+P(Z;]ZN]@TU#(_=H9>U"_<+R!A+N>1,&T\[6YA"= ML1L8F!%HEDH`_H]FXT1?DPZ480U3``\TCD(A#U2A;^?BH`?)J&>PNI6`ZDF@ M.[*S&0M?IU";$H0Z);4I83#7.>PM3CQR--&0MM-%(WGM0I*.T0Z#Q6BWVY&M MY,BBQ2W:F0`U@=0$F`)HSL(W3W<6R9"JJK-&++>2DG3IN("J]WUC0W:2<5-# M/UR2FDN8`FAJH%RGJT&RH<8HCJVDQ)T:$D11;,N1%$7.QVM2&^)W*@?W$?]T,U2E+!91X@>14:*I MI-SBPQ1`T[JPM6)3?%\K+C*U&MUJ*SD0MEN)A8:0W<`9>@\U@=0$F`)H.O`' ME=+M2G(49TV`FD!J M`DP!-&<)9,/TR'9L/;1A:*3XMB<(T"V_8D58-<=D.HQ4DMA*F([C/.OND^RTD)'?I6;M9$(Y)T\W!G(=1" M4@MA*J+[C/-NNL]R.NIQUEO=EDB.ZK*)4(N36@CK$9D\81(D:O;H&G#*3=<@ M9Z*FP4IW96YVS65'3(1:2&HAK$>DACF)R:\UX&2;KD'.04U#:/["P)<:Z$/S M;BB;??R]AW1\.'3YU$*8BNB[@7-KNA(YY70EUH]S913VVV$BE)A(:B%,172? M<49-]UE.-,B(]RI7&7N]SR9"B8FD%L)41/<99]5TG^5DT^-L5JXR_7J73802 M$TE[I*_3.'RKRRN+=`TXPJ9KD`-/TV!5KC(4>PTF0HF)I#TB-2S@/5RMT\X, M4Q=I&N"LXA,:.K8Y;E<@W M[Y+71[[CYW/CY.()ST$":"`C.I[1W`?X_FG@6[*$]V2T.SZ`HY-+=N1_9?6Q MJ!KGS`]@TI\MH#G5\O!%WK3BTKWO/X@6#DVZCR&ULG)M=;R([$H;O5]K_@+A/H#^!*,G1T+9W MCW166JWVG+TFI).@`3H",IGY]VN[#%VNEX\F7CMKK++?MT=^OZWGZME M[T>]V2Z:]4,_N1WV>_5ZWCPOUJ\/_3__:V[&_=YV-UL_SY;-NG[H_ZJW_=\> M__ZW^\]F\WW[5M>[GNUAO7WHO^UV[W>#P7;^5J]FV]OFO5[;3UZ:S6JVLS]N M7@?;]TT]>_:-5LM!.AR6@]5LL>Y3#W>;+GTT+R^+>:V:^<>J7N^HDTV]G.UL M_-NWQ?MVW]MJWJ6[U6SS_>/]9MZLWFT73XOE8O?+=]KOK>9WO[^NF\WL:6GS M_IGDL_F^;_\#=+]:S#?-MGG9W=KN!A0HYCP93`:VI\?[YX7-P`U[;U._//2_ M)7>FS/J#QWL_0'\MZL\M^W]O^]9\_F.S>/YCL:[M:-MYO;SDYW83-RB=T]_U+U=FY'U'9SFQ:N MIWFSM`'8OWNKA2L-.R*SG_[?S\7S[NVAGY6WQ6B8)5;>>ZJW.[-P7?9[\X_M MKEG]CT1)Z(HZ24,GF8T^?%['4H9.K'_[CLI.XG^=*0%[-9;B^'`A'TMU3-,&XS4*-6G< MBT;%:!A+#$K2["")DK;%W3UI)W[HVXIN<\S%I:>DH47I)J"20$F@)3`,1,': M*_-@7<%F=F\Y/U.ND=5%08NJF9*&!2V!(C#Q]9TDX[$U!)&YEFT,`U$:=BNX M/@W72*8A*F-*&I:&!(I`Z=/(RRPM,`W9QD1MAJ-)PMM$B=E-A"=V?EZ<6";4 M%JE?#%/2L(0D4`0HH9LLR2<\.-^)EFT,;S.9I%&3*)]1G$^W>G.-9%[Y8?%1 M7J2AJ"6^0L#FY*F MG;1*`B6!EL`P$`6;V&V.S]KY:+WZTD8=1"Q>(`J(!F(XB6-VULLJ[4+,9-3Q M/BW\?YJ0B,52**`:"`FD/W&5N:GB\599?NSLT,73+$U%EE40M#.C M@&@@)NHV2;)T/&JW\WABG%MVSXF\E>41!IR!40!T4`,)W'(S@N[ATS. M:4N#U5+K&638B?3;"H@"HH$83N*8G7.QF+N=-1+R.S[/UUXD3L,9&$OCPIY/=A>'+\_F"8G8"FBO'98U1\RWD'<4J;3:"H@"HH&80((IY&=NBE);WGQ)=$S&M9+% M(V\C?-?120*(`J*!F$`HF7SB_QPVD7AFG(.R]=TQ&?+=>)VW?D-;;$HB7E62 M*-!H("80>RSU^]1MXOR:_6GWESBSJ[S;/4:4TY-#K9&(9R2)"AVU&@W$!$+3 M,RI.WZ^F5WFU5\L2DS+GW2\E\[9%?N;@$41\_*E92Q1H-!##21SS58Z='G'L M',99^G$5FO&8I4:#Q@1"-9.4^>F#MWN`=<61#P9:M82!1H-Q'`23X"S1N;#%R:`C/3\3I.1J(VP M`J*`:""&DSAFX;#==O;LB-.6K7?0V2&(>.S@M*#10$P@AQVGR,H3QX5,6&W' M9/#VF%\A)`/WQ_YB_)RG@&@@)I!K#T+9EPS8MY)[J3P0!1&?)FG)"C0:B`F$ MIFF<3M)1:T%QR0E#[CA+Y+#18:*4-VZ9M.$*B`*B@1A.XMBO,N:,_/3"$I>F M6X5F[8PH(!J(X22*.1<^?'Y;\FI1,^`+0=1&6`%10#00$PC53#DZ;0NY\.-N M->-;B5Q*6?]!Q',!7P:-!F(XB(`J*!F$!"R0R'23D5.(LO&6U.CLF+)BOELY0@XE4#1@L:#<0$$HX0 MR6T[:G$F7[+9_)C-RN% M'#TO(1EIV%9JU^2D@&H@)Y+")=7RT M70B+[UATY.)1TPN;`='S@`C MF"8X`Q22*"`:B.$D+C'A^!=B)LL^?]8JI*]70!00#<1P$L?\)6\OCGD[+'+I MY%5HQI>%U&C0F$#V9Z[Q)!]G[58?9_,E>R^.V3M4#XG:V*O0K"4*B`9B`KEV MD;LU41SW>MSR\8WTHF M(^_!@X@G`YX/&@W$B@7>IN$WG!8U9O7NJJ7RVUO MWGRX-T52>\H\T,-;+-]2]PU^P55RI_VK((/#!_;EDO?9:_VOV>9UL=[VEO6+ M[7)X.[(>N:'74^B'7?/NWZMX:G;VM1+_WS?[&E%MOP@_O+7BEZ;9[7^P%QX< M7DQZ_#\```#__P,`4$L#!!0`!@`(````(0"[.=M*9@X``.5.```8````>&PO M=V]R:W-H965T&ULK%S;;B/'$7T/D'\0^&Z1PSL%2<9J&DX, M)$`0Y/+,E2B)L"0*)-=K_WU.=]=,UTV79OQB>4]5]YPY4WVFYL;+'W][?CK[ M=;,_;'9XAAE>#E>#Q^/Q]6(X/-P^;I[7A_/=Z^8%D?O=_GE] MQ#_W#\/#ZWZSODN#GI^&X]%H/GQ>;U\&>8:+_6?FV-W?;V\W87?[[7GS-GMUU^?L-^_-=/U;3=W^H>9_GE[N]\==O?'!+W9Q M]WO8'&XA*:8Y'\_B3+>[)Q#`?\^>M[$V(,GZM_3W^_;N^'@UF,S/9XO1I$'Z MV=?-X?C3-DXY.+O]=CCNGO^;D](>]9.,:1+\I4F:V?FB&:TF"TSRSL`)#<1? M&C@^GXYGBV7:^CL#IS00?ZMI#[,$2=&P/JZO+_>[[V>H4^SDX74=J[ZYP,2= ME)E&+^Y;VD+4.,F7.,O5``L,LAU0$;]>-]/EY?!7',1;RKEQV,C%&SY?#-=`'U M21WEP!%!9U%#)R9+.AGA4A@D<$1L.YXJM2N,4.N5MA"GD:PR`E9R/8@E(&82]*-7LGH?J`7.2OGE"&VM;8Q4!"0)!"MD!%()^!I M:EQJ5UM#KLK994@I-M>*]5F=U('FRKLE"4?_9(0_4"R[K3B*W("S2%UJO/*GIQ2-*-)LOH?J!7MF3!B5R:F11. M_TFO`@4!20+1/#]/(%NM($#N*\]LJKUK,<)PXI#D%$WU\YRR!0M.Y,KL3-\8 M*`A($(@K@A.(1;11,4MU!$F:M^LBU9113R\U3LDE.5>8^M>1,$V;NM MM18*`I($'/,^L8JL=X][5^:"Z=ZZ9'6[$`0D^4:?_?2RBXM!5Q$9=3&>EK)8 M804!20+1)C]/()LJ7_=C\EE91;K++EE%E'X@(,FIRJ#'UJ`)$E5$!ET**X@L M22#:)!,EM0`G=-OC;+="+G)@X41SW6_30+8#04"2;95UCZUU$\0*IK50$)`@ M,%'6_;X3I6QISP0I)])M=\GJ:TA`DE.5/4^L/1/$#D%KH2`@24#9=2/?=):L(1M:=EH'D6V7=$VO=!/$JLE`0D"2@K/N#*K+V/"%[ MEDZD6^N2543I!VHGFE39<\I6E4WV7&RGI2Q66$%`4A1ES[&*QK,3+MXFUKD) M4D6D6^N25?0BYW:*J,JY)]:Y"6+BM!8*`I)Z*>?^H(BL/T_(GWD13;0]EZ2B M23_.U%"5/4^L/1,D-,E9#`HB2V@R5?8<:V@^.2\WQ3]]4SG-)`N<(%5$^E*D M9/6""4CRK;+NJ;5N@I@ZK86"@"0!Q[I/%,Q:][1W8&[=^E*D9!7!^H&ZPJ95 MUIVRU4',;BX$,U"@@3E+"J:L^_^H,&OK4W)G<:Y;Z,N4DE4$ZP<:P:IL/3XF M4%TW0?Q<9Z$@("F8LO7W;6IJO9L@V3$M]*5(R2JBD'?;:[=IE7>G;%5%IL5N M*8L55A"0%$5Y]\GGNJFU=8)`A*VZA;Y**5E%+_)U>ZZ;5OEZRE9Z&1-O*4OH MQ;.$7K,_S-?33)(<04HP?2(L6;U@`I)\JWQ]9GV=(*9.:Z$@($E`^?K[JVYF MO9L@M>KT=4K)*J*0=]M5-ZOR[I2M#I0QZI:RF$Y!0%(4Q[M/NV,RL]Y-D*HB M?9U2LHI@;WKWK,J[4[82S+;DE"4$XUE2L"KOGEGO)DA5D;Y.*5E%E#>]>U;E MW2E;B6*]F[*$*#Q+BN)X=W/"'9.9M6Z"5`WIRY225>1ZT[IG5=:=LI5W7>>\RNE3MM*+>SCI9:!``[.$4B_'Z4^Z(S6W M5D^0TDMWZ26KZ/6FU<^KK#YE*[V,K[>4)>J+9PF]%LKJWV\Z4[8D0)`217?B M):L714"24Y6C+ZRC$\04:"T4!"0).([>C!LM5!-`[>4A;3,`A("N:8^DDO\2RLJQ.D]-)->LDJ>KWIZO'>(G^`]D'1 M9POG)\$T@7C_I+50$)#4RW'UIIF>+ M,N*VG$]VE"5$X5F"P%*9=VP.3NFETCSR>!&D:D@WZB6KETM`DFV5K2^MK1/$ MM&DM%`0D"3BV?MJ-\Z6U=8*48+I7+UE%L#=M?5EEZRE;'41KZY3%-`P"DH(Y MMIZ;J?>7W]*Z>`=-RILS!6(K!GE295$JXR]J4U=H+P5E%W?%H+!0%) M`HZQ?THQZ^)+@KAB/?2N8FY6:5,EX2IC7V9_YAY&D%",7+R(&$26)*",/7H8 MO8CP09%9CU\2Q"7KH75]*I\?F5]OH,X)\KBG`A*69*`X_,G MW)!969,G2)K\2O>B):LSD2`@2;;*Y%?9T?D")(A7DX6"@"0!9?+OK[J5M7:" MY#V]E6XW2U81)<^%@8`DIRH?7UD?)TB(DK,8%$26)!`]5+]BMUB><`6X(C=F M+]D3I*I(MZ(EJPB6Y\J[(/E6V?C*VCA!3)W60D%`DD!T4"78:;W5BKR8"Y8A M)9AN1FD@VX4@(,FWRL17UL0)8EMK+10$)`@T(\?%3U,L3R5]O<.49KH?96E] ME4E,D:[R]F9DS;W#N'`.AD^6\MBW^&E1\^ZJP^2RRWD,`PN.21;IZTMU;FSF^/@?I5A;6O0EIZ#8 M?=V)$TK?G8]'I3LG[4I:69,"4ZSKK-[]-#1;..O0\T\TY!\4>-[L'S;MYNGI M<':[^Q9_?B'6V/5EC^=?A[AIFE'\?8CTL,G$1E/$8%38)1N;Q5C:NHW-8RQ= M3MC8(L;2%_,VMHRQU)O8V"K&5AZ7%8:A&7%8KC`(78(3P7DXSO?&?L??S,`I MTATWCK%T]6TY3F(L72#KV`K#<)WBS+C"(%Q`>!'(C\[>BT!\]-=>!-*CN?4B M$!XMIA-98G=Q8\^+@#7NJGD1L,:]+2\";KB'XT7``/Q'L*6ZS>Q%L!_>_O0@J!7>AO0@8X/:P$UFB4'#?U8G,,0;/`YW(`F/P",Z+ M0&L\&_,BT!H/IKP(M,;C(2^""L'#&2>1%HC1?`G,@48_!> ML1?!&+SPZT6@-5Z[]2+0&B^]>A%HC;=1G<@,6N,E3R!%KC-7@O`JWQ,KH7@=9X$]R)3#`&WQYY$8S!1T%>!%KCTQPO`JWQ M88P7@=;X/,6+0&M\..)$QAB#M[^\",;@PS\O`JWQ19X3F4!K?!?G1:`U/ECS M(M`:7XLYD3'&Y"Y5G\W&&)-O2IL(M,8GNMYLT!H?PWH1:(VO5+T(M,;GHTZD MP1C\*H$7P9C&'P.M\V_U:-8-M,Y=GXE`:WRX[FQG#*USDZK'8(@[(K5:[M%I MH#1Z/&UP^;OZ_W#]N7 MP]G3YAY-\"A=%^SSKY3E?QQWKVB.\4MCNR-^72S][R-^3FZ#N_6C>$OR?K<[ M=O^`I,/^!^JN_P<``/__`P!02P,$%``&``@````A`!@@&(Y:!@``71L``!@` M``!X;"]W;W)K^V,?%J8OK&/SPZ7MQ M\KZIJL[+\]9G\X7OJ7-6[O+S8>O__=?GV=KWZB8][])3>59;_X>J_4^//__T M\%967^NC4HT'%L[UUC\VS643!'5V5$5:S\N+.L/,OJR*M(%_JT-07RJ5[MI% MQ2G@BT44%&E^]M'"IIIBH]SO\TS),GLMU+E!(Y4ZI0WPKX_YI;Y:*[(IYHJT M^OIZF65E<0$3+_DI;WZT1GVOR#9?#N>R2E].X/=W%J;9U7;[3\]\D6=569?[ M9@[F`B3:]SD.X@`L/3[L@L5!;_7G-@-_5-Y.[=/74_-G^?:KR@_' M!M*]!(^T8YO=#ZGJ#"(*9N9\J2UEY0D(P$^OR'5I0$32[^WOMWS7'+>^B.;+ MU4(P@'LOJFX^Y]JD[V6O=5,6_R*(&5-HA!LC`MB;>?YA(Z$Q`K^O1J)YR)>K M]00J`;K51DFF3?KX4)5O'I0>$*\OJ2YDM@'+U_"@,UW`[L4+`J6-/&DK6Q_V M#(2BAB1_>V2EBP+C# M[ADQ6+XZ<(D[(*T!0@7L3J>BP5#_A,K-Q390SXB)VQJ8,286J\7"B51",5&X M[$$D@0!B+6P,<0&VH>V"KN#P[@:_EH!>Y$8U[+*%KB#&BJH[(*T!0BFBE,:K M48/=J"X=*HB)VJBN5RL2#"Q0&S%;]X,N;4`8"VWBEA?"?O41]AKLLH\<]HA9 MMNQOST3>(W,2Y]#KEN\]QEJLG28F0"G&XZX7N0 M-H!'$4D+B7E,/1AGKL$N\[7#'#'#,1^9DSB''J^6L>T2("XM5,.^01QFR^U[LAILA!KES M$=J/-N1M!%OV$9+88*&X7RU,:XW%7_>\]PN^7>4T/7&+D$D"RIC5]KCGJ"VV9[PGB>V_LW"H>Y"$)R1WF=JB4!82"#4 M$:U=EB/O[`14.ML!)MQ#'AN1RL1,8J+B:"`%MICR5OX[Q:#,M69-9XX*1YF[ M9T*&H#O[8&12FI77^EN2\J.TM7!-IXTR1VF[YS]F:^%,1'%?<1**86RP:HB= MB,>D2Q$O^(=4M46[#=T].AK0K7TGO1%ICU`^'Q)*WA=*:!E=F:'`&)!)*>=D M#V%',9#!>I%T/5N,!--1R?$]R%'X:$FX7<2`1LE?!52_!;N-D*X?)0]$IM:S`=WACQ8&)Z59B?SU,<_NUY2^5IS);8VC/I$:#MU3B0$- M,DO,)#*+5P-"0A!Z\]WG[FC@M&,)']#"T-5"`[KC@RUUPS[8"+X_?L4EI)C$[D6"D0U'ZCH).#"M*HMU"U[T*00Q^Y!1LX*T4;C2T M?B#"V=/ZNN,VZ;SYH0=XFX'?Z0M5'52B3J?:R\I7?5/!X4-:-]K=HCQQ_3W; M&7]F&_BJ#N-!-P&7&Y?TH'Y/JT-^KKV3VH/)Q7P%>E7A]0C^TY27]G;@I6S@ M6J/]\PC76`H^+R_F`-Z797/]1S^@NQA[_`\``/__`P!02P,$%``&``@````A M`&G)Q58"!P``]Q\``!@```!X;"]W;W)KQ(,A,!J=T^7@-N36JFJ^O*93<@&71(B8&_O_GW'C`&/[1"V M)^V1C)\9_,S8XX?P^.G[^33[EE=U45Z>'+9PG5E^V97[XO+ZY/S]%Y]'SJQN MLLL^.Y67_,GYD=?.I^>??WI\+ZNO]3'/FQE$N-1/SK%IK@_+9;T[YN>L7I37 M_`(CA[(Z9PU\K5Z7];7*LWWK=#XM/=<-E^>LN#@8X:&:$J,\'(I=GI2[MW-^ M:3!(E9^R!N9?'XMKW44[[Z:$.V?5U[?K?%>>KQ#BI3@5S8\VJ#,[[QZ^O%[* M*GLY`>_O+,AV7>SVBQ'^7.RJLBX/S0+"+7&B)N=X&2\ATO/CO@`&(NVS*C\\ M.9_9`_==9_G\V";HGR)_KY7/L_I8OO]2%?O?BDL.V88ZB0J\E.57`?VR%R9P M7AK>O*W`']5LGQ^RMU/S9_G^:UZ\'ALH]PH8"6(/^Q])7N\@HQ!FX:U$I%UY M@@G`_[-S(98&9"3[WE[?BWUS?'+\<+%:NSX#^.PEKQM>B)#.;/=6-^7Y7P0Q M&0J#>#((7&40YGTXB"^#P%4&\8(%"]SP`Q,)9`RX=FS@XT06P+=-!5R[":PG M.X?2&:[=G2?G<8DU:4N<9$WV_%B5[S/8-Y#U^IJ)7<@>(+"H;0@KQ%Y;**KP M^2R<6E=`U[`@OSW'[N/R&ZRAG81L+!!&(5L+Q*.0Q`+Q*22U0`(*X1;(JH\S!8199*(F;5]TQ%O;A\CM.&X4&F/TQ5@ M2I?I76&#&.0K%K7)5T5X@0E("&`MVI.V_%-$6%/&[6.$M%"2RB$U3EJ`==+: MT;-!C-*7T""KWG+4.22Z3ZH;>&<8Z4LQ92)6+4BW.ZM6..F,M)-R@Q@D,`]9 M9-1@BPAK#9*[WNF(-U>]M5N3,C)@JM9Q&OO62Z>OJ8"-!%G9;<<&D['!=&R0 MRT',N>@3PZJGM(7^4);OM%;%4+7`6=?+"^;JQY($*0NYM]!%B*=0/RA$NCB/ M4\/"I:5CQ4(W&G8/Y24$A<)K?%LRE!^4SR##VNEL).A&&3&"=3`9\TS'!KD< M[`C?+J.0'=/IHDBA='5YR!"DEJ^S6,O7#0[ETRU$@ACYC&;$$086Z1Q*B'6%<&)_YS! MR3?,@29"J(V/)P(U"DV$KJ'$8S*T;K7`:,'Z`.^0N=XP+[E-=:_4B,.E!>,` MNS90GV/*3\@*A=^=?8HBA/+211)#D&1AT<(4H*9>4B0!S(>55`:X45KTU@:YV*!0C5#NNEIB MG9P9*JF*F):.25EW2HTPO+>,U-+[7S*H]=)D$--ED`3)?;D*0DOG)9BUV'IZ M;0F"!>O`C))*C+X%V]7#;PR2ZGH6571?"K=>>A9T521!2M>5%LR+X&P^S2:& M5VI8>&\9*^^'9)%GD45,ET429$WV=FPP&1M,QP;YC4%:0]AEZ@X=/UD\@=9K MITLB"5)KAVY8N[GG19I+8KBDAH7WEK'":8+H#AN+$&*Z$/)4(01SAQ^:C>VV M)2`662`)@?BA&X9FG)2`YGZTLLDJ3E!KNA%H<84*4=KOG72@9J%M5SL--^)G M=BJ'I$4V+.#NKU:AUJT3PRTU+)P$BJ)5'*^'NU->0CQ,YX520^5E_#CHJ6(& MM)A/LXHGJ@19]W`R-IA."<]O1*#,/R2)/%,2&;\12@R6S_/-C?7N_W`)V3&]'RT:.W8TA_9-A*D'%O2,M[9#+?4L(A7 MNZ)I8B![9\-7M_A>[YJ]YK]GU6MQJ6>G_`!/Z>YB#7VWPA>W^*4IK^W[NY>R M@1>N[<0R,O^E?WS?P```/__`P!02P,$%``&``@` M```A`.W,67J<"0``23```!@```!X;"]W;W)KZWWTN69!U^ M-AU/S;YHDT]+2]:O)5E+]K[_X^?Q,/A1G9M]?7H8.J/)<%"==O7S_O3Z,/SW MO\(OB^&@N6Q/S]M#?:H>AK^J9OC'X]__=O]1G[\U;U5U&9"'4_,P?+M:G/Q^V%_CR_CIOW<[5];BL=#V-W,IF/C]O]:<@]K,Z? M\5&_O.QWE5_OOA^KTX4[.5>'[87NOWG;OS?2VW'W&7?'[?G;]_[Y_WU`,F^^!JY?M]\/EG_5'7.U?WRXTW#/J M$>O8ZOF77S4[4I3A08IL?[;7C_WSY>UAZ,U'L[N) MYY#YX&O57,(]'3WZ.1&Q:FH2%=1\6YTYTR6 MWATU?J,>E;9W3==^#/I8LBL0X?;)W3A<']$,VIP7"K6;EZ#OTHUH/OV$M M<'[31QDQC@J9WXS@F$=\.X'\[67[>'^N/P:T*E%/F_9 M_FHNT21B7IZ8FX=L!L@/I``2`@D`A(#28"D0#(@.9`"2*D30T*2HX>$S)I6!G->+RP- MA1$MT9K02]-HTQEUX0@D`!("B8#$0!(@*9`,2`ZD`%+JQ)"5GL$]9&76K:Q2 MC#4G;KO-:9>^#1`?2``D!!(!B8$D0%(@&9`<2`&DU(DA&.T]>@C&K$W!."'! MM*!S)U;0=4929Q](`"0$$@&)@21`4B`9D!Q(`:34B:$A[<)Z:,BL30TYT8,. MB`\D`!("B8#$0!(@*9`,2`ZD`%+JQ!",UC%#,+;9<6VQWFR-22$RL> M[?U-9]3%(Y``2`@D`A(#28"D0#(@.9`"2*D30UYZ`ACRWGX\,VM30T[T>`3B M`PF`A$`B(#&0!$@*)`.2`RF`E#HQ!&/)BJ$8"TAOP9+4OA'9NC+E%,B*2==: M(Y55%Y2(`D0AH@A1C"A!E"+*$.6("D2E@4RYV29=3W9N!RA+!ZT(%4@/440^ MH@!1B"A"%"-*$*6(,D0YH@)1:2!3/[8O[Z$?W\;3[E%&UIIEQR2I%9*>'9*= ME:SHJXH2!8A"1!&B&%&"*$64(NZ\?/+T;L'.ORMM]]6]>TI-)$ MOC+5/3JG$*<78E^OR\J1ZW7!NV''(VP]F';(%\BC+9K*?=RI&<^!LI+BAP*Y MRERR1\IY(Q+T[\^G,FUL[OE3:*.>91,IY+I%R7DC$G4\] M=S*UTYM2VK3.S6%@.4./8>`IAK%2!WL,L@R_6-B24-FJ^11(IY[%$*D].)+KA/)4VRGDFD7*>2Z2<%Q)-Q9W/ M[^#.2VG3.C='@24B/4:!YRW&*(A4QIP,]MD*'5_!9.@JJE'@R&.S[\>C,Y^, MEC`51"W:L*JYYUE9=83-Q1+QERLL#A*!NN:\T60Q4?_!1/E,TYEL1Y\[T-/" M:GHV&]E+0)DC&.')FSR;,TV%`--HZ>BDE?(A63@43T M--(&">:3\*5"/I(5E?M8(N4^D>BF^U1:*?>91,I]+I%R7TATTWTIK:[,*99, M]1@+GGN1/SD/U@Y'Y@/&@SVHL%*1YE^O:,VA0%B)N)^,G*D*>O;+&O10>E5/ MB$@BU78LD;$0V(^RI&?;J?2JVLXD4FWG$MULN[#;=JUM2BG=X-.*I0,]QK0U M-S<-`NF;8$0^H@!1B"A"%"-*$*6(,D0YH@)1:2!C?7+[Y;6MN:4?3W59$]J: M8HW@1E0D*SF9?$0!HA!1A"A&E"!*$66(DC)S:Y9S9(0D()^RNG8WJ69Y@"A$ M%"&*$26(4D09HAQ1@:@TD*D?2QEU_?[GTW^V=;"EYS('V?ZXK$R'RFVQF\LE(+:%=1H@"M0D01 MHAA1@BA%E"'*$16(2@.9DK*4J(>D/(,R).5(B[^-"\A'%"`*$46(8D0)HA11 MABA'5"`J#63JUR_U9]G&&LI+QYR,*$(6((D0QH@11BBA#E",J M$)4&,B1E!P(]0K(U-Y_I`K4'+]PU_TJ6?^1WK,ZOU:8Z')K!KO[.OH"EX7V\ M[S#_/'?M3E?LP4ER0\F,2EKG4#*GDC9+A)([*FF/,J%D025M*@XE2RII,T.[ MQ'%7[/W)E7MS/"II3PCL.NZ$O+7[%RBA+Y%IUW_%FTOMT'[V6@FU0]NR*R4D MP54%2("K_:?N7^T]=?YZWZD?]#KS2LL.]8->U&$)O9)8L1<.6$)O$U;L70&6 MT(N`%3OFQQ+Z';`!*N`D>TT[;_?M4T8!IHF+TFX.3[' MY][+M==W+V7A/5,A&:]BA/T0>;1*>,JJ?8Q^_WJ\N46>5*1*2<$K&J-7*M'= MYN.']9&+)YE3JCQ@J&2,R%I2D9E%9 M!%$8SH.2L`I9AI6XA(-G&4OH`T\.):V4)1&T(`KV+W-6RQ-;F5Q"5Q+Q=*AO M$E[60+%C!5.OAA1Y9;+ZNJ^X(+L"?+_@*4E.W.9A0%^R1'#),^4#76`W.O2\ M#)8!,&W6*0,'.NV>H%F,MGAUCQI2=WY[,^?&S8.DW5E'(-M1) M5V#'^9.&?DUU"!8'@]6/I@(_A)?2C!P*]9,?OU"VSQ64>P:.M+%5^OI`90(9 M!1H_FFFFA!>P`?CT2J9;`S)"7LSWD:4JCU$T]_$TG`/:VU&I'IEF1%YRD(J7 M?RT&-TR6(VHXX+OAF,S]V2*`?&X M'S"BL5L-CA'T-.Q50A&>-U$X6P?/D+BDP=Q;#'RV&-PB`A!ME4'MYTHT$2AUYDP;=4],$$!I6#4(. MM1F^871!V8:H='^_KB)N16 M:OJ&J:MFA3[E>OUX"HU4:F1<+!;Z2'SG_<+#>7$*N9[^'S?.^(.SWVF1=[IO M.#(,08PZ8]W>!>QA65*QIY]H44@OX0=]SD=P_+71]@ZR-2GIQZ>KK;V;!.T_ M<#>HR9Y^)V+/*ND5-`/.T'2TL+<+^Z!X#0T%5P2NX%I@?N9P"Z1P!(8^9#7C M7)T>H!N"]EZY^0<``/__`P!02P,$%``&``@````A`%,QERWW!```:1,``!D` M``!X;"]W;W)K&ULK%A=;ZLX$'U?:?\#XOV&F"1- M0$FNFJ#N7FFOM%KMQS,E3H(*.`+:M/]^9VP#'L/2Y&I?FG(8'Q\?C\>:\\;)*1;%QV63J.KQ(Q"$M3AOWKS^?OJQ',491[7\%B>O.I2\O@@&^69 MYT^G#UX>IX6K&,+R%@YQ/*8)CT3RFO.B5B0ES^(:]%?G]%(U;'ER"UT>ER^O MER^)R"]`\9QF:?TA25TG3\)OIT*4\7,&XWYG\SAIN.5#CSY/DU)4XEA/@,Y3 M0OMC#KS``Z;M^I#""-!VI^3'C?O(PLB?N=YV+0WZ.^77ROC?J<[B^DN9'GY+ M"PYNPSSA##P+\8*AWPX(06.OU_I)SL#OI7/@Q_@UJ_\0UU]Y>CK7,-T+&!$. M+#Q\1+Q*P%&@F?@+9$I$!@+@KY.GF!K@2/PN?Z_IH3YOW-G#9+&Z(?SJAOYD[B^6*]G[2,.Y M;@B_=\OVE`72T2BNX^VZ%%<'TA0&65UB3'H6`G%CI9+1FOM?WH*I2/*(+!L7 MUA?85D%"O&W]U73MO<$D)CIFUX]A-&+?1.",(6UD`![H;46#Y_^#:&1!T4UW MNP8P1F$I;"*:)I$!$(4PN;;"&>3Y<(8V+F*CC0NS8+AH>;13,6S9JM[WD,A$ MB"J@-E6-J\%@R`HZJ3XU9*>#`J)Y1H/V;5!KFXD0A;#^;E>(P5)AP[M3B"_+ MATRA?0^)3(3T_4#[EDO!7TX@_L[5@$14ET)`ESFU<\NF-J@93F0B1.J22AV? M2`RF,N:E6,58"%]EZ;D(CJ4HAET\*RJ0UJ;3(1(A72TI0Z M;A,&4SD*,6WJ(9&)D+X93+;9.:;3C_DDF:@R#5E./5A.=5&M502B>K'8&O,Z M;A93I1FJ0T.]TY!I5Q^*"$0%8"V]78"JO$2`AF!*C`*ZM$UIHQKE$3,AJ@E+ MZ>V:=.$U35$0,:4'1C@N[80B7?M7_X_?U#0]!I M4VCV?2@B$!6`5=R:938%\,[3FZ]W`Z-2:@C]Z%9]8!],NJAF`!&!J%HL^8;: M\42$V[2]UC4D[[>*6=V7U>TNY^6)[WF654XB7O$NS`*XE[6PNJCOV"+$8@IZ M[3<^WN'EC;?WQHZOEQ#OQ#+W:@:$C0#GP?M/TAA$/_ MP*"7(1S(!_!5&,D\]5HOX$/')3[Q[W%Y2HO*R?@1)G\Z6<)^4JI/)>JA%A=( M"OC<(6KXQ"'_/<,G+0[W[BEN/D&ULK)O9@>#^`%J0L,+V":-]`28FSLQV?/P^OH^_UZ;QOCG=C:S(;C^KCKGG<'Y_O MQO_Z*_EC,1Z=+]OCX_:U.=9WXU_U>?SG_=__=ONC.7T]O]3U900*Q_/=^.5R M>0NFT_/NI3YLSY/FK3["DZ?F=-A>X,_3\_3\=JJWCVVAP^O4GLV\Z6&[/XZY M0G#ZC$;S]+3?U5&S^W:HCQGKM[<_=LWA M#22^[%_WEU^MZ'ATV`7Y\[$Y;;^\0K]_6NYVA]KM'T3^L-^=FG/S=)F`W)0W ME/;Y9GHS!:7[V\<]]("Y?72JG^[&#U:P<=SQ]/ZV=="_]_6/L_+[Z/S2_$A/ M^\=J?ZS!VQ`G%H$O3?.5F>:/#$'A*2F=M!'XQVGT6#]MO[U>_MG\R.K]\\L% MPCV''K&.!8^_HOJ\`X^"S,2>,Z5=\PH-@/]'AST;&N"1[<^[L0T5[Q\O+W=C MQYO,_9EC@?GH2WV^)'LF.1[MOITOS>$_W,@24ES$$2+P4XA8]L1R9Q[3&"CG MBG+P4Y2S)ZX]]Q=MY0,%0;9M-?S$"EW9ZH&"GB@(/Z^KT1<%X:S&WYA_%T(*1PVN3T?]D%"V,/_L%JYU];@2P,ZP;E*]-Z=@,C&5!R9S-X8PPW0YPT+P_=ZQ M9[?3[S!Y=\)F26TLW2)$"S93F6QD@M@$B0E2$V0FR$U0F*`T066"E0G6)M@H M8`J^[AP.(^;_X7`FPQR.KEHBD!&P#>^B!1:)3!";(#%!:H+,!+D)"A.4)JA, ML#+!V@0;!6C>A6E(O.O"L.[?$7#TLE)W8YB'W>BU77/T$A(1$A.2 M$)(2DA&2$U(04A)2$;(B9$W(1B6:<\%!FG.'G)Z MSQBXG5$W<@F)"4D(20G)",D)*0@I":D(61&R)F2C$LW1,&"O<#2S;AV-[EER M`EY%$A(2$1(3DA"2$I(1DA-2$%(24A&R(F1-R$8EF@OAC'.%"YFU[D).'&6Z M$Q)QXJHCW'9]??#&G1'&(B$D)20C).?$=KJ8%IV-.G<6>O5E9X355YSPGFDN M@]/=%2YCUKK+.'%ONA:&A$26:[>W+A[CLU-!+$[U;2S8<<,T'!T MC:Q[CAHYT2@Z&\5WXA@1S8]147F6=' MM.*I+S^;LZHA8];V;L>\=>/-9L8T2ZAVBFA0.S.T+;A],;1S%)+M M+A`-:I>H;;4KE75C$>T*A5IM/2KL\$^SJBN7`Y:/&L-9(!O&@Q(L8P$,T4H9 MT`*Y04<6G%I6K(4GPSSN3',0[22XRP2B&4?,E9T?G!YUVM[ M;3MN3QA$"Z1V^BGM#*U\[M$YU M0)9V#`7PK^8-5JZ/4CE+9"]J!#EJ+P#U*MD!7*UR>'=A%S5\/LKN.+:Q4BZ% ME9[2S,V41EKA0(LHBBE**$HIRBC**2HH*BFJ*%I1M*9HHR'=\3"VKG$\,S=V M+8YT+UOFQLXNM*"@D@A%%,44)12E%&44Y105%)44512M*%I3M-&0[F5VTK]B M>//$0%O[./+D9`HMCB#ID0.W0W)>P#UV-\W;PVU,"R8"V7(32`6"&E4M(ZG) MI!4V(J?RA42*EF><$$IIA5J50$J[5M)*U3(VWK6T0JV-IJ6'AR435X2'YQY: M>#C2PB,R%#4\!,5PB\7FA1+$1""ESZE`1BR,S"*35MCGG,H7$JG^,^9K*:U0 MJQ)(:=>*6JTIVF@%=<>S;$-U_&\E:^QBRUR4.-+BP9'BZ4@4]&0J$5.4"*3T M.Q7(E]842H]:"G[[FODW/^0D:2:D4$ M>\:Y*T$KJ94B4J85HD&M'*VD5D%1B:A]#<[CA4@67"&2C5@CD@4WB-J">BS, MC'-X6MDTM13(F%;&+AZBE1RQ$46Q0(XV^F@L2%J8HA9_6<^N&;)/:>584+:K MH*B46KB:5-1JA4@V8DT+;M"JK5&/!_&>L'Q457:'"8'/7:,6=L7`MSW:,5&BCB>OQ9DFYNCS^7KQY M:J\>#-E<9-F^MNOXQGDF1"LYC2*!/+FBQ(C8NX7O]W`H7-QXGG%B3JA4BN4@ M)1Z*-V^IQR_/>@Z&5+E`9=G($A&7@7@;RT]%95989K"!:[3BW7=G[HWC&T>I MC117NOK>[1ZL-'K0/SB?\"L%+;HB"B**4HH2BG**,HI*B@J*:HH6E&TIFBC(7TBL^SP"L?S M9%*+*4=PK$7_A39!$44Q10E%*44913E%!44E115%*XK6%&TTI+O4S(Y_;VVD M23-[8\361IG[A@(Y/!-(O"GPC'XNE%48MT>2U'K'=]XI!TIKKV[A`;+GI M)JQMKD8A6BG+ND!**AVCU6"^CT;T9`^'!+TS+#RVQSY<_-$GS'BNHP[^5LQ\ M?^J;"1=:*<<3BF*!7/ZVDKWG8?_T&]A$*Z<'R%S]G)L?MP_>EQN!>[& MR@;+/W?//RY\J$_/=5B_OIY'N^8;^TQ].]@ZS#_P#V^_`O;>!_I.GLSA22MN M/'FP_>"!?TO`>`*[<,#VGQXU>P%/VI7+*`,7[E!/WQ-8W0*V=E$U^)K"0QL< M0VL)7U]HXVAR&RKOT5DZ\'6''O[@!@_P7I)6O`1O]3H+?-7K*G#O`T_:C";! M^X^`7?W2.N`U2,!>%)GWOAQAB>]*G!NY&@ZGT"KT@"=A7<4P]4TUL+ M5-)G7_D!?""(ZBRAAF5O#?!6*@A[GT3PA%VO4S5X^Q2P6W;Z!%Y"!>P54]\3 M'Y[T]04NY^%)GUH$8GU:!82ECR_]8-FG$_I!V,>(' M21]/H6M].BETK,\^]P/XZ!?H3[NA"%^M>=L^UZOMZ7E_/(]>ZR=8)F;MIUY. M_,LY_(^+>)/_I;G`EVI@MX>O'<"7J&JX[IM-8"M]:IH+_L$JZ+Z6=?]?```` M__\#`%!+`P04``8`"````"$`-8C2@@0&```$%P``&0```'AL+W=O MD^*074]C_>^_EM\&NE;5\?407XIK.M9_II7^??+[;Z/WHGRISFE::Z!PK<;Z MN:YO@6E6R3G-X\HH;ND5_G,LRCRNX6=Y,JM;F<:'QBF_F(YE^68>9U>=*@3E M5S2*XS%+TGF1O.;IM:8B97J):WC^ZIS=*JZ6)U^1R^/RY?7V+2GR&T@\9Y>L M_MF(ZEJ>!.O3M2CCYPOT^X?MQ0G7;GX@^3Q+RJ(JCK4!I\UZIS\;XJLT.475/(-HP3&8'G MHG@AINL#0>!L(N]E,P)_E-HA/<:OE_K/XCU,L].YAN'N08](QX+#SWE:)9!1 MD#&<'E%*B@L\`/S5\HR4!F0D_M&T[]FA/H]UUS=Z? MJ[K(_Z5&-I.B(@X3@9:)V,.[#BYS@)8[0,_O1/"8`[3,`6+=L8=G;[H%+;,? M&H->S_,'?4!W''WF""T/9/1M:^A^XM=G?M!^K4Y\YVI!@.M*DQN@H.E_JFBUJ!+Y\K7-0\2Q86Q(PUG?Z9?.2 M(%]XD$]<>%'8G:JXUR.3UGXSE>9Q'4]&9?&NP?H$_:IN,5GM[("(\4E$GU=, MJU_-*IA.1.6)R(QU&%"8,!4L!6\3U^Z/S#>8O@FSF6(;6[:8<0LR5XGL7`4+ M%2Q5L%)!J(*U"C8JV*H@4L%.!?L.,"&U(K]0!/]'?HD,R2_/S)2#-N&.DDQN MP5WF*EBH8*F"E0I"%:Q5L%'!5@61"G8JV'>`E$R8%%(R/U[I>4T2Z[$.-2UJ MTD$U26WLODCL#)$Y(@M$EHBL$`D162.R062+2(3(#I%]ET@IA'0\D$)B#2N# M/*\'HND(^'5E?9EZ9TP MXM+[KK0T`+!;DP;@@T3#?HQGFEC+F::$;-DZ651>^3-FY(L,S1EI%]P%(X-F MU^`,W*$W<)716#*;H=!9(>40*:\E9=OW>JZO[#@V2'B+A",DO).$/=>Q/,>2 M1V+?%9;R#FOI`WDGUG+>*7&[JZWC*$ORC!G1HTJSDQ)NO#(6C#A-WN&8/%Q\ M4[802V;2SJ85$@Z1\/ISX0T2WB+A"`GO&/'8$_M]],3[KK"4=C@T/)!V8BVG MG1*EW-67'#/JE+MP$VFGQ"53ZVUB^Y8Q5(N=^4#3SBQ7J:\5,VI#A8S0DRX9 M\S4E(I1K6`.K_:A3@?E#\^NP6V;4AHT8:SU#75SWS`>:#T-)`T<. M;P^,7&,N#QU#\I1QE>[/N%5GSG#4OI47',%&H//HZKSA5IV)PU$K'W+4RJ\Y MNBN_X5:M_):C5C[BJ)7?<717?L^M&GEY+,@IIWM:O/_2(*=G91HQ),\CUY47 MSQFW:LMLSI'TOE'?$PMFQ6K/,N!60?HH@[[DJIT7"T=M[)"CN['7#\;><-4V M]I:C-G;$T=W8.S6VH^PY]ERF"2:/*3EL/3"F]&P&1P*^HDW)C0<,<[,"4&EZ M94?O&?*T/*6S]'*IM*1X)==Q4%^3D<#TKG#N![#E`DF%AWX`^R7,(S^`S0[F M<.?XU%PY*CI3"TB76F;@!G*,R?O.")WFFJ`;P`3@?88=H+8!,, MW!0.<`=YBT_I+BY/V;72+ND1DF(U6]^2WF+2'W5Q@V3!3611P^UC\_4,M\TI M+.V6`?5P+(J:_R`!Q/WUY#\```#__P,`4$L#!!0`!@`(````(0!@!M9HE@X` M`$-)```9````>&PO=V]R:W-H965T"3'9DXO8?J;U MCM1J:=0:P=T__MB^7GU;[P^;W=O]P+L>#:[6;ZO=X^;M^7[P[]^3WVX&5X?C M\NUQ^;I[6]\/_EP?!O]X^/O?[K[O]E\.+^OU\8H4W@[W@Y?C\7T^'!Y6+^OM M\G"]>U^_T96GW7Z[/-*?^^?AX7V_7CYVA;:O0W\TF@ZWR\W;0"K,]Q_1V#T] M;5;K:+?ZNEV_':7(?OVZ/%+]#R^;]P.K;5+SYG5S M_+,3'5QM5_/\^6VW7WY^I7;_X07+%6MW?X#\=K/:[PZ[I^,UR0UE1;'-M\/; M(2D]W#UNJ`7"[5?[]=/]X),W;X/I8/APUSGH/YOU]X/Q^]7A9?<]W6\>J\W; MFKQ-_21ZX/-N]T68YH\"4>$AE$ZZ'OCG_NIQ_;3\^GK\U^Y[MMX\OQRINR?4 M(M&P^>.?T?JP(H^2S+4_$4JKW2M5@/Z_VFY$:)!'EG_<#WRZ\>;Q^'(_&$^O M)[/1V"/SJ\_KPS'9",G!U>KKX;C;_E<:>4I*BHR5"/WL$3E3,%`%Z:G M^.72VW*7BNC]4&N',I2[D1$MC\N'N_WN^Q5--]3FP_M23%[>7*CQF)"==!HE M/QHD-#J$RB*"U`69"W(7%"XH75"YH'9!XX+6`)9W:1B"=P,*Z_XIGJ-7E+H? MT#@\1:\?C&SO+:2--SMY/`02`8F!)$!2(!F0'$@!I`12`:F!-$!:DUC.)0=9 MSCWO5&%-LXHY)_B!YWA5&=%\;[C>#=R3T2ER@<1`$B`ID`Q(#J0`4@*I@-1` M&B"M22Q'4\!>X&AAW3F:W;.0Q.]60]U$&@*)@,1`$B`ID`Q(#J0`4@*I@-1` M&B"M22P7TMK%%58VUZ5Q`Q,(!&0&$@")`62`*'.("E\J4@]:S''\+D?V3EYW`G;J!>[+B@I$NR"A&E"!* M$66(&?G/0)%"DU&W'^://&]?U.ZK0GJ:B)756$=^@@531KI@A@5SMM)W+!CI@B46K-BJ*VA'I$@"+G"6 MS!DL9TDTIL>)X2QW1XI*=+.E?+4CMZH5LL;7&(:\M`KD8/9NIZ.1,P03U$X9 MG=7.E!5K>_1VT='.64C7NV!T5KMD;1G3WJT'VA4+==IVKXB\PNR57YLG9'9" MM^%1L_!4PD(_C,YRAEO(5CK.(H4"/6IC1F)B^O8POH$&)JB3'V"H5,K&QX$@UJ3_O\L[%3M94VALAG2"VCEJ%USJK';)5DH[&,^@ MXI46-SPPT7FN-69\D<&=&S._[]Y_]&PU'@>=C-.#0OE^,-7C*%16!HH0Q8@2 M1"FB#%&.J$!4(JH0U8@:1*V%;%=?E@CZF`@J)#I8Q_;$302U%4]@$:(848(H M190ARA$5B$I$%:(:48.HM9#M99&@F0%]?AU#.8"(4G.V5\CVLN>N8[25]C+F MAFB5($H198AR1`6B$E&%J$;4(&HM9'OYLMS0Q]Q0(6,N"!6B1%"[5!:T<\.) MFQMBP40ABA/62O4=S='CI'B9MN*".>HI<,@B$N3,()+*Z1R*K>P#%XLV72%!U)R8*&6U.%2)YH\T3 M)Z?*M!6W.4?Y0B-#:^J,UU);L5:ED%&O&JT:1*U5T';\7Y*JTD(+^D,BJS]4 MJJH]':F"4YTVQ8@2A8QVIPK-]*O<#%&ND-&WA4)T1]/Y3AY3:BOM?%E[HQ(U M6C6(6H5D0=OY(H^\8.J7::> M7B9VN7F%,C67L9SD5K!A*[G"G@83+W!/9;26N-V5(G^]H"MENFMUI41V`C%U MFA=2[XB1-C83"$`Q6]'#2'?)U%EW)6REM5)&YK!2\F>U!J-1:>HJ#2M1<4%>BP8(M6W5WM/I"A/,% M?=&9VP]VA9QQX:R"0K;2810ABAF=C>6$K;16RDB'9,;HK%;.5EJK0%0RTN%= M,=(%:T:Z$@TC7;!EU!6T^^)GJ?.'MJ5IZG&?]0J)588QW3@3?,A6.BPCA29Z M6S-F1+..H>4.%]1*%3*VKK(/:>6H57!!7:^2D5Z\5%BP5LBH1(,%6ZN@W45N MROU+.X)CS,05$L&AW3ISUO\A6^F@BQ2:&"LTA:;JQ4O_0@&E4BY'`:3KX#Z' M,[;R?[100.5"(:.2)EHGV$-RYN08(5N90U(6G.H9)5964_$RA'G]UA)]J=N6`4(8H1 M)8A21!FB'%&!J$14(:H1-8A:"]GCB!X]E[A4F#LNE1)LY41Z*59P85MKQ M$:(848(H190ARA$5B$I$%:(:48.HM9#M99$"?WQA/989L[FP5LCP7X@H0A0C M2A"EB#)$.:("48FH0E0C:A"U%K)=*O+P"UPJTW;+I1(Y@>L\@D(Z[@&!"RA& MJP11BBA#E",J$)6(*D0UH@91:R';RR*'O<#+,N6UO"R1%;B`HC&@&%&"*$64 M(/Y-XB4G+J+'X6<;,%9Y(9L960+"AD[M#%;G=U&9B/<,`I$.F#.*R(C MHD])B[K]I%TRD3"GF$Z,=DOM*<;=QV,K(^M%%"M$W2"R('%&0ORS#]4E5CF[ MD]Q%_R]E>@'F`@HY?>?DMR%;F7TGMG,2.Y`^"-`B^8]K3F MI/6!S(V^A.&B!N("N%.X'W3;J=)W\EL9Y&?/M^O]\SIKE:[K^(;%VAD M/=R=L/PZB,5X.A=+2FH\7)G1E6[7"J[GM9$^/]%WA=I(9_[Q"KW[IC;V]1D]$>9B MOL`^3N[MZZM/P?R3_%H1UX54UUZGD\][74[QV-`-7HXP7D@[XK"_+!HM<'=-1_ M+HZCHQJ=^)^+0_U]5Z9TI:\,G?B?BP/I6(8._E.M^]3HM#I=Z2M#!__GXD@Z MJ0U/P4Y?8?.^?%[7R_WSYNUP];I^H@EWU)W2W\LOP9%_'-6)PL^[(WUY#2VO MZ=M`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`TZVY5`$P0[Q`T./\)0>M>=-#]Y9H>"$;!(NP]^B8J`$B$F%P> MX>S=#.U9U(WNQIB%@<5LMJ`1--8GJX:H6X&H$"%1H>LPJOAZZ:/1SL@*.JD5 M"\Q2&[DPZ10*Q`5(N3:);VV M7@H5=*%?S!Q3SIGFA@%F$\,1UI!Z>!IQ`AL2YHK!_SI)UI.!8)>1*( M"A%R[0RSS8FZ*IU,1S0P!S&BV-ILO=?`%(%HN%IK@WG]F*O,*C/$H>^Z<9"Y MW]*>M49>WK-55"8[-5TK36:]F.XPK]9[]5$J`M$PM6I>'J;3V)``"X7ID@E( M$8@&H$4Q"$#K3[W0%4SJPLJLO)+9<8I+)8C=7%K7,!B"(A"-5PMI$.\/,L;* M+HG)0I&,T<)W><]6)EG&L*$UF1-3C;=15#^T8LIRH7%>5&/*G&6,]QH((!`A0/>5$*84 M6=,!28]60HI`-`"FQ:;^J$54[84&N>ER0\(X+6P]^J94P2BTY4DL?I. MP2H8!V%2^JNU$E($H@$P)=;Y4M37W)/R0:7[2!H'D8PIIF*!.?WU0U"^H<@8 MK947*TQNE354&`=%,D:KVN4]6PU$SSX7BBE;#$WNE))F#*]WO5?/G"(0G;`D MBJV^H"$3C39+D M0DJR@PAAUBN`%/&B`40D^4K"I"07@]AZW0E*09 MT^:/)-'CO3Q?3L--'43#3=+PF=1P!Q&^K%<`*>)%`_AI M&CZ3&NX@1AB_Z7DO3YCMRPZ!QINDX?J]/2NK'11984R24UV4)`>K804@6@`$4V^[EW73&JR@UC& M,.%JO9KG9XDR<:;T67U M-Y(O$:W5#ZV)+W#F@]"&TL,JX\9YL41B7JWW\LPX[94/'/,D[37>C!E1++?. M*\@M12":2$RB]JV^H"$2#31+JN11J!P74 MM!)2!*(!1(3ZJF4G97H^J*U/P:SFI;/W\G0-#0'1:)-D>BYEVD&$+NL50(IX MD0!*IN975XZF(YKX#D(@(5^\TO9>`U\$HN$FJ7JIO5E,%@K(:9U7`"D"T0`B MJG[5VZ)2RKJ#&%^\TO9>GJ]W9;U,DG7CS?@2977KO`A?H1?EBZG_Q_5E.8A\ M/[;&08P47DU[K[ZA(A"-*4G12UE-.RA@H)60(A`-(*+H65Y=\-$`(J)^U=:$4JJZ@PA?Q93?!+V7 MY^M=52^35-UXLU4G)+QU7H2OT(OP5454/MO[^4)<$(MJ\PJ M2:B--YN44(+MIWGG%:8,@>@,,*'6A<`U=5,E)=Q!+%]X4>Z]/%VV+SL`&FV2 MA.MW\ZP.<%#`32LA12`:0$3"KWNI74D)=Q`CC$N2]_*$O2OA59*$&V^67T*O M6^<5<*@(1`F+2+@MG'ZP(J5B5PXJ_#=B#_EUFRW8NE5Q+U^0TH"31+RR6AR^ M.'40=@OT\]-*2!&(!%!'1/P2QDP[.GD]%##FH8\8BWOYDI0&G"3BM11Q!X6, M24@1B`;`M%YKF/OX_W&2U5:7P]GKH9`RYP6E1<=VU[A,,M\P]/(%*XTX2?9K MJ_$D3"G[SBM_7+1!&(AIND^[74?0=! MV/NKM1)2!*(!1'3_BI`+"Q'"BHPKN/?RA`T-^9)<)"FX\699;T6=$"8@Y1K&9NSG M*/A"*KB#"%LX:9!Z_-1<:^4#;. MBRAXSK>=MM[+$_"N@B^2%-QXLW2QHD[214#*-8S,0#:-2;C^`);X_<5V1(/K M,98R[,Z(%C6] M&TL=?B\+W(;"83I"T6911"0Z*W'V%K*5G$12I+/I M(+9^<>93KM*!6\#=T!08BSI)J/7Q:?Z.I<>")+(GI.UYWEUW?.K:[N7E--H< MONK3SYK$^]L![P]G3_/ERAW/9C:=-_KHMGG$EK9"V\P#G+3-M&VF*T9N6Z!+ MU``Q"SK$G3AF07>X#<8LL!FW)6-*K1R)SA$I8%+(M( M=R!IJ@=K]F'Q5C6.ON.!.A)XC<'BN3%FP6#QB!:S8+!X=HI9,%@\J$C+JL9@ M<9>2%CP0H$UTK#7&BJ([TF:!H:*\C5DP4M2=$4N)WO!Z/6*IT!M>6DO+JD). MXH%)6O!R&&VBZ5.!4;R`C;4!HWA,CEG`J'U8Y3-7@5$\+,;:5+#$8\-(\<(I MTJ9$;/BP%[,@-GQ+BUD0&SYRQ2R(#5^88A;$AN\\,0MF&U]9I&4UGRU7>+\O M+=CNL538S!&S(#9LJ8A9$!OV+\0LB`T;"V(6Q(;O^C$+&,77]8BE1.[@0W;, M@DS$%^:8!;F#[[O2LIJ5RQ6V9$D+=MLM%?;2Q2P8#W:TQ2P8#[:32+`-25I6,UP'FQ*E!?MS$5OT.C-Q`C5F0U]@'&K,@=[`)4UI6!=8VMB1+"XXS+!5.*\0LN`[.#,0LN`YVY\^V>86 M4!`?#:Z"\^_R^JM,5T31V8%%'QF7;9H,&8JSW#$+L@"GIJ4%OXNSBO>%!A'_ M1@\QANO%$<%72$RC0#;@(` M`%H'```0``@!9&]C4')O<',O87!P+GAM;""B!`$HH``!```````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````````````)Q546_:,!!^G[3_$.6]#85JFI!)U5*F3MI6 MU-#VT7*="U@$._(95/;K=TX$)*UA6]]LWWW??7<^G]G5ZZJ,-F!1&3V*+\Y[ M<01:FESI^2A^G'T[^QI'Z(3.16DTC.(M8'R5?O[$IM948)T"C(A"XRA>.%<- MDP3E`E8"S\FLR5(8NQ*.MG:>F*)0$FZ-7*]`NZ3?ZWU)X-6!SB$_J_:$<<,X MW+B/DN9&>GWX--M6)#AEUU55*BD<99G^5-(:-(6+)J\22I:TC8S492#75KEM MVF-)>\LR*4H8$W%:B!*!)8<#=@?"%VTJE,64;=QP`](9&Z'Z367KQ]&+0/!R M1O%&6"6T(UG>K=G4Z[)"9]-G8Y>X`'#($G)H#NMEV[>]5I=I?U![T*KKZ1D: M)63H:IPI5P+>%U-A74CRH*VY5M$H;@3M;I%?ZYQ/M*-Z\>^ZN6UEVLKW.8R- M1E.J7#C(^8THA9;`LW>9_HL_GXJ_A\@<1?*=AMP4_+ZB"]MS^](WB714=2$/ MD/\'Q`<9"UP$(;^$6UOP+C=K5!H0.3TJGJFY5H4*0J86"K"6:I4MA(5.-^S5 M9\[()>7F.[NA?!;64G>=<+^A3LSYV*SHA6+])H+QQX:"2T_L94^L-39,>CJW MBR#Y<=U\)EZ.0]YK]_[4QT'(:67](.9MV?DM.*%*Y#,:5>L@Y$0R!/X`Y$3- M`@5H!!X/GB;6S'P[8'8UD6WJ2\4+H.>0[G_<&_XL\-5]E>G%YWAOTZ(-HG;'D M\"FF?P```/__`P!02P,$%``&``@````A`!R$&OZ5````J0```!````!X;"]C M86QC0VAA:6XN>&UL/(Y!"@(Q$`3O@G\(G[GI%Y4)18VL!]&4,2^+)&?!NZWZ^X(2IKCQ:7"9.!#`K/= M;K1WR5^"BZRZ@<5`:&T](8H/E)T,927NS:/4[%K'^D19*[E%`E'+"0_C.&'N M`K#:JVK@/(&*_0.H]$NT&O\C]@L``/__`P!02P,$%``&``@````A`(OG0:(R M`0``0`(``!$`"`%D;V-07B^CW*^UW7R"-@0H=P*,YN[PHA:6B-TSS$H]MBR\4[WP(N\OP::PA<\L!Q!TSM2$0#4HH1:3]< MW0.DP%"#!A,\)AG!W]T`3OL_+_3)65.K<+!QID'WG"W%,1S;>Z_&8MNV63OI M-:(_P2_+AZ=^U%29;E<"$.OV4W,?EG&5&P7R]L#V;ZY.O-^5^'=62M';4>&` M!Y!)?(\>[4[)>G)WOUH@5N1DFN97*9FN"D*+&24WKR4^M8;[;`3J0>#?Q!.` M]=X__YQ]`0``__\#`%!+`0(M`!0`!@`(````(0#X\2[1P@$``,X0```3```` M``````````````````!;0V]N=&5N=%]4>7!E&UL4$L!`BT`%``&``@` M```A`+55,"/U````3`(```L`````````````````^P,``%]R96QS+RYR96QS M4$L!`BT`%``&``@````A`/5IOGVR`0``?0\``!H`````````````````(0<` M`'AL+U]R96QS+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`.'71+M+`P``8@H``!D`````````````````D!D``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`+B7%-BA`@``8P8``!D`````````````````[R```'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`)66FEQ!!0``-A8` M`!@`````````````````FS(``'AL+W=O!]&UX_ M``!PWP``%`````````````````"Q.P``>&POP`` M>&PO&UL4$L!`BT` M%``&``@````A`")BWP%\!@``H!P``!D`````````````````T(L``'AL+W=O M&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`+LY MVTIF#@``Y4X``!@`````````````````\:$``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT`%``&``@````A`.W,67J<"0``23```!@````` M````````````5;X``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`#6(TH($ M!@``!!<``!D`````````````````^=P``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`)1Z-`-N`@``6@<``!`````` M````````````-0`!`&1O8U!R;W!S+V%P<"YX;6Q02P$"+0`4``8`"````"$` M'(0:_I4```"I````$`````````````````#9`P$`>&PO8V%L8T-H86EN+GAM M;%!+`0(M`!0`!@`(````(0"+YT&B,@$``$`"```1`````````````````)P$ I`0!D;V-0 XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R9.htm IDEA: XBRL DOCUMENT v2.4.1.9
Stock Options and Warrants
 3 Months Ended
Mar. 31, 2014
Stockholders Equity Note [Abstract]  
Stock Options and Warrants [Text Block]
3. Stock Options and Warrants
 
The Company follows ASC 815-40, Contracts in an Entity’s Own Equity, as it relates to outstanding warrants. No warrants were exercised through March 31, 2014.
 
In connection with the December 2013 private placement of 72,007,000 shares of the Company's common stock at a price per share of $0.25, the Company issued an aggregate of warrants to purchase 4,320,420 shares of common stock at an exercise price of $0.25 per share to the placement agents. These warrants expire December 2018. These warrants contain provisions that protect holders from a decline in the issue price of the Company’s common stock (“down-round” provision) and contain net settlement provisions. Due to these provisions, the Company accounted for these warrants as liabilities instead of equity.
 
In connection with the private placement of Series B redeemable convertible preferred stock, which occurred through two closings on June 26, 2013 and July 15, 2013, respectively, the Company issued an aggregate of warrants to purchase 30,040,195 shares of common stock at an exercise price of $0.14 per share. These warrants expire June 2018. These warrants contain provisions that protect holders from a decline in the issue price of the Company’s common stock (“down-round” provision) and contain net settlement provisions. Due to these provisions, the Company accounted for these warrants as liabilities instead of equity. The Company measured the fair value of these warrants on June 26, 2013 and July 15, 2013 and recorded the initial liability as part of the private placement proceeds and expensed $759,000 for the warrants issued to the placement agent.
 
We estimate the fair values of these securities using a Monte Carlo valuation model. The following warrants were issued in 2013 using the Monte Carlo valuation method with the key inputs as follows:
 
 
 
June 26, 2013
 
 
July 15, 2013
 
 
December 23, 2013
 
Warrants Issued
 
 
28,394,834
 
 
 
1,645,361
 
 
 
4,320,420
 
Risk free interest rate
 
 
0.0109
 
 
 
0.0109
 
 
 
0.0167
 
Volatility
 
 
160.94
%
 
 
163.08
%
 
 
155.24
%
Expected term
 
 
5 years
 
 
 
5 years
 
 
 
5 years
 
Exercise price
 
$
0.14
 
 
$
0.14
 
 
$
0.25
 
 
The Company re-measured the fair value of these warrants and recorded $9,929,000 in charges to record the liabilities associated with these warrants at their estimated fair values totaling $16,311,000 as of December 31, 2013.
 
From February through May 2013, in connection with the issuance of new convertible promissory notes, the Company issued warrants to purchase up to 7,030,387 shares of its common stock. These warrants expire February through May 2018 and are exercisable at a price of $0.14 per share. These warrants are considered to be equity.  
 
On December 22, 2011, in connection with the Biocontrol business combination, the Company issued warrants to purchase up to 1,355,164 shares of its common stock. These warrants expire in December 2016 and are exercisable at a price of $0.46 per share. These warrants are considered to be equity. The Company re-measured the fair value of these warrants and recorded a gain of $87,000 to adjust the liability associated with these warrants to their estimated fair value totaling $646,000 as of March 31, 2014.
 
The Company’s warrant liability is adjusted to fair value each reporting period and is influenced by several factors including the price of the Company’s common stock as of the balance sheet date. On March 31, 2014, the price per share of the Company’s common stock was $0.58 per share compared to $0.50 per share at December 31, 2013. There were no warrant liabilities as of March 31, 2013.
 
The Company re-measured the fair value of the warrants liability and recorded a loss of $3,149,000 to adjust the liabilities associated with the warrants at their estimated fair value totaling $19,460,000 as of March 31, 2014.
EXCEL 15 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]A8CDP9C-D,%\Q,C0P7S0Q965?83ED9E]C9F9C M96%B8F8T-S8B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/E-T;V-K7T]P=&EO;G-?86YD7U=A#I%>&-E;%=O#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYA='5R95]O9E]"=7-I;F5S#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O'1U/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE M/E-T;V-K0F%S961?0V]M<&5N#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/E-T;V-K0F%S961?0V]M<&5N#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O#I. M86UE/@T*("`@(#QX.E=O6QE#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T#I0#I0#I0&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP M/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC'1087)T7V%B.3!F,V0P7S$R-#!?-#%E95]A.61F7V-F9F-E M86)B9C0W-@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]A8CDP9C-D M,%\Q,C0P7S0Q965?83ED9E]C9F9C96%B8F8T-S8O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$"!+97D\+W1D/@T*("`@ M("`@("`\=&0@8VQA2!&:6QE3PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^4VUA;&QE3QS<&%N/CPO6UB;VP\+W1D/@T*("`@("`@("`\=&0@8VQA2!#;VUM;VX@4W1O8VLL(%-H87)E'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^36%R(#,Q+`T*"0DR,#$T M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^4')E=FEO=7-L>2!!;65N9&5D($9I;F%N8VEA;"!3=&%T96UE;G1S("T@ M5&AE($-O;7!A;GDF(S@R,3<[F4@ M86X@:6YC'!E;G-E(&1U92!T;R!A9&1I M;F<@2!A;'-O(&-O;G1R86-T960@82!V86QU871I;VX@ M=&5A;2!T;R!R979I97<@=&AE('!U28C.#(Q-SMS(&YE="!L;W-S(&9O2!E<75I='D@9'5E('1O('1H M92!S=&]C:R8C.#(Q-SMS(')E9&5M<'1I;VX@9F5A='5R97,N(%1H:7,@861J M=7-T;65N="!R97-U;'1E9"!I;B!A(')E8VQA2`H1&5F:6-I="D@=&\@4V5R:65S($(@4F5D965M86)L92!# M;VYV97)T:6)L92!02!O9B`D-C0V+#`P M,"!A2!A28C.#(Q-SMS(#(P,3,@=V%R2!R96QA=&5D('1O(#(P,3,@=V%R2`D-C4U+#`P,"!I;B!T:&4@9FER M2`D-#`X M+#`P,"!T;R`D,3$L-C(Q+#`P,"X@5&AE(&YE="!L;W-S('!E28C.#(Q-SMS(&YE="!L;W-S(&EN('1H92!F:7)S="!Q=6%R=&5R M(&]F(#(P,3,L(&%S(&%M96YD960L('=A7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$6%B;&4@86YD(&%C8W)U960@97AP96YS M97,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M3PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S"!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA M2`H9&5F:6-I="D\+W1D/@T*("`@("`@("`\=&0@8VQA7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAAF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XT-#4L,#`P+#`P,#QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!%<75I='DL(%-H87)EF5D/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PP,#`L,#`P/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2P@4VAA2P@3&EQ=6ED871I;VX@4')E9F5R96YC93PO=&0^#0H@("`@ M("`@(#QT9"!C;&%SF%T:6]N+"!0871E;G1S("AI;B!D;VQL M87)S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X M+#'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!R969U;F0\+W1D/@T*("`@("`@("`\=&0@8VQA'!E;G-E2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M/B@R,CDL,#`P*3QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$2!F:6YA M;F-I;F<@86-T:79I=&EE'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-TF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE28C.#(R,3LI M('=A2!O M8V-UF4M861J=7-T M.B!N;VYE.R!F;VYT+7-T#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'@[($9/3E0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE2!A8V-O=6YT M#L@1D].5#H@,3!P="!4:6UEF4M861J M=7-T.B!N;VYE.R!F;VYT+7-T&-H86YG92!#;VUM:7-S:6]N M+"!O#L@1D].5#H@,3!P="!4:6UE MF4M861J=7-T.B!N;VYE.R!F;VYT+7-T2P@=&AE#L@1D].5#H@ M,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M#L@1D]. M5#H@,3!P="!4:6UEF4M861J=7-T.B!N;VYE.R!F M;VYT+7-T2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D M(%-T871EF4M861J=7-T.B!N;VYE M.R!F;VYT+7-T#L@ M1D].5#H@,3!P="!4:6UEF4M M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N M,C5I;CL@34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE2!O9B!M;VYE>2!M87)K M970@86-C;W5N=',N/"]D:78^(#QD:78@F4M861J=7-T M.B!N;VYE.R!F;VYT+7-T#L@1D].5#H@,3!P="!4:6UEF4M M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N M,C5I;CL@34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'@[($9/3E0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE65A#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'@[($9/3E0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE'!E;G-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'@[ M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE#L@1D].5#H@,3!P="!4:6UE#L@ M1D].5#H@,3!P="!4:6UEF4M861J=7-T.B!N;VYE M.R!F;VYT+7-T#L@ M1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE#L@1D].5#H@ M,3!P="!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT M+7-T#L@1D].5#H@,3!P="!4:6UE MF4M861J=7-T.B!N;VYE.R!F;VYT+7-T65A#L@1D].5#H@ M,3!P="!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-T#L@1D].5#H@,3!P M="!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-T M6UE;G0@87=A'!E8W1E9"!T;R!V97-T+CPO M9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U M<'0[($U!4D=)3CH@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T M6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U) M3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@ M,3!P="!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-TF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P<'@[($9/3E0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-T&-H86YG92!P&ET('!R:6-E*2!I;B!T:&4@ M<')I;F-I<&%L(&]R(&UO2!I;B!A;B!OF4@ M=&AE('5S92!O9B!U;F]B#L@ M1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-T#L@1D].5#H@,3!P="!4 M:6UE#L@1D].5#H@,3!P="!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-T'!O2!R:7-K2!T:&4@8V]U;G1E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@ M34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M#L@1D].5#H@ M,3!P="!4:6UE2!E2!U2P@2!T M;R!F86ER('9A;'5E('1H97-E(&EN6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE. M.B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4 M:6UE2P@86YD(&%R92!L:6ME;'D@=&\L(&-H86YG92!O=F5R('1H92!D=7)A M=&EO;B!O9B!T:&4@:6YS=')U;65N="!W:71H(')E;&%T960@8VAA;F=EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%2 M1TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D]. M5#H@,3!P="!4:6UEF4M861J=7-T.B!N;VYE.R!F M;VYT+7-T2!L:6-E;G-E2!A8V-EF4M861J=7-T.B!N M;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%2 M1TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!F;VQL;W=S($%3 M0R`V,#4M,C4L(#QI/DUU;'1I<&QE($5L96UE;G0@07)R86YG96UE;G1S/"]I M/BP@=VAI8V@@2!T:&4@ M9F]L;&]W:6YG(&)E9F]R92!R979E;G5E(&-A;B!B92!R96-O9VYI>F5D.CPO M9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N M-6EN.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$ M)U=)1%1(.B`Q,#`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)U9%4E1) M0T%,+4%,24=..B!T;W`G/B`\=&0@6QE/3-$)U=)1%1(.B`R)2<^ M(#QD:78^/&9O;G0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M(#`N-6EN.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE2!U;F1E;&EV97)E9"!I=&5M6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P>#L@ M1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)U=)1%1(.B`Q M,#`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T M.B!N;VYE.R!F;VYT+7-T6QE/3-$)U1%6%0M04Q)1TXZ(&IU M3L@5TE$5$@Z(#DV)2<^(#QD:78^5&AE($-O;7!A;GD@8VQA6UE;G1S(')E8V5I=F5D(&EN(&5X8V5S3L@5D525$E# M04PM04Q)1TXZ('1O<"<^(#QT9#X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B`\9&EV/B8C,38P.SPO M9&EV/B`\+W1D/B`\=&0@2<^ M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#PO=&%B;&4^(#QD:78@ M#L@1D].5#H@,3!P="!4:6UE6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4 M:6UE2!W:6QL(&UA:V4@82!D971E2X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB M;W1H.R!&3TY4+49!34E,63I4:6UEF4M M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N M,C5I;CL@34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE#L@1D].5#H@,3!P="!4:6UEF4M861J=7-T M.B!N;VYE.R!F;VYT+7-T65A M#L@1D].5#H@,3!P="!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6%L='D@86YD(&QI8V5N2P@;V-C=7!A;F-Y(&%N9"!U=&EL:71Y(&5X<&5N2!E>'!E;G-E#L@1D].5#H@,3!P="!4:6UEF4M861J=7-T.B!N;VYE.R!F M;VYT+7-T6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE#L@1D]. M5#H@,3!P="!4:6UE65A#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE M2!O9B!C:&%N9V5S M(&EN(&]T:&5R(&-O;7!R96AE;G-I=F4@:6YC;VUE("A/0TDI(&%N9"!I=&5M M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A8CDP M9C-D,%\Q,C0P7S0Q965?83ED9E]C9F9C96%B8F8T-S8-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO86(Y,&8S9#!?,3(T,%\T,65E7V$Y9&9?8V9F M8V5A8F)F-#'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0@0FQO8VM=/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)TU! M4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N M,C5I;B<^($]N($IU;F4@,3,L(#(P,3,L('1H92!#;VUP86YY)B,X,C$W.W,@ M0F]A6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG2!B92!C;VYV97)T960@=&\@8V]M;6]N('-T;V-K(&)Y('1H92!H;VQD M97(@;V8@=&AE('-H87)E6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U)3D1%3E0Z(#`N,C5I;B<^("8C,38P.SPO9&EV/B!);B!C;VYN M96-T:6]N('=I=&@@=&AE('!R:79A=&4@<&QA8V5M96YT(&]F(%-E2!R96-O2!F;W(@82!C;VUP;&5X(&5M M8F5D9&5D(&1E2!E2`Q-2P@,C`Q,R`H9&%T97,@;V8@:7-S=6%N8V4I(&%N9"!R M96-O6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M28C.#(Q-SMS(&YE=VQY+6-R96%T960@4V5R M:65S($(@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!R M96QA=&5D('1O('1H92!P6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG&5R8VES92!P6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[0TQ%05(Z(&)O=&@G/B`F(S$V,#L\ M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4 M:6UE2`R-2P@,C`Q,RP@/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG2!T;R!E<75I='D@9'5E('1O(&-O;G9E6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG2!A8V-O=6YT(&%N9"!I;G1O(&5Q=6ET>2X\ M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4 M:6UE2!R92UM96%S=7)E M9"!T:&4@9F%I6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M0TQ%05(Z(&)O=&@G/B`\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H M.R!&3TY4+49!34E,63I4:6UE3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%]A8CDP9C-D,%\Q,C0P7S0Q965?83ED9E]C9F9C96%B8F8T-S8- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO86(Y,&8S9#!?,3(T,%\T M,65E7V$Y9&9?8V9F8V5A8F)F-#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2!.;W1E M(%M!8G-T6QE M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T M#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[0TQ%05(Z(&)O=&@G/B`\9&EV M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;B<^(%1H M92!#;VUP86YY(&9O;&QO=W,@05-#(#@Q-2TT,"P@/&5M/D-O;G1R86-T6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG2!I6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG2!A8V-O=6YT960@9F]R('1H97-E('=A2!M M96%S=7)E9"!T:&4@9F%IF4M861J=7-T.B!N;VYE.R!F M;VYT+7-T6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E MF4M861J=7-T.B!N;VYE.R!F;VYT+7-TF4M M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CIC96YT M97([(%1%6%0M24Y$14Y4.B`P:6X[(%=)1%1(.B`Q,#`E)R!A;&EG;CTS1&-E M;G1E6QE/3-$)V-L96%R.F)O=&@[34%21TE..B`P<'@Z M875T;SL@5TE$5$@Z(#@X)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@ M3U9%4D9,3U6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXP+C`Q-C<\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C M965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ-C,N,#@\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXU('EE87)S/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO65A M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5. M1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@ M8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXP M+C$T/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P M)3X@/&1I=CXP+C$T/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W M:61T:#TS1#$P)3X@/&1I=CXP+C(U/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[0TQ%05(Z(&)O=&@G/B`\+V1I=CX@/"]D:78^ M(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPGF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E2!R92UM96%S=7)E9"!T:&4@9F%I6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;B<^("8C M,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1% M3E0Z(#`N,C5I;B<^($9R;VT@1F5B2!N;W1E6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG'!I&5R8VES86)L92!A="!A('!R:6-E(&]F("0\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B2XF(S$V,#LF M(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49! M34E,63I4:6UE2!I6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG28C.#(Q-SMS('=A2!R92UM96%S=7)E M9"!T:&4@9F%I&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$ M,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^/&1I=B!S='EL93TS M1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`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`N,C5I;B<^(%5N9&5R($%30R`W,3@@/&D^4W1O8VL@0V]M<&5N M2!V86QU M97,@07=AF5S('-T;V-K+6)A'!E;G-E(&]N(&$@6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;B<^("8C,38P.SPO9&EV M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I M;B<^(%-T;V-K+6)A'!E;G-E(&ES(')E9'5C M960@8GD@86X@97-T:6UA=&5D(&9O2!M87D@'!E;G-E(&EN(&9U='5R92!P97)I;V1S+B!4 M:&5R92!W97)E(&YO('-I9VYI9FEC86YT(&%D:G5S=&UE;G1S(')E;&%T960@ M=&\@8VAA;F=E28C.#(Q-SMS(&5S=&EM871E65A6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z(#`N,C5I;B<^(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG2!O9B!T:&4@86UO=6YT M(&EN8VQU9&5D(&%S('-T;V-K+6)A'!E;G-E M(&EN('1H92!A8V-O;7!A;GEI;F<@8V]N6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P M="!4:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O M;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^)B,Q-C`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`P,#`[($9/3E0M M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,3$R+#`P,#PO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,S@L,#`P/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT M.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F M9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM M04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B!B M;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,'!T(#!P>#L@ M1D].5#H@,3!P="!4:6UE"!S;VQI9#L@34%21TE. M.B`P:6X@,&EN(#!I;B`P+C(U:6X[(%=)1%1(.B`Y-24[($)/4D1%4BU#3TQ, M05!313H@8V]L;&%P"!S;VQI9#L@0D]21$52+5))1TA4.B`C.65B-F-E(#!P M>"!S;VQI9"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!A;&EG M;CTS1&QE9G0^(#QT6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M"!S;VQI9#L@5$585"U!3$E'3CH@8V5N M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO&5R8VES93QB6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@ M8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M"!S;VQI9#L@1D].5"U7 M14E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R M;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q,"4^(#QD:78^.2XQ-3PO9&EV/B`\+W1D/B`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`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$U,3L\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$U,3L\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T M:#TS1#0V)3X@/&1I=CY%>'!I6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@ M;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N M;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H M/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@"!S M;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[ M($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q-C`[/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P M(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L M.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,"XQ.3PO M9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[ M(%9%4E1)0T%,+4%,24=..B!M:61D;&4[($)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV M/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D]. M5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q,"4^(#QD:78^."XX.#PO9&EV/B`\+W1D/B`\=&0@"!S M;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[ M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%, M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4 M.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO&5R8VES86)L M92!A="!-87)C:"`S,2P@,C`Q-#PO9&EV/B`\+W1D/B`\=&0@"!S M;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!M:61D;&4[ M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ M#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,3`L,#@Y+#8V M,CPO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@5$585"U!3$E'3CH@ M;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P M<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\ M9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U3 M5%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P M,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5)) M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P M(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\9&EV('-T M>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\+V1I=CX@/&9O;G0@6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@ M,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I M;B<^(%1H92!A9V=R96=A=&4@:6YT6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;B<^("8C M,38P.SPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1% M3E0Z(#`N,C5I;B<^($%S(&]F($UA2!H860@=6YR96-O9VYI>F5D(&-O;7!E;G-A=&EO;B!C;W-T(')E;&%T960@ M=&\@=6YV97-T960@3W!T:6]N6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S M;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$P)3X@/&1I=CXT,"PP,#`L,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M M86P[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E, M13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[0TQ%05(Z(&)O=&@G/B`\+V1I M=CX@/"]D:78^(#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D M:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/&1I=B!S='EL M93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1% M3E0Z(#`N,C5I;CL@34%21TE..B`P<'0@,'!X(#!I;B`P:6X[($9/3E0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE28C.#(Q-SMS('!R979I;W5S;'D@:7-S=65D($UAF4@86X@:6YC'!E;G-E(&1U92!T;R!A9&1I;F<@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG"`P:6X@,&EN.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E'!E;G-E(&9OF5D(&EN('1H92!T:')E92!M;VYT:"!P97)I;V0@ M96YD:6YG($UA"`P:6X@,&EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E28C.#(Q-SMS(&YE="!L;W-S(&9O6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2`D/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'@[($9/3E0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE"<@8V5L;'-P M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT6QE/3-$)U=) M1%1(.B`P+C(U:6XG/CPO=&0^(#QT9"!S='EL93TS1"=724142#H@,"XR-6EN M)SX@/&1I=CX\9F]N=#XF(S@Y,#$[/"]F;VYT/CPO9&EV/B`\+W1D/B`\=&0^ M(#QD:78^2!I=',@4V5R:65S($(@4F5D965M86)L92!#;VYV M97)T:6)L92!02`H1&5F:6-I="D@=&\@=&5M<&]R87)Y(&5Q=6ET>2!D=64@ M=&\@=&AE('-T;V-K)B,X,C$W.W,@2`H1&5F:6-I="D@=&\@4V5R:65S($(@4F5D965M86)L92!#;VYV97)T M:6)L92!06QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@ M1D].5#H@,3!P="!4:6UE6QE/3-$)U9%4E1)0T%,+4%,24=. M.B!T;W`G/B`\=&0@6QE/3-$)U=)1%1(.B`P+C(U:6XG/B`\9&EV/CQF;VYT/B8C.#DP,3L\ M+V9O;G0^/"]D:78^(#PO=&0^(#QT9#X@/&1I=CYR96-O9VYI>F4@9&5F97)R M960@2!R96-O2!O9B`D/&9O;G0@"<@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT M6QE/3-$ M)U=)1%1(.B`P+C(U:6XG/CPO=&0^(#QT9"!S='EL93TS1"=724142#H@,"XR M-6EN)SX@/&1I=CX\9F]N=#XF(S@Y,#$[/"]F;VYT/CPO9&EV/B`\+W1D/B`\ M=&0^(#QD:78^861J=7-T(&=O;V1W:6QL(&9O"<@8V5L M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT M6QE/3-$ M)U=)1%1(.B`P+C(U:6XG/CPO=&0^(#QT9"!S='EL93TS1"=724142#H@,"XR M-6EN)SX@/&1I=CX\9F]N=#XF(S@Y,#$[/"]F;VYT/CPO9&EV/B`\+W1D/B`\ M=&0^(#QD:78^;6]D:69Y('1H92!K97D@87-S=6UP=&EO;G,@96UP;&]Y960@ M=&\@=F%L=64@=&AE(&-O;7!O=6YD(&1E2!A;F0@82`D M/&9O;G0@2!R96QA=&5D('1O(#(P M,3,@=V%R2`D/&9O;G0@#L@1D].5#H@,3!P="!4:6UE28C.#(Q-SMS(&YE="!L;W-S(&%T=')I8G5T86)L M92!T;R!C;VUM;VX@6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2`D/&9O;G0@6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF M:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT M9#X\+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[0TQ%05(Z(&)O=&@G/B`\ M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@ M34%21TE..B`P:6X[($-,14%2.B!B;W1H)SX@5&AE(&EN=&5R:6T@8V]N&-E<'0@6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I M;CL@34%21TE..B`P:6X[($-,14%2.B!B;W1H)SX@)B,Q-C`[/"]D:78^(#QD M:78@2!T:&4@0V]M<&%N>2P@=VET:&]U="!A=61I M="P@<'5R28C.#(Q-SMS(&UA;F%G M96UE;G0L(&%L;"!A9&IU6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M(#`N,C5I;CL@34%21TE..B`P:6X[($-,14%2.B!B;W1H)SX@)B,Q-C`[/"]D M:78^(#QD:78@2!I;F-L=61E9"!I;B!T M:&4@;F]T97,@=&\@=&AE(&%N;G5A;"!F:6YA;F-I86P@&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D M/CPO=&0^/"]T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N M,C5I;CL@0TQ%05(Z(&)O=&@G/B!4:&4@<')E<&%R871I;VX@;V8@9FEN86YC M:6%L('-T871E;65N=',@:6X@8V]N9F]R;6ET>2!W:71H(&%C8V]U;G1I;F<@ M<')I;F-I<&QE6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF M:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT M9#X\+W1D/CPO='(^/"]T86)L93X\6QE/3-$)TU!4D=)3CH@,'!T(#!P M>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'@[ M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UEF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U)3D1%3E0Z(#`N,VEN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!O9B!M;VYE>2!M87)K970@86-C;W5N=',N/"]D:78^(#PO9&EV/CQT M86)L92!B;W)D97(],T0P('-T>6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA M>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^ M/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\2!497AT($)L;V-K M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/&1I=B!S='EL93TS M1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@ M,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^ M/"]T86)L93X\2!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P M="!4:6UE#L@1D].5#H@ M,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE65A2!;4&]L:6-Y M(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M9&EV('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N;VYE M.R!F;VYT+7-T6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N M;VYE.R!F;VYT+7-T6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPGF4M861J=7-T.B!N;VYE M.R!F;VYT+7-T#L@1D].5#H@,3!P="!4:6UE&5D M.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO M=&0^/"]T6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H M.R!&3TY4+49!34E,63I4:6UEF4M M861J=7-T.B!N;VYE.R!F;VYT+7-T#L@1D].5#H@,3!P="!4:6UE2!F;W(@ M:6UP86ER;65N="X@268@8V]NF5D+CPO9&EV/B`\ M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U! M4D=)3CH@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J M=7-T.B!N;VYE.R!F;VYT+7-T65A2!A(&)U6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-EF4M861J=7-T.B!N M;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=) M3CH@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E MF4M861J=7-T.B!N;VYE.R!F;VYT+7-T65A2!A M(&)U6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE M9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\ M+W1D/CPO='(^/"]T86)L93X\6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0G/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CQS=')O;F<^ M(#QI/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPGF5D('5S:6YG('1H92!S=')A:6=H="UL:6YE(&UE=&AO9"!O=F5R('1H M92!E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I M;CL@34%21TE..B`P:6X[($-,14%2.B!B;W1H)SX@)B,Q-C`[/"]D:78^(#QD M:78@6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPGF5D(&]V97(@=&AE:7(@=7-E9G5L(&QI M9F4@=&AR;W5G:"!$96-E;6)E&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$ M,#X\='(^/'1D/CPO=&0^/"]T2!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6UE;G0@87=A'!E8W1E M9"!T;R!V97-T+CPO9&EV/B`\+V1I=CX\=&%B;&4@8F]R9&5R/3-$,"!S='EL M93TS1"=W:61T:#HQ,#`E.R!T86)L92UL87EO=70Z9FEX960[)R!C96QL2!;4&]L:6-Y(%1E>'0@0FQO M8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G M/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CQB/CQI/B!787)R M86YT(&%N9"!06QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[0TQ%05(Z(&)O=&@G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS1"=# M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^ M/"]T86)L93X\2!497AT($)L M;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/&1I=B!S='EL M93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[0TQ%05(Z(&)O=&@G/B`\ M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@ M34%21TE..B`P:6X[($-,14%2.B!B;W1H)SX@5&AE($-O;7!A;GD@;65A6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%2 M1TE..B`P:6X[($-,14%2.B!B;W1H)SX@1T%!4"!D969I;F5S(&9A:7(@=F%L M=64@87,@=&AE(&5X8VAA;F=E('!R:6-E('1H870@=V]U;&0@8F4@2!T;R!M87AI;6EZ92!T:&4@=7-E(&]F(&]B2!B92!U M6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P:6X[($-, M14%2.B!B;W1H)SX@3&5V96P@,28C,38P.R8C,34Q.R8C,38P.W%U;W1E9"!P M6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P M:6X[($-,14%2.B!B;W1H)SX@)B,Q-C`[/"]D:78^(#QD:78@2!D;V5S(&YO="!U6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U) M3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P:6X[($-,14%2.B!B;W1H)SX@5&AE M($-O;7!A;GD@97-T:6UA=&5S(&9A:7(@=F%L=65S(&]F('1H97-E(&1EFEN9R!,979E;"`S(&EN<'5T2P@2!T;RP@8VAA;F=E(&]V97(@=&AE(&1U'1E'1E&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG M/3-$,#X\='(^/'1D/CPO=&0^/"]T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[0TQ%05(Z(&)O=&@G M/B`\8CX\:3X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE M=R!2;VUA;B6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M2!L M:6-E;G-E2!A8V-E#L@1D].5#H@,3!P="!4:6UE6QE/3-$)U=)1%1(.B`S)2<^(#QD:78@6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O M=&@G/CQF;VYT('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U!3$E'3CH@8V5N=&5R.R!- M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)U=) M1%1(.B`Q,#`E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O M=&@G/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@#L@1D].5#H@,3!P="!4:6UE6QE/3-$)U=) M1%1(.B`S)2<^(#QD:78@6QE/3-$)T-,14%2.F)O=&@[0TQ%05(Z(&)O=&@G/CQF;VYT M('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!O6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6UE;G1S(')E8V5I=F5D(&EN(&5X8V5S6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P:6X@,'!X(#!I;B`P+C"`P:6X@,"XV:6X[($9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^ M/'1D/CPO=&0^/"]T2!;4&]L:6-Y(%1E>'0@0FQO8VM=/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)TU!4D=) M3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CPO9&EV/B`\ M9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/CQB/CQI/B`\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[0TQ%05(Z(&)O=&@G/B`F(S$V,#L\+V1I=CX@/&1I=B!S='EL93TS M1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M(#`N,C5I;CL@34%21TE..B`P:6X[($-,14%2.B!B;W1H)SX@)B,Q-C`[/"]D M:78^(#QD:78@2!,=&0F(S@R,3<[2!T:&4@8G5S:6YE65A2!T:&4@ M8G5S:6YE6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U) M3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P:6X[($-,14%2.B!B;W1H)SX@4F5S M96%R8V@@86YD(&1E=F5L;W!M96YT(&-O6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE M+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS M1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[0TQ%05(Z(&)O=&@G/B`F(S$V,#L\ M+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4 M:6UE65A6QE/3-$)T9/3E0M1D%-24Q9.B`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`@("`@("`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`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@ M=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,C@L M,SDT+#@S-#PO9&EV/B`\+W1D/B`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V9F9F9F9CL@ M0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q) M1TXZ(&)O='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD M:78^,"XP,3`Y/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ-C`N.30\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@0D%#2T=2 M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`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`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA65E(%-E'0^/&1I=B!S='EL M93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P:6XG M/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I M;B<^(#PO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1% M3E0Z(#`N,C5I;CL@34%21TE..B`P:6XG/B`\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U)3D1%3E0Z(#`N,C5I;B<^(#QF;VYT('-T>6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!O9B!T:&4@86UO=6YT(&EN8VQU9&5D(&%S('-T;V-K+6)A'!E;G-E(&EN('1H92!A8V-O;7!A;GEI;F<@8V]N6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[($U!4D=)3CH@,'!T M(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD M:78^)B,Q-C`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`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,3$R M+#`P,#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@0T],3U(Z M(",P,#`P,#`[($9/3E0M4TE:13H@,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O M='1O;3L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^,S@L M,#`P/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5)) M1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R M;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$ M.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B M;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$,24^(#QD:78^)B,Q M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V9F9F9F9CL@0T],3U(Z(",P,#`P,#`[($9/3E0M4TE:13H@ M,3!P=#L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+51/4#H@(S`P M,#`P,"`Q<'@@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG'0^/&1I=B!S='EL93TS1"=-05)'24XZ M(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-EF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#$U<'0[ M($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE"!S;VQI9#L@34%21TE..B`P:6X@,&EN(#!I;B`P+C(U:6X[(%=)1%1( M.B`Y-24[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P"!S;VQI9#L@0D]21$52 M+5))1TA4.B`C.65B-F-E(#!P>"!S;VQI9"<@8V5L;'-P86-I;F<],T0P(&-E M;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U19 M3$4Z(&YO&5R8VES93QB6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"!S M;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I M=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H M=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/ M3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@ M1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^.2XQ-3PO9&EV M/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P M)3X@/&1I=CXF(S$U,3L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXF(S$U M,3L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@ M1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4 M+5=%24=(5#H@-#`P)R!W:61T:#TS1#0V)3X@/&1I=CY%>'!I6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T.R!& M3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R M:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%, M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4 M.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%, M24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4 M:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!4 M15A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!& M3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M M5T5)1TA4.B`T,#`G('=I9'1H/3-$,3`E/B`\9&EV/B8C,38P.SPO9&EV/B`\ M+W1D/B`\=&0@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1) M0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H/3-$ M,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@ M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI M9#L@5$585"U!3$E'3CH@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@] M,T0Q,"4^(#QD:78^,"XQ.3PO9&EV/B`\+W1D/B`\=&0@#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=2 M3U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E' M3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@1D]. M5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q,"4^(#QD:78^."XX.#PO9&EV/B`\ M+W1D/B`\=&0@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!"04-+1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1) M0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R M;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO&5R8VES86)L92!A="!-87)C:"`S,2P@,C`Q-#PO9&EV/B`\ M+W1D/B`\=&0@"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D]. M5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1) M0T%,+4%,24=..B!M:61D;&4[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B8C,38P M.SPO9&EV/B`\+W1D/B`\=&0@#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q M,"4^(#QD:78^,3`L,#@Y+#8V,CPO9&EV/B`\+W1D/B`\=&0@"!S M;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C8V-E M969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[ M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%, M24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4 M.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@ M;F]R;6%L.R!0041$24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q)3X@/&1I=CXD/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D M/CPO=&0^/"]T'0^/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV('-T>6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;B<^(#PO9&EV/B`\9&EV M('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;B<^($%S M(&]F($UA2!H860@F4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U!3$E'3CIC96YT97([(%1%6%0M24Y$14Y4.B`P:6X[(%=)1%1(.B`Q,#`E M)R!A;&EG;CTS1&-E;G1E6QE/3-$)TU!4D=)3CH@,'!X M.F%U=&\[(%=)1%1(.B`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`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9#L@ M1D].5"U714E'2%0Z(#6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D M:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A8CDP9C-D,%\Q,C0P M7S0Q965?83ED9E]C9F9C96%B8F8T-S8-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO86(Y,&8S9#!?,3(T,%\T,65E7V$Y9&9?8V9F8V5A8F)F-#'0O M:'1M;#L@8VAA3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S3PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S6%B;&4@3VYE(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S6%B;&4@3VYE(%M- M96UB97)=('P@5V%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$3PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S6%B;&4@5'=O M(%M-96UB97)=('P@4')E9F5R'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!) M;G-T'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M6%B;&4@5'=O(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^-2!Y96%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'!E M8W1E9"!T97)M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XU('EE M87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$&5R8VES92!P'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'!E8W1E M9"!T97)M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XU('EE87)S M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$&5R8VES92!P3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%]A8CDP9C-D,%\Q,C0P7S0Q965?83ED9E]C9F9C96%B8F8T-S8-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO86(Y,&8S9#!?,3(T,%\T,65E M7V$Y9&9?8V9F8V5A8F)F-#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'!I'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^1F5B'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$&5R8VES92!0'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%]A8CDP9C-D,%\Q,C0P7S0Q965?83ED9E]C9F9C96%B8F8T M-S8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO86(Y,&8S9#!?,3(T M,%\T,65E7V$Y9&9?8V9F8V5A8F)F-#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R65E(%-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$65E(%-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!0'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'!I65A7,\'0^."!Y96%R&5R8VES86)L92!A="!-87)C:"`S,2P@,C`Q-#PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA65E(%-T;V-K($]P=&EO;B!;365M8F5R72D\8G(^/"]S=')O;F<^ M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA6UE;G0@07=A65E(%-E65T(%)E8V]G;FEZ960L(%!E65A'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$2!!8V-R971I;VX@5&\@4&%R(%9A;'5E/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XX.2PP,#`\2!%<75I='DL M($%C8W)E=&EO;B!T;R!2961E;7!T:6]N(%9A;'5E/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XY,S(L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]A8CDP9C-D,%\Q,C0P7S0Q965?83ED9E]C M9F9C96%B8F8T-S8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO86(Y M,&8S9#!?,3(T,%\T,65E7V$Y9&9?8V9F8V5A8F)F-#&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA&UL;G,Z;STS1")U XML 16 R8.htm IDEA: XBRL DOCUMENT v2.4.1.9
Preferred Shares
 3 Months Ended
Mar. 31, 2014
Equity [Abstract]  
Preferred Stock [Text Block]
2. Preferred Shares
 
On June 13, 2013, the Company’s Board of Directors approved a resolution designating 10,016,080 shares of Preferred Stock as Series B redeemable convertible preferred stock with an initial stated value of $1.40 and par value of $0.01. Each Series B redeemable convertible preferred stock is convertible into 10 shares of common stock and is entitled to the number of votes equal to the number of shares of common stock. These Series B redeemable convertible preferred stock shares may be converted to common stock by the holder of the shares at any time. The Series B redeemable convertible preferred stock shares shall be automatically converted into common shares upon the closing of an underwritten initial public offering with aggregate proceeds to the Company of at least $7 million and a price per share to the public of at least the Series B redeemable convertible preferred stock stated value upon the closing of which the shares of common stock of the Company shall be listed for trading on the New York Stock Exchange. The Series B redeemable convertible preferred stock shares are also convertible into common shares upon the election of the holders of two-thirds of the outstanding Series B redeemable convertible preferred stock shares. Until conversion, the holders of Series B redeemable convertible preferred stock shares shall be entitled to receive dividends of 10% of the Series B redeemable convertible preferred stock stated value per annum.
 
In connection with the private placement of Series B redeemable convertible preferred stock, the Company recorded a liability for a complex embedded derivative that required bifurcation under ASC Section 815. The embedded derivative includes a redemption feature, multiple dividend features, as well as multiple conversion features with a down-round ratchet provision. The Company estimates the fair values of the conversion feature using a Monte Carlo valuation model. The Company measured the fair value of the conversion feature on June 26, 2013 and July 15, 2013 (dates of issuance) and recorded the initial liability as part of the private placement proceeds.
  
On June 26, 2013, the Company issued 4,999,999 shares of the Company’s newly-created Series B redeemable convertible preferred stock and warrants to purchase 12,499,996 shares of common stock at an exercise price of $0.14 per share for an aggregate purchase price of $7.0 million. The value of the derivative liability related to the warrants was $1,886,000 and the value of the derivative liability related to the preferred shares was $5,064,000. As part of the same transaction, the Company converted $5,491,000 in outstanding convertible loan notes (principal and interest) into 4,357,936 shares of Series B redeemable convertible preferred stock and warrants to purchase 10,894,839 shares of common stock at an exercise price of $0.14 per share. The value of the derivative liability related to the warrants was $1,644,000 and the value of the derivative liability related to the preferred shares was $3,804,000. As part of this issuance, the Company issued warrants to purchase 4,999,999 shares of common stock at an exercise price of $0.14 per share with an initial fair value of $759,000 and paid $350,000 to the placement agents. As a result of this financing, all outstanding convertible notes were converted into shares of Series B redeemable convertible preferred stock and warrants to purchase common stock. On July 15, 2013, the remaining outstanding convertible loan notes, totaling $829,277 in principal and interest, were converted into 658,145 shares of Series B redeemable convertible preferred stock and warrants to purchase 1,645,361 shares of common stock at an exercise price of $0.14 per share. The value of the derivative liability related to the warrants was $674,000 and the value of the derivative liability related to the preferred shares was $155,000.
 
On July 25, 2013, 1,132,875 preferred shares were converted into 11,328,750 shares of common stock. In connection with the conversion, a loss on derivative of $5,035,000 was recorded in relation to the conversion. $6,518,000 was reclassified from the derivative liability to equity due to conversion.
 
On October 17, 2013, 23,227 preferred shares were converted into 232,270 shares of common stock. In connection with the conversion, a gain on the derivative liability was recorded in the amount of $5,000. Due to this conversion, $97,000 was reclassified out of the derivative liability account and into equity.
 
The Company re-measured the fair value of the conversion feature and recorded $11,882,000 in total charges to record the liabilities associated with the conversion feature at their estimated fair value totaling $46,323,000 as of March 31, 2014.
XML 17 R2.htm IDEA: XBRL DOCUMENT v2.4.1.9
Consolidated Balance Sheets (USD $)
Mar. 31, 2014
Dec. 31, 2013
Current assets    
Cash and cash equivalents $ 16,435,000us-gaap_CashAndCashEquivalentsAtCarryingValue $ 20,355,000us-gaap_CashAndCashEquivalentsAtCarryingValue
Accounts receivable 12,000us-gaap_AccountsReceivableNetCurrent 8,000us-gaap_AccountsReceivableNetCurrent
Prepaid expenses and other current assets 345,000us-gaap_PrepaidExpenseAndOtherAssetsCurrent 297,000us-gaap_PrepaidExpenseAndOtherAssetsCurrent
Total current assets 16,792,000us-gaap_AssetsCurrent 20,660,000us-gaap_AssetsCurrent
Property and equipment, net of accumulated depreciation of $491,000 and $473,000 as of March 31, 2014 and December 31, 2013, respectively 356,000us-gaap_PropertyPlantAndEquipmentNet 145,000us-gaap_PropertyPlantAndEquipmentNet
Intangible Assets    
In process research and development 12,446,000aphb_InProcessResearchAndDevelopment 12,446,000aphb_InProcessResearchAndDevelopment
Patents, net of accumulated amortization of $101,000 and $93,000 as of March 31, 2014 and December 31, 2013, respectively 392,000us-gaap_FiniteLivedPatentsGross 400,000us-gaap_FiniteLivedPatentsGross
Goodwill 7,562,000us-gaap_Goodwill 7,562,000us-gaap_Goodwill
Total intangible assets 20,400,000us-gaap_IntangibleAssetsNetIncludingGoodwill 20,408,000us-gaap_IntangibleAssetsNetIncludingGoodwill
Total assets 37,548,000us-gaap_Assets 41,213,000us-gaap_Assets
Current liabilities    
Accounts payable and accrued expenses 886,000us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent 2,147,000us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent
Deferred revenue 140,000us-gaap_DeferredRevenue 244,000us-gaap_DeferredRevenue
Total current liabilities 1,026,000us-gaap_LiabilitiesCurrent 2,391,000us-gaap_LiabilitiesCurrent
Long term liabilities    
Derivative preferred shares conversion liability 46,325,000aphb_DerivativePreferredSharesConversionLiability 40,791,000aphb_DerivativePreferredSharesConversionLiability
Derivative warrants liability 20,110,000aphb_DerivativeWarrantsLiability 16,871,000aphb_DerivativeWarrantsLiability
Deferred tax liability 3,078,000us-gaap_DeferredTaxLiabilities 3,078,000us-gaap_DeferredTaxLiabilities
Total long term liabilities 69,513,000us-gaap_LiabilitiesNoncurrent 60,740,000us-gaap_LiabilitiesNoncurrent
Total liabilities 70,539,000us-gaap_Liabilities 63,131,000us-gaap_Liabilities
Series B redeemable convertible preferred stock $0.01 par value, 10,000,000 shares authorized, 8,859,978 shares issued and outstanding at March 31, 2014 and December 31, 2013 (liquidation preference of $13,336,000 and $13,022,000 at March 31, 2014 and December 31, 2013, respectively) 1,021,000us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital 707,000us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital
Stockholders’ equity (deficit)    
Common stock, $0.01 par value, 445,000,000 shares authorized, 182,535,562 shares issued and outstanding at March 31, 2014 and December 31, 2013 1,825,000us-gaap_CommonStockValue 1,825,000us-gaap_CommonStockValue
Additional paid-in capital 358,748,000us-gaap_AdditionalPaidInCapital 358,828,000us-gaap_AdditionalPaidInCapital
Paid-in-capital - contingent shares 1,837,000us-gaap_OtherAdditionalCapital 1,837,000us-gaap_OtherAdditionalCapital
Accumulated deficit (396,422,000)us-gaap_RetainedEarningsAccumulatedDeficit (385,115,000)us-gaap_RetainedEarningsAccumulatedDeficit
Total stockholders’ equity (deficit) (34,012,000)us-gaap_StockholdersEquity (22,625,000)us-gaap_StockholdersEquity
Total liabilities, Series B redeemable preferred stock and stockholders’ equity (deficit) $ 37,548,000us-gaap_LiabilitiesAndStockholdersEquity $ 41,213,000us-gaap_LiabilitiesAndStockholdersEquity
XML 18 R6.htm IDEA: XBRL DOCUMENT v2.4.1.9
Consolidated Statement of Cash Flows (USD $)
 3 Months Ended 12 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Dec. 31, 2013
Cash flows from operating activities      
Net loss from operations $ (11,307,000)us-gaap_NetIncomeLoss $ (1,645,000)us-gaap_NetIncomeLoss $ (64,583,000)us-gaap_NetIncomeLoss
Adjustments required to reconcile net loss from operations to net cash used in operating activities:      
Loss on derivative liabilities 8,773,000us-gaap_DerivativeGainLossOnDerivativeNet (87,000)us-gaap_DerivativeGainLossOnDerivativeNet 49,330,000us-gaap_DerivativeGainLossOnDerivativeNet
Shares issued for technology access fee 0us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims 0us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims 3,000,000us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims
Amortization of note discount and patents 8,000us-gaap_AdjustmentForAmortization 311,000us-gaap_AdjustmentForAmortization 2,667,000us-gaap_AdjustmentForAmortization
Warrants issued as investment fees 0aphb_FairvalueOfWarrantsIssuedAsInvestmentFees 0aphb_FairvalueOfWarrantsIssuedAsInvestmentFees 759,000aphb_FairvalueOfWarrantsIssuedAsInvestmentFees
Depreciation 18,000us-gaap_Depreciation 21,000us-gaap_Depreciation 82,000us-gaap_Depreciation
Stock-based compensation 234,000us-gaap_ShareBasedCompensation 154,000us-gaap_ShareBasedCompensation 1,437,000us-gaap_ShareBasedCompensation
Changes in operating assets and liabilities net of acquisitions:      
Accounts receivable (4,000)us-gaap_IncreaseDecreaseInAccountsReceivable 12,000us-gaap_IncreaseDecreaseInAccountsReceivable 15,000us-gaap_IncreaseDecreaseInAccountsReceivable
Tax refund 0us-gaap_IncreaseDecreaseInIncomeTaxesReceivable 618,000us-gaap_IncreaseDecreaseInIncomeTaxesReceivable 618,000us-gaap_IncreaseDecreaseInIncomeTaxesReceivable
Accounts payable and accrued expenses (1,365,000)us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities (380,000)us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities 454,000us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
Prepaid expenses and other current assets (48,000)us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets (219,000)us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets (149,000)us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
Interest on loan notes 0us-gaap_IncreaseDecreaseInInterestPayableNet 96,000us-gaap_IncreaseDecreaseInInterestPayableNet 233,000us-gaap_IncreaseDecreaseInInterestPayableNet
Other 0us-gaap_OtherOperatingActivitiesCashFlowStatement 0us-gaap_OtherOperatingActivitiesCashFlowStatement (155,000)us-gaap_OtherOperatingActivitiesCashFlowStatement
Net cash used in operating activities (3,691,000)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations (1,119,000)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations (6,292,000)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Cash flows from investing activities      
Purchases of property and equipment (229,000)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment 0us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (102,000)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment
Net cash used in investing activities (229,000)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations 0us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations (102,000)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
Cash flows from financing activities      
Proceeds from December financings 0us-gaap_ProceedsFromIssuanceOfCommonStock 0us-gaap_ProceedsFromIssuanceOfCommonStock 16,887,000us-gaap_ProceedsFromIssuanceOfCommonStock
Proceeds from Series B redeemable convertible preferred stock 0us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock 0us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock 7,000,000us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
Proceeds from convertible loan notes 0us-gaap_ProceedsFromConvertibleDebt 976,000us-gaap_ProceedsFromConvertibleDebt 2,000,000us-gaap_ProceedsFromConvertibleDebt
Net cash provided by financing activities 0us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations 976,000us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations 25,887,000us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
Net increase (decrease) in cash and cash equivalents (3,920,000)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease (143,000)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease 19,493,000us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
Cash and cash equivalents, beginning of period 20,355,000us-gaap_CashAndCashEquivalentsAtCarryingValue 862,000us-gaap_CashAndCashEquivalentsAtCarryingValue 862,000us-gaap_CashAndCashEquivalentsAtCarryingValue
Cash and cash equivalents, end of period 16,435,000us-gaap_CashAndCashEquivalentsAtCarryingValue 719,000us-gaap_CashAndCashEquivalentsAtCarryingValue 20,355,000us-gaap_CashAndCashEquivalentsAtCarryingValue
Supplemental schedule of non-cash financing activities:      
Conversion of convertible loan notes and accrued interest to Series B redeemable convertible preferred stock 0us-gaap_DebtConversionConvertedInstrumentAmount1 0us-gaap_DebtConversionConvertedInstrumentAmount1 6,316,000us-gaap_DebtConversionConvertedInstrumentAmount1
Accretion of Series B redeemable convertible preferred stock $ 314,000aphb_AccretionOfSeriesBRedeemableConvertiblePreferredStock $ 0aphb_AccretionOfSeriesBRedeemableConvertiblePreferredStock $ 618,000aphb_AccretionOfSeriesBRedeemableConvertiblePreferredStock
XML 19 R22.htm IDEA: XBRL DOCUMENT v2.4.1.9
Stock-Based Compensation (Details Textual) (USD $)
 3 Months Ended
Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value $ 0.58us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options $ 2,072,890us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition 2 years 6 months
ZIP 20 0001144204-15-023064-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-15-023064-xbrl.zip M4$L#!!0````(`#6+CT8KP&HLVX,``#I-!@`1`!P`87!H8BTR,#$T,#,S,2YX M;6Q55`D``U;7+E56URY5=7@+``$$)0X```0Y`0``[%UKW9CPX$A;>01!"W_LR4`[D@00\VW>@]_QE\//]^7`\ MD/[\]5__Y?,?AD/I)^"!P(J`(STNI5,KLNX#R_XM3+^7E`/E8"SAOQC#Z3P8 MJK)B2/\M:T?HCZ'_C_2_-]_^3SJ[NY>&TO?OWP\<5$(4EW!@^S-I.$SK.;9" M5``Q<>X?^7$&PO/++F+X]?!B]1-#\Z/,1%6K.Y"^T0/WY$E:>OXZ<.?/\@^[)Y MF#Q\?W6CZ.]:_*XRF4P.XZ?OKX:P[$54J'+XZ[?+._L%S*PA],+(\NP<%DC! M7GP?AKZN*B/:%\D;Z0<.F`?`QLU+_&9R:`5VX+O@\,FRHR%XF[N69T5^L#Q' M_YT69/L++PJ6>;6%P#YX]E\/5P]QRVA#61FNV\9>!`'B'NF[U=.X2?,?.@"6 M?X,>E+P.WNR7\O?QDY(/H/<*PJC\D^19B32>!>VP_)OX$?Y$R7\20KO\`_2@ M[/5H'A#>1T]*/EB$PV?+FK]_\V2%CW'+KAZ4B/[F4OCSZV6&U(LHH-`&/1V@ M'BQ)GW%'.`ICBM^")RGN&$?1<@Z^#$*(>B_F;_S;2P">O@QP#Q^FO?C@+70& MTB$J*#$4)[X7@;=(N@-VA.Q/;"10%8F9L%Y]67O0DK\G MD-Z_`%X$H^7JM_=?H8-_?X(@D&+8("=FJO*3B[\.OLKHGXFJ*(K^^;#X<5K5 M8:&N'((Y"*#O%!&@?AU$R-R"KRG-9"4M9_TL+2HCCI/Y2$.MNJ[<67V2A92I M//UII<-5V2S%*NH'5*RB-JQ8/<-8O8N*U>LH5F^,L=/PVNN<0A/G'I5H)GTB M2C/&`_K36E"-+ENY41WW,1JJ1@.=49$?9#5U'_*#,NJP M8A5Y**N5W8<\5$8-6;G.*333EPN:$6SE.A>IY#6C-F?_WS6C=D\S:J.:Z=RP M(<>9[6,&/.`ZA3/@Q5,]["%7/LYZN$.E@_#X%C@`#?T>78`&;Z\@B"#ZZPT: MZ@$TO'?N(M_^[1N8/8)@$>(AZ5V$["&J,SIQK3"\?HI?F+[!<,=M4+3\X!F# M>J]O]XE(N5OK:AE!^;`U/'@3B>L=P;"SH7WHDUAY'E]GQ(7Z,JZ,?FQBV(+.@! MY\P*/.@]ASTIU@ZD3#,_&!O*5SCZ"*.C$48GUGSR5.L#E'8%*!VD4!_?=".^ MZ2"U^O"HK>%1)\B4V][0DZD;9&K9E@XBF?H0O?,A>C>HUH?H+0[1NT&A/D3O M8(C>,FH5%D][!]A-![C[%=-^DJEM'FP?'.A=4#=3B&/GX<^.XEG,$( M.%DZ'"]"I(\PG-I(;V'<8;I-!*)`\9YN@B[V0@!E5]OM[N8O?_%=G(`DO(F6 ME]%')@!!%WLAP&YVV*U/6?66H$V6H"LY*#+\Z0U)BPQ))_B37Y#K[4];[4_+ M5MT(_.GM3UOM3UOYD]]8^8L5!"C""B_"<`&<:^\_%AY03?PHT5*63JM)R-4G MU\$M?'Z)NDTHBD@QI?C4TRT/M^.MNYLJ=)>*T3.,R+`R]?0,J\"P4V#'VE&U MGF4$EI%5U#.M9%VZ9U@G&;:/+0R]N^N4NVL'1?J8N\4Q]TXH(O!4[L--`%_1 M\QO7LN.75>KP1]GUT+"6*>SSP>T^'UQ+#/^'-+G%D..]":_\"(0WUA*W;([I M+WX0W8-@=@H>H_OE''27BK#TV12$]E4HVVZTB^'Z/7?I:3B%[&;GL;*-E M'[&U*&+;1S+=OO.WKO/O?-JB#Z`[GU"YS>%&MY/T%"%2E_B4E*W:+;C M8U"W(`168+\@%9Z"5^#Z\WA>I"=9]IPU4T4]Q2A10&_)/J8EVWFF\=Z2?31+ MMN/\X[TEZ[@E:^O1OF)F\MZ2==:2M8QBA37>L]G<]9<`Q/,!UW.LV(\[?9*^ M0E3*C[KFFS0JVGT$ZV$1'&8STGVLF)-H^["MG^;E"Q7I1+ M^7B.1A01N$3C">?"0PQ^QJL+TS`$47B\_&;]PP]BY7>;2)6$?-\QGU767DS, MCI(`XL,AS/6_#[EAL379HW=X+T7]O3[]?M=Z^UUK(>C$%HNN,?CCV<'V[4KK M+3(7G[GV_/06N=46>0\;=[K&X(]GD9NP@SV?FYB0Z;G91A_=YND817Z0U91( M\H,RZHG4&2(I\E!6*Q-)'BJCW1&IO_NIU7F&6D6AC6N!PE2=4^\Q/\?SZ6?((4]^_CP1+>I44G(]4=Y??7+VO0-6;VQ:9FQZ02--LY:]#1J M,XU:?)XB0Z-S&(31%,GMK!6&ISG>?XIGHGJR;4^V*CCBB:9<$ZPFG\J:J^?W MMOSN'E%[@H@*QWH#V`"OVF)S&^5W6^/$&OS^L$3]2`0I3'KU^R$[M1]R9YD; M>UYTBA?-[F38,J7KAXF;VC)P[#/2"E[D^6!7JW:#OWN_XK4I_BZ0"XK)&[Y8 M`2CR:`:LJ-^V0](X(<[ M#+!0BP-?$76+ZL2?7BUF:&`2^4&1M]S0L@HOEEA2X2GP_!GTZ%6R5%VL<[/0 M]&E&<@X=SA<;JLM#PB]PM<_G/PR'9V[<9:4[8..>-!PFKSH`'IWZ]@(_PYO< MI!4G;\$3<3PYB.&=6Z@@YT$9?%7DX=\.IY\/BV6E=):.FRG5I@UR7)A9<5O,Y#&W+_3NP@G/T2UBY;CVI M.U]KH5!RO0F\>C4;@Z]_4\KJS12:K?D^L+#MO5O.'GVW!96OID1CJ/$"R[WP'/#V5["LC&.2CS:(!6=K/ED$08ZK=;N? M(@^^#M/Q#*WD3;G/H0N"U?Z$ZE(KR)+=(3Z@,J1;,/>#"!,,;ZJRO&56"[EJ M4A3OFZVL$.<0P?_"N[)>+1>/#:?1B14$2U3@?UKN`I30EH!)S?`6^^L,:9&> M%%/7#-12GP\K52\(\WJ^((]9HV)69=3)ML<\M6U_@5Z[!39`G^"-V"!:485? MO3I=O6H.)ZW*[>"1-&E0X8UKH[L)P-R"SBJ[#=+]=?0"@F2>H[(.32I(3<\W M-D?50M"25#JBDW,RVA9M32V.&1U]-"F0<0L,)-U,&!W7-&5^##>!CP8`4;QQ M+$*:PUT[SJF$:,FM%E6FD\LP"\U%KG,[?`25J0J]V3;(S\87#VXO//0J5HJ?OTQ_(>JZXD&>6K=#B%)@W1O40_A>^8XWW>^0]?EUQ?=(8Q0=)AKT+0" M_HI):J";>NZ*DR[)+R_#>(\,?5S2Y7EK)0E+-\*ZHBH:3ZTKC[;.DZ\.&.Y-VBL=.&= M6',86?Q!E\[T!WF<=<`T(Q!!\SK=IXSDD7!Y,O.4U6:8=,8(8:P6)FL*%54' M0E(:8R!0%%?(E1Y-:G07>H*'Q#"\)_1[_3IS(X]<]W;WHA6&G*'R[DYO4DG3O MI8^TG-Q):T[A%PKFU%1PIIG--!F%J8.O\@'> M7%Y1+&'::/"B[YPV1GO41C(!,5U$+WX`?P?._CB1#15(FQCDY!^B$HK2;"W\ MKB@PV9?P%V&XV&.KFS);\/'8F$Q&8X; MLD^IOO2[:G9M!])GY@WJ>/T\8+V67^*`(`0U(00SC3V@KN)%\VA--BGT>)V= M-#W$LOJ54))TRK'!4#!*ME_*(^2)'M9;(!G5UD9'TA^/>Q>'CM/6Y[>06^*\LUP0WH)7X"T`<@BOT`;AQK:9\F0,>:CT"8C"O!>A MUJW!D?1(GW,8*\V#(V]6'3%V+LIZ'7342_"JMRY]J&_J2F&:D%*Y(*2DIF8L M9.KF9+=0*0W/F-!.%JEK0F7HX/3B'COWI..E)";OTQ8W-D<1_X1HU;0"(T\9BY'])L"!.E M'1G[Y4UM7!-2VM?ZL3<(WIWF.SIL`S.!B5ID9$\9.>[FP+L,"(!`Q M@1H3QLY-4S/W`YERL([N?K8!>X&0H$%;[6!]0O="A="G4%MM,*2F9>S$+/@> M(6@HK4;W.?Q`4$=>&_OIJP7=^-(0/S/T7BU2'ULAM*NW(<,'*6;A/$I%0(W) M0Z(!W5L-30-]TCZ!*$QB>#,%!>U"!4JWW*03M/%+>"@(W454G)[C85C!LQ&G MCH?R@:RMQ6#@$`:;=+)-EOEQF_J.<=/.0BL5]&W6QOT+@,\OZ/?I*XI)G\'5 M`J_<7#_%GV:F`;=ECR)S+&^9YD0>CY5,'ZB'KFD9B53C6,12\!XT961HK1:2 MQDN=0\C-.68Q0E;:1Z86@#-.4J@3/1];"-X=J#XTLG*JR'37WZ1`M>[ACK)&CVZW1-$46^LBX M.7$$\(0^CFX.NEB+RLB#TB2AA-A11HJ4)CI&\;HA,7(PQN.HJQ2.MHF5HX"& M.9AN%DU3YH;N=)L39WMSP\C6TAQTL>:&D=2%5XQU.@6=E@],)AN*8E:*/&&NK5C#0W M'UWI`FP/=ZCS(14LV$(R9E%Z0R(N>&2D:/IX6J:$A(S$4FIA"\9'5%A3_HT> MC']TI0OP;]S#@@^I8+'^C9&AK+W1^@='+.E/9.;"B M1?%I>52B*D$)':FW76D%VQKZK'Y0W301$C)1]/YH2 MMP]P&,D$=Z"P&'UR@/!T$2`3DOB)V#E<@>_QDQK+8HR,A%KQ3"@7C,:P-]4= MN,<'>Q9?`)$927CU5C6WV,"#D2U9)D#CIZ!QLKR=XS)FU3[M^RK3H';#1FYO98GG<%2/O)2>9 MF0:_O6NAR@1TE&K[$KNC&L%^DQXC=E=-HCRLD/!1E'Z**>E; M:)4XTJD8LF+*8X73/;51=]N;)Z/B1E`A&DJNK^6)!)7J[IN1<#:](X"O^H80 M-T1Z1CI;(W-YPW[%%\!;YB1E"\04ZR(9"7/;(;(@=\=(DBM>UL(09*^]F"?? MVR3^AZZ&HDR-Z4%`=^;('L=H]#K2\@5%=9P0Z^J358X.`>!V+&=3I&>'+Q M(K-DF(JL\GBF%BI.@&GB.0:=Z(C+??,KB6>Z(WYV/<<6)CQ[`X$-PSH'VHOI M@C?2N''/<)8"VHE$3742(;.;>U2+@"[`RD?9`7((]L.,J[Q+#DRW3R6B/"[W MKM6F])`8UK89#IY,_*XMT/T[4G+R`8_4JLNSS8FJUC?QDHYKX_T%A%*K):L M$8@4:_M>P[@;H:%>TUAV`\;M"JC7&./&J2:FUS#FC;2)J1`0PR47+O4DUBP`(I$@ M=%^KFB8IYY]@C+2&IR^=C*L!C*NGE!K)Y,4TO$#>9%4`J'$] MILJX]B"=,.%&(!HWD0F,8;"1V6>Z'_`TBC!WI-3#G;+J%,P#5&!-.Z`P\B?D MS4"VKGHX2$VLT'W:6!6)@]):C"L%E#$WCO0:I'QFL!HMQ!@+&H6+MTNKW18< ML=D8MX(7\[(V@([6F`P/HM51'0K[`KQN>0J2?U]X4SN^)S&\!3:`KSCNK]'* MK)OT\AV`!X18X$0&L%+T&_L$3B,'W:GH#H&;Q??FW`T#C*O2S=Y#>]VXMT$8&Y!YW0UN[6ZB!85 M=AV]@&`:AB"JPTR&YU8F#.%X8#4M')&8=%^OZ*T7CD9,>CR@LTR[&-G2>Y%7 MW*YS<[W*R#"^<4$U&X-8W$1Z,=(!;MQEO5/@%.HPDF!OB1G]=&*%+S>!_PH= MX!PO?T:!_H5W/0_5,&&,/--#12D8L>T` M[DI<$NL8&:"'ICI1NR8NC:OTX&*HF9.->[4%BHMHGJ:CM?^Y@`%`Y:*7H^6- M:WD1LI9X)6:.7ZE!7.Y\?/PHFL!/9"+C^*BA:#QBQXC(",O2`@"+Y,Y MQR;,(G?BN>V0[4I.(@M9EP7*7.:P3=+2Z,J8DBCR5:RTJ!@;`"?$)PG6"VR9 MQ>KJ-&7D%+ERNP(PM<$U*`,"=Y[7"@@)WNT<>HA`#<14.MW[%CFQ';Q="4MB MEL%8L3:*OJX#XE((RDZOVHRIJJ!I1A(B'1G+\Q-]TBI1:%1CK"EH$U5N6)0IHG`0+!$S2^Z%RVT75@O8 MZ3Y];*H%/TAUBS9,T^.-S]$DJ%'=R>3:]/7KT MHY>DI.'Y]-O%Y=^/"D5]BI_=7?S765+5IS6,"A`^24](`\,0_@Z&5KQA[TCR M?`^DOT?/?@$;(_[+9JK&`\+W%^K:CBW%_ M]NO]\.+J]`P+(!^H!O0^23N3;3J;N_#F!4K'T`]1?T,CM5`Z\8.YGT0_TK]' M+^#_VWO7YL:-'6'X^U;M?^`[>T[M3)7LB+IKYB15&MLSXV<]L_W^J#?3>;158XQ M9=J#X3TRO/4S%N=J3Y87^O![,#$";29<[,"BJP*B"VG6[Y9M M(X4M3XM!X+_[Y\WB>L=E'3 M6'@P;TW1K@2]8)FD0\;<)T5=(4O'2+?:H``.L2[N&Z1J:>M@6/P6:'H-'`*-_1@Q6"RJG:-G@`LO M/@%QC4)4WF'9J!*1!1$Q8=OV&&S6,0M+[099T6//8:VB%()J5.F(^$55S^XP8$/GUH^=HVN::ZG?;NZ M(-L%;T&K`$V3I-Q*.TKO?O`UH!OL^X@0""3(BA%/U]7>(@TL.@+$1W!*`6C2 M)E"OY4"/L&B6Y):#CM\"T<]2[WD'L@3VD(\&%A!@QC<6;6Q8'FJ3T(,'^J'- M]8X;1^W&+C?B@HG'F`;F43#Q-48R^M7P1A.M";8:NL;T>G3U:_2T$5B$VMAV MGW=Y!/V!3XE98>;Z5):O&03APHTQ-TP-DW%#;S4^?@CW2M:;4=?B-4_E*@F(4KDC1XSL;S[IORO8G$`B6!4`.B:%AELA-Y&X,H.%7&%@ MH3RCTL.&,B3P1ARMG8$],;)F:#$],H?Q@`7\#O9XK/Y^.I M5@^JQJGQ';9+R4JD(<",":>\C3@/>1CC,>RFW$IC,]?#IQK3R"TR>((^WFHK ME21)-8T7CNBT[Q'?O.H>_A93Q+%6>2S>F!-REX3QK'U?,ZG/FG(/ MD9&,#53504C6';(/^4$ZP3@_W$]>C M,A9#KAIVM>)N#HN75+@#8$UYP1G87E/0C;*%@5!N9/L9H`<#]##G4@6!I),* M`C<5?$U?J"/%8P+[$-0OJB*/&VGHH8SB=!PT]EP.$#(;?PT:LFIXQ\;X-3X: M&R[P#<&S_.\`1.!9PS"@LE#T#\%HHXBSB+33_F")2A/-(YW$^5E%GD.&5B@J M2,Q)\L'3?9Y8X&\9LYGG_A!:']U.H(#WG04$">,*5KC`N-M,N0<&D`+Z;"XO MEA&I?7A5>W:J7K>2E"696EP;?'I8G[!ZC-;/B\O+I8F$:H%L*5,H.Q#^L3&* M+[!YKL`<@V+N,Z::GFN4S.5',1O3#8?!.+25F+07&TAXT$8^M$.&GN^3M2D, M.M`[0U'N;MN,.[1D9/DS-D+%J(T`17<*ME==C M5*KB.CH8-1GJ>>RP*)0_.,WB1?C2MS->H`(*V:<`4Q2F0I5JD,^.&'.3FP+X M!MJ^\$S_74VSX"72,W_V,#R`)CP`\6B`9N=;AT*U05IT#)&YA&7!P+S\MEE3 M[7(%!\>-G[>"\HBUL.[-RC(]8F1EJ12/<L:4.?H3:P+;!KI8KU MF,W5.WG9-25&P$U84(P^.LD4$:^\V6-&5G0IT*YDH`.YBCH4:!>AAWDJ&F]5 M<'JT.&DUPEP-60@24,LV`8R^)!'4RJ\:.-G+(V;4RJYS$: M"LY0/@*+54$R9FY@V;T\G$^8';[V*!A(AOGA3?@#G8R"7D#WP@)8+`^A).=* MAM;P5(%^868M?@S]2_&$3/3-P+A08*4WP6-`>_DSES?VCM^AV=@D&T%\=("H MQ;@OB?77V_#-29[-[QFSR_A`!:U(D4&RN/TT:MP@14N6HK'?[KYH7UP;^<#7 M[L!0O@G,1%(..OAG$_>99Y11GJYM#3V>4_?,,-6,-Y:@#"-#&\KB!A"C(6:^ M46KQ($@#)6)<<4+&`QXH-?]HUOJ-/J6U86"`)[\)R:&4HM@[3T`KLHQJZ*=' M3X^>($5FB^VZDH"CP6PS"=`7)2#."]5NK"D>T28X:F8$4:Y&GNROKV'_3K-Y MJNQ?^:)[\D4YZYX>IB=LGMY)=9,5H3+XB(#%6['[W0OW-OF8 MY:VMU9<;6U35$.UL#Y26.5-D(&9UR@5$I`J\L/G\5!KZ^4OCZ&%C_VC"__1WGX:?/OX+OV*"]>,JCVTMX-O%^^TKMZK:4E6 M6\%D,@TGSLID!J9)RH/R47+69:O.Q>>ZLT,L#8\!G5DR9Z&OI;46O7@*N3U0&YJL*-?H=`?["S$?02/'O/*=BRK"3P*-&`ZVT!\/_ MKGUR/7A1-#A2JW?/VN_CAX&=QW-Q\+8_)HP.XPQ'NW:`G"'=\1:H=06FH(GF ML)"&=_`*N,9D/[CJ@SNN@#1!L@#Q]MG1:)=8N3$0.1)+P5.HUB\'3WY2H_]& ME&K/TQ,XBW#XE'T##R$,@F`A3;Z2X1*@L:2F<5R;]KL\%U*LFKC"0AFCH9"! M_]76E1A5+%D*?U?QG&/5Y\*F]'D=3>+\,*ZJ65&)DY(,^7DPN)/JR61C=,V5 MI]8PYF,,;^TFW!0DN>8-6&-"@MX)$H]U=).8X@5XPKH MBIF\A_#129F2A^5+9)X4KL%]B>*%LJ)_YJ&;0949SW$)+.8PBVIN@^<4!UB` M02DL6-^+O3"P6$O=XMX:>)IN!?R1[V1D2)3.`>O2I^+DH&.$X>G'I[,E]Q&Q)'L"E[+]\.:PJ+PU`%>L^(.T74S>$'*+!22CO;, MXI6ALWSM\P3129'=<[F@V,UO2"H&$PNIGD5D.]`#:"&GQIP2L7UN:P@:*$][ M7TGR\4CR#=4LZ=F6Q-^ABY8EB9[83,BLX*+!/0S+1-8=Q7N0(F960466%5,4 MR12-;9B"XG6@A6S#RS1"$GR#;*-H%HS8QUJKXIBCXYAF-LV#'3<$HSL@\M)#G\A0V06V/125M M(I(U`EPM'LA2>$;9+6K)\X\JN>"H<%,51-R.)%Y.F3N24!D^.GEFQ(],!F&' MS`%/DV1X.3+JO]/"`'CF/^C1B%U(&!6)EK2:Z/G*M*\`-7P-VX,$L>J*E-5M[RQE647.$9]-\G%SO@H;]9@YNF M!H\_4P<#($:O\*E#X_'/Z;<2M]P>FO10ED-K`E M!DO3!-B^]M M+HF:.#:/))=O-$+6>*V"SQPLGGBB`Q3EG=C^4`IG4NBH6TC*+[RMAV=A5&G& ML(0KJO-0RMG97%4%Y]HW"PV!M581PFWA&3[O_,27P8?%@E^Q#XG<+(-$O!61 ML&CN.R_=`%O#YIV=+#_"'$T#"N"D$5E2]_2$Z&0/B.Y%.ZS[..VC.M$Y(L94 M31)>R,W;N?%5Y>W)4*&YMOLX!TT[HCK@&K77,(;4;/^)VJ\RRK\GE^%1[:-F M/(*-$#E;,SZU2;F!"D.ISSYI99$*!+I*>`N M]&AJ6C@[`RRP&(S?!H8:PJ\\#SO;^3Y]3^!(MM9<8\ZBJ*&G<*&P`X50XWWP!S!RO=8OCYSA'.1!P?W#$+GJKV-8G:ERB/ MX@<>44<^8S8#''DSEHCHE2X]*MS6\!B7A97"$[G*\N`K,F^H3)1OZQ2_,,\Q MW<11[I!MZ:>A'6#O1XW94HS5P,;8M:G/,R;.=.KMLX::._-5WGO%[]4&BCK( M2$]47X#=(T"I^&/NR_/WH?4S9!B!B4@!%J),0>'5G<4?\^R]2]AJ1N>]VP1R M?UQ?/GQ!(.K__*!]O+V_O+H_N[B]N1G%@\Q;445\K+,W&%ER.>6;8L&RXNUC^%H#_%'C*W]2=[01$2C-L\"U_?C.B MN.R;-5Q4"=@K$K`!QN.<5!%SH_"#B`5:Q!@,K5@15(]]8,H#K>2LDK-*SE+? M?LDE;$[958I[9/EQWT84,_2?A%.3-EE%%OSQA*WYTMZH=MZE2D'>MSL(/>>\ M+-)9&9$OECU2<$+N\/G6>/Y!VTD@5S.\^@Z;C>'W7>Z,H,N0GT3+:7%VBN$" M3!_$TBA9;Q:E*R;:^(JF7]]3`:KJ'FMC$]QOK1HS$$4($2')`I()<,)@IM3^)PW[75Y MG_3E!^+AOH--V4580/3^16,M;A$B]ABU%GL>GW!$$J*4+?Z'"X\,,E"&*D\I M6`J@5`E"Y=SOEHXHKAULG$J:\EZ-G%W&D;/JR.*(]%3:>A*^^(^ZJMK;Z[O[ MZ)?+=S(1U&-R(M[(F%D!^"O_(;V%1Z@V"Y33":%1A$F9F-`I>TG(C@UI[23P MQ)6GX5T$U?(3=7F6$QC.(Z60 MR41HJ=*4@5Y#PR;UZT\8HY$/$SI`IR*'&1]9YK%'PS-M87`\BV)%GMTAGBS' M4!@V'>CR$^:0"@9#7TSJDY:*2GHDS)#1$$->)"JK,1!\.N4`P_[,%F;/`CXU MF2.`@3"E^5\@RL:QM-[6Q-I2*@`\>`@*P'7D`G;36#P(D$CH0H1:1/-G5$5K:!K0--S-JV MY]7YTU'A5E3?Q23W+'7CP:=MTVHQ^;CEKCSMFM[17]!PCE)6DB])3'0H2^^Y M2A#*VX[J;%%E8J>#5>VHMA(`?;T`=&N-7KL2@$H`=L;M?G62@:^D"_A@.'H6 MSP@2"3AN&&!79\5A=SV1E2A^D4D^-- MDC$$R8$;\GY&G,T23&I)43S6?,R)CP>;9$H6[]B3#D`7WX7\&NO<%N MWC, MF(>MBYV0-AC>92QZED]J!M,?<`-7)K/*>:R?P&"*IDO\N5D M@@5XR9;26[U:I]^H==JZ?+ILLJ#,U90-YACGC:35@O]&BXFLIMV>T>1+U^W6 M6OUZK=%J+#Y'FI)X9]6=^I20Q4F6F/`8]W*\\UP'_AXM9C^>"@E.>)^ZQ;Z# M0R_$8K:VE&R47VS8206UH*,&WWZ#F\[IU[-Z0TZ^-4UPDP`493BYR',5YUH8 M,:,T!7#(Y#DOF<9\OLHHG(8\:5>,9@+=Z+$)EL]0#135U[P=W%Y&P M*,[+?50J:;9GO',+]3F88M8]DZ5$CC\S>`$S;IQ*#5+&Z_!MI-I60XX0"4<4 M)WZFS%4'QS.(R[-A_T0+G[2^Q2.U2W2*F\2AWA?`P/?QJU:\"+?X63@$CR(B M0TWL=ZM7AK8Z&D9/<6LL^8X-!+$K4]V2-16;@!]GJN`$=W$=Q5XI6FN,X>I8 MT>NJZ&9.T+FDE8R9.B*3P1V+2_T\T+#I,=M5,5A=DF6"RB M@DOTII4]NBR3UI&/M>=]B^81/\F<5/6,(76IED_;E7PBGJ`RI&Y(E!0BM,JS M90:3]SQ5A:XYLXTY\.'[L?6#F1\V2B;AF0[17^9"-H=RV)\\Z__73Z%_]F@8 ML_PK`_L1_`1'-GOO_SW?_WW?VG:O^0#+B-& MO!VKC7SO>=8^S78B)X=.W._$V77T.+(_/+@H*.=6JPG5[5WA2S;6T)QJZ[-_S@.H_XL76N M9;;MCJ\L=K_>!^*'FY:SIV7-W?2PG$(?KI"HT#7?Q:P>- M6MR#[FS#D<5[L3NCMA:Q04C.J(6`%=W%NW13WXZ!^%-NV[!NHECO[&_8F;@I MP7?>"QXS[OOR;_V3,Q&A;=$-Y#%[^]!CW0($-*O`LVM;X;Z%CR7(^T49< M]!.AF^)X0QI=>.-V`/P2S`8J5J939\R\F\YL=TZUA6;T&P4]QV-KQ,0'R?-GO M2#%0Q@3*`$M*\_?SZ!7LQPR+^AU7PVU, MI!$$.1QJ5@*<%>4 M=XSL)A=*FS(9C]ABM>.$-4<:54D>YE30R'I-83P)SV\R?2Y:*WA-Q-]J4(3< M#5G.AYRC+`1/DN-_8XS;DWTL(\F,VUZG(9@4\"("$`=R%OEK?R/DL52QJ_?B M,L7LT0E)VB<:!8GSA)2.MRES$_Q(GT3=*)*3#)*FMVBKP?5D=&N4&\2%9"$K M**V/KDA-D6W/18]SQ#^1YN@GIEDDIC1(+$4=F3J(B2K)8GP6YC;(9!?2JOLZ M[CLH@WU;1T-B(#,]Z50\8^P>$"=4/M*R-]I28( M#=G$>+)BI7M4RP\[ M-3B1/GGD)A-_IU/!D6E@P@$EUI>Q6]@H$EU?E+>)DA_<_5"./>,BS7-&_X8=3<&8+U03:LA^JU'\IY3QJA9@H"OMX^_!P^_6] M]C]]-NS`Y@^DT&B)H[*QFZM/#ZF_;UIC=OO[U?VGF]L_WFMHQ@`(T=4/MW=9 M;[Z__OPE[=6[E)=]N>(/TQNS'VDE9,NE89S*#W_>7,FU3*[*(IER<=74 M,DU;5-V=_2$@:M4!`8J!_ORFT\RAIK03HY37FI=5Y>ZL83HGV!M+J[LZQ#3]"+3;?3L[NO\<7#Q?Y_O;W_[]1(6 M>TS_VW6Q"U6_I<,P#U%=M!RXL&EZO'\72(+]2S@ZEI0AXOU$/[W]S3%"$V<3 MOSM6CLA;>;\^CFA6'%%Q1$P?&6A:LN(DBTB6.4;>*(NYL*N1E"#%:,18<<;" M-_60,R7@49@AN!N.>W?B#K.$B6C#LB;:&_9TJ'U$Z->/>O4KYJZ8NV+NXT2O M8NZ*N4_9"LW74UEGE7[FB5ABD#O.<\4\$$H4$H=]AV*)C1V3X]1WA?I=_\A7 MC]T-+B^O?_TL#]W:\DCTX!R=ILST?@<+^TJ_KA7;5FRKLJW>J-CV\.B=#ML6 MI5WUU\ZF);$3IO\$*$X)%B<<:4JQV3ND M3JQ$H!*!@XM`ZZ#6:R4"E0@42Y4T4[C6:!TTU%`&KB^),5QLGM\#=;5:5Q7Q MFGVBM;+?!-DWW9`R_`^_^CF>'6WJ_&])EQ*'M?(\>6HT6Z\]G%")SM&)SD%$ M16]7HE*)2B4J&UGFK6;W%0@+?;NGTN>]S49[D_KZHIZ;^)`7*9&4]L`:B@C.A]A MK\$G*Y@O)[.?5EE^\?S)=X,;VGH.4["O-`>)_Q'2(F>9MLM6RR^527)XZ+X+ M3G>+.:DE1*VT*]!9[ M2?C[+2%^77IB_^QQ#>MN.;XUBFGR._9Z?#6+7)*SP_Q.B=/LN%ME1)&Q/.%O ME\KODSD\+A-Z1U!.MN]LB%P/^MJU;N.@J<,5PQ_\=.(5\'G]7.^7G@5.G,./ M5Z6W]IWCF2?K]\_U]M'PQG&R_O[7N7!E?Q142.'V3JW5UFNMEGYHGC@DRQ?I MP4G5R(\L>@>K@DMSZC[SH0V'6OIRY>*\(O1*E"^SE;(22+?U:DW+GG]>L6S% MLJ\O3!JU8L]2L6=YW9-BSYQDNL'!')0R^*:O$KT21=6/ MS-HK[YJ6[)"[8MF*95\Y>@=J^7ID%F!YU^_U:M2*/4O%GN5U4(H]/_G$1Q97 M)RBO#KTJ''UZ:_IZXWT5RU8L6T;TJA#U<:_?Z]6H%7N6BCW+ZZ`4?8(RL[SJ M_*3\_4Q+2(`JH/T:5_T$8XH5VU=L7RZV+R$!JF#[J:]PI=DK%C\2%B])1X5B M#X\6.BI\I;%$HIU"ZS4[ZP=5<%L3X)#5N66Q;+<6E--JR5`)S=[6/_>6T@>3 ME5)4_QZRS4,E-=56^\UZO$I>SB4FTR!Y:26DOOU!K-@_6$*X.HE,2% MW4N!%K7P+HT+6X8`QG'$Z"J[HB3=UO1ZK=[KUSJ=1B4T91>:RKJH.A-64E)M M+4G&I-I7#2DFK5F_U:\UNY\1%A;ZM)NV5>])>3N"7:?18_HNS M,!#O(-/P=U:$\XID.S?,UD`?.FEL-, M+?1I5![<,;)=^GN&`WXT=TQ?7KC3F>',^=+V&GKW@X]#Y*>NH]%<>;SN'WE* M1OV\W4M*![PJ&6@Z+YZ]%&+N?G&;.:Y/ZPI7&//\UW&1JW> M;=1Z_7IR+1T6X(L!$GJK"0)'%=6AA\+Y/+$`6Q5']F/&1H&/"$2(:NX3\S1# M>Q;SJS2#SRO29@"/:RXC%CR[FN'`=4`R>ZS-<231?EEH?YOP"4I"8?MNBH@U MET4,.)-Y3\!F/HV\PUNL8$$)`A=KXQ"Y&+2K'QH.*%##%Z-(_>4YHZL_5&;` M)MAQVUA.C\J>/)HRN9<;]^H@TIA`/]X;8>!&C^C5MQP>NO'PSR5XBAW_&1!= M':"KE]>`P4[W4.,_EY!Y52,"]X']9N,_E0F!7$GN==$/N?X4NBZO(KSDA3 M=8,GP[+)(E1L^4<(UP[N6=83T^YLPSD4:Y0AZ>E5HE>< MLBNV,TBKCIKLD-JL#&M:$FU6K.'VA^&1ZGK-VU;!!\&G2X`2&7-;Z;=FK]9" MBZU5X#3'\J]Z2?3;R[:R=5&F!SU./XDDU<^\/N0-28*8#F?DJQ_R9[26N1KXA.7H>N!.TTG(>*- MQ`OO\;#F@T;7G-G&W`V#]V/K!S,_K#U1B9[O17^9$33JGU[\IUS5?_T4^F>/ MAC%[?VGYF`$!?O_M^$(Y2;_G9^@7KA_XM.-\-'QFWAGS*0,+^X']"#[:[NC[ M+__]7__]7YKV+_DXN,KR;\>#T<@-G0`@O0-9'\WYOZ.[M!$0"S[V%,#+T7.' M\@^+GDX$QM/8.S0`G(`6B]YO19`,"X(I1;X*/?1,%>=BSMR5PV+\L/1FS"VR M\,3&FB+ST@[&,SDLQW!&%MAE/JP%(^F`*T=V:#(*GAE<%/R%U")*S<`3]>>) M:]MSS7W&M"0_'/J6:1F>!0A\M%R4$\^U:]I@.K.MV<32S',7_J]&M].7=_#E M(/0#S[`MXUP;V`")]>A88VL$OC`'>B3?*6'!N^$.D/41/^68&$^@HQAS-&9; M4\`)<.,/<\+ID'D^YB,A^*GXXN/,2)&H3_-<#"-2*@[>[3"T70.-HLL:^S%B M(*R484#/F#%/?`+B&OM*>%JW]GM/`"F$&4UMPCQF.AA=D<@5]$+;<87W6./H6U$F544+&:CT+,"2UQQ]6,T M,9Q'>OC4\GVXM*:YGO;MZN)=1U2KN5`CVP#($$)X:#CMX[KG*7>\PZX=L1\W_#F M2(`9U[O:V+`\E-O00UMY M%@X^;63X$VV,&30[/(+^P*?$K#!S?8MRXXR4W#J%&Z:&R7C@9A#)G+=>$XVO1NV!C>T360:CQF$$-SS M[]"A/8R4%B'%Y0!5%V6'KGLJ%WX@RC*_I7XHOTV_F1&^:+K_YH,+<"525/WM M3?1.O3+1\0^@(^J\B)(G:IRGZJU44X6;&5Q-`6%6&"G(<*C.K&#.1=F(V!=S M\^&.&5H=C\R!?005&_P.UF.LV'YS2."_!<2^'OL[M%`1QI8#*KVI\9U%>=A< M]L$4"*8&&#UC,>P(W%+A\U>V).R`UHW$Q!4?N:&7JRP('?0V2D#1N5 M#!OI M_>)H14\GBE19N&-C67G"&]7&PGV+-%-^7:4,D3\"`O3-` MSWXNMRT\+<$-:!:"1VGX8@M3/%7P%F#+QNW+XR8[>H8`R1/X+U@T@*:_RP%" M'N2O0;=#9L+W9^&@LX^-&A&?YWP&(P+.&(=]]T"\'$Q[V6]C7>,"!;`KR M+3#@Y-$^QME<19Y#ACX);JH!U8_)BBREG,HG=Q\HX'UG`2\HY)NR"#V@A3+E MGB]`"NBSN;Q8QMR.>1/=:)M.WVOQ,FUL MC.(+4&5K=%J`97Q8U'>NW7DN%GK),*#IAL-@'-K*@8+'E/+6H4'!(H?\'M\G MYTOX-Z!2AP0/%I,Q'KDAG\.?L1'J?&T$*+I3K'553RM/8R#H4<+0#P:L&GQ75&A6EHQ,R%S"\QZST7:QN,<`7X)3&\PQ(SV`FW%WFB$17^["-4NZ MS9R2!W0T#2S*Y;5)KN<';)+E=W/9DFE'I^#V)*C#)'52+7T>_\/C9C:#WRS: MO.+6('BHCMET9S8H8VW*@@GV67@253'Q=A?Z#%6R;3VQZ!A4]J#@D;^:$K?D M+A+L3CX&[GA?AO.LE+_CU.>;JN9%E?[9=C$Z/>*9XO(6`177>4SH0641F)YZY&@O1]M%(T&IB]2W1(EG M@94OPU6\70#6[F:8H6^]=G$?>:9>!-L M+65;0X_G(CXS3-$;<3<3\\4,;8B&$HH,B-$0,P:!\<'G#=)`B1A7G-7R6`-U M46O6^HT^I0.B3\Z3!H7D4()8[!@GH!4Y8S5TD:.G1T^0(I.>\Y3J@E<2<#28 M;28!^J($Q/FTVHTUQ62!!$?-C"#*!\J3_?4U[-]I-LO"_H441)R*0[.Q8[+H MT<3E$VJ!!6](2`\3?1704_)W]FW:)?5M]ET@0&:4*=UM5[-2U:.]YG)'W1Y*%LG-?%#$RTDF<+RUU`$3U,%:>" M@B2*FO%,$!E!PKIW$O8\M4&1">-H)LL$MN5713$A@@Y\`*9A<2XVE!7=.=\& M\QF@SN,_3$.'),[(>L=AY3!%^="P8^%EQQS3WT'S2>5IS";#]Z*A`UQZY[$Q M`U?&Y-7/%Y1$@`=2GQAF);`;D54WSZG>K-.IU"D]72P!R4&T"+(&/5X&3:R# M%BU$I6_3].VS:%'"KL\KPV79F#]M5Z>EM1OI?`JD]4L>&K6C?Z'0'^PLQ'V0>/LP>= M0$R9AU]KU[X/:O3!\+]KGUQOQ'@N+BG<>O>L_3Y^&-B?_(P3;_MCPNAPUW#` MX`6#/Z0[W@*UKL!$-=&V%]SU#EX!UYCL!]>/<,<5D"9(U@K=/CO<"EBY>Q`Y M$DO!CZ;7+P<_5%9#.T:4T,,!D$P4(V[A&J]UQU\Z*UK/#A MR[5XM]+BT=.+"%=W,_VKK2N>#>.D517"J]1,E M*VZ6NY4PJWU>C)`(?<>E"2O*&5)2:#X/!G=2^9ILC!$3Y:DU/$0%O6+Y$ZR& MT,:>,67/KL=;BW-0DB'XFC#(A1,P$I5P:N6;,<32505TQ5-(R<*L:@KIS;A0 M*2N$.QP==LLR7CXF@]*"G^-J/,S2$26]D;$S4^@"7(0O0(;WY!!N-\=[T3-F!FS$^"HJI.%O5[U*=`3/.6$,VW>3O)H@TL1B'L;8YDM> M*N)(%@HO/OIA37&4`YTP\81I=XB>HL&SH6>AD"JTC!:O#)WE:Y\GB$Z*G)S+ M!?5'GC4D<<:L`TJF%H=B]`!:R*DQIU0YGULM@@;*TY9;^5=20V^^H>1T/7M; M^SMTT1XD-A=*DO8XSH;<+[!,9)-1K%L5EK;2*K"J!5`6H+'-`E#8"Z3+-KS, MC2RQ1KA$BL3@^6XLC=7J9*Y.,WMU%NFJZKF*LAN8;*;+>#(S;A1F;$/']IH5 M6].HX"?@QE/C!6$QB2*<,VPZ49.[(_:#=CUF/3IGV!2#.:,Y%=[XY]H7]QD6 MUEL<&H.M*0*>L4!U/<(V2P=#%,]0?C6X6-18PO`3U4&V"[NG0^T*R)8T60`> MM$@>5\;0+#GRT3`:+$Z*G7I^\49/HJN$SZ^P)K,H4&&](W(;XS&/`N!F#SM\ MLJM(3;/@.C8=NJ8@'-TTLIF!=@GA#R8K3FI2YE5-T.!1Z()Z!Y\CMFB'!6=4 M+P5J*[#CSBT486(>6C1SZN%!?144:GLL2A(7,8P1X&KQ$(;",XH6K"7#XY4H M;B"*<65Y3#B94Y003A_-7S-:>28#74/F@`U.TK(P;]]\G%SD!HDM?@IJG!@WU484BV,"\FC/0-[/8HH'B[Q?\>T*@$11?-)O(&9=MX?4M'BU8S94 M?E;#K,)[44LZD?/]D%F5EV\`)Z,*Y-5'3&1^TF6'<4()4?APX M)MTM!6NQ%M0Q;-$H07R0_F144@2FGVE:7(/S&3#B[#"2&JY.!7OS1#N?.9CY M]T0!8N6=V(E)RD.2SZF`-N477NGJ6>CKSAA@&R MCW!;>)#)&VCP9?!AL>!7+,V56T*0B+@@$O!\=\IXWB'LJ#9OD&'Y$>:X`9); MF49D2=U32059':->C&;?\^8<]_$)\LN#VKV2!K4/V.-UN6*FN$3TO)XL6$-3 M>&,Y;^KTXM[;'Z#RTAG>U(>3C#>I07WLVN[C'#:*$;6]J?$1A:`VN!;$5GV4 M^T9V_:/:3<=X!&,B\HCHO-14;\!N/KBUN;QZ2*1S@*J5RR;.59>!T.)4#]$= MP.=M"1U0G'`7JI.:%L[.``M,Q.:W@8V'\"O/P_Y&OD_?$SAR5^!;@$S621I^ M44)W3"O8)UQ1V40[XXQYU#4.-XPI[%_@^3@\H`F8.YAE'L//-[YP)H*CX#-9 M\%2UG#>JVE4>Q:/(45\F8S8#''D-C+.'MDM M5+S`]VMRO\US/"=WE#MDD]EI:`?8&TMCMF1PU2\7TUCIQ+]3;Y\UU$/_K_+> M*WZO-E`$)2/Y2GT!5K*!N/EC[HKR]Z%9,V080(A(`::?/#OG-0>%1)5WW@K7 MYC_7;>B+#+SUK('=WY2R=VZ\ M,%%V2V==1/.J.$!%@YI-&SRS+!! ME:+^M?PM$"ZVA7_:^-)*W"IQ*XVX#3#TY:0*G!M%&T38S2+V8FCUB4AQ[/)2 M6ELE=97455*W`=277-[FE/"A.!>6'S?[0:%#[T.X!&D=WF5I%L\AF2_MFVHG M.JKIXKU/@]!SSLLBJ\7)99[`P2(`:%'B2FZ6#%@RPC MB=*"$M75LLT4]S;Y\9,XH1.>0B$1^W3LN^WMT=]G>&0ABJ]`WMD>\(]);YZ: M6DD'GJ^21=V`HP@*VJ.1QY[T*L7:IJPZ;^;E\M:0RP_$(TH'^U`*[U#T!,/= M.:Y?%&H$G5Y^EAD]G3=K$?RBU.;\A[.2]#4I+XH?C"[YT:<2A%X;6EZ.1?,H MQ,`Q+^,8Q!5O&;USW6$UF"G_%.O$?G;M8$LC4I_W:AQ)6<,3#167*$4Z;1$( M>?Q'70KM[?7=??3+Y3N98N8Q.3AF9,RLP+!)9=&QVLQF@1)Z%MI06#R)D5&R M`#V8>&[X.$FM0:E1N+BY,9-)[@T!<&(&DT:C]EQS^.+ABR-K:Q M&`ZY,CPT;_T[YE'A^HL3\[K5`+RBJ\WS?/*OX+;<8!=,G#I\P7#D50"79<:VT3-#6PO-@B?F83\]/DI:M%"* MGN63TL2L![3BE,%UJ/@O`05X`A22E0S MIE$Q,Z95C-*N';*1@?GJU#:**H)X!CA(I2P-JJEC_3C\/*$0Q19P^0B0F0Q\ M9UY<%%BM M7JW3;]0Z;3UI\PFX4\8HR[YHXZ&^+(QOAMT3GEWAPB[HA'+2`E'3)$8X5' MN[9/9/FMCS6FQ%)#R-&$F:&-@RFG,]N=,_:-FXOI_=(&W$;$SFGC^^BXZXY8 MA)IVDRLP&L\?:`]UR"GUXPN,I^LBDN!*/=;[_(GS(V5\ M-/KD,^8)NX/7ED_!XII@=1J6-8,)LIQNON&'4U!FA3H3VK(>4E('E4P^-;GP MX^W]Y=7]VT?[S7LB0@@1%<_W-YEO?G^^O.7M%?ODN+XY8H_ M3&_,?J3E-JIIGC8;!U+`'_Z\N9)KF5R512Y94@D?M,6\RJEEFH@^7?B'@*A5 M!P3(COKY36^.E2/R5MZOCR.:%4=4'!'31X96 MEZPXR2*298Z1-\IB+NQJ)"5(,1HQ5IRQ\$T]M$H)>!1F".Z&X]Z=N,,L82+: ML*R)]H8]Y;X=$?KUHU[]BKDKYJZ8^SC1JYB[8NY3MD+S]5366:6?J8&;&'YM MXFP#/Q`=VL1AWZ%88F/'Y#CU7:%^US_RU6-W@\O+ZU\_RT.WMCP2/3A'IRDS MO=^)\KG*O*X5VU9LJ[*MWJC8]O#HG0[;%J5=]=?.IB6Q$Z7)O!\[<65!UH&M MQ#(X#KL>;90L:+U_`A2G!(L3CC2EV.P=4B=6(E")P,%%H'50Z[42@4H$BJ5* MFBE<:[0.&FHH`]>7Q!@N-L_O@6HNUU5%O&:?:*WL-T'V33>D#/_#KWZ.9T>; M.O];TJ7$8:T\3YX:S=9K#R=4HG-THG,04=';E:A4HE*)RD:6>:O9?07"0M_N MJ4!YPT[]1]HEHK"V#ZO[2Z0_F;*$;WF2\&#$AW<^(+PO:231*&LCB15@#%W; MS+_:6C-LZ]'Y^0U/G"^J\=::#@G[:H]1C%9X2`R1$S7CU$Z`)NMQOM4,P;>% M#)$K4;E^\5W`^"YQ0UO280KY$Q,NY#^"J>50FW;9:OREI.->_M*"_T,63[]!9[3/C[+2U^ M77IB_^QQ#>MN.;XUBFGR.XYX>36+7)(SQ?Q.C]/LN%NEL:ZQ/)-@EXKPDSE4 M+A-Z1U!FMN\LB5P/`-NU;N.@*<45PQ_\U.(5\'G]7.^7G@5.G,./5Z6W]IW[ MF2?K]\_U]M'PQG&R_O[7N7!E?Q142.'V3JW5UFNMEGYHGC@DRQ?IP4G5R(\L M>@>KCDMSZC[C')*]=ODL<8[.*T*O1'DT6RDK@71;K]:T['GI%U;K=W#TRJ11*_8L%7N6USTI]LQ)IAL@5K!'9@&6=_U>KT:MV+-4[%E>!Z78\Y-/KC=F5G6"\OK0 MJ\+1I[>FKS?>5[%LQ;)E1*\*41_W^KU>C5JQ9ZG8L[P.2M$G*#/+J\Y/RM_G MM(0$J`+:KW'53S"F6+%]Q?;E8OL2$J`*MI_Z"E>:O6+Q(V'QDG14*/;P:*&C MPE<:5R3:*;1>L[-^4`6W-0$.69U;%LMV:T$YK98,E=#L;?US;S5],%DI1?7O M(=L\5%)3;35'MM7TSGN]2ES*+B[5)G-@*:FU]$ZMT3Q83[@RB$I)7-B]%&A1 M"^_2N+!E"&`<1XRNLBM*TFU-K]?JO7ZMTVE40E-VH:FLBZHS824EU=9R).(" M+FLE+J47EVI3.:R4M&KU5K_6['9.7%3HVVH"7ZX3^'8=C"='[1FSR5!Y'#QD M*FZ_,&968-A\MLX]@[5X8N8GU_L4!J''KGT_-)P1>_&XO699Q^TMCQ#;^URZ MEV-1($5HKMF;=$DJ\F4#7W/'R6A/LZ8%$Z:A!!C.7)L8IN8)AM5\XE^\Q0I\ M'$4/_*W1='H@OJ>-B9LU2["S9OAB9I^_/)!O]8>\\3WLJ+ZBL..;B!RSDCVB M+V7^I!;KY25-\>.]$09N](A>?
  • QM/R5N"I]@Y>0'1U0&Z>GE-XNIT#S4G M;PF95S5+:Q_8;S8G3QFEQ97D7A?]D(N\MW.1):P+.A=)$V:RWC276W^:&R?Z M%>=>Y(1N64M$<M@D],3I<`)3+FMM)OS5ZMA19;J\"Q9^5?]9+H MMY=M9>NB3`]N8-@:#T)$`=K7O*N5";W3=TH+34ONKE%S>KU5TUN=0^JY/7%\ M=?,]DY4FO/#O^[+KFLV7;R;/:@7_KZ`UQ1JO_]=%R\6?/M6^L*?:8 M_4H#UT,?'_$Q]"V'^?Y@]'=H^1;&&0<_+'_A8+?U!EQPBS_^MV^7;S23C2S@ M61\)]$NSTVR"/,5'VA*L'"2VMV M[=QY[@A>A4N#!Y0#Q[QD3\QV9U,&`E$PQ3N9*'0;O3:AL`FH.:&5R\IT,]%J MZQU]:[3D*@X<>(5EAQ@6^L9&H0OT&YVV7C`)I#*[GLX,RT-!N7%] M?Q.^SD%M]?1,^4[1N4DP5R;9'MD9&2<%# MRVP"T#'/OP((@OFO;L!D,._6NT>/QG]!CERO?10Y<@=(6GJ8,)&NA7ULG@7) MM6FO71B>[6I/AAV2JM2F+)BX)G@XP82N^L[F M<"]H4C\S)^P$B'A:F5^]*O-K55RBU2]-YE<.L>0CRO0J/K/K_X4.B]%O=&K* M!]!^>UW;?/+:BHPQ5GQ;'KZUYS'Z>KOBVXIOCX%O+]F('!"%79L5[Y;J+#/' MYB,I=I-T[[1K\]EU&=`KH(2UI*>8ATVM[=6:_5:MURRPO\YFZ)=)X95! M`"KYKN0[AU9`M4ZK76MV]$,S1"7>E7A7XIU_HXEFHUYK-0Y>&%,F\2Z)NY)C MN_\4=^7>\K]K8X\QS4(7D_F!YAD!._%4M-*C5Z:AD3EE5Q8@VJE]V.IZO<#6 M4@?#]:C9N9+62EHK:3T6=JZD]=BDM3CI['0/O9YEDLZ2N`3%GF#\[MI&8-E6 M,#^T-WBBFJIH/>@G\E'W?K8#N41@=_XGW"U&YA%[;A^]'S!9@I_<(Z&_1H M[#7[K5ZS)9I/;H[4?FEAS_7VRVC1W:!78:?5;G;T4I-"=FUH-%]&C@W:=[;@ M%:U&?6=R2''[9%C>[X8=L@'<.N4SO;"8YY/'V+4HY;DW`G8P,5$;>[\<*9%.,]DR)%PM)OWX2E,A)1OKZ)M3H=(NAACP0CW-<#RDC M_48&+5J@.L\[]7XKFQ+I&.V=%B^7DN9:6C3KO2.@15YRTEI'CW:[43AO/#!O M>C#I:+_YY:[]YV8H(J![0NSEK-XI(V)Y\6VW$.3XV<8='FUDM)4O#JM>LDGP M7S/F_46-LU6Q;.#VU6BOPUW!I5CD\^#5_L:(ZVNUT1X1?ZGV:=;KQ2+.9WF@ MI[QL^R=N^)4]TQ5^8R.Q5H:"J%A_"T#S8\MJ[I!C+WC7@8\^8OX7O.@)?K^S MC1%=E+@S'/J6:1G>_)L1>?M$[@"ET(HD62CG3CB+VPUS?R/]\QD;(HAH@O7>6)>@/V4[SPV9I['S-6\ M*41S%8Y;.65-O[;`6)'B7C/2']12=O=U8QI#B0%GR)+VIC3?F!82RY^GH_5:G M'N^N&3#F@DL.K)0]`+!#Z!2)S;*?N^O*9,\!U#N@%[;'157O.&3RPO6/=WO3 MLV<*=MO]F$"IB"]JBR1$N\]Z:NJ]LLYZVN],(H!YB'\USK6(MF)T-&4F#*,< MA9P3-TYH]-+>5RP'F).SHK-'`L!I-`4,]:SAB1$FO MH7<_^-I'U_!,S1UKEY;'1H'K^9HQFWGN$W"H@7/-71S/Z#J@4WSKT0'=ZCP2 M^+D-1=;KM;K>J=5[O)&K'(^L<4,=05-D!A42CC#C"E7["!!*E8KJ2>I4;1;= MXM,M-`G-<#0+]*1EV/"M@27&.#&-X2O^D2=*^GEK`1?#,;69X17T/NQYE7C? MN79EC"9;$\GR$S];3N#FNM3ZRA4>46A%@('$`E!@W[,"&^O`7>)>AQPOO/H) MO6J-_1W"0B[]F/[0-C7FVC"ZDL.4@'DX)S!X`AF^'#^)FXT` M4)I3YB*!L2L0\!_;1C!P1MP4)'$$G^<*4+1@$BQ^3PB&%<$RLEV:&0B@@1B$ M#H#Y[%E!P&*9F(5#VQK!%?!RFD!(,O/XZ+%'/%>>X2QB9OJ2Y$*;T!,#S6:& M'^3+UMTDMTPMVT9%A.QA\((A#5Q4CJD$*L(AABG8A>*J>DBCX?/$&DW415YD M8L$"DDC1VMF6CT\>NYX6>(9)C^-/1[+\Z7K?A9*[^C&:&,[CRU@&*0-VH+LL MURO8A-FP"2"5!?PB(Y(^/KMGP<3R3%_^Z(8!$,HA)'8#\%S[#:3<%E?Z\.+: MXFM?*BRJ&H$=CH%OH,'6:YG,X9CDO)DEF/:?DE0O8D#DA&&UVDA) MM^>N'83<$7P2C1B=<<=(FTG/:(?%2Y@IN%J8-HS2;D>>)@J.@=P[L]D/#9TE M$R\Q(\CRX4*E8SW6?G MS',!/FQD/IJP`+4MSO1T'0Z?I`GS81LQE\WW*0_%#9K.L>DGEI+B($<&YJK-6K=_OXS^K M#+=5;H7#GNWYVAZS#:"V'Z/ M!UJ#3.?K;]5Z/7`@ZRE.5[`+I`H[)VK=YI+4%\K@V2VLXWI@S-1,\=2, M.(B"M>!K1%PTMAQ@(M#5X(Z`*[)*>7.]_0QJ>C&25(`"38;DR)Y5?`3.[QZ\ M`-82`R-K]QNXPPT,&R_(E?J]1K_6Z':7=L#TW4V9E9Q&QUR%L]/NU?16^\BV MNL0DQK)KE-+M=)WN<>US>KN]O,OMIRZ]4,=\Z752@34B!9:SV.C-1JW779#V MY04L6NGH>JW9Z-6Z[8T.<,Y7A0C5**\!6MSW-3I8C'@V;R$'-FPNLR(Q?!1V M`JU.`H*0"@F)X3S/69!K;;VW$AY,\K#&%IX.>.YTM3P#E(SR9C0S9/PD*H*W M#`'B/83!;D>!B^=]>K<0P6LT:XU&]\!2ES-!HDGR7HRP_&A@><%;S[*+( MX87&U`WY,4'>0K_D85V&XH0P.N+FD.?ZXGYW`]$&FS9SLS9&(Z**L"^EJ+\* MP5;/(#QVMOTQ1.(\(5^3!F.,C=2H&'D@&EC-WB/SQ2DC0$`PRG5%FQQ8P!U9 M9(FE2%&,`YU8`[+RJ,=4<2_&W6EU8']OIMB8I`^^&N`3:$V=5&UKF1/S5'@) MY538@U>W+CJ=CDRG\Y+C:2>U(G$VD7JD#/D[YE%F:&9.=;'Y MQ)M6HV">F\@KWA2KA8SR87#M^($7$E`Q"M=C$6Y&1=">.>K\R%O@W MF-PSX";$)HG;A9*L45^=@GW6P4*M>J)^(!^\-RSCH@78LHJK6&IE5/*I MM3%BV6GL/-UZ$`83U[/^`[OJP>2KT=B@KA'["=5[]56Z91&;;-SO#._6*Y6. M:6Q>%UW75Q%A%5J+Q%@I;[*6CY>AQ)>404:R6NE@X8O"&MOCE\TNER*A"1OO M`$U'<(?QN%ECH6)ITLZ@B4Y5XZM8)1VE'4K%]1*088.ZZ%:?_K=5.;A^@*+H MAV=WR[KHQI&V;RR6)3:H<-8;Q!3K&WB4H%;^UEE?+E\P1?N;;-(][)C:+XJB M+VG842AQFMOU&3JVKB:'Y[[FYHV)CI'`VVO]YN8MBEY.$-6NNH@B=+>>]6@Y MAHW?:??T5CM/ MZJ;Z?!^9P\;6R#+L^.&?Q-G"U@7\S>S6`KK>ZS66=,ZV8"VB-K!M=X1./1'@ MH^$S$T^%F./3*3WVX73\#'68P%5Z;10/$-ETVMGY$Y9Q*PW+J]X2F'4_IH%;92+!O?,9WC\!$2X9$_, M=F?4-N0%%&AEA&J!`JTR$&!5"Z16=@LDO=7LE@KZ0EBXE=TF25^P@@Y.@P)8 M.-L0!$>_S^S/I_7(M8!$\G-W7J=G+@0#I M%P_0V7LD\#[.XTO`EL2O!L^&9][R'LBWV.V>,3$3^A!TL MR=8&X3D3=(#R:(S53D%VB9U9$ M7D$VZL-M[I-<&\0^57)MC4O>W/7)]<;,HI)Z2?4]DJM=WRMWI2";-SU!GUH> MW7,0>NI[I6<*L@?82/*GX@99!D>XD0@=8D2GV_L@97.CA(U>O]-IY,F7"Y@6 MR)5_,!PHP)W!=!/KUTZ]`YP#IL18S M-H:X`))[0)S0L/&8=[/I/3FMA?[FE[O^G_K71NMR@=3[Q;F\9"]"\7>`N^]Z M?^KUKWKWM.B^6LI6@;`J5:(0NC!UT71B'T0=8,SOE9=%L$5C?`B85-GS=XF M6W$53:!-!K;U6HUV5TVH6P?X$J+Q/,<+8V8%ALTIA(?=WA,S@4"?0G3#Y;"< M?6"^4=E!2V]UDJAOBTK1Y[OPZ1(0SMH%-LD5Z6XQDVYQ,%[1V"R2,&(`H#CX M1>DP_(K)CS@!@%[G/V`[!_5WG,?TJQO\R0#ED?OH8&VG>H2Z^4S!;G:N6*/> M;?3ZBGK9"_A[HQE?.6![\15>MY'AO$!$]#L:?W:^[H%.J2`O%VJZ(`+!_,X& MGAPX)E9V\EP_.7CUPKJB:VK,;I=M_\\HD-O1!(JX&.<,/'B?;5F+\0XVA"*':^ M8*@U8$,.D)M3DL0R][OL[/YF/YG8O>)].X.U*F6[FYUPWUHP\C<$"RP1,&5P M10>^SP+_5Q9G'2][)3X1GT1RDU>GP_(J\C:6V?=M.J] M%X-\`_N[XS/8Y<1F#_8T;(DK#=F,VI->=M)Z(\F<*U^<`X0K*9J=5-[3]P-A MAG'26S.DM][:#<3;8,(\L-C0L*'YACR)>>[9 M$9ZS=D/O]_<-;Q879)>DG?6ZW>8+P%U;E;>V%'8E6V1O4"L+=U?#D#_L*YDD M>Q?K-/5.1NGQWC#(8)M^]AZ7`^QR%P&%L[C9+'Z^8R>;.7>(#?1(U*87O1=]*J?8AA.L9=Y<<7<=0-QY(U)A!$AC#JY*%!40W6!U,;(# M5X%ZW\9!&4U$91)CX035>>]L8R1G-,XU0QN*B`VVGQY:#CF)Y]H@2'NG?$RQ MC:1;_926N!/CB6E#QIR(5>5HX9G"QC&W2G:TO)@-QRQRH)4P2Z.SS(Q'V@=U MZZTPP^U.<=PRW$3]+Z%-U.A&QM,^SK\:_W8]"NXLQSSZV5X;,,@JYST%ZF5; M1[;_OE&Z1&<=E(OPRL:QP`5DUE0-]WJ+-EP*?"]'8H-0VP:X9+N"[7JGM0]< M7M+NY86+N::`N-,J/0'R882U9<2'I,-&C6E>R`C9[G"G6WK\\^&#=;U=VIN3 M8UA)NOY0`QMY#3[@E-_^387ET_C\P_QWZ`;+G M_KH.+A`@.PC>;2?C=IF0+QTT\ZP(>>(E\T;PX'K?6&8;8.!D6%2EY*?"%NMHY4+9PAY^#AHX_=_ZW`U&9TI/T[3WV9+FA;T>C M:I.#8^1`4L,&[,3&+B(!.$13CBCTV!1\9@T/Z>$+4_3MA@LG%CQ,!`Y&'CX? M6,X*_.7)7#0:D<_AH=0:/AT6A]&#FVXE)LXQ<0PA)JEQ1Y@R7SP<)/!\U&HW`:\LF/ M)K7>"R2QS7#$HR[YSDRMM5)FFO.%&-N@(GA4SK:F(KJ#^F)QF<^UF^6Q@.H4 M);F.^<.OUWK=])F[^4X)J[4:*3,`33FAC'%&83*XM;CN^X\/ODQ='#*RF9NB MT\#:H#F+5)."X6EE70)F3#F;/UGP/(HNRS&Z?'BMP=M7"9Z/8Z2)P2(K_7+X3`^:$^B2YUQP`PHKB3SAWC`51S+06 MC>+C68?GVB>7Q\N5T*T19\WE/",O-:8*-$E@M3PU#R<3BX`]#B0TA.JKR4`K MIZU4YF/`*(HT)["50L5S'*<`P`3G_F)_&\:3VQ?V+#EE=\,;FI5X[@WRI9GG MC-()(L.='TVD62H."_CTV;%@_4P6*'3'Z:6,I\U[Q]$;M7IC>7`]'W,=T2(: M?XWN54$(U\_KS15#MPGKMSF_+#G"]9WR-FY-"L,$,77%1,9XM2/*2!U`EBE8 M5]'XSD73995EO`V_-14(_D$#18DR>JVCTQ*N7#6/*B?%M$S?F++S4QJAN">? M;7=/>##E)Z2?(BTJ\4KU*Z6H_1T:7L#D^?6":H\/ M<\>AAVEB8$_P"P/W_?&L%3\,3D28SAYN[[9\C5R;LX^W#P^W7^GNM>?%&ATX M__P&3YQCB0@\"#F[/!S?5G0#QP9\IEIKSLC^O+AR^)8<#*@?/: M:^7JK$L*^C:?#EV;/YXS4+^NKU-M"1@6WQ89J7.*1/`2`^VC%A<9:$H<5(N. M.C2*3?)(`/TY<6UP>'V%KS5^Z*&]O>3.^SMR#]ETYGJ8@9^<`,^S8>`Y"<&` M%\'U9!K+2`9N'Q9L:5$$6%A0W#0V%*M;^"M&L"@T>:=9Z&"=Z*E.P3:4V9+T MZ&R)[&^1#I2<+@VFI`@FY8UN;]D2BRP,#&PQZ2:N7=,(WGSC$\WE,=R+QGH<4Q)R2CK/)UN>N+>DJ4D2(?R?=_C@(*@R@RD#7@E2^05);O%2-)[E::\XYX"O,/5,,_PH5`WV0#QM M568(1O=1'%XY+XFR7N%)#$_0\%%BAU]XSNK-FWNOPE/%YZ'<`M\9"E!Y\W^G MU4F11=HTDU9#Q?A'Q_B:*L)C!^) MHQR\FKC=YY%O+@[`O#.,Z3J/F^TT^9NCG;2@'+PUHH2R6ZX.G!-Z.4/6;J6< M'&5`IH*#]O3=ETH.CTX.IZZ)FP^NYWBX+6FWL#*TZ@\2YW M9!%O/%LBU+FMMRJ]E+08#$4NY?Y6T^#M&$S)/L!^2)QUJG@E?=)\#Z!J_4Z* M!Z8:CJMH&&^C_)PM5[@::4J'CNJ)9`(L06$%%$7B$VNP]B#=!+N&XL5Y!_D[ M[73UF;]17-J`W&$!R^%@S`@"SQJ&7.FC4TB=2'@X0@1D,I>TAD:@B*7*$^=B MLDY:]90M,?<3-#`*4F)4*\]B-B-?4:=L;^OG=?U=DB+)<[:\W]99];8-SL1> MR&K-_;%:(\77R9W3:IW6LOI]2^J6=\L(3^/`HQ6O;5!XT*]V>AU$VT+U\#_0H3U^E_UAD2X_I?> MS1/A#29J-YJ-1C=_=+<;F;U]#[$%1#>8;2U6MKX6UQ73K+=!=,6BYH#H)J,7 M<46W1I-*3^)\W3O#,J\=T:@3YXK&J;KB2"NST^@]B\ZYXTJ.5)R_C9AC>):; M@FMVO52O)0HHMX8\HY8,MJY;)_Z\41OS^'(507P7N"Y\IGB`K0@_4D-"JK6] M`&@>771M4]#.[F/2;S5ZJ^K$%J#/&<\\UE3/;G&B][KU'9'CS;+<*5VXZ=SN ME^.37=YTUDC6*R>`?#D&G]#8I*R>&'24AN@K*E[,!<_L`J?NP;%<`'=-'7E' M[^<+<5)2]K@NV47F9WJOUSXXI@L@KVD]IC?JC2U6Y\KP?6&N$, M:,L.@Y4C:0O0!!O-1&L`@NB**+UZL^'/!]V7+]I&0\:HCK7>+3]R^:SX1I.^ M.$V:!Z5)+MAN.EGK9?R=/L7]VKD312?[0K>1;:@LME59`W;"R+Y?R%_[Y+G3 MY6+_^8,KO>BUY,>9^"C%%\:1:+WG4M9)[*^%+5K1U^4$.KZO2 M:\UZ,[.P*GDS&F"+56MT`E9T<=F.ZKF@XACMM58^1-4*I2I0X$4%+ZXC$+G_ MYUJYLL=%QO?J).]D@C=/RLY..=%.+JU7I.*F9]]J1Y3,&25@[IIS&>5);ID: MJ569=E%VW&X)<2*);7]Y:R+7;(VLESXA2B0Q28M$Y!KEF%ZT@=6R0:K.[FDX MJL4E,USR36IY2SB^2T&RJ2+YKY]6^<^),(PZLV[@F+))W@MZP34Z)]<+[H.& MJ3AG/I@)9WQ_>:\YKL/D]P'8(*,)?N=-#3N&.>ZC#RX`5WARNB'J$4ELRI@I MMN?^?E'?8[%]2IN5XM?UN*82+/=X&KNV[3[[VN#;A=;3VV>M>HW>SZ9XJ1Q( M[@N;Y8_K3"_#Y2C%8@-CP*)[G*,-UXW_O57;`DF>A(:BKC MUK)KJHJDU-Y[1?#77E-@TQ$=)B.+2AU/V,3`#@X$U&9R(B#N2GFF'VI==(RZ MR_F?L0^FF!#_ZRGO.N6D&@)V!)6C?1I@'&-1_#&'I%<`$+$ M<1@UDG&R5JW9J-=:C;J"WA)"3L2?`C5$"(%(;L'DNT;+8CRF.DX,QP*R7%N;5`T3N75>[-:-%+=..9S@(1T> M&'1'HY#[T$*M!\]@W8(1C$>YZ/GP0:(=T0\*U___A?9J\.&J??;JQ3D9AHD7Y6HM[(*$PI60=$\V$K]Y*)^$L::.';C M<9*Q82U%1Z/GKA3)^D*(/Z+"(F2(2QL.1.1<` M=]LIE8LRDK<8O4S?>S<<,52(FM7;\,V>W9*#=[KB]`I[FA?0CT!?,`Q]Y*;0@RN.I(%\S;.O1^?D-OUHIO%<;!HQL9G@< M&J6P];T1!F[TM%[OGQ^TC[?WEU?W9Q>W-S>#NV\`U`A6TICY0)';WZ_N/]W< M_O%>P[T%'KZ^<<`JT*+6`5^NKC]_P95JS'ZD]0Q0J*%)%(P/VF+'`B!,X$[%A7\(F+KUN/5!J__/1#PD;B^0R@?I30T. MB4Q+04;/`1?!)[*-Q/_0@/*ZIL]^:+YK6Z;@VA(LG0[H(A<#GSJ8P[F(.MHF M,?I@I"@?0!'N=6U![&[O(VJ69:TKOBTGW]KS&'TPI2N^K?CV"/A6!@85=FU6 MO+O<:V4W(\EFXV`7*GP<7/S?Y_O;WWZ]!%*,P)$>C_,@19K=%,UJXT6Z.RSV M?I&<6J9ILSWJJL.LH=`PU%,L1;WL#7N:99V._MW@\O+ZU\]G]QR*MO3T2D>2 M^C)-&KU:L]^J]9JM0W-$F11>&02@DN]*OE\NWSRMJMG1#\T0E7A7XEV)=][B M':5D')HARB3>)7%7QO2_HMR5>\O'8/SNVD9`:8F']@9/5%/EMWS'HZERQ#DM/-FIG_=?Q]'#/P^- M9264E5!N*)3-\WKOT.M9"64EE)50QD+9;I\WJIVR-*9\L=']JQ\SWB,L8-[T MT([JH*NZ0MXYJ:W-F>/ZA%[1,@8IM%2Q<8BH>UA\^Z`L_XEB0]Y=4JB!T==O7+"9:%# MU?X;5!7;K&AG5$ZG:;''SC9OA9?HA*:J6W3L7&;H;#VU/B5I;LD.I.X7<7GN>X M`?-3FYFF-B\-9_@QSR77NK5ZLUYK]KK))8\[F%I!LI'F/IJ(KJ)W;X$O<0!' MW#.<>J\I;:;POY9!%'85C3CX,3Q_HM;>.TL&\03I$7RE` MRJR;(;9%Y*-:IT,QGN^@,J/7FNUV3>^T7BHS@'N>@*GMOSL'%I56)U]1R6?[ M-[1';.F;-[J]E";Y-%R3YD^I6_]\W<;/.]BNV/@+VO?%%*VT3?\5#E]8-1%H M>9Q3-+^,LZVR3LR@68AB#)B4L])H]U8H#9K$90CU MD/=+ZZM>"@IRV>A%_L!QE_@OQUWB"F[;+XG.ZS"6MU+2L1&_=.+_Y01,#%8?=U< ML<6IY)^P$3V[L9Z8>1T-$A[@'&%_$,]X'JB#?9AT(K!/WN7?OW-M:S3G_W[)N+I^236DO0F4*P(J&%!X*4$&?<_VF`)!C"CHOA$-)P&]YA/@V\? MI2LZ^/8;6`?G].M9O2&&X(!:Y2<;IN7C[!O8'&&[HRFS\8QJ$)/IPG1ST-W@]N+Z'9\<@G"0R1G(*=;:A-DSC>$@ M-YHX,L6Y)7R00@!ZV4%T^/95FOV6]#M_&;=N5D"-$8G@+[+5IX[G/ MM6NP4UT\^7$#/E-30S."@=XA#ERB4VQ>XX06`0Q\'[]JQ8MPY/PL'(*RB,C` M%S!K9JZ&9.T+FDE8^7AI)X3[)=BXU(QN3DZ?86*R M._`0O,D&:\UT9VA.`4`TVL_P3,'HIF72.HKYLS0\$OO&=K,&*K90$, M/1.,1JNU"Q@/QH\;Q878G"B-3&B:]6XO%9SD^W:%:B6-FD5`]<"FH'%AV^/C M/F\L^(])IAH?Y8TAC4Q+G(^.^QC/`U?&@4?3P,E;4`W4;U(?D!UZ.Z8+ELW1 M9BN;/9O-9B>!]";HY$,"Q0`OE@3M-22H-QIYDP!TD(CUG]'9WI` MWCE-X4JWQ)N*);[(P)U,3%:CL`DXA6*T4B2S/<>.WLM:F<.BE>$R-;.=P*;> MRALMXGTN/\R\]2X,VV;F9>CA;D@&#-V_PP+U-V6YS2`H#NZ_BM$>K>S]O4P$ MN*`X]&I$.7>AW>HZ:!BE()MM190)V0$8D"@7AGUG6.:UC'&!6T?14EYMIET5NJ-*':[,[PLYW%18T?G2+&*3%7;WT;,,<"[ M2U'7V?9-KQ_CO1[JG;>J_:&;;<'TFYG!X]4());W$KCBR<"C2YD'=!-E?V6= M'>2!8"?;'NFT.O&"9L"Y%/(P;.:+\R5@^B=KQ/Q?V::&10YH95L5>CUI9JT` M=Q&KS\S!O-2!8P[,J>58?N`1.;!YG^/OCRL[:T[8DFE&:Z!>0M)US6?+MC-9 M+RY%N+&F5L!,%8./HCAA,`(I\,EX1ASR03W;4-$[O:2A(K'9"(\*)MN< M:?4[RI:Q$<@+NE/>(732'C'+-FP:@A/7@)G`YL;U`R>8D#I-BATENI'@:4+R-"YZZW-9HYS3 M@O),FWMO4"")@S01F9V")@;1)+4R@:Y>JH?AI7M^@&5$4U"N-F6.SL0++,R_3Z?P(WM?D3_OP3 M7OA&7!_,9W`]T(T2H=_\0@__:>GI\/V_?L)'6>_QWP3%_P]02P,$%`````@` M-8N/1A-(!P`9"0``27@``!4`'`!A<&AB+3(P,30P,S,Q7V-A;"YX;6Q55`D` M`U;7+E56URY5=7@+``$$)0X```0Y`0``[5UM;^.X$?Y>X/Z#ZOOL.$YVV]U@ M%EHWURVG`@=)E'P^?+QK=!M_FIX?S\TP]_^O+G M9M.Y@Q`XB__5_^Y]P^#9RF\_+R,/[?.3D_/6_G`1CKR8B;HRNB7\WQLN_6/7QZ>W#$$I$E# M$9'075`I-F5T[<^?/[>2;^5002]$0O_`7!(EIC+*Y52.4/]KYL.:ZE*S?=8\ M;Y_,A->0-G"<+YSY\`@C)Q'@(II/X+(A:##QE>#)M3&'T66#3,9#9>8/I^G,4`D&HYB^NWQ?D5V(GG2R9@.*5,@M-28EH9'2\JW M10F?I`=``&$D>J/>1#F7-.ZFHE8QVY7,O=$U$>.NSU[>+/$*JRW(^Q0Q-W$O M[YH%$PA%8HL:4E8QV()L?7D=.)?:CPF'.J8K4.[,4C<0$>K7D2GFU+ MU+,E65WBN[&??/L@)5N1&681A!YXN=2*\ULB2Q+WY#U]YJ[Z!D2'T:41"=T$NL M,F:^)Q]FM_^.:33/[^F3(?B))+_9D^9&W)M*=M*O"+J$=X>ORDRXFS.4'PM@ MKS[@LA$M$0=!PJU)99C+Z4>?(*C\&K M!5$!F=@EY%<&AH&72HQRK M,%5 M/VIB#HSV(!UBM.M%8^`+P&! M"=&9$NJKDM^`+3UW,ERNB*"NQM5J<]K/=%H1TU8=%)-D0ZC69]":8HC3B6QF MA,]6@)6.Q@9;Y7.I3/A#@.9VIO:1M36.DK$(8-$X5R4X"P7,T#3WF#`(D-88 MRP7@#4S!9Q/UI,EDU^8*6CI,F*U[73%+T*J">&*EG7:^VG/S`AI2$?&D#FJ& MSTAY2``:E4&\LGHB/HAL+^X)^)2Z(.1#0%=,JJ+`!)DY3E:J@1BL!RFD="A5 M+,LD-N\6:V@0`&9PO^(>9:4RB,-DLH[_RD*VZIWF*&DB1`"@7<)HT`/QE%ML M[MW)I;Q2LA;EUTWV4&U6 M-Y>9IOJC+#R5J:KJ,Y4/.>9)_#@0`3>0_M7MZ=9BL[E@)PTZ050+V-NY`IFAN_,/\P&.9!0D;[_$%&Y MBE(U"TO/*%"]"_@+6B/N)JNPQNLNS[8S"6O&"#QEAYF$M1EPN\[A=DYMP>D/ MMY'J^'=<=H/PQCLR2&KWKVE)GHWD;]-U&<]W>WO\VB!>X2RJ=JVZ$WRCU.^2)X'9$6R!() MH;0+LRZ#H\.RK@'*@?V(8=K>P(2#2TTS=778T0%:KF8Y;'_!`%MRHL!5\4BU M2@"K"(X6RBJ%RT']*P90UQ>$]V%^;,XCN"!3Q*&O[Y:P(3]:P.W4+X?_$X[D MNJ!!NA@&MXC1W#=^0U=@:I\!H-^UO=-P MEO,^FCL7O1'9N1KI47KJ94P^!:_+>#>.8@YY'577X5F?%Z:U?4>5F)X3![J: M+X9D[6B=%\*]7N)1HA='ZG<)U)E97^-@"%QCE!W<"\$$W]AM[(H(;S(/XCV] MC;5-=>N-4BN_]LI+,]^INN@N_,]XRS_C(TX&FZO#7B(YYY]Z',)Y]51WJJ M8-JKFI[-?<>8]T)]W5FO=N3HX;-38R>SKJ*32VU",!>$*#^AK*I_RTB&`(HZ M+K?2FV54#G%>TJ6AM,H#G:JE?*2RJCNN[XZOI#A0"(UZ(8Z2%I$05;1["SX; MQ+OR`L.7UQ^Z30SR?U!+`P04````"``UBX]&I,>SP(4I``"AKP(`%0`<`&%P M:&(M,C`Q-#`S,S%?9&5F+GAM;%54"0`#5M`L``00E#@``!#D! M``#M76U/Y$B2_G[2_0>N]S,-52YH&$W?JFB@ESN:0L#LW.IT2AD[`<^X[!K; M1<.>[K]?I%WOE:]V9CFJIJ75-@.9Z7CBR=?(B,B?__HVC/=>:99':?+Y0^?C MX8<]F@1I&"7/GS_\\G"Y?_)A[Z___J__\O._[>_O?:4)S?R"AGN/[WOG?N$_ M9'[P>SZMO]?YV/EXLL=^.-KOC[+][F'G:.^_#[V?X']'O?_9^]_;;_^W=W'_ ML+>_]_W[]X\AM%"4+7P,TN'>_C[[3APEOS_Z.=T#P9+\\X>7HAC]='#`RK\] M9O''-'L^Z!X>>@?3@A^JDC^]Y=%2Z>_>M&SGX+^^7=\'+W3H[T=)7OA),*_% MFN'5ZYR>GAZ4?X6B>?137M:_3@._*%6EE&M/6(+]U_ZTV#[[U7ZGN^]U/K[E MX4PN*!,6L\\L-G!T4/WQ`ZAK;^_G+(WI'7W:*V7]J7@?T<\?\F@XBAG&\G!B,VUH'#NFH6->90YCL:4ABE MCS&%$C`K%1'\>`N-T"QC)=/@=^BEY;\O:1S"M'7QQQAZ[#E]BH*HL`"TL02N MM#-X^N+G+Y=Q^KTQGTM-69#WQB_&&1T\G8WS**%YSA04/2<1:,2':24(TC', M*\GS+4@21#0_IX4?Q?D#?2O&1J.JZ8U:TO6KGM9:PXR97-65AD8&`%K?/!TD65I5G^8J9N:R>MGP53DR8^+7YAM MDZ.D.`BCX<&DS($?QQ^4&`4;]NE^F^W4CTKH96M-18*?@1W`O!_2)W\<%Q8% MY+1M4=QTZ$>)&VDG33<6MFQG?TB'CS2S*>ERNTW%?`&)LF#\2/=G*K`H++?U MIB(G:=&W.I:F#3\LS-'PU3H.E M3\7LH)]F7%`EH)P&'Y_3UX.01@=L7F0_E!/D_F%G'(Q@. M])G],/][G,)J_/E#D8UI,_*>_/RQU,0XWW_V_5'%((V+?/J;52HGOR:SL]N7 MV,_AF%H=1-\B7A=4UB%>K^.05LFLJ*1Y1MHRQ9J0^$QWVR)M4MM& MB!0*GY-/FQP>EU%,LR\@T'.:R0?'4DG2.=HV)D0H^"2<;(:$A\QG5]_W[\/' M-!:H?ZD,Z1QNF^+7Y>>K_'2CRT(Z'*9)N8&H;.V#<<%NZIFD\C5"4I%T7)Y3 M7"X8*E"",^GA9HT##]"LPB#`BI"MFYM6I1>HN[,9=?=!E)"):(6Y9\VC8&A#`$3#0\<9LR46W8*N$NX77*ZK8QPH0A8V;!U>+Z-UN=D5IJ<;#X=0U*H3W$G,9?ZQXW3JNVYXW+UUKIPDM!E>M?4$:[? M6WO5U'5J!;%PT\1TKGUWT17:1+;VGJE[N"W73(9,.;YDJL]8/\]AJ>\_LBN8 MH)"PM5R0=%N\;JJU@''D=W+/U)2*B>E?FY&5\J3;XNV31-K'+)"B7WSQL^P]2I[_[L=CV:9/JS[IMGB^45,BF.ZTD3FY MMVHPW*I`BOR.!A3$AFW2#2TFN&6C3E*-=%NT(=7D$LW2FJ>[UI%NBW;KVL-L#8&; MV[$F`RN%$V;Q?AO[E1LR3.2\2H)XS"Y@OZ9I^#V*8XV-I$DSQ#MJ\;;:F%)S:/:N]-:#D=AO M0"3H9P'-8<'-*>!FNZ=S^DKC=#3D3X(ZU4BWQ9NC^MI>9DT;J)O;OOH#\9+I MFEY'KS2\A3,I[*:^9FDN,R(*:H!6$!RLF_*H!=+-W6!]#J?`)*1-BQ"O17AVA6NXLH%N$)A,;+&ICUA^`=G644!Y!B#>-NT_%F06Z+LU^\=U MY#]&,6B.YMQ<'QH;1]TFB(=@43.R%ALA$S#;FH5D07A]:[*X$O$0S(]&A"@Y MY2$4L-B>:61BE[OUWYE1#E##;[(Q#==Q:)@K-5HA'@+SLX(DN0E3%Z3@6KLU MR\OY)'_+'1QS$ND]PDI)TFO3L;\19UPD`F):,[`8#35>9T-P'U"+'0$6`3^M M.80LB'F3)D&=Q6Z]'O$0V/_MKG<"D`(Z:YA1!+:N`!1G!0=N4,1U,`L):,WQP,9HN7L1#8/^ORY88 MD8`K#$83/89(#]<&W<)FHH0D(*8UF\<#'8[2S,_>*T2EU]'%V\3PV0_#J)+T MUH_"J^2+/XH*7V8XKM,<<9O(9F-4U\8NZ!.M65!JV30E*G.:3VIS_"H0"ES* M6S..+$29*[TL5XJ2'@++I4+=?(ZX2`3,M&8=,9]6A;,'`LMC+9YD@`1TM68L MJ3P"9P*KV>)7(#T$1JU:9$GP"+AJS:'DCF463FAXX6<)K+IY/PC&PW',8C1G M.?B%O*DKDQX".TDM#C6Q"?ALS;ED':O1%H3T$%A/:O$EP"+@IS6CB6I;U>`2 MG/1PG]C9^S?_MS0K8U858>\&K9`CEUO$)H'P1\+IS10>LM!XB?ASX5F& M5658MF%+,)Z<'MZTH^I-"33N!F+TR*+P6^T+N`+X6^L4:`/^)X[XWY8VC+RP MKL5R@`C!H;_6V.0SRD&'+!N`WM<8*KF MHT$6[=^<(%P+FS6F5`M5C1M=@4/1/6AT"RS5O`O8BOW@E&T!CI'6Y=?ZB+$EM"@Q77DUL_&V2E)L+R%OR69J53 MK+[CCJ@%"1 MBPA;?@.NS%=Y/C;GKJI%CA!<[.C8.8`F@<%:R*U.>FT^5V:%2PDN;#D.%MSZ:NQM-&J38P0^ MJF9LZJ+"EC]A[?4CK?V,I!;!8*:HS1T7#;;,"&OR*O.MF31D2;+D/ M#-]9TZE&W%Y3;X2Q53CR/`8M>5O-,.:#I\&(9N7"O)6/B7QJS016U]'JV*55 MP]31BJE/<;4WEWH7_*SL7MD>N[1L-+FR97297MD>BP.EM_5&\-BI!VQ M\-$7`1ID;DS-"=J6*UM#IM#Z%MW[,#")G/T34(666/GTJLSD@EK`,($?B,:='`9U"!#)D'D@"H^9@CGS"8 MD.K3)H.%S"EIB8(60YG=0$*FJ23PAV)G4HU,&%S35H M#:?)1$D^(=B/U&&*CP2;[\Y,RJLD2(?T6O[^`:2HA4UB6?$+B[&1.I!PN;\\U54M",YAI; M_)62Y!,"WS9CDG@@L+G/E*!NTB1=7G?5#,DK@EJV<7[4`87-::9ZCD:]/5PJ M1WJ'"/@QVGEPY,?F"[/B1<=>3"AC1QY2%GDT+`4MO;#ZX6_CO%`$X]1HC?0Z M"([.1K361HG-P6:I?_9?_2AF5[L/Z8++R22YSYF?1X'N2%6W1$ZVS4I9!R"V M!T:FV=*F#I6EI,QV%\5C%ABD/A)JMD!Z2%W#Q?P:(87.\KH"_,X>:75J@3+T^#IP7_3F,,U:I,3!#9RH^E;%Y3\O10$OK(: M\?[LT%\R.N=B>.CTK6G"Q/14G\.>CV3$7V]/NMKC8&C*%UL6V2?8DXS9( MKX-@.R@82GPV#;$A<\"=]=]J:\?VMFG"MH>Z2QRO'CG%FOQ/8YD3`D+F?KLB MIW(RY9:'#9W3BP[S%4^H?H&U18P*F>NM-;Z0+H"VB'.0'M!ZB+!RP5LK"\@0 MW-%+1HO0UL'#@&80M6#3K<-4`&"FUOS`6B&#YOG;M-WHTX17.&8&BZY M(+#YZYJD)5E/WG&*X%AM2`L7`S;GVWKN9:_9R&;%:&*;GT$+ZC,.KSJ)@&;][2+$K#.QJDSQ4KJE=@77^:G.+T1I3T MEXVH!)NWL`[H!2,A\TO_-2I>JE^QX_8E]8NQ-".?K4^04P1^_?:[E#9T;&[* MY2:DRH]V/LY@M:NZ?=G7;^CW\B]R>ZQ&?7**P`918W.FA0N;M[-`\FI;TX#2 ME09(YQ"!F<(*J5QDV/R8,3BQ;]UNH#9,;&[-LNEHOM`,GA;6H7L:0$GVB&W- MZ5O9+@P4!(82>_.Z)F!LGM'26C[7H=2F=K4F' MPZM!;8"R-?8T8UCV?)W-&%K99YA2M%H=P&R-<Y5=69+Q$L:(QT,3AX6-\<2E`+J+3ZW*NN2I71W M-*;,WG\)*KC(04??ZZS?HK8`)@('$$NKMARD@,L:5K$Z:[4E,N6-`="ML6HT M12D(TJAAYFIR5NW6&8SSV@!E:PP-QK`$#-4P-C4ZJYI2M%H=P.R$/8&/2T!2 MN[Y457P(#0?9%S^..5U-M:%1-D!ZG:WS)S%!)J"U/4\LE>Q5[VS":]4"].JM ML2S5@B9@%DF(/)R@_?SE,DZ_;^5C4ITZ1KIV8]T[79<;>--@]U*!HEZ^+O>/ M:/?5$-A.U^4.ODD<8$F8@EH^G!T+>.]TG>[9+42\EUKG4R7"LV,Q[X`):8G*^260+V?E!$KZ5%'?8.\(LQ_&[^^*1& M;B0['R!>#^>A6[)XVD2.+)R^7CA`IXM@FV^3%2'OJZ"1Q=0ON!C?I$D`ZB@[ M,W-3@]U;$,5T"<-#JJDQC>G`]:=!WPB,!.X[V6;TB"RW@-NW'#I=!,X0F^&5 MWZS+(JEIP:@=T`0";XHV M.TL-=:%+IS#5'DB\^)2&UO*U4@<0(O"M:+-#*%1C+QN#X&;ITH^R5V9-'SQ- M>V)UH=+/KY)7.A&-<@W69@V0CH?`FZ(-KNOH"5MRAW,ZRF@0J4;Z8C$`@L#C MHMVMP:HVT"5TF"2Q7HZRE=ESN14`'`)WC#:IEND%6[((4$'&/$W.:?7O`NA) MI*S&D52_$5`"`BM4J[L^0UUARV.Q+G\_*!],RT%Y%$XZ\GL\G>H`'('OB2E1 MNG2+\&)+D[$N>34B'OPW6I=K;@L`'X%5TQ7=$LC8LE*(^^JM_\[$9@\R!T$& M&]7KR'^,8E4\8KT&03D(#)"NA[]:`]@R3ZQCN"5L:[=!>AT$E+N_C3)4"+9T%\T4Y,SY`080`IOR1B[, M&VL)6Y8,`:;*0.K0K\;P`Z330V#*MN)74PLYMA<*8?6<9GX+_AA'&064('KQ M?AO[20$;*999:*18GO0;`24@,&S;))3?94PU@NUYPF8:MQ-("E:4!I6'.0GOG+B`+ M[V?(UB5578",P'1NDS[!]^C$[RU5AUJN&:$D',FD&%('`]&:V[33'9R\?BTNB M^]"CL^P=.JHJCX16?=(YVCJ3EP$P>QE<[''*K@"FKDJS,W,2'C MC&J<,)LV3;PC!+TG&RSV'K%@@]9KKI#YG;`2\WIFD3 MH``$,[L=&OE=Q$P3]K+."/SR9UGP!T_WL!;1_$SC*6F1CWZMQDBOLZ.4-]4) MFL0T-^63-8.GLW$.LV">@U+NH^HH"9J"OO(Y8;ITTC@*F'O::9)P_P-?& M(+E1VAI19K+Y]Z9?N99DI%'6(=ZQQ23LZQ\2Y9R1EB>=$Y?'9F[J&4U-<7JV M',6/1#1K:2E.7)YQM1+1:/#&7[44J'8M'\V)TYVGC7PT)^+7L@5X=BT?S"&H#2Y:;/[60HQ80L%PQ/ULK)@BI'G;(N MZ9PZ=5#1GBBEC.B3R`&'+#>,%5-L#5NXD1'@]'+W]*8O1R=WQ;O MUT4H?)I>5AQD1N#*HSED>$<%&2QK&4L$%)Q%*3ML`-+K:!@55$&!H#C(BL#5 MI3X%4EC(.97`'`M>M98F6YY M@+#EM!!&L5WD131DC[S\DM.G<6-IY?FMP/3B099'?1\XO64TSR MBJ3;7HP:5S+5$TWB2J3KU'U,^ER3CI*E][Y"/+O@/_H]2K#8@0W!HKAP['L&."SYK#C393\7OGJ#Y3O-J` M!,'ELAVFQ/BL^=)H,G5.@_+K7:\N6^(6`!&"&P4;C*DPNO:0699G\9'>FS&3 M8OZ.@1YKLA8`$8*X=/-C0RV8R%X"8@]3E)&0W6128#]N%NJ2+ MX7$FVY2N`90[S:"Q:-<*T$1NV#YJ[7;6NF';Z7,VC0S;1T)G5!6>73!LWX\? M\RB,_.S]WH^I9EBHJ`ZHQ>5!TIIA6YQM7@$-F6%[04;F:C=X>@"LN1\P^90& M4G5ETG5[_ZX?.RIG14"E)CYDUNX-<(K+]NV07+2QI[?E4\?T-O:#P!S M*P!&!/DI=0<:GTD9,F3QI[.H:.;-4[PSU[LT*=-C::91X-4#I"ZW1IM8,]7P MD$6>K@BJG%:YY0&94\.<>68%L?[YQ$E@63.4(R,,V=)GG3G5BM>:Q7PAY;1R ML5LK"\@0V$4EPT5P?N3C0&;CGLSV2E:6RI'>5C+"P8#-!FTW3U/7:>[J36XN M^-"P&9R;9@+JNLT8:R%;4ZEVJ;UL#0^VL$L+)"'=1S1G2QDL:R]=IWX*246> M$<-V`":"IZA$@V69K`8`L3V(?O^29@6[*F198Q_@:ZI%C5<>.G3KN;8:+FAB M6-BB.]=$5=L?^36@0^+(32%1OB9;BX"PA51:Y0O9"F>1..42UYJ98V%>OTD+ M.GW[7./`+*D'D!%X=TH'DNCXK$2%+6;27D[)[I%+=_<-K'-28-B>ZG:;BK![ MA,-0+*5$GT4..&S/;#OG$]?JZ(I8U4I9Y]%KMXD-NQC>6=$<-)R3GA26O1>D M10=R=H1<]\@O4XGD-_1[^:>\*^)$LSHL&EO@T+[N%6:.T=[;SF:$+3EQUN9- MT`I`0^!S8)<^*51[SRD;!PVQ_3*@O'@;1=6S>2(*#9H@'H9'R6KR9XS3WJ/& M*"*^O"V((3"FC@_3WI/$QLPM30=-"!0T!`"W('+/F$I3-"@/D[5W9)(BPO=M;;I94T3?S0J3;V\H%2X0$VYNW\S"@\+=Q7K!K1.F< MIU4/H.*Y8ZM!F@8X>T_:"F:T21$$YQ6GGRN]6/2ELL3[[C&_"3HU\M7UM+'!3E%2==I M^FN=4#*>;CB=5BC\3L2-V753.W:Y\])_LD)(F6!IEP-"%BW6V.WIV.FIQ89O MVK$J2>$:'F317Q8XPG4U89&LS24T:\\SS>F;N0T\TXX%]M1:`+&%==EQ3#O& M\2*NZ1(F!H,L:,NB=].Q4S-J4V^T8V'X@A00LI`MJW0A6],L\N8@8$NPJ`G< MJ0:)V+],JQ[I?D)@GY,.#<[*I8?*6JB6&2EE`LI>Y)76)>,5TYH? MERML6-[K3Y](U+MY%-<'.`BFO287DRILV&*LEJ6_];-!IL>K60,`'IDMOL;@ MDX/#%H7%S`1725YDX_+":,$:,/$0K=:/>1'9\=J\,5`*GL`$?<;K`L46L[7< M<\^CURBD2WX\R=5*H%FIGV!UGT'(%@[+?5$LQ;];3K0@?=)I." M(2Y[@6`NJ)SLNM@#[].-6+5L5QU5GU=50Z",;=J@-@&)+?Y,N,\^HPF0$,!& M>P[QDOK%6&I.JM,<*&:;INSF4.T%O2F#I58B<.8"&41/J=L`6-MDFZ^)SUZ, MFZVA.T4P%32B-XW:()XN[2A%<`3<&;//F-\ M,*I!G:@E@+A-ER>-4`J(;,VUQDT\M[>5=R,:F`3TM>>*X[^7ES03F*IT%CK5 M`.@VV5#U(0FX:]%%9W;\?5IP?I@=DV3'1V5=XF$+#M-B41.7@,KV'D#EBZTV M`\@K$N]TFPSD)J`$#-ISZ;FC`9,[@H-FF>'K$G"M;XK?']+JPENTFS%LAO0. MM\D:5Q^B@+\6S313@;^"AJY3P)_,?W=#>7?(VG4!\G::W[1P":@\W7@VE!+9 MHY_3D#E]TB0ON^,D*4H;V5`N0,KTG=)[FKW"9KZO'I03E;`=#*7U. MF.-B=18H=Q_7&GE4+'^)=$_;>[DC>*'AF#WR:0>4ZAUQ)]\CW1.7FV!IWA@G M?8$_0SC4W8^T-6LI+)QNYHR2]#OD7=#1Y%K9M=PWITX=(VSDOCD51U$(\.Q: M[IO3#M*`ON9DH7W)_"J!S1Z=(;V>S"J**552"]"B>?EDXY.J4B_(4N<(Y%6. M7FD]0.KT?DY[LE6R843B(CADJ765YDI:'@XHW-6>IWQ;3J@P807`UI##H^NP88D3VI?D=S"EIZ`='/Z2N-TU&9 M/$"36XW:@!K!C4-M9K41(GN0?;*-F#CGK.TR)@`DU.HU`-@1F$`W:!HQ48L\ MR1`6"VJG#1.J@")VI_YIB1VS M=7IN+[PMV#I+K6N;SSS)[?86EYUY8Z`3!!9%QUVIIE:069>;CHC+-'NB$8L`G0T+A],6YVN@503W$KBG+:': MD)G$F^*ASVA=7OD6\#H(( M%.P]D:LT;"\76#P__4K90ZPT[+_2S'^F2Q&OFSGVRB0`]2/(2X6[SQJI$MN+ M#O5M]]SSEZO>;$\*H`%!5%G+/=JV.K$]+&XD"A/RP^SO1*;;W M:RR>EULZ2&I*`.K_81.VJ4I[[_A8[,EK[K+KX!^-3]%WE'$+O_^2)D7F!\78 MC]G;IEU5K]ZL-$#+G\/0W(9:L3V%U%01XJ$N4H0L\U$+T@`M"#*;X>[MM=6* M[7DHBQ;2*\`;)7D4E,D!-V/@7OXF\;H_KF&:*0_;`U86!^HRW`U-NBL?!27_ M.2Y='&I/_AX7EC"R[H\P,DZO:>])BBT+(^NZ-(4Z#R-C-`LF![LJ^A%&MA89 MTG5I7VPKC*PKSLTFU\2NA9%UG;KZV@@CZPIS!XCP[%H86?=X:\+(3,GZLX21 M87OH='&X\/E2@/D11F;O6T##CIB#)?LT-TK;E3"RZ?LSY5_S_BN<^-A&Y3+- M2O\J%[U1\4G0[XY8;1UT2BW=(8LJFTS_DX=5!MD=,S,O#"OUID18E7C>CMA) MQ7U%3P?(XL-`$<,T*9?P+_XH*ORXZK$LZU;V2D/HL)=CYOPS?;=%U@E,VP*- M[(AM4M(KZBE%&KF%Q>+X`&V.0;P?=L?U'E'GQ90_I=W1VVJ[H[<)NZ/WP^[( M,R5XNVAW].K8';T=M#MZZ.V.GI$IR]M!NZ.W/79'4[+^-'9'!,[AHN%B;G<4 MSH-;:W=<34D#_W4.G7QCKD]:WP>Z=L0^*=G/;4Z1R&R66LF=;]C;DCGS2F28 M\X<43KJ+?V<)GF_2XA^TF*=^7DRCHS-[N?P^:'Y'K)GB+KQ!12(S;3I#7HWF MRS2;_(J5DSGZ;580XO5VQ.S:0J>6:%1JQ-V@=>Y+FF4T8`T.GBZR+,WR]BUS MI1QSP?)^$MZ"(K-*G?,7W)D%=/8:A,Y+G$W:);VC]K)BS)^?TH2P@,#@D3?ZB9G-.5<:W9FK9*:O;?4`3'U#K6MP6RQ//Z=.)==]S:T2NPLRV M#A^9B6TJX"])/J)!]!314&G%$=8!A$[WO^8&MW7]B\:Z%!(RFYMUTI!:X*RP MA]8(MS"AS&<9G<>Z1+5(S^DS+KH[=?E0XC.H1&7-(N>/7AY+1@Z]"1_L-Z0/ M'PS+S_,7MO5"`,?EG@?!:B;";,VTI.)".*GQBI%>UZG[JW+Q$:E+IM1%T:V9 M.ZRK%40,^74987,PF$$[JP+$C;8D8I=X/_AA'>:5+^0E&4`/087R3VL$91JH`;'F8><*R'S-*E3MC95W2\]I= M6;0HT6>1`PY;/F/G?.)8TEP3JUKTZJ3Y%:QZ]Z.7OZ4Q\U'.;XOWZR*4+WR" MXB`T@FR*FH.&LR!*8=E+2BO@X"Q*F3$1H%Y'PZB@"@X$Q4%8!/X<]3F0PL*6 M.?6(>;;U:(`#$'XDF(PB>97'A1LB1'OF(.(8OF5HD+)8#*`B.T[HDK$LN(,&>U:(?AE'5 M^JT?A5?)),095KE^$(R'XQC6M)!M,(.(EZ+"N`WBG2(8%=;=UFKJ04!OBP:1 MZ:[R.LWS03+_;ZU=]6HE`(E@]#GS450!%[#;FDGCAA9729`.2W$EA"Z5`R@( MGHIVQB$'JX"V]J)W_"PI;=HTF_K&1P$HX#R*QX7T87!%38"+X!4.9]1JH1>0 MW9HU@V45`06^,#GI*XW3$<-[E=QF:4"EHU91D_0.$=@ZG)&MA5Y`=FOFD0T^2O;7>+^BH1])4:1AG! MSGM%--@B9I1][2&]]3-14+!F38"PBXNV$7J!VWAK5AVQW'6DWU(.@*]2P)PG&\GSG/TD>EU]'_F,4@VRB02RI0GH8:T*RRS(1#("$O MLK)/7KRQ@&+9#*RH"7!W>=[50B\@NS6CUMQ-S32AJ!SR-(^ M_WS`/L\R-)>:_']02P,$%`````@`-8N/1@E*&[#T00``V)\#`!4`'`!A<&AB M+3(P,30P,S,Q7VQA8BYX;6Q55`D``U;7+E56URY5=7@+``$$)0X```0Y`0`` M[7U[;QRYM>?_"^QWX$XN`AMHV98]D\Q,DGO1EBQ?[=J6(&N2#8R+H%3%EBI3 M7=6IJI;<6>QW7[[JR>*K'B3;62#(R!(/BX?\G4/R\#S^^!]?MPEXA'D19^F? MOCM]\>H[`-,PB^+T_D_?_7)[IC`/2AB!NP,X M#\K@-@_"7XN*'IR^.'WQ(\`__'"RWN4GKU^=_@"^O'KS,_K?#]__%_@_UQ__ M+WCW^1:<@*>GIQ<1ZJ$D/;P(LRTX.<'?2>+TU[N@@``-+"W^]-U#6>Y^?OD2 MM_]ZERM7K]Z\K!I^1UO^_+6(.ZV?WE1M3U_^[X\?/H[A(\1Y/E+ M3/\RA?=XL?`7?L)?./T=_L)OV*\_!'3EA[&UZFZ._S\0E/UKC2>5F,\'__H#&T!D=_%K"-()1-3Y,+=&KI'.BCXF*Q-UF M8:?#!"OG+._R&^P>[O!&]/VK-U3#_@;_YF_G6;C?PK1_/+YNW^OR`"B`Y00M"C!EXKVO_Y(O]]C:IUWER#(PVJ$Z$<%5ZS%RS!# M&_*N/.DPN,FSK?&"#\%#%_<9X\O(QB_Q$##/Q#$G;PZ M9;OZ;]"OZI&T!G`;W#7RV8*9O+DU9"E&+013!T&DM4/XZ$Q]A1C]>3<%R28H M[LC0]\7)?1#L*%)@4A;5;_J08;_^&]K_2X@'=)8$17&U^5QFX:_KKW$Q@!L- M&FO@T1E_'T&D"<@V@#1"V@T`;NA6K\@FNJU3U+.\+!3.$!3S(+E$QZVO_PL>I%C@ MVCH``S]>`1I80T!:`M34!SP(9IL'A'2JET+$V3[/T77XW.D MK@2@$#>WB@O)J+E-A#8%M"W`C='1-L(&*\?J0C7U;83HS?NR:N,B3F!^ACYZ MG^5RI=%KZ4!E],9UQ62&5X*!+=Y@.W`GP_;NXR;?,9# MKXW5A>^/K[_D[.^`-G"[UH-SV5YER40N?#;(MMLL)2?4SP\!6J.K?8EMY'@T M\H."E-#%J4'.B>@(0:CHC6,%*"%H4?J@(W36:.!XH;U`2YL\;E&W"C,';>+$ MM,%&)S1GX+_[8;]HS^.0S8*?Q*56=HT^%^%/7B2!2$WTVEA=V_[X^HM;_QW@ M!FY7=W`NV\LKFMU@Y1 MTAZS"B/$ON`=0KA9%^-#,.4.7CBN-A=Q&J1AC$";%;'B+=:,W-V[AYRK/KQJ M,OP,4A."BM*+%]DQ"R=\(M%>-0>`%+W/BAJZ`YGH3;:!D_.'6/GL"O'A]/&U M_7YWGFV#.)6@8:BQ=40,CECUSDH;>H`-\7SW\:&:;`?:XD.0 MR0-]A/E=5KLY3AVO>]@.0Z`/6=GZVX8K>X'41BW7WA%X^7$/8V(%JI=BO\"L M'G\U[L`K;`OP,@QQ*5@LGN^"XF&=1O@_[_ZQCQ^#!`VJ6)=G09X?XO3^ST&R MEUT`-.GMGP(U^>*0A0A`D$:`_-`B78&@!!4U(.0K0!S]W8K,9$9#_`-L2!=B M9\?%>?\(Y$6+6KK0J/' M4Q]FC`HP,J*_"2'H'<7="L\TYB`E*PAW&>$N].R@;H#(OH`9P]'1=57WFNKZ M>JJ^EBZ[GY2M(-W1(R8#]`[E6GCV`KG7>89.J^7A<JB5!$1[T=MEBBS4NZ M-<<-PG"_W2O".F_??_[-_0?Y'GF(T+^`WASN@(80*3% M.3K@;._0WL)^^V:%SF[%#H9E_`@3AQ[M)ICF-Q==0$\(^;Y,T6="6*`S8@'Q MQ*(/G4,T:1GYU("\Z9'9#?16<]''YF4*=I0$(X70$"1%#96;8]?1\1,QOQDB MN_,QM+Z_STEF!Q!6!K9@BV\S6`7$:FZ9LD#G,7`7)#B[#2@>(-(\$>KSA>/` M?4VIZ\3L&XFC:Z1C.+;IOO\ZR0O?8**:SOT>*Q]]%(6YZ0 MIH"U70'2VNWM3)^%>M0#VR^2K+R,_]ELOZ>O6MOO3\>^^RHPVM]XM0!J3\(N MD6Y-[^.[!-+C.=K^+],PV>.(E?=9%CW%2:+Q'FG6C759-.22W_\J\MIZ@GH` MS^H^0-7)-N=FV;V@C8%J7_K&X]2>2'Z(@[LXB:8P[?@!D80;K%E'9QE M*1I%2>3Q&F$-YCG:6:DO(9Z*]M=^^YL?7Y_^_@_5]#R+X"8.X_*Y>PDV179? M>L?!VHGDZKORR(A<2J?:*::#6M\\>XPXJ0:?-$1>28NFHX\NE.R_6U\'!ZS' MD-2BW^1[&/%#U7C&UNK%V:NV'H_"]V!&3M0YZP`,29A7C]X3>=ZU>`X8S]6C MGGL!'`%>T2.Y,7+MB>@Y.TW82EWON);618T?*Q2D^M9XD)[)Z M$<0Y>,0.Q_A5)&H8KQ<1_SYL&86XE??YA7*,ZNJF&!^MMV91N'\)Y%679N=.WO+QTI=O7V]#FMY`?Z*D@"]]Y]9:_\ZR@B M&8^"Y#J(H\OT+-C%:)XE>![7G77@C^2:0UW5#7L_7H'K(*?AQVXU_TS\U:_K M>?.Z+KA(D=?U?WOUXM4IV`7L!+8"IZ^PPQIQ6JNN6OOR(X*/"K!HE0:I(!X]AN'6-*A_[]ZO5K^F^][KN^=!YX"$P1W;XFFBZW-C,:C?#R\W^U+(I%EAM6.3P;MT?Q5[CC0.W<<4%'SNV;WW__@VSC//WQ]>J'-S^L?OC=ZWFV3O?R M)<(FEWE""DR+SCK&1V-_3K_Z!\"F)X M$NT.^,A(MP_W0B"'45\&=#!D3P1N8!G$*8S>!3G.8E6LFX"N[!RC&%QWXN1)J[FYZ)927X2+.9;)IF;0EZZ^ MEC`5+9%+0XHN\*Q6@3Q616##(S:C'TECYS+YM(4B/! MX@R#=6O^T3?[>/`".1@!IO9_HO M,ICM\=K+IWA'C3=4#:@Z2_@8_#W+28V(]==8,T6'NA>7:3LT>)2F M\N!BZ,'=`9`N`"T'\@7WXD&!AQ'K*DEK8;:H5F,1FZ-RDQ$,_9Q`4@,IC=:M M5"7"#%DR>^ALGW`1Q3C7[,CNF.V^5Z#NG48]MOI?@5[2NE4W:YW+MY`CFRKP M+$Y!E"5)D!<>;(ISB^%`R.4",NC%)MMBK:8!QB/4K7(CG`BQJC++2RH7)YYK;(D$.)$F%.(4ERP#F6(.J[ M9BH]%94?DE/SH`VR13WVQFU82[#B7%:ZZ-*2DR%H.9:1J\:]T510.J1^2$N7 M&VV8

    63-N<"!DMZDE%6"B'>`TT*01>?V M(*G'4`WI$]31ITI*^V[O2EXX'WA,44G"JI8-6@7'FP!]8[:DHFW5$UL/79Q; MM@FT;(:.#9608V6,)9*BH',0,";G@X=3JUA@BZ*JP>U)D-@$II3U'NW&4&G` MC`^?TL:8/8%Y#U.8!PEV3(NV<1IC\<49>=0BHZ2T+C1J7OH(8Q34K;%#XY7@ M3&,LZ-"X%QY-R/7%QPAO%N/U=Q"/([UGXY!%'PRTM1^E/S!>+D"_:E-)@0\) M"W4&3J-ZLGKX_M1S$<*$"\678\0AL#4N'!(:]T"7G,9YP'MSM1C'AL?`5]TL M-#'D0!"H>>R#O`CT8&MWX.^,68P79L5\AALNG%'"3-E+QX]_#3#D*I6?I3XA MGL>+$.LBL%C..V2BZH?;N\DZI*,;2=(A_]2[T?!C)J:5>O?@?5>*F\$\0[[H M]2:___L@3K'L7:7-[SY!&?HU:!VDV%?S(ZY2L0*8BNT`($M!^T\>I-XWYXWR MDU3\#-2N$.8U'\^66<*A,6R13<^0'[M%!C3%BJ\W8"13%H.W6S%<5YMS>%>> MQP6IK7F=PVV\WTH4A0:M_7!K#7ZX.+\6#4X`CJE`10:>,<+9L_:8B=,B+=ZNO\H@-G@_%0DP["$9;4E:)H%>.^LH[H^S#P;\DMXQ``B2S+DT".CP M@(]Z+N,$'8]1\RBM.TH]PXHME>9X;G>(J"JL]QY[_0]$=\PV6IL:=U"']?6M M1($Y"[C!M>Q)3I7;[`9&Z&_X9^(;OH[^OB]*1;:D4;VY#L?1Y%D=G5-WA)5[ MTU55\J'IS:W0S\-^PRPZWAN68%J6_]L1T>>S3H*L^!1"1EP69)X8.A[%A;@< MAG"9*`)%1)>Y%G!TV%P_!G&"L7N;M1S_69[&MT$1AQ+59]R3VP.K%J\:1]JJ M&PSL=C`+ZVD%2%\>O'W-PSTYP@6](:*<+2 MTYBI_-I36%66^"I4CPP&^S[&R1XGQE(_,6KW8%U!Z?/6AVM=)*`.0F6*AWKN M4GIO7B?'\WE=A:"".-UD^9;@6H*/@7K&2T>GR;?>.4JIHC)$$%C;5?MK:+3K&46<=M56YUTR9YDR>IL9P4MYF@UB(9 M[%U0P`CK%)@6Y+1X@XMJ%'%9Q1=>D^6]@6%VG\:U94;F>['XIQV4&EU\-OE2 MG_4G\K`%Y`OP]:`_`BU,K!!)/S&INUL-6A>VUC M2W;YDJPV!=8":+F4)DU3>[[/T<&1JE"B M-S_!)_(7^9U=B]Y-P4T-O@9W9Y:'&%!*=G995<_EB)PV<.S9,YI%F@$MICQN MLAS7,,GA5Q^.($9P'*P=:89%YX)&%V."I'$=^")J/&2/7I2+ENGXKZ3%?&Q#3M3XNO!>1:9,=FA#07&N?:@NFT!]:'= ML2_Z0W\FQIP`CE:#C)^6653($1TOYM8GHR1(1Z$$NX<[HB9>O6%*`O]&[^)Q M.J`)C*BMB;L93Y-NT*=N)'<:AQ+Q7(B=*`OWVRH@979^F-]"O-T%(7&=*1\@ M*S.`(V318E'5P^XP$5U3W(@^P;[`OK?)/D(ZI^C<=F)<01C@PIG8O+C;WR5Q MB+I$$X8[0%>A`!00*9`(!ROT_OS"GZ)\! MKJ:9%3S40!H\RDX(RWM>2,,CK:X>N$J7>IJ9HG,U^/RTW][!7$_!^JD*10I& M1Q?*MYH'BK:\3-RW>A<>N)A M=S#TBU[?HY4-4Z8$WW=:.&H.OT4-VH.FM-=]T;, M*\B@0+=@U&*?U%?O(U:5I@I%_ZRXA+)<_G61_.V*!)87[[["/(P+:$D9`V87V!NC,O3?TC>,\88U#.F`C6039[Y-%#L7'2IQIE)=J6= M^2*\\R;*N&O;W/PH:*V@OQI,0YZ-7A9GTF$C3%CT^SI[2$7MO@I"?Q2YF99M)=JLZ\4%Y*CL<\>QV5^C*?`;%P'H6=R(!5 MSCHTR#3O9^&GCM*3;GU+CRLMU?7/>#W)7>NU)WJ(YVF2N]9K__2,FL.VKT3' M^HR/!.NU\:G*)&0+^["9:J2>'(O=-(` M5].<@#S42AH\&JHEUZ8CJRL*;I\R#_6P!I\F;EV>ZD>1UAGAUS5"0\YHV+\A M.;]A=)6?!4DRH,E5QGR-#MP8\'4X&Y;`BA)OW91V\-#G@0E^#(_HHO``@Y+I M24_LT=HP'+1!&V+0(Q&CNF"*C%4]^"=D-6]CI>RS!*'CV3/+QCV>RZZ<>1AI MIH]+8Z$;`J63E+]G0?%PD61/.N5[Y60N$_P.<2'-ZXL)`*'P-9VO<&$D67P5 MJV*U\`0>RW6>/<81C-X>?BE@=)G6I:O781D_$H>KLRQ%O]BCW[$_9JD.%.?Z M@(LR%?/,S%!-`X+JJFOL._$,]P[B]#EHRK8W7R!AT>P;H/F(-YGD%YLK,D\; M(OWM@F5H%H*Z2_?*8%XA&J@(,;L$62P(RNP>+'/Y.HW^PA+,760YR^-8H(TW M">*M[/1HV(_]8J*&?,KL0_14B9/Q57T0*U'5"SEFDG[<2OU4EOE<224,'](L MR>X/2+X1,>(;>E"3:A2&N;*FXP'L(HQJ4\D>M6FNB\OT$;*/ MPT$KAFD'=M]>3#CK8PK3_KEZ.ZPW'*:5@P(T'0#<@\/7ERE<#C`6-XQMEF-, MZP5B"F=(5/;TKLS*?6,##:X@]AP[F@0L$.M)R;_K]PECZ>R\4(P437M;ZSG< MY1#G4Y;OIMUFUC?0WBC[6&O_V8N,_@;C=;\E#D&@OPN*U]]RU9VW_>S[,GNC M@,!-_9VAD>O&M'@!:GTN\$W"R^(2<@@-UK-1X,>BR2(-<^R,>`[I?UNV%I;B M7\`!;B18K65Z M+`J(ZR.@VU82!W=Q0HQO((7D$!:$M$@)-KYY4!+3',RR5[-1Z[@PZV0B0&H%B\5^EP* M%JU-?1M\A6-E2]"#!^(EXDU3PEA%>D+OL93IO3BUC?; M9-1<[UIL<[H(X.F?)M-[194*#OBH?8+XF M5PXCD=?KT`.1U^1<4^19;X!U0[!/.@*TIX5$?>JN/'(2*FXKJ2;L9H3=<(\Z MPH^"A-9'<3>!O%KC0.$ M2M]V9$T&&2=9ZE6-'Q,4ZARAY1!T4GCW$YJ)H'BX+.&VN,UP9>`TC,G@Z(G_ M0U:@WVNZTVE8>9?_M,M"O4O-IJ2`+Y)Z^E%`OKK"3]?UA[%&J*[9S_#'G^,_ M&_K2>N,TZW:BT=W^'_LXI\X!>3W#V(B=X(S/;7=;[&J,6N&_D:79T_D=],;U MP.1M2Q](B@-;4`;V]"LY0`VY&[,@ACJN0:(H#?JPKO%,^.M+%+U:"'SVJ]`5 M4/?@\B%L,ION)=L8B7T1'0E#>[+&\F;BZN(AT<](/Z#AEH=KM!XENLW@U!\[ MA;"9=&)=VHPXY.Z[C!AO1XP<5/0K0'I8D3MPW8D7]_UI/*-!/03XZ$R$$9G<[!.Z[GXPC"X`SE0S/\;91P'(NN&!]7:_R!(],=X^-J#72(-R:" MQ>:J'U?[+2J4D7&UDR3(XD4AST((HP(GS&Q""\](9C'B%BR['ZAI[5\+-/CA M7[\H#<5P.X*6TM%`6KWJH)VZ2\@^N,X M*5-WZ(GH:7"N+X]-D;`FMKWISU\YG3P)GV&.WQS>@ISD&"+N..T27UH%Q=T+ MMJX8Z$F[F0RX40&MHF/G\$YJ;9-1.15FG@Q;5"@CC6&3),B> M@L%#1]<(_!_\2O@8)/@ED29P[7LN2M2(63?6E84AEX,PQQ=O\D.KAU55PWS` M,]>#4\1$MK$FC&O&HK;+<5C-"/D!-IV[E_8QB.[+]'@X6_0MR^^#E.7Y0IJE MR)(X(O^@5H&B2IQTM6&J*$AJ'QV=D\%,_=OW29MI7CA'KE:_9,-O>JZ,)W)8]HB_K(C.&W[YX5'V`5B=5T"CK!E3]@"^X)T"Z\D`01B]W'_03 MU]IB1K6X").LV.?T`:G.&W1#L]Z=945)JPN2!$F5?YG&IC&U8_M9VZ;.!)Z0O:8V1=]9GX!TNAHJ^N[7!C$/2K@T;3-"Q$.)>=L>M(ND2/;"UF]H'6_<2/NX0@TP MJNHF?H-J>.+[X)'-NG,KJ;8.TZ3WQ2ZJU&`R@ZC'D#-:1DV;H!]:[#8/HB9C M!Y<%CXY2`E!->NL`U>6+2\&&Z=H9;/@&J-6-`)]4Q8RB.6ZJBH9.6,9GZB*8]T M+RI3.[1;[V0*YZ(<6E5G8%TK7-8?2QT&S.$[>1:TJH?,.1M=(T;0F+UWE&5< MIDL[ZYCKDB*3!:138F0FZ;"W2;W/LN@I3A(TTDL$H?0>.X[2<59_4IZI#/JP MODV9\-?'>=6`8+>AKK,$5G_W>\LR7N'^GC5R>;W`8B_1M*%-^1'BDZ8:]J-Z\Z1TCXIG_;H^5\UC M?MT7N:,47H-_`A3TJNP8X&#"58759*MCO7#P%RG_2D-:"C2$"QB4Z-A996<^ M&-UFA M?>5Y:DUF*V:33F;83.:&3695&.C@^@HTM^!U;D3+2)W-FHQY_!A@G6?P#"(C MM&_@(TSW$N3_O4U(.3!]B&K36D:;# M3Q]PC`:TB/P&GO:B]?%GN&(V85A`-`GXT>\VPSE%;J/5;.F9IP\*DQ?X31 M199?[+$)I\K?I122N3]@UR([Y\S(A*6=HG)5UTQGYMGJ$\3V2#_2Y-/3%1H[ M5MDEYPLUV"=!#B+./)NE)&:&_@O/(S/%YNV)V]")B]GG7)MB9Y>YCBUV(8&; MHF-B="K8Q&'`/.!PS*B@7+2BO64-(!XW)]!-TW9<,&[M<"?3FOTN>+2FWG[L M.BD%41![VOIK+`ML$5(XBT/GQRZ,-F\U!5]P8P^.08HE$$6-2^??+8!H61%X MGFV#F-O.%)SW:+T`59\?'7BMJK(YZ!A!"3V%VN!BZ8!.LE)3]K+=PW]F243, M6.7A0QE])#FYA5N9J+GEG4PX:FXCN_Y/4#4%J"U`C<$7VMSY3B:?^^Y&IC/Q M$W#P-L[0D$LT]@_Q-BZA`@?"YG9Q(!XUIS/JEH`U]04%BIGOH$!KVNW[L&JX MICKT.)4XDKI-_#AZ@"Z<5$5;U?`"6RR2G)9Q%"=[["+Q&8;[G"1S?/I8=G46W1_0'>5\G!6V3.5-U-!>_NN#H)Q?!H)YWBVD\&O.N\/(A:6L_/+E4'*W'$`\N',JIYM)JR.?9XC$OBH@9 M)$BN@SBZ3-D#@!(H"CK[QS(%']QQJVX/,,%)G-9/:O[`26MQN*.1_LK8]"HM MD0:$47404^)+1.#`=U0P#1> M4T[)C5M0B]YD>&M_R)((Y@4]#7[*2JB12UA%:-\+3,4)]S30(@#L1(])O,KR MJ[<^G$.6P>(X\5P<'!^+NBNN\IOX_L'4\=BX3Y=^BL;\2]T3!4!>@:I'D.6` M]NF[9^(X8$@<$J>@PN+=-PF*XFK#QL6&)7(JTB&R?QN6<[*FLOA&%4*?R,)C1^8$O@<22#EB>.1Q95.VQV!D7W7[2_[E/X>O?H79OZ(U'[F"B2^TD MJXF:)T'.D@)02I"E`-."U[];`4P.**7BZCN9.85CPL(\NK_7CP#F4%X0(U3. M*D+)X?2'\2(T3.U:A`0\:<$K.8#3'XY`A.;BT5L1D@%3(4)J5,XH0NI^7GU5+34@)6*ERY:'5\B/L0IO"SAUOAF MVB+TXRK1YL3@-H')`*'S]4;!+9'6I4*P/K-I]/-]CFL6D?C\3WN,ZWH$0U@R M[L&E1E?PIM)RE!R4#Y"EA5@!VDL+@0(_-PZT!@<]&4[%WZW,9=3."3\+/!_,05/[F0'YM;MBDR^YOW.%BZE3R$AYEIJ8![&!;S.X]!\ MF^K0>B(W77[T!8?2`4+HH^3(^:K'OQ./W[WL#&!-3WB$0+/H*;B_*^(H#O+# MYZ#VXE(XKDAH['OZ2<;/>?+5;5<`MZX]^KQQ7%&N!N=^I[<44]*6X!YY.T$' MO)_@$VE1O!89`DU[L9SDQ)3'00?GGC6PL@1V=?`*H(X`ZVDAA8S.&0J#H".& MP>U3YC31X%2VU39$V-FQL(8IR%3Y:D@<)][=A#D39'N1UPE\&BVN-NAP&N># M>%!;40>Z\.5]8HB[$0\4I!MPM0%-1WZ:]G7X%1R(XNF/)L*.S(%^D4$P)I0#`<`LE]-561/;C=P4OQ79T<@?949`JT8.;BX'R\RZ-8LUUI1/ MP1;]>(NP6`0AEFAE&(X.L7U\Z'#$X:9M)4,W>42(_]DB]2@Z1W_-.+P9+I@] M'%Z3FI2XGG)(=@!E7@L1@76\"4?>QQAK".J6'O@'ZTU_'T8Z8N^IK+J#[=WL)$-CYO?TU"[$WQU![CE"N"V_ECR9;//[W?*J9]BP4<' M/UB\O8$1A%L<)$U+*YR'\M6?',^.4R1+L!;=-"N.F&EN4DO M[;K=GN29F[3"73/NI.5UJ-?4YS$1A7O=)CYY#6LW?PY;\E50:CC7"3!K:.,D M)<5U<,"(UTB&*:5SD!A3S@>?)+/1980`,`H/-)G1VO#9,[47QH5G4O3W?5'B M(Z'4]JU)Y]`C:9@/F3=23:&V7KMQY)$LC=B)1[DNMA-`:Z21ZS=TE/)9DB:. M)=3R*2G<\.P.)W=VG?2M>TC32>DFI'!@+1"-G3<75$=PYKKE57XUQ1KP%@.- M!9AP]>OU+RN=.-C4[@5N>+1J`/A0*U$RTYU;EG*:)ZRVX!!TE8H/MIIT=G&@ MP8?^P191>7"X-5J?#F#,%F=^]-P^9:/0TZ+S`CUM/O31@Z@\1P^W/CKH$2R. MJ[,*+2Z\WIT/')98`3Q?ZUJ@IV-T2^'6-$RR,_SA/76]76GA\_@QCF`:X20(2`!#O)??Z^M@$;EC#2SD2JE_ M*TJ2R&,%&F+W8#59.+GFU5FU":=UH2Q<;F)Z*+G>WR5Q>+5!8\*N[GD60A@5 M'R$LBP\P*$IAX>"9^[=[VI]Q7LR4\.7FA'T`[,@7D#ZFGT#'9_H-L,4?`>0K M()!4#[9S95APJF[189\R".X.X.DA#A_(!:#M]!.AS__V-V]^^D,!XLU)/4=H M%PM2L$\CF#_E<5G"%(CF%34-L^TN2`]L9O$GMJCU=K^M/A_.N:6U M*U:/./Q,@&;- ML#,IE.W>R*C.*'`%]SR^C],@P;^E6N%4<0%3T#JY;ZGX&=S9&Z(5J,B8D^!: MLE?;ODIIK=70S@S0T,L_L4OV#2XQ")0U85C%SH>PX+J_>0\P*"L6561>#H#WYI06\R?L05C8?V%`5(8U2 M*NNR).>!?^PFA=KKYJ!J[TV(H\::]#&IO2#VD,5P#Z-AL<`9;M-"INIU.[". M-VW.^M"K"86:%S!B]R`T6[X^'L>LG<70CEGT]@>-@D^S?\E^<,GL<\5%I\Q^ M+/G@4R6JA<#&A7E?$C9/N2,EQ9D]XZZG3YZJ./T8$@C4"7LCJ0."Z@.2># M09=!J,6@33DS0F=?WD9`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`F*HB[V>I7?X/-G2S5+E)>: MU+H2TN"F#WY"TBIM#)`($#*-_=V6+AC!5E6]U[V$ZB*L+VEF\+(H,=EVFZ5$ M&YX%N[@,$BK2..]V_@@C)-$71(7BHI\XRE`F0N9]V9>I$?QR0D;ZH%O("K!N MJJVWZHCL/K0K4/6UU-TB0]]72MT,C-]F+49S1NB!3([%,">DTP!\!(=[04(T M]*_SH(36C!B:WS^>8[_AO-K.D8A/`G@@>L:.HSCQCD'RTGD%-6#L6?V]3[C$ M<8%-M)BM@BCX]M]QO;)/6?E76#:5S(A^9#,@T1&6ON]GK;X9YG5"!;_ZZU0Y M%*NN4D$?!@=8@N;3*W8?9E]WKQ:L@G=4E;]YD?L-J`6J!-$1B?T*MY.]5]L> MR+>C*$0SO9S&P*,85!NL)"B^Z[0&\PWK#RG*K2D2#8B;:I0"AB_NL\>7$8RI M,D$_]'4(^M7?SK-PC\]!ERE:]"T9X0=)91TUB36YU!A]7X*JYJ#5WI/"-KIK M46'2;"'L[4?7>;:#>7G`!OARG4;O_K&/:8VWHHRWN+KU+P7<[),/,9(2R79B MV(_UW<"4SSX4*_H5>:HH2=6_NH\5J'L!M!M`^G&OB$T!>%P4L M90BM&EB'7CTR[JF,_&$%R)[CTC@I'"&U.`;DS^[!W%WB/DJ'UM=F3>\235Q\ MET`ZCD\0J?DPV>/'A?=9%CW%";<"G;+3.N0.*GQK<37@W,+(0(5Q1`F>U;2@ M(G[N$O8CN:-"$3<\^B(?)ACD2YB;`M#BG3G(L=MB@8[=U1D^#G%%VCC9H\U' M=LE54=J_E2IYX:Z1C`)?]N@5<@4(%2VK3.F6W40T7Y;-><-:(5B^Z>M#D;J8FN+3XKA4D^+7M M$:;[ZM*,%8'L)4I$8?_M2#AV[K4'MP2LZ:JRSM`]RH/#F#XC="/*:5/WLJ!` M#_?ZHP,=>]CO.\_8#JU+SFC.E='5G&-DQ_.;V\3<[E[S3T/` MIB&MIZ&@TX!^"JD32T&+8+92/(OW/TKLP:8W353Z>F`..;&G)J[*!YA_RE)L M$0E*XFZ.EA*^^XH-QC*?#16A=;%7OOHR9`(NB\Z-0?%PD61/:&`A^O&2/+2@P2$IOHC3(`WQSV$9/\9E M#(OSN`C176"?P_5=0>+39+Z.D[NV[_HX?38X3TC4#\!]DA=$W"NHNR4;:]TQ M:'H&3=?@2]6YX"7%UMZ[P-Q\WN]V"?$B0D)>A`\PVB<0[[QIEIZ0J=K4DQ/4 M7?_L7@/,)36<=^6L(F-/BYS#N_(,/]+F!7F.Q3^A`\!EBH9%GM/6VVR?EC)? M!_TNK&L%`^ZXUU%$"AK:%:BI04.^`K0#M_(]@6W1)CB#U_(QR'=GC`C31.7$#\41@,69XD(JPBM"ZZ2DSZ0*<$)H0##+R3N\:>W/GW4 MF2R.#M:"W<,=0="K-PP_^#=_^QS?I_$F#H.TO,Z2.$2B_4'B^Z)!8PTU.N/G M3C!-)"&Z@Z]2I;=.L*2IS]]B-45-;MM;/OEM4;)^=V M1?\.OM`6'N!H<&8YCRGQM-J\..7Q8X##ZS_$P5V*(+\.)=K3;X@-X)LYBT^P],,#4K%TVMG M_]&\-TY!R@R/5,K@S'*/L>)IM1F3P*QR!)+J,^Q@ M`$0V[7Q(@&K.)]AYJG0S.,T#C,[W>9S>TY"KRCF@:C%D]#?OPJX5R(P[42H> M0,D!I:\"`9G#S56=@*@X=6/X=\`IN$J7RO`2L<`M$K*U#+>W#W$!('VP!#G< MX?0NF*GR(2A7)&5:XT7T5'$^*I\6CG67!OE*R1P8CZ5<\+9DVKRYM%<4),&"!P%<.LO"FYIU MU\1B+&X88B\#G&K^`>=R*G#0<)YG^5F&[@PA2<"BX>1GUHW]N%XS+KGHWYH< M,'H:5(Y[`*TNE$YZ5D-P1ZPL%Z@[>EG]0O`M_%J^16/X=2*$6_UXB>$VG^-! MC'L!I)LC@3&WO&-P+%A;FPEF*V@U%XJ/F^JT3I9C"=E;M=7&TZ_IQ$Z"VBO+>F?T;T*-?!!W\DFG%-AZMF>8`1?1Q%)9A@DUT$< M7:8L#3O2CNBPN]_N$YSLZQQNXC`>NKB/Z,.NX=N0/^ZV4Y,#3`\NT[K\`.H" MM/H`K!.7]MZIS))($:QS@X;M'68[3D'(V&:!-S7;$>T.Q]OL0_3O,D,_;A*T MRU+;HBN`FP,$O>9W[K6_>CDD3J/2M9BR#R#E$I%PL>&]?ZB194W> M&R&OO=C?G6_SX@GMJ@[Q;-J\L--#Q2]IL8-AO(F1ME+%O4AH'%ROQ>,7G0-7 MH-7:HX`5Y5KPMUNMA;"'IM;EN;E1*]WYI%36$27GH8^IMCVE96;QQ\=/8TGZ ML-)>#ZO`@HCQ!YP."#[")-O1M-K7>1;"0G9955*Z`)B"EP&0$0J:.JNA(36' M*)470--9H@&PZ:_/A`/.#0RQUSN)1L4']@O$`!^,<[C-<*[K\B`Z`AEW8_>0 M9,XEC[5N#P!W`88BK\!M!F@W+N^\46DFY`M(?X M7V%MT'-]DQV)[\Z)=!*XEZI_41^3SV$1YO%N"`RL/,-P4ZOU+@2C%5]66NW< MUK:0S7.[IH5ZDJU&JG:E ML*-K1W!UBVV`:1GG2*,V6U@WMCEU<(IHU7TL?"R8/7371GRD-!>6")8V-OWCNE,)(4]A5CR)X0 M?()/C>\6NEFDZ,>07'`+DI?F0/]?Q[_/O"OK8C."6SY-_Q-H>?IU.UG1Y$0' M\(7]URM/O[%KW8?PM(6VA^U6'HFS?9ZC\4G0.]38.CX'1]Q'8*O1"K!F'N3J MUQH[S3,)\\ZXI5!O6OJ%=BD' M%/!)AF.\8+[U%O(\?"2H%V''XN,%5=_U>@]>$5J#\-R+<7T@@T,O-= M&JFT@M5)[?'>F1D0E.`C>1AY<[H"6(C<:YOE999[!;8DL`YM%JVJ(":&BPZ9 M>^M%EPL]$T:+QC,[AA8W76-&IF+&J45C`&1*LX8085:%99?#!R3W\2.D54`^ MP?)J!K`7$-55ZK!+G//:3G2;`-0#RNP+I&:N]N79`\I M,[0)Y]1OS)/:&*.XI\5ZPLX@V<4=FU:_TM< M"NS@96#B3`R5 M\R4UJ:HN\?WV&>X5[3W/0=UQJQH5J5K#^@9-YQY8NQ:9'5)X:D\G!#1U])H" M5.XUP#SRP;^?S"<<4P(;PC"')8VX),KWK8:^$KF9C.S,Z\,\1 MH"4,SQENYBA(2QB$TPK3$U@D6]B/.BK#L7WA(E;>TNKV"\ M?-$@U`RT5MKY9472VD-'\45^CW?(LF:0!0N4&8C1-KI#K#V2 M1M[E0]4'94=03!%I[\XO'AG>M+?DY4LD;"/ZL'Z3-^%/)8"KE@0BJ#8=R`31 MY@75>#'[=]&1*VDS1<,F3M$E&:;HA_(:+=?;`_Y_4F?N+"CA?89/G(K$/$:] M.$CB8,(CG]6!4`-&#C#EBI8A!`VQ\]C_"0O*9WT8N9H3#B>7*9*,H("7*7YP MR?8X*).+_Q*=3S2)[1Y1=#GB_4XH'4GYPR@'PR`=FCK&\N:',4?K)#:6Q9;U M(JY6$F',"O\`""HMAO=]@@Z?J$9B29G4/:"+&8Z M`J$+N`E2T,_3U'(K1E]/\+XN$@#7]14N8UD]#8KW0C&3]7Y@;] M:^`F[/QY17LMN`HW>@OA(H.FTI./;^HP6Z;PA::U)[M_G%'-LC@=IEN_,MV4 M\D4KH=H'C<+8$_NU7X9]XCQPI=I-*AH4W9(&'WPJRCT+0+BZ[_.AP_+12^T% MW6[EYO@E=O"E!S!O-M6!&1T\A+E5D1^#K_%VOU6N?*^=];7OC[._^NSO'FV6 M@S/;1X!D6BUB($[U,-!M9Q\#O7%R&*!_]PD#0S/+88"?5C16.G:T+_R*_HW^ MA7[`\:&$F?\'4$L#!!0````(`#6+CT8TW>`C3B\``)DP`P`5`!P`87!H8BTR M,#$T,#,S,5]P&UL550)``-6URY55M#,/7#>>K.;B8TDLW,/+BX$1:(3SLB21Y+3 MR5GL?]^B9,=O?)4HLZP.,)BD'9+F4T^1+!:+Q;_]_742';R0-*-)_,NGSD^' MGPY('"0AC9]^^?3;P]7GDT\'?_\___M__>U?/G\^^$9BDOHY"0\>WPXN_-Q_ M2/W@SVQ1_Z#S4^>GDP/VR]'GP33]W#WL'!W\O\/>S_#?4?__'_S7Z-?_/KB\ M?SCX?/#]^_>?0F@A+UKX*4@F!Y\_L^^):/SGHY^1`^A8G/WRZ3G/IS]_^<+* MOSZFT4])^O2E>WC8^[(H^*DL^?-K1M=*?^\MRG:^_-]?;^Z#9S+Q/],XR_TX M6-9BS?#J=4Y/3[\4?X6B&?TY*^K?)(&?%Z)2]NM`6(+]Z_.BV&?VT>=.]W.O M\]-K%GX"&1P<_"U-(G)'Q@=%!W[.WZ;DET\9G4PCUO'BL^>4C'_YY$^?'YF8 M^X>]LOZ_7B3!;$+B?!"'EW%.\[?K>)RDDZ+7GPY8N[_=7:]UWX=FZ?29/M*$ M\?"%E?DB;^8+]+)F/^_S)/AS.&7M9?`EO_MIZL=Y9M!%80NV>L?H"<^3R93$ MF:G\1`U8Z-MYDJ8D8,T-QY=IFJ0F0N-5MM"G6S^?I60X/IME-"89X^.>/L5T M3`/@9!`$R0RT*'X:)1$-*,D6/PUZ7OTKFM/6!_\Q,@*A:*&K,R# M<0:UHNHJFVO$.JK<9W533K*/E>F\^UIAQ8D0W:C4U8BM5MPY7> M3.&?(/IB#-W`EZ]U"V8R$HRA.WV7%O=Y:=U<9':3K7??38-$X_+I%Y[HG:E[B MR[18&CX'SS1ZUX1QFDPJ2'7>ET0/U"R#[B6%1V73V!M31?J?%-* M2`BAZ'\AQGJ,COWLL6AUEGU^\OUI22N)\FSQR2:_\X^]]\GM//(SF,?+F?J5 M9AR2E76\7K_CDFL58>OT:L+AL]S=*Y97D5TD$Y_&$GJW"X,@NBYYU62*3Z\( M#I_7G@->:\S'L"22:Y`);[BJJGC]_1FK.ECXA/81$UJN17?DB;(E*,YO_8EH M<>45]3I.1Z4.)]LL"H'PZ3M"3]\YP$_]Z!H,T=?_(&]2_C;*>AVGIE$=`GE( M^`P>(V;P?)8R`5W1+/"C?Q`_O8S#"UAC!"2*BGL=C%.I@D@XHGI)4/A372GJ=H_TC4(2#S]T)8NX>4I_%;-R_31Z32,#:6AFO<[A_ M?&TCX#-UBIBI^>2?3"9)7%C4I<-F.,M99`J#)U__)!6]#L:]H]YBJ((E\!0< M(F9Z(8L':%:QN6!%O#V<0#?[+V#)A4-'EZ4!]#]D&*XB7S3TULIXQ_O'TQ8` M`5$N?#*FPVE$4IJ$(KN`SE>=EJ[QWNK]$ M%G'PS8_^E2^E_9.]IW(-2@"&C$[8-X7A@N2!2F=EE&J\D5PI:C7 M/]S#?;L8B8#!.@X8$,J7S2/8!H]F15'11J>RM@[&-D,5;I.<2(YO]2IZW0V? M7YV#9E%`+@C_#-KY4W3(K*H'ZN34G#<1Y?H`,8!G__36Q6#9CM)W,%8N8#6) MDJR(.%GMRQV)6`#->9+E6;$Q+GH[\M^*H"&-L52O8:]S?.CJQ%6[YV>K/9>- M7$LM@U"<^EEL4LL_\+4BH+V?'3AW91S,#,M(L_-G/WXB;#XN>K/LGLX\8-*, MUSMQ-NIU^JDSQHW:`<`H1K0Y2?SQ6P'\WH_6RO?#'(SI8?KDQ_2?!?QEG"S3 MM3@P89L1]LM_OB1TPB^M.&5GT0E],CH)UIB8$T\(2"5E<>%EU``.\P?R;I?*K, M[DA``#F[BE/@EBB/5GT0E]-CJ)TICX$T\(2=5E>>49I,29J_C2*_O"0!`V9: MG-QI3SZZ38#0G)Z;[$R%S`3B-OI5X%\&.4Q]&EZ^,A]*L0\KQL,\;WC'UZQ9)+!$Z)N_6L4JM`9C%87?MW$EJRP;M_'5`J-J?AQ="F?UUGN9.('E M(KPBA3OXAOJ/-*+YFY&-9:M]$"&*2Y_-FEQVI84HSKO&T35)89?+!I2![TE< M"23C]);;SJ8IE0@0A9=75XX[\D+B&;DC0?(44X9%7T>4=4%./\:)AJ8D$,6Y MU]&8C(#XF2_V`F!'2>$$F>]QE7:11FV0U8]Q[J$M"T3A]=7UYM)/8QH_92.2 M%BNR_CRCJ`DR:K&)MJ(-J1FE$=&V(VEN9=+DR M6;,C@IR^P&1<3$F&BUG%QD'0*-RYN]#1>C)R&THHNNKW#FXEV?@KF3R25&B&\8L#0!0[>4TF>!:6#)C;*'8!A;`GH)F3UIH%RC#5OR>L3[KL&C+5%+A;QD9SR)FW\JX-VK'Z_6=FNZU5*("T@9RD*/:Y=\2VMDOY2G`9H+A1VEBJ-'.$4 MA:Z@<%[P!,0QLX4(/@(_-@_?NV[S3>9"K>U^%Z4PM!H+GI7"+O"JG:D$-$`F*^\<2 MOC0)7L6#,@AD9=)AMRBSD?_&M'@8$_D$K:KG=7&D(90RPIF5]7"YC0HQH_+A M>U*)RO=Z`!E%8)TE*C=PM2&"X]VN+/>#S,^=Q,6]`,UM$*\>R-6]X[?J5D@, MJ`T!%QOHE,LLM[S70S)#JSGCDRU!U8J<=?.,!LJPFK5R@!_%9"TAA\\F!T4K MPB\T=[VRXB`-%,'1QIR*P;0B"]S*95DEKUMEO1Z.N&EC4@5(6A&EL>J^N9%$ MQ$G+>SVWN]:!FC.(#)Q`%1R_3B%4[.LQ+5?(T>PQHL%P#%TL$\$&A(39KX3DV0WQLUP8 M?FVU?9`ABBVAFN>H/"]FS%M MBD]`MN,[6&(4EZ^PG-&,C%(:D#IT"QH"J:#PS=MB70I30+[C^#0QF&(W5(?T MC09@OD,1(FR+;"X\`U6<2Y+F0)K[M:[4!RM0'%%+()[].D^LA5.@!L9^OWIJ8.DF MO4_38C<\"/^893FS9J1^`ZUZ(*;]/#740"4@?[^"_1:/:Q8-N'1_C%?BI-[WNS)/@+*NU\-W8U6+?$UD`@W8+]>@ M`*O:$22OZ/7US?T:+`'QCL,&[TC`P!998EC76#ZP[1W*VT-2!KF([#S# M9KS^X7YY?ZN#%-"^;_Z]!1YQF3VO4N\HFS-;54O[EPY\_UBA(PJ2L!%!1&M([`!8NJ`EL;DC1Q,2IN M)POK>-TN)O-)2)P!W4M8+4K7M`Y1-V\3KQ:(!E/DC(@[`\)7<:',Y+3NZ1O& M_SZ+2?<8RO7*6W_RG!)ZM0$^)O-8S)#2$RI':"EITPY\X`Q']-8YJLXSKS9( M`9/E6Y-G,4)+29QVPO,%"8J>=WM5N1:W`-+`=+95BV\52DM9G3`<;'#%=:-_ M#5I0$>2$Z03;AKFV@0UE.JC=QK-W,3FSI635.M4N@5K*&85AS"^/[P#[I'1] MW-'LSZN4D.LX)\!CSFYZ:9UKRIL`V6$ZXC10DFI(+66:PJHEEZ]3$K!KQ$D$ M##*'<`4]X3<"\L-T4]*2ILBPVDI8A5U96/J^BBK"JH*P4#C[FE&,)4);F:_P MJL-*L)"Q/JS4];H]O*[`&@JQ!=%6PJQMC=CQ&T"R]'9%E4*3KE`6G1R4OVA"Q2KH9PGJ9]E$XS;LQ'+8U;' ME[9=V,-Q]F4^2M<1M.'EBO)M,`W+8+V@A^.82T`,GT4.`A3'&S:)/)^E3&[: M?&Z4]W"<:G&8DE'*`]&F0PP_8Z\(LQ\L#.?%CUBD^B`_AZW9&XV?BKV6;%'5 MJ>_A.-\2$RI88[6Q63K1P*`0@R!@^0JR.Q(0@,SRV9%\+C/9B)=4\W`<:)G2 MKX34HG.-44JF/@V9:RW.""C],'\FZ9K$).1KU/9PG'B9ZH`NLA8=7NB2OB$$ M%&=5QD-\"X.MDX4\R?W(\9`6O-PLC\N75?-PG#-I6W!*++8.#MPG3^`\R'P= M!]$L!#ME\:R[AN%NTHS7.T*QT]96!W-PS1TC6(A8N8Z+W*`9&"@9`9$Q6_6" MO)`H*71<%*:BJ.;A.#(TYXH3J*(#U=9#'!B6[I4'VD=^SC8KW](DDUZRY]<` MB:)PP=35`BV8ME[LP*`!"Z%(*%\4\7``V6K;W._1*KBL,9!<5R%[TN3%O/96!0E(MYA^]@0QM+S^@V2GK] M#@K+OQ+C7"RVGLG`0*O1,.>I.8JSMDK<"M#8>A<#E=UWF\1!E25^NY[70W&R M9G>5%\"T]4I&(_[8G6>X[J$XNA.&6K MR2L?EJWW+S"LU`M3Y,%_U4U8SJL`)@P*EXPIWSJH;+UB@8%NKGQ,%VVOA^)T MK2K78DRV'IU`9:3IL>OUL6VG+!A@!2AK;TLX)_6!3*9)ZJ=OI2R*R,W+U_F1 MP"`,:8EQY-/P.C[WIS3W98+N8S," MJFJ'`B..%RXL!<\GDTD2%X"5);0$:6P]1N-_LJ8S8&F$U7A^;_\;"7E^,U-8K%9LZ@>JA@@=H=`;PVO1> MP4;4UR[W1+;?*\`1Q*0C<,%N28&M%6EV9H\9#:F?OMW[$=%,LR.J`V)!L6]2 M$2=87>6PVI!U9P78K3^!7Q]`0!D,`P"ES,*CKNQUD>R;Y4P*Z->$UX9$/:/B MK)>,(C\H8GN%^=#E%4`@.#;/FM3QB9=A:T,NG_<([G+U.T\FTR0N\F%H9E/C MU0/QH%C=*T[U:FB6<@`Y97X#G7*&YY8'<2#QCR@YXY,M064I'9#;3'I+G[YR M&M\J"V)`X0Z1<*0\R5A%XO:!`CN$SNMW-PW6RF1R@"D11,2;TD6W!LY>.I2*P@X/>>I)1D9W[]GLXS&),L&`>Q&Y@\I MR"=P00V0"8K0WVI3N!24K40[Z(AFOZ9$/9TKZX*<4#B^I#3J,\_!9BN'CET3 M_8PF01+GT/(-G="#;\GWXD]95S20-:N#[%!,RSH\\7;5)BAMI<>I$YIO M1O;:BVZ5.1>T`D)!<=YLEWHI6%MY;QK0`/%CPFQ7`O*Y?)W2M.!&1+]!$UX/ MAX^T(O?&2&UEQK$[Q>_VK6T<5ZZM,\X':BM9SJX(7YNVZO`N:`BD@M>*JT._ M%*^M/#G-:0%[R/0\R?28?B\,<)">ZI'B92&OBR-S@CF; M(BRVTMLX97'YQ'+XQRS+RS=E)1.S5CV0#Z:3RPI<:\"SE>[&[K1K.3M5%T<> MBXI3L!*9K40V*QRZN.WTZ&7G5S<D MN&):K(+%3%IT>N2_38J`3/4MJ'H->]V3$V8CP3%%""I!:)!85WN?!)0RJ0-=\@$()4S@K0>B`>%3TC)H!'QJ]C:<(GL M&XE)ZD?LA89P0F/*;"^V"YN_K*L,IM.J#^)"<:BKP2E?&0Q0MN@->O[KC+J: MH5$;)(;B$*"R7FAC;-%#]'86WAN-."#+WP1,X`CMW;4-TX@W-K?H?7.T3A<[-!M\J#:T54'U[;3<]7[Q"':\XN MSZ:>VD(*'Y[:&`2!PW\G9TK;4UO`:8.G]MTF6Z;"5.ZLA76\WC&*6S$BPA3; M$SZ<-CA8E7.?:.K3V2;7;QS80;%!V*33MN118*SE8BPOW79->;,10QY[BU6"`V6UD5R]W891SNM1[/32[F MQVE^R^MU4)R\X=9C@=ALI8YLAQZO#/;?";L%1\(!;##])[)V1WPWL[2L M!T`>CK-"U#IO)$Q;"3;WQK\F],=S/3=-C0=[O0`:<1R8NAT3M@5J*P'I'ECK M*M$MI.-\4!AU!&C$<52(>UQ4D*FME*TM&!HWEY MK1WV!DC]40Z*70@60RYN'"-%/,F(1-AI<*14Z`T0^J,<1KL0K*WDY4A&BAW# M]!HD1>.,!D4NTMWL+-:_T^MU/XZNZXK/5IYV)+IM9WI8%]2.)ON-+P5Z?I1# MZ@;E9RL!/6]+@"GK0OU7UH4NBL,;&W0+IA>[HOK(NK!U MB[V+XW3#+L^B.S12*7QD78A!$#B\^W*F^/2*X'QD7=A*4_`514B,B#`^O0HX M'UD7=I!UH8OCQ&,GBX4E<7UD77!^T:?;FE.([M;3S`V+K47)@2M+:/$^8O'7 M;/`"VW4V>5PE:1%,W(0N*[X2N&G-<4$#*JTEO18E8."^8+4RH-5;`&%5K]=K MC8M>K&EZ4K"42@&%QB2321(7EO2Y/Z6Y'Y5CA:4'3U]("$/E:L:B712P]H[\/AK;=AZ[7"X=W; MA<.[]^'PYCD0>VUS>/>J.+Q['P[OTN&(XU5W!5/Z#F_QH^T_ML,;Q:`7$6;N M\!:.W@^'MU7[OM8XYQ M`U%:OW6>/@=C`6)3.T_ M.+AC+^YY`IT,6(/#\66:)FGFWH,["()D%N?LJL\STXQL$(=%WY:=U?'7FC3C M]4Z^NO?.;O4N#D>@>FFI@(/PCUF6LS%Q!QH\]R7HNV6K-@ZB06%"FM.I\K[6 MDTBKW*[W`8E]0*WKMFU)%GG!^Y17S^EVG\?PB M$W>%DZ"P+$!S&JH@%C>'%C&`-GAVSF89C4F6#8*_ M9C0KMN@*6U90`T2"(\=RH]:L%+Q]IP8.?6"_IH0H[5IE7:_?0W&Y2LJB/O$< M;)9"%.U.U_?3YW]+(A:LFXWRMYL\E,_8@N(`$$5\F283G)E<"LS6TT-VJ3NC M2<#2]B31#9W0G"BH$Q0'A"AB/*I3)P5FZ\4=IQ/O!1F#;,(S$L,O^2CRX[,W M]O]!EI'\'-:GIR2E)%,LS@:M@.Q^@`7;6""VGKUQJDPE0,51[*DVR)`PMMIO6\]`..7L5_^5 M3F83)6MKY0`_BNW4%B5\YCA]M_5"@5ON:*S'W6HYP(]B/Z7+W7;?;>75=QN5 MIKFF9"N+RHU&<'RM=D&^/\"VRH*(;"6TMWS*%(:T[-+(I^%U/+^?#/@&03"; MS(H[C&PG$E!>#)5Q&U[O%,4R8(%0WI&6L21L)6Y'LOVZ2;)L&"__K;41VZP$ MDD&QW%C7$5WHMG*4.U6*6Y)?QT$R*3!*]&"M'.!'<0>S,>HY:&MG[3XMV8[) M$YM>G"83N?33N#AO(.DBKIH&(+P+&LWR9:\/HYTR(UI4W6A"%3,<<#2_%8.]("']COZON9&NW`7)KM]EB M*`F!!NW*ARJ8.9;[KWG:O^R&^H\T`D"B*4-2Q>OCR)/8S%RA!"Z@>+]=G3A&XE)6CKQP@F-*;LZ MR/3_\I7=!I8M$XJ:(*-V+PY:^`67I?;+`_HM2<+O-)+M019%`#6**S;-L;X& M5$#OKGR9@A7_.@8[Q<\(;&P2,&!F;$/][I-5K?U:E0$]BI"49JP``Q$(%,`X MP+!>KF2AY;?`,;=F-`P_40VOCR-[1E-VGQRW@.9=N28%_&Z>KRPZS:+K2!"Q M^$H1T1I5`7D['8YF`A!0OU\>Q[6#F?=W`AZ2E=S=STD$R++",Z][H*5NR>L? MMU.):LE#H%/Z+D;AH=C.$^?$61+1D/7BS(]8=O?[9T+R;%2P\DQR&KA)G_.> M]6`XOJ(Q=(SZT2B97U-1I\W1J>YMQ%:[0*?,?+,>!(0DFDE7N()-^3:F-J2A M`5'0'-:A%Q)>`R?Q$P5T1=!\=O;VJ_\'S%\LJZXB:MR@%0]'W".'3C[OIM#: MD)%&@GF)^-:?J._S&K8$"Q6*4#93THU51PR^#8EN1C"VP*I11D2OE0/X*&:& M2JSQ%8"#KQ5IQ:V^&('C[HGV>B`'TH;LW'7??,!Q*47.$Y];`1B4"73N";O/ M>,:.A,F$Z>PY2Z^:YFRV&BWZ52!1I&HP;`>F,13FO(`KCM.E&L(V9.:YWW(J MZ,S0*QZ(XSV=FS<@M"&KSMIM!^@W;%\9'O@]*J)#V(G@)`&M_F?Q^2A-IJ#C MQ>WVG*5K_6M&B]!&B0;8^@KO",7YO$@;^+IC%;RM9P9)ZO@E2XDQO"*P5<%4 MVPP*&O/ZAWNH2E5QVLH?A.$)U(T@MI&?#M-"BF$1NK8(R=N\ MYKR7M;PC%-$@%CA?P6,K=Q#:T:[W<+JJJG>,(B[$`O>;H&QE&D*H`#<4?H1S M\YEA(?*GSW6J>_T.KCUJ%4V0(&M%1J*5L(0*AJ!&;0]'O(>9$NCBLI7@",., ML(+9P/B3U/)P>",K,\_%8RLM$DK&E2:?H(:'S!E9C>D5++82**%D6<_,DU7S M<(0"U.1[$Y"ME$7;I#L,PGN7438<#Z,PA$FDZ?BU&8)HPV1=7:C)(YQ^;>65)E&21P+G5K[%2-7-TKB&)?S MBLN3=I3$<4M>:*M[8/X5EU=*>Y2N(VA%C!K_#K5.$+Z\IM=#%M^TSIV`:!U, MEF+7,&Q';@!@G)%!'"[0SL%+>!?6`>F@"$S5(I'/OP*;I0`W#,S;RS+Q%8=+ ML3KI,F"6HMMR]H:[4[[GV\WX:9X`0>=U#L13YAF%D\S/U MJ3.&2.MY7U$X%>4D\HE7X[(4A8:!_.82QGQ%8T]Q5KD*C&LKT!PUJ\EWM:\V>2FEAEO/)@W^XA MMV(D;0KO6J8Q^>;3>#.UB7S3I:SK?45QFB&ADL^]'K`V!7FMQK$/QQ?D,;^@ M69#,XGR4D@F=360W3E1UO:\HSCV,U4`/6.W@+D3/%%S'.0%R-#9D&R6]KRA. M0HPIYL&H':J%B-!"(+=)G*Q;*FI^Y15!I/LYL^O`LA6XY=YZJ_;43/\0!;=& MUAH'@:W(+/[I=9*F%Q?>_DU-6`K7K)X127_:>4+G]D\2Q?6\4Q2;=_-Y70BF#4E_-\`I MIW=N>:^+[/Q'2)G`&R,&Y38'L/5+^LHI?:LLB`'%.;V$(^$NF(>D#?E]!2^* M*\F5UO.Z'11[+&.B-5"U(1'P'//4`UVT#Q(9B4V8^V,T0VKH'@<.]).D7A M(3$DEHO"UF4'++Q6BXD\Q37I:O&YC<#6C07W>:A7GEU]2`1[AD*?'_V,A,RN M`*.BH.N.P)R5T7QQF[Y\QO6.!,E33-]C`J7[KF:_VCO%Y7[1TK6=",56&ET, M7ED=@:UXJMGED]]I_EQ^E$'9*^+G,VG*75M?X9VBN+YC7R&UP;6]AOI4) M3"]F*:SRY8`K1MDM^5[\1;XET:COG:)P,U8P;+60M2FUKP!U:0S64(B-!KS. M(0J'I!65X&)K4R9@##=.]M`*J@S4\I63!^?VN6PN7:ZQP_'*$GQ/`BB9T\JK MC[)=&*M71N"T09\M\:1*8`JUIDZ.U'$:6U$;2F-?!$0%H<4,BP2E0G!U[9"M8 M,"6R.Q(1=C!V!>*[S$"\WZO8+:*V0$0HH@0M62MRF`)-V+$;MHJ-8DD5Y(V! MD/;(!U87IT`9=IP]NXYOHEME(EC6!C'LD5O*&)C@[MZ.'9NU?!.F!&]6!T&T MQ/O$1R:@>"]SZ13`RYN()!RFYWX4<91<908J&_#ZG3T,5S/!)E"*OQ8VIK MQ99W.GOD453`$/!J[";D\8HA;]%P?.YGSU=1\MW)2\J\?ICE'=JJYG6ZA^ZF MQ&KYACI=7/X/H5A%D^(VFH],0YN)7SI=7(Z-%;(4M/*A?"0;BD$0N+P7?*;X M](K@M"'?4-U+K)TN+I^%_EC=P-"&5Y9O2L[>?LM(>!V_/VXU M"'+Z4ISM@HD#'\S@L_D?P>31,"?L?('7Z^.:##94@:\X-K&WZ&WG:K'MVXU6\#524TAUTT%X,0+*@_U!=AV_D#DHPCV^ M-&O`Z_10Q#.ZT),JDK*57PO#A'-!H,\!5349VD;E4`P:`X-W"I*#+)M.FQ#3'X&HE,=A(;"-]W<&L='7#M_ M&*(YJ!@#O(/*>_R%1%>TV_#Z.(*IFS^O-12)M7?MG>_#ZHFVL;`F&+@H MSCUV$LQ26TZVDHSE"IX_BN,5*M%TE[#CRGME1.K`7 M%JFP@[]F-"4@(8"=OXTB/\[!\&1WK::*156_$1`@BL,7F^K`5SA3F=3.M(;( MGJ\GW<9F,!`TB@.=YI7/AIQLI71#N[!>T=B/@P875L,O`+&C.!2RLK!6PMZF MU'`@D("0,&.)9Y9!82NOE*XQV;Y`N643U1M"D]'!_R^HOD8#^4 M'Q#X8S5U4C4(@D5Q*N1*Q_3D@R.]G'W%VW@!1U.[-FJ!B%`U6A;A"P)%\ M#H,]U9@=!8)&<3;4O+;9D).M!'CNS7LF"IB>V0^VIW[Q([;O+E,`;1Z42)3/ MI!D0(0H7K9FI;H[05A8]K$HR@'&4IF\P/%3YU;3J>YVC/72-&D"SE7(/RY.O MN](*%#[/9K1"Z+HTS[F'(P77XMAS$1#[[C.+0\X">T&S($JR64HT_$1UF_9Z M1RC.I,TUJ3[JV@G\$!G0;%NP?"YAOE]@%AP`GC&Y#B8LQ(SW\H1I$R`\%):* M'27@*YB9+&PE#&PD,_#[PX##\3W,AB0[*Q-E7WENF]"=(.N4F->O]-: MA:DK%5LY";=59\<9"6^+%XR'X[-9!C-XEH%0[^E33,3980KRZ.:1#1@ M0<(.,A0.TR<_GM]V76909$I8N.+>13(;V@USUVEH=T?=70&7F"&@`"Q::1)UJ1"UP"9&?#X6]?6.<>_8P4 MHOL?4$L#!!0````(`#6+CT:5,5)@U0H``%YH```1`!P`87!H8BTR,#$T,#,S M,2YXL#A<*`E.B9.%G4DE1<4_>\=4I(MVR)- MR6Y600TLLK(T,WQF'KX,*5*?OG^>1>B1<$%9?-KQ#PX[B,0!"VG\<-KY<73M M?>R@[[_[]IM/?_(\]`.)"<>2A&C\@BZQQ"..@]]%H8_\`__@(U(71]Y9PKW> MH7^$?CGLG\"_H_>_HG\//_\'77T9(0\]/3T=A&!!:@L'`9LASU/EB&!*9AA) MS!^(O,,S(A(GB61#29TC%E2K$+Q;P_[/=]@!Z1&8GE->.S M2S+!:21/.W^D.*(32L(.`E]C<8*3Z=C1GE98DGWJ'S#^`"*'?O?GS[=?--K" MDG\<\*N3[7?5XC`4IQ-734,X5RL)'W>SA7#2RV/WY%@R7C5*+,(V% MQ'&P`+$&.G?1/SX^[NJGA6@JO`>,D[GP!(NQ%LT?Z,!YA[XW#]U)P-)8\I=E M'P4)#A[88S=_J-3Z*VHIYU`-37KYTXKR0D*K=>!!A3AY#J;5\NI)A0*-'XF0 MU2K9LPIO8DP#4:VC'RD5?UE%T*!:`1Y4B`,!\B4AHI(:_:3"%R$3;B@$GE24 M$I*$DT"U?V/].NYB'G`6$4`02(\\)Q&.L63\Y1I^SP/"XCB=51L))>\JQ%T0 M\D"*IISN+P*I94OMR`53[39740A0!9)>;E%PA",J$QU4C]0Q_Z MQT*]?`FF4&8+E8Q]ZJY:^/:;5?.I(.$@_DY?`X<"K&E=U7'D^KF(77=12%W- M`$=!&AD+S=6Z2W243#;EZ8+%@D4T5)7V'$>JX_LR)42*C"3S8SM#/:#E"X20 MY!25[:#<$,HL[>EI0L\00P\OIT120+:!JV59.W%]=^+0+TN&?]T3Z4CD/+YB M,!DD*F$$,!4-SB!G)_"]C<"%1<0F:&%S3UT#ZNY)2""W'4<$)"##EQ0NAYQ, M"&1?(,F"WV%`TO]/613"%.#JCQ3&)DB\:4"EG>]MC=LKR9%[)5D`024D:`X% M:0P(Q_E5CN8O?^X?_QUEF-"['-5?]_6L;CT;3"ZPF%Y'[,G6092E[,Q_<&)> M$:\L(FURSYJ%M3LL4TX&D_-4T)@(H5HE?8AA0AU@2&X#/8>C\<,0HAQ0DK-8 M6\O.ZM]4%DQ%$#$!9N%'9E_16)20M=!%&6A1""I*V1-M(7K1^4XA[.?*#"K;V=-BS2B@;PE4J8/)%>>, MSW.(M?MV.OQ5.A86U!B3V=A3L<,T8;MTP2UM\'N[21O0N^)JG^`W&,!&:G)E M'\9R$3N;???!#+W++.[YJC^JK=%EDK"S]=YUA-MS];_H7R^)Q#02(_(LTV(! M=4L;=KZ/=M77YJ6BO-A]M:@Q::MBW2YB)_7#I@G=GJY=C)!Y#*U#9"%C)VQM MH<0V1N8F]Y0UIVRII;F)V@E<6T)Q('#?]IIG.^M-SRAB)ZYZJ:4RW]FWNVWI M\AWX\NV$]9R78!;MS-]3UIBRG@-EO0V4K2W3;*:LMZ>L,67K@]LF23M]:\LQ MF^G;CVR-ED&K"-PH92=O;?6E:HGT_YHX]4,L$1M M>""B6X#OH.X.'0-&ZCJV3&([W8KPN*Y;H$*B]GH$#:"N1RMM9K=^9>VMO%D7 M?I4W\^I;X!;C$L65AP1,N]ZS\P6W+-"F+"KJEU?H>>J6Y_>\OG_P+,)%].N` M6/A8#T2AUP!$]9D"Q^(+!57ND6N)UD,!AH)UH96*71))4=SQ%J9J^6_9H&\# M5*&67WL+$XV`5!U\<$%2UBM^;(VEZC"%$YBRXOS7MARMG;MP@3)7TE?;0E@_ MD^&"8:&577H+`XU0K![T<,%0Z*B+KU`X^ MMYXKXGQ)2W5?QZK;]#]L#<.Q\RQ!D#LIWGZJQA52VT)]S=)2?5+Q!.[1^.%&DIF:5740SJ5..Y*G*FG54I`F4A:.M%Z8\GS_54RC M2+T\+F1%"LI4INKI#YRE25$(!?/9-%CEO;^YH32X>!,/.0N($/S1CT`)B_5/DWP9&H=#!+.N6Z?YGH.#NF`H$@8[7/WM7KC"HXWX]-S;&HG@-\[9-8S`I'9#Y0B#AIVKF_F:K@(MG3:I&W8BUK\KL/C(ZX)GQ>U!0 M*_[7G,VN!.2C3V^U`IG]:5)MW*+3OLJRJR@L=\N]MUHIRAYL-;#TVDZ\@Z?7 MF/)'%97!I$@\,FMGXD8OI.F/M1"UW?3UV*Z9-=?PP1`%2#<33$.8<)-8$+4U M:""GA%_H%3-Y)H0ZPZ[V/[YD?]6[L_,((E]$)?M2#! MDC$5OR9Z_^@\3VUS@';GCJG'@,E[F$9$#<TAE"=3T.1!.B8W*U$P8C0Y ME4S_P2+U:2XQE"^W,OQ,9F/"5T@-V0S3^'475(S(#)Z<4Q:P6'(6W=(9V&J/ M)T9D]JXL'Q,&\3_3F/0^J'F]J1@QL! MU^9Y1/A,#":0WM$"J]L8^56(KD!;V^.EV*U7\*](=@/,#MZKO.F"B=4FW*II ME@&OJ14#(B+.';XBU)J^NCYD\W2R)-RZK+82GL&54@CNF"1BB%^4_"`FK:%M M,\1ZOHV>6-M]*T%TJH(W:K\F3-S4UY6R1;!AWGMNW:,:7XC56+MP1&I\X3>6 M-X""ZQ?&I8C=9/M4<31,QS!Y&TR@'-5;JU>L)!2?U2<$;PD6\FRF-FJU>3US M=S[6'HI_6EY9:W.4:CCAOBAQ2V/=(E:SZZ^P*<*.;NOI0QO>>M5"NZNTTG^+ M>:79_[,PU-OSH5/`-+R)\V6[LS@\"X)TIK:$0PG%-R!;NR6BGANF6,!UJ#<2 M/=/7;\&0A(442E?KRRM)V`HP`_Q[$D18"-WHE6WU\FZQ562^5CUBV7+W4VWH(4?0V1Z4TK MY2H+RX5;,\.HAF7P8434UE:H6EDCG5,[8D/,=8[5YIKH@MZXHQ1DL2`P"C$P MDJIMF6M]5XM[7T?\QAE6H9WW8U_#Y9JK53;,!C=OF1!JA7XU,/I#2T$$F7;8 MXN4Y)_3*\T_=;*>Y#L)_`5!+`0(>`Q0````(`#6+CT8KP&HLVX,``#I-!@`1 M`!@```````$```"D@0````!A<&AB+3(P,30P,S,Q+GAM;%54!0`#5M`Q0````(`#6+CT832`<`&0D``$EX```5`!@` M``````$```"D@2:$``!A<&AB+3(P,30P,S,Q7V-A;"YX;6Q55`4``U;7+E5U M>`L``00E#@``!#D!``!02P$"'@,4````"``UBX]&I,>SP(4I``"AKP(`%0`8 M```````!````I(&.C0``87!H8BTR,#$T,#,S,5]D968N>&UL550%``-6URY5 M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`-8N/1@E*&[#T00``V)\#`!4` M&````````0```*2!8K<``&%P:&(M,C`Q-#`S,S%?;&%B+GAM;%54!0`#5M`Q0````(`#6+CT8TW>`C3B\``)DP`P`5 M`!@```````$```"D@:7Y``!A<&AB+3(P,30P,S,Q7W!R92YX;6Q55`4``U;7 M+E5U>`L``00E#@``!#D!``!02P$"'@,4````"``UBX]&E3%28-4*``!>:``` M$0`8```````!````I(%"*0$`87!H8BTR,#$T,#,S,2YX`L``00E#@``!#D!``!02P4&``````8`!@`:`@``8C0!```` ` end XML 21 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 22 R7.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Nature of Business and Significant Accounting Policies
    		 3 Months Ended
    Mar. 31, 2014
    Organization, Consolidation and Presentation of Financial Statements [Abstract]  
    Business Description and Accounting Policies [Text Block]
    1. Nature of Business and Significant Accounting Policies
     
    Nature of Business
     
    AmpliPhi Biosciences Corporation (the “Company”) was incorporated in the state of Washington in 1989 under the name Targeted Genetics Corporation. In February 2011, Targeted Genetics Corporation changed its name to AmpliPhi Biosciences Corporation. The Company, headquartered in Richmond, Virginia, is dedicated to developing novel antibacterial solutions called bacteriophage (phage). Phages are naturally occurring viruses that preferentially target and kill their bacterial targets.
     
    Basis of Presentation
     
    The interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries Biocontrol, Ampliphi d.o.o., and AmpliPhi Australia. All significant intercompany accounts and transactions have been eliminated. All numbers on the financial statements and disclosures have been rounded to the nearest 1,000 except share and per share data.
     
    The interim consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) necessary to present fairly our results of operations for the three months ended March 31, 2014 and 2013, our cash flows for the three months ended March 31, 2014 and 2013 and our financial position as of March 31, 2014 have been made. The results of operations for such interim periods are not necessarily indicative of the operating results to be expected for the full year.
     
    Certain information and disclosures normally included in the notes to the annual financial statements have been condensed or omitted from these interim consolidated financial statements. Accordingly, these interim consolidated financial statements should be read in conjunction with the 2013 audited consolidated financial statements and notes.
     
    Use of Estimates
     
    The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
     
    Cash and Cash Equivalents
     
    The Company considers cash equivalents to be short-term investments that have a maturity at the time of purchase of three months or less, are readily convertible into cash and have an insignificant level of valuation risk attributable to potential changes in interest rates. Cash equivalents are recorded at cost, which approximates fair market value, and consist primarily of money market accounts.
     
    Accounts Receivable
     
    Accounts receivable amounts are stated at their face amounts less any allowance. Provisions for doubtful accounts are estimated based on assessment of the probable collection from specific customer accounts and other known factors. If an account was determined to be uncollectible (payment has not been made in accordance with contract terms), it would be written off against the allowance. As of March 31, 2014 and December 31, 2013, management determined no allowance for doubtful accounts was required.
     
    Property and Equipment
     
    Property and equipment are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, generally three to seven years.
     
    Prepaid Expenses and Other Current Assets
     
    Prepaid and other current assets as of March 31, 2014 and December 31, 2013 consist primarily of prepaid insurance and deposits.
     
    Goodwill
     
    Costs of investments in purchased companies in excess of the underlying fair value of net assets at the date of acquisition are recorded as goodwill and assessed annually for impairment. If considered impaired, goodwill will be written down to fair value and a corresponding impairment loss recognized.
     
    During the year ended December 31, 2012, the rights to SPH Holdings Pty Ltd’s know-how and phage libraries were acquired by a business combination. At December 31, 2012, goodwill in the amount of $3,929,000 has been recorded. In management’s opinion, no goodwill has been impaired as of March 31, 2014 and December 31, 2013.
     
    During the year ended December 31, 2011, the rights to Biocontrol Limited’s patents and phage libraries were acquired by a business combination. At December 31, 2011, goodwill in the amount of $3,633,000 has been recorded. In management’s opinion, no goodwill has been impaired as of March 31, 2014 and December 31, 2013.
     
    Patents
     
    Patents are recorded at cost and are amortized using the straight-line method over the estimated useful lives of the patents.
     
    During the year ended December 31, 2011, the rights to Biocontrol Limited’s patents were acquired by a business combination. At December 31, 2011, patents in the amount of $493,000 have been recorded. These patents are amortized over their useful life through December 2026.
     
    Stock-Based Compensation
     
    The Company accounts for stock-based payments under the guidance of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 718, Stock Compensation, which requires measurement of compensation cost for all share-based payment awards at fair value on the date of grant and recognition of compensation cost over the requisite service period (typically the vesting period) for awards expected to vest.
     
    Warrant and Preferred Shares Conversion Feature Liability
     
    The Company accounts for warrants and preferred shares conversion feature with anti-dilution (“down-round”) provisions under the guidance of ASC 815, Derivatives, and Hedging and Emerging Issue Task Force Statement 07-5: Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity’s Own Stock, which require the warrants and the preferred shares conversion feature to be recorded as a liability and adjusted to fair value in each reporting period.
     
    Fair Value of Financial Assets and Liabilities — Derivative Instruments
     
    The Company measures the fair value of financial assets and liabilities in accordance with GAAP, which defines fair value, establishes a framework for measuring fair value, and requires certain disclosures about fair value measurements.
     
    GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes as fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. GAAP describes three levels of inputs that may be used to measure fair value:
     
    Level 1 — quoted prices in active markets for identical assets or liabilities.
     
    Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable.
     
    Level 3 — inputs that are unobservable.
     
    The Company does not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, the Company has entered into certain financial instruments and contracts, such as convertible loan notes with detachable common stock warrants and the issuance of preferred stock with detachable common stock warrants with features that are either i) not afforded equity classification, ii) embody risks not clearly and closely related to host contracts, or iii) may be net-cash settled by the counterparty. These instruments are required to be carried as derivative liabilities, at fair value.
     
    The Company estimates fair values of these derivatives (and related embedded beneficial conversion features) utilizing Level 3 inputs. The Company uses the Monte Carlo valuation technique for derivatives as it embodies all of the requisite assumptions (including trading volatility, remaining term to maturity, market price, strike price, risk free rates) necessary to fair value these instruments.
     
    Estimating fair values of derivative financial instruments, including Level 3 instruments, require the use of significant and subjective inputs that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are volatile and sensitive to changes in our trading market price, the trading market price of various peer companies and other key assumptions. Since derivative financial instruments are initially and subsequently carried at fair value, our income will reflect this sensitivity of internal and external factors.
     
    Revenue Recognition
     
    The Company generates revenue from technology licenses, collaborative research arrangements, and agreements to provide research and development services. Revenue under technology licenses typically consists of nonrefundable, up-front license fees, technology access fees and various other payments. The Company recognizes revenue associated with performance milestones as earned, typically based upon the achievement of the specific milestones defined in the applicable agreements.
     
    The Company recognizes revenue under research and development contracts as the related costs are incurred. When contracts include multiple elements, the Company follows ASC 605-25, Multiple Element Arrangements, which requires the Company to satisfy the following before revenue can be recognized:
     
     
    •
    The delivered items have value to the customer on a stand-alone basis;
     
     
    •
    Any undelivered items have objective and reliable evidence of fair value; and
     
     
    •
    Delivery or performance is probable and within the Company’s control for any delivered items that have a right of return.
     
    The Company classifies advance payments received in excess of amounts earned as deferred revenue.
     
     
     
        Based upon the terms specified in its collaboration agreements, the Company receives advance payments from some of its collaboration partners before the project has been performed. These payments are deferred and recognized as revenue when the costs are incurred.
     
    In Process Research and Development
     
    In Process Research & Development (IPR&D) assets represent capitalized incomplete research projects that the Company acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The fair value of the research projects is recorded as intangible assets on the consolidated balance sheet rather than expensed regardless of whether these assets have an alternative future use. The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company will make a determination as to the then remaining useful life of the intangible asset and begin amortization. The Company tests its indefinite-lived intangibles, including IPR&D assets, for impairment at least quarterly.
     
    During the year ended December 31, 2012, the rights to SPH Holdings Pty Ltd’s IPR&D were acquired by the business combination. At December 31, 2012, IPR&D in the amount of $5,161,000 has been recorded. In management’s opinion, this IPR&D has not been impaired as of March 31, 2014 and December 31, 2013.
     
    During the year ended December 31, 2011, the rights to Biocontrol - IPR&D and patents were acquired by the business combination. At December 31, 2011, IPR&D in the amount of $7,285,000 has been recorded. In management’s opinion, this IPR&D has not been impaired as of March 31, 2014 and December 31, 2013.
     
    Research and development costs include salaries, costs of outside collaborators and outside services, royalty and license costs and allocated facility, occupancy and utility expenses. The Company expenses research and development costs as incurred.
     
    Net Loss per Common Share
     
    Net loss per common share is based on net loss divided by the weighted average number of common shares outstanding during the period. For each fiscal year reported, the diluted net loss per share is the same as the basic net loss per share because all stock options, warrants, contingent shares, and Series B redeemable convertible preferred stock shares are antidilutive with respect to computing the net loss per share and therefore are excluded from the calculation of diluted net loss per share. The total number of shares that the Company excluded from the calculations of net loss per share were 148,692,651 shares for the three month period ending March 31, 2014, 20,000,000 shares for the three month period ending March 31, 2013, and 77,490,242 shares for the year ending December 31, 2013.
     
    Recent Accounting Pronouncements
     
    On February 5, 2013, the FASB issued ASU no. 2013-02 which adds new disclosure requirements for items reclassified out of accumulated other comprehensive income (AOCI). The ASU is intended to help entities improve the transparency of changes in other comprehensive income (OCI) and items reclassified out of AOCI in their financial statements. It does not amend any existing requirements for reporting net income or OCI in the financial statements. For public entities, the new disclosure requirements are effective for fiscal years, and interim periods within those years, beginning after December 15, 2012. For nonpublic entities, the ASU is effective for fiscal years beginning after December 15, 2013, and interim and annual periods thereafter. The Company elected to early adopt this standard which did not result in any changes to the consolidated financial statements.

    XML 23 R3.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Consolidated Balance Sheets [Parenthetical] (USD $)
    Mar. 31, 2014
    Dec. 31, 2013
    Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment (in dollars) $ 491,000us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment $ 473,000us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
    Common stock, par value (in dollars per share) $ 0.01us-gaap_CommonStockParOrStatedValuePerShare $ 0.01us-gaap_CommonStockParOrStatedValuePerShare
    Common stock, shares authorized 445,000,000us-gaap_CommonStockSharesAuthorized 445,000,000us-gaap_CommonStockSharesAuthorized
    Common stock, shares issued 182,535,562us-gaap_CommonStockSharesIssued 182,535,562us-gaap_CommonStockSharesIssued
    Common stock, shares outstanding 182,535,562us-gaap_CommonStockSharesOutstanding 182,535,562us-gaap_CommonStockSharesOutstanding
    Series B redeemable convertible preferred stock [Member]    
    Temporary Equity, Par or Stated Value Per Share (in dollars per share) $ 0.01us-gaap_TemporaryEquityParOrStatedValuePerShare
    / us-gaap_StatementClassOfStockAxis
    = aphb_SeriesBRedeemableConvertiblePreferredStockMember    		 $ 0.01us-gaap_TemporaryEquityParOrStatedValuePerShare
    / us-gaap_StatementClassOfStockAxis
    = aphb_SeriesBRedeemableConvertiblePreferredStockMember
    Temporary Equity, Shares Authorized 10,000,000us-gaap_TemporaryEquitySharesAuthorized
    / us-gaap_StatementClassOfStockAxis
    = aphb_SeriesBRedeemableConvertiblePreferredStockMember    		 10,000,000us-gaap_TemporaryEquitySharesAuthorized
    / us-gaap_StatementClassOfStockAxis
    = aphb_SeriesBRedeemableConvertiblePreferredStockMember
    Temporary Equity, Shares Issued 8,859,978us-gaap_TemporaryEquitySharesIssued
    / us-gaap_StatementClassOfStockAxis
    = aphb_SeriesBRedeemableConvertiblePreferredStockMember    		 8,859,978us-gaap_TemporaryEquitySharesIssued
    / us-gaap_StatementClassOfStockAxis
    = aphb_SeriesBRedeemableConvertiblePreferredStockMember
    Temporary Equity, Shares Outstanding 8,859,978us-gaap_TemporaryEquitySharesOutstanding
    / us-gaap_StatementClassOfStockAxis
    = aphb_SeriesBRedeemableConvertiblePreferredStockMember    		 8,859,978us-gaap_TemporaryEquitySharesOutstanding
    / us-gaap_StatementClassOfStockAxis
    = aphb_SeriesBRedeemableConvertiblePreferredStockMember
    Temporary Equity, Liquidation Preference 13,336,000us-gaap_TemporaryEquityLiquidationPreference
    / us-gaap_StatementClassOfStockAxis
    = aphb_SeriesBRedeemableConvertiblePreferredStockMember    		 13,022,000us-gaap_TemporaryEquityLiquidationPreference
    / us-gaap_StatementClassOfStockAxis
    = aphb_SeriesBRedeemableConvertiblePreferredStockMember
    Patents [Member]    
    Accumulated Amortization, Patents (in dollars) $ 101,000us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
    / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
    = us-gaap_PatentsMember    		 $ 93,000us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
    / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
    = us-gaap_PatentsMember
    XML 24 R17.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Stock Options and Warrants (Details) (USD $)
    		 12 Months Ended
    Dec. 31, 2013
    Warrants Issued on June 26, 2013 [Member]  
    Class of Warrant or Right [Line Items]  
    Warrants Issued 28,394,834aphb_WarrantsIssuedDuringPeriodNumberOfWarrants
    / us-gaap_ClassOfWarrantOrRightAxis
    = aphb_WarrantsIssuedOnJune262013MemberMember
    Risk free interest rate 0.0109%us-gaap_FairValueAssumptionsRiskFreeInterestRate
    / us-gaap_ClassOfWarrantOrRightAxis
    = aphb_WarrantsIssuedOnJune262013MemberMember
    Volatility 160.94%us-gaap_FairValueAssumptionsExpectedVolatilityRate
    / us-gaap_ClassOfWarrantOrRightAxis
    = aphb_WarrantsIssuedOnJune262013MemberMember
    Expected term 5 years
    Exercise price $ 0.14us-gaap_FairValueAssumptionsExercisePrice
    / us-gaap_ClassOfWarrantOrRightAxis
    = aphb_WarrantsIssuedOnJune262013MemberMember
    Warrants Issued on July 15, 2013 [Member]  
    Class of Warrant or Right [Line Items]  
    Warrants Issued 1,645,361aphb_WarrantsIssuedDuringPeriodNumberOfWarrants
    / us-gaap_ClassOfWarrantOrRightAxis
    = aphb_WarrantsIssuedOnJuly152013MemberMember
    Risk free interest rate 0.0109%us-gaap_FairValueAssumptionsRiskFreeInterestRate
    / us-gaap_ClassOfWarrantOrRightAxis
    = aphb_WarrantsIssuedOnJuly152013MemberMember
    Volatility 163.08%us-gaap_FairValueAssumptionsExpectedVolatilityRate
    / us-gaap_ClassOfWarrantOrRightAxis
    = aphb_WarrantsIssuedOnJuly152013MemberMember
    Expected term 5 years
    Exercise price $ 0.14us-gaap_FairValueAssumptionsExercisePrice
    / us-gaap_ClassOfWarrantOrRightAxis
    = aphb_WarrantsIssuedOnJuly152013MemberMember
    Warrants Issued on December 23, 2013 [Member]  
    Class of Warrant or Right [Line Items]  
    Warrants Issued 4,320,420aphb_WarrantsIssuedDuringPeriodNumberOfWarrants
    / us-gaap_ClassOfWarrantOrRightAxis
    = aphb_WarrantsIssuedOnDecember232013MemberMember
    Risk free interest rate 0.0167%us-gaap_FairValueAssumptionsRiskFreeInterestRate
    / us-gaap_ClassOfWarrantOrRightAxis
    = aphb_WarrantsIssuedOnDecember232013MemberMember
    Volatility 155.24%us-gaap_FairValueAssumptionsExpectedVolatilityRate
    / us-gaap_ClassOfWarrantOrRightAxis
    = aphb_WarrantsIssuedOnDecember232013MemberMember
    Expected term 5 years
    Exercise price $ 0.25us-gaap_FairValueAssumptionsExercisePrice
    / us-gaap_ClassOfWarrantOrRightAxis
    = aphb_WarrantsIssuedOnDecember232013MemberMember
    XML 25 R1.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Document And Entity Information
    		 3 Months Ended
    Mar. 31, 2014
    May 05, 2014
    Document Information [Line Items]    
    Entity Registrant Name AmpliPhi Biosciences Corp  
    Entity Central Index Key 0000921114  
    Current Fiscal Year End Date --12-31  
    Entity Filer Category Smaller Reporting Company  
    Trading Symbol APHB  
    Entity Common Stock, Shares Outstanding   182,535,562dei_EntityCommonStockSharesOutstanding
    Document Type 10-Q/A  
    Amendment Flag true  
    Document Period End Date Mar. 31, 2014  
    Document Fiscal Period Focus Q1  
    Document Fiscal Year Focus 2014  
    Amendment Description Previously Amended Financial Statements - The Company’s previously issued March 31, 2014 financial statements have been restated to remove deemed dividends which were accrued on its preferred shares and to recognize an increase in derivative expense due to adding several features to the valuation model used to measure the compound derivatives and changing from a Black-Scholes valuation model to a Monte Carlo valuation model. Additional paid in capital and accumulated deficit have been reduced by $8,464,000 to reflect the elimination of deemed dividends. Loss on derivative liabilities increased by $1,870,000 to $9,428,000 due to the change in the valuation model. The Company also contracted a valuation team to review the purchase price allocation of Biocontrol. As a result, in process research and development (IPR&D) was restated and a new intangible asset, patents, was recognized. For the Biocontrol acquisition, $493,000 of IPR&D was reclassified to patents. In addition, amortization expense for patents was recognized in the three month period ending March 31, 2014 and the three month period ending March 31, 2013. As a result of these corrections, the Company’s net loss for the period ending March 31, 2014 decreased by $726,000 to $11,303,000. The net loss per share decreased by $0.01 per share to $(0.06) per share which reflected both the increased net loss and the removal of the deemed dividends. Amended Financial Statements - The Company’s financial statements for the quarter ended March 31, 2014 have been further amended to: reclassify its Series B Redeemable Convertible Preferred Stock from Stockholders’ Equity (Deficit) to temporary equity due to the stock’s redemption features. This adjustment resulted in a reclassification at March 31, 2014 of $1,021,000 of Stockholders’ Equity (Deficit) to Series B Redeemable Convertible Preferred Stock, including the par value of these shares of $89,000 and the accretion of the stock’s redemption value of $932,000. recognize deferred revenue and deferred costs related to certain sub-licensing agreements. This change resulted in an increase in revenue of $104,000 and an increase in G&A expense of $33,000 in the first quarter of 2014. reclassify certain warrants issued in 2011 as liability instruments. These warrants were previously recorded in error as equity instruments. This adjustment resulted in the in the recording of a liability of $646,000 as of March 31, 2014. adjust goodwill for the acquisitions of Biocontrol and SPH for acquired deferred tax liabilities and errors in previous reporting. This change resulted in an increase of $1,685,000 in goodwill related to the Biocontrol acquisition and $1,548,000 in goodwill related to the acquisition of SPH. modify the key assumptions employed to value the compound derivative associated with the Series B Redeemable Convertible Preferred Stock and the Company’s 2013 warrants, under a Monte Carlo valuation model. The change in assumptions resulted in a $4,969,000 increase in the compound derivative liability and a $285,000 reduction in the warrant liability related to 2013 warrants. Loss on derivative liabilities declined by $655,000 in the first quarter of 2014. As a result of these corrections, the Company’s net loss attributable to common stockholders in the first quarter of 2014, as amended, was reduced by $408,000 to $11,621,000. The net loss per share attributable to common stockholders increased by $0.01 per share to $(0.06) per share. The Company’s net loss in the first quarter of 2013, as amended, was reduced by $26,000 to $1,645,000. The net loss per share in the attributable to common stockholders increased ($0.01) per share to $(0.03) per share.  
    XML 26 R18.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Stock Options and Warrants (Details Textual) (USD $)
    		 3 Months Ended 12 Months Ended
    Mar. 31, 2014
    Dec. 31, 2013
    Dec. 31, 2011
    Class of Warrant or Right [Line Items]      
    Share Price $ 0.58us-gaap_SharePrice $ 0.50us-gaap_SharePrice  
    Fair Value Adjustment of Warrants $ (3,149,000)us-gaap_FairValueAdjustmentOfWarrants $ 9,929,000us-gaap_FairValueAdjustmentOfWarrants  
    Derivative warrants liability 20,110,000aphb_DerivativeWarrantsLiability 16,871,000aphb_DerivativeWarrantsLiability  
    Biocontrol Limited [Member]      
    Class of Warrant or Right [Line Items]      
    Warrants Issued During the Period, Terms Of Expiration     December 2016
    Warrants Issued During the Period, Number of Warrants     1,355,164aphb_WarrantsIssuedDuringPeriodNumberOfWarrants
    / us-gaap_BusinessAcquisitionAxis
    = aphb_BiocontrolLimitedMember
    Warrants Issued During the Period, Exercise Price of Warrants     $ 0.46aphb_WarrantsIssuedDuringPeriodExercisePriceOfWarrants
    / us-gaap_BusinessAcquisitionAxis
    = aphb_BiocontrolLimitedMember
    Fair Value Adjustment of Warrants 87,000us-gaap_FairValueAdjustmentOfWarrants
    / us-gaap_BusinessAcquisitionAxis
    = aphb_BiocontrolLimitedMember    		    
    Derivative warrants liability 646,000aphb_DerivativeWarrantsLiability
    / us-gaap_BusinessAcquisitionAxis
    = aphb_BiocontrolLimitedMember    		    
    Convertible Notes Payable [Member]      
    Class of Warrant or Right [Line Items]      
    Warrants Issued During the Period, Terms Of Expiration   February through May 2018  
    Warrants Issued During the Period, Number of Warrants   7,030,387aphb_WarrantsIssuedDuringPeriodNumberOfWarrants
    / us-gaap_ShortTermDebtTypeAxis
    = us-gaap_ConvertibleNotesPayableMember    		  
    Warrants Issued During the Period, Exercise Price of Warrants   $ 0.14aphb_WarrantsIssuedDuringPeriodExercisePriceOfWarrants
    / us-gaap_ShortTermDebtTypeAxis
    = us-gaap_ConvertibleNotesPayableMember    		  
    Series B redeemable convertible preferred stock [Member]      
    Class of Warrant or Right [Line Items]      
    Warrants Issued During the Period, Number of Warrants   12,499,996aphb_WarrantsIssuedDuringPeriodNumberOfWarrants
    / us-gaap_StatementClassOfStockAxis
    = aphb_SeriesBRedeemableConvertiblePreferredStockMember    		  
    Warrants Issued During the Period, Exercise Price of Warrants   $ 0.14aphb_WarrantsIssuedDuringPeriodExercisePriceOfWarrants
    / us-gaap_StatementClassOfStockAxis
    = aphb_SeriesBRedeemableConvertiblePreferredStockMember    		  
    Common Stock [Member]      
    Class of Warrant or Right [Line Items]      
    Stock Issued During Period, Shares, New Issues Two   72,007,000aphb_StockIssuedDuringPeriodSharesNewIssues2
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		  
    Warrant [Member]      
    Class of Warrant or Right [Line Items]      
    Derivative warrants liability 19,460,000aphb_DerivativeWarrantsLiability
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_WarrantMember    		 16,311,000aphb_DerivativeWarrantsLiability
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_WarrantMember    		  
    Private Placement [Member] | Series B redeemable convertible preferred stock [Member]      
    Class of Warrant or Right [Line Items]      
    Warrants Issued During the Period, Terms Of Expiration   June 2018  
    Warrants Issued During the Period, Number of Warrants   30,040,195aphb_WarrantsIssuedDuringPeriodNumberOfWarrants
    / us-gaap_StatementClassOfStockAxis
    = aphb_SeriesBRedeemableConvertiblePreferredStockMember
    / us-gaap_SubsidiarySaleOfStockAxis
    = us-gaap_PrivatePlacementMember    		  
    Warrants Issued During the Period, Exercise Price of Warrants   $ 0.14aphb_WarrantsIssuedDuringPeriodExercisePriceOfWarrants
    / us-gaap_StatementClassOfStockAxis
    = aphb_SeriesBRedeemableConvertiblePreferredStockMember
    / us-gaap_SubsidiarySaleOfStockAxis
    = us-gaap_PrivatePlacementMember    		  
    Warrants Issuance Costs   $ 759,000aphb_WarrantsIssuanceCosts
    / us-gaap_StatementClassOfStockAxis
    = aphb_SeriesBRedeemableConvertiblePreferredStockMember
    / us-gaap_SubsidiarySaleOfStockAxis
    = us-gaap_PrivatePlacementMember    		  
    Private Placement [Member] | Common Stock [Member]      
    Class of Warrant or Right [Line Items]      
    Stock Issued During Period, Shares, New Issues Two   72,007,000aphb_StockIssuedDuringPeriodSharesNewIssues2
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember
    / us-gaap_SubsidiarySaleOfStockAxis
    = us-gaap_PrivatePlacementMember    		  
    Stock Issued During Period, Exercise Price, New Issues Two   $ 0.25aphb_StockIssuedDuringPeriodExercisePriceNewIssues2
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember
    / us-gaap_SubsidiarySaleOfStockAxis
    = us-gaap_PrivatePlacementMember    		  
    Warrants Issued During the Period, Terms Of Expiration   December 2018  
    XML 27 R4.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Consolidated Statements of Operations (USD $)
    		 3 Months Ended 12 Months Ended
    Mar. 31, 2014
    Mar. 31, 2013
    Dec. 31, 2013
    Revenue      
    Licensing revenue $ 104,000us-gaap_LicenseAndServicesRevenue $ 22,000us-gaap_LicenseAndServicesRevenue $ 81,000us-gaap_LicenseAndServicesRevenue
    Total revenue 104,000us-gaap_SalesRevenueServicesNet 22,000us-gaap_SalesRevenueServicesNet 81,000us-gaap_SalesRevenueServicesNet
    Operating expenses      
    Research and development 1,011,000us-gaap_ResearchAndDevelopmentExpense 641,000us-gaap_ResearchAndDevelopmentExpense 6,469,000us-gaap_ResearchAndDevelopmentExpense
    General and administrative 1,627,000us-gaap_GeneralAndAdministrativeExpense 714,000us-gaap_GeneralAndAdministrativeExpense 5,996,000us-gaap_GeneralAndAdministrativeExpense
    Total operating expenses 2,638,000us-gaap_OperatingExpenses 1,355,000us-gaap_OperatingExpenses 12,465,000us-gaap_OperatingExpenses
    Loss from operations (2,534,000)us-gaap_OperatingIncomeLoss (1,333,000)us-gaap_OperatingIncomeLoss (12,384,000)us-gaap_OperatingIncomeLoss
    Other income (expenses)      
    Gain (loss) on derivative liabilities (8,773,000)us-gaap_DerivativeGainLossOnDerivativeNet 87,000us-gaap_DerivativeGainLossOnDerivativeNet (49,330,000)us-gaap_DerivativeGainLossOnDerivativeNet
    Amortization of note discount 0us-gaap_AmortizationOfDebtDiscountPremium (303,000)us-gaap_AmortizationOfDebtDiscountPremium (2,636,000)us-gaap_AmortizationOfDebtDiscountPremium
    Interest expense, net 0us-gaap_InterestExpense (96,000)us-gaap_InterestExpense (233,000)us-gaap_InterestExpense
    Total other expense (8,773,000)us-gaap_OtherNonoperatingIncomeExpense (312,000)us-gaap_OtherNonoperatingIncomeExpense (52,199,000)us-gaap_OtherNonoperatingIncomeExpense
    Net loss (11,307,000)us-gaap_NetIncomeLoss (1,645,000)us-gaap_NetIncomeLoss (64,583,000)us-gaap_NetIncomeLoss
    Accretion of Series B redeemable convertible preferred stock (314,000)us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment 0us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment (618,000)us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment
    Net loss attributable to common stockholders $ (11,621,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (1,645,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (65,201,000)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic
    Per share information:      
    Net loss per share - basic & diluted (in dollars per share) $ (0.06)us-gaap_EarningsPerShareBasicAndDiluted $ (0.03)us-gaap_EarningsPerShareBasicAndDiluted $ (0.64)us-gaap_EarningsPerShareBasicAndDiluted
    Weighted average number of shares of common stock outstanding - basic & diluted (in shares) 182,535,562us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted 66,908,810us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted 101,201,753us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted
    XML 28 R12.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Nature of Business and Significant Accounting Policies (Policies)
    		 3 Months Ended
    Mar. 31, 2014
    Organization, Consolidation and Presentation of Financial Statements [Abstract]  
    Basis of Accounting, Policy [Policy Text Block]
    Basis of Presentation
     
    The interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries Biocontrol, Ampliphi d.o.o., and AmpliPhi Australia. All significant intercompany accounts and transactions have been eliminated. All numbers on the financial statements and disclosures have been rounded to the nearest 1,000 except share and per share data.
     
    The interim consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) necessary to present fairly our results of operations for the three months ended March 31, 2014 and 2013, our cash flows for the three months ended March 31, 2014 and 2013 and our financial position as of March 31, 2014 have been made. The results of operations for such interim periods are not necessarily indicative of the operating results to be expected for the full year.
     
    Certain information and disclosures normally included in the notes to the annual financial statements have been condensed or omitted from these interim consolidated financial statements. Accordingly, these interim consolidated financial statements should be read in conjunction with the 2013 audited consolidated financial statements and notes.
    Use of Estimates, Policy [Policy Text Block]
    Use of Estimates
     
    The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
    Cash and Cash Equivalents, Policy [Policy Text Block]
    Cash and Cash Equivalents
     
    The Company considers cash equivalents to be short-term investments that have a maturity at the time of purchase of three months or less, are readily convertible into cash and have an insignificant level of valuation risk attributable to potential changes in interest rates. Cash equivalents are recorded at cost, which approximates fair market value, and consist primarily of money market accounts.
    Trade and Other Accounts Receivable, Policy [Policy Text Block]
    Accounts Receivable
     
    Accounts receivable amounts are stated at their face amounts less any allowance. Provisions for doubtful accounts are estimated based on assessment of the probable collection from specific customer accounts and other known factors. If an account was determined to be uncollectible (payment has not been made in accordance with contract terms), it would be written off against the allowance. As of March 31, 2014 and December 31, 2013, management determined no allowance for doubtful accounts was required.
    Property, Plant and Equipment, Policy [Policy Text Block]
    Property and Equipment
     
    Property and equipment are recorded at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, generally three to seven years. 
    Prepaid Expenses And Other Current Assets , Policy [Policy Text Block]
    Prepaid Expenses and Other Current Assets
     
    Prepaid and other current assets as of March 31, 2014 and December 31, 2013 consist primarily of prepaid insurance and deposits.
    Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]
    Goodwill
     
    Costs of investments in purchased companies in excess of the underlying fair value of net assets at the date of acquisition are recorded as goodwill and assessed annually for impairment. If considered impaired, goodwill will be written down to fair value and a corresponding impairment loss recognized.
     
    During the year ended December 31, 2012, the rights to SPH Holdings Pty Ltd’s know-how and phage libraries were acquired by a business combination. At December 31, 2012, goodwill in the amount of $3,929,000 has been recorded. In management’s opinion, no goodwill has been impaired as of March 31, 2014 and December 31, 2013.
     
    During the year ended December 31, 2011, the rights to Biocontrol Limited’s patents and phage libraries were acquired by a business combination. At December 31, 2011, goodwill in the amount of $3,633,000 has been recorded. In management’s opinion, no goodwill has been impaired as of March 31, 2014 and December 31, 2013.
    Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]
    Patents
     
    Patents are recorded at cost and are amortized using the straight-line method over the estimated useful lives of the patents.
     
    During the year ended December 31, 2011, the rights to Biocontrol Limited’s patents were acquired by a business combination. At December 31, 2011, patents in the amount of $493,000 have been recorded. These patents are amortized over their useful life through December 2026.
    Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]
    Stock-Based Compensation
     
    The Company accounts for stock-based payments under the guidance of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 718, Stock Compensation, which requires measurement of compensation cost for all share-based payment awards at fair value on the date of grant and recognition of compensation cost over the requisite service period (typically the vesting period) for awards expected to vest.
    Warrant and Preferred Shares Conversion Feature Liability, Policy [Policy Text Block]
    Warrant and Preferred Shares Conversion Feature Liability
     
    The Company accounts for warrants and preferred shares conversion feature with anti-dilution (“down-round”) provisions under the guidance of ASC 815, Derivatives, and Hedging and Emerging Issue Task Force Statement 07-5: Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity’s Own Stock, which require the warrants and the preferred shares conversion feature to be recorded as a liability and adjusted to fair value in each reporting period.
    Derivatives, Policy [Policy Text Block]
    Fair Value of Financial Assets and Liabilities — Derivative Instruments
     
    The Company measures the fair value of financial assets and liabilities in accordance with GAAP, which defines fair value, establishes a framework for measuring fair value, and requires certain disclosures about fair value measurements.
     
    GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes as fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. GAAP describes three levels of inputs that may be used to measure fair value:
     
    Level 1 — quoted prices in active markets for identical assets or liabilities.
     
    Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable.
     
    Level 3 — inputs that are unobservable.
     
    The Company does not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, the Company has entered into certain financial instruments and contracts, such as convertible loan notes with detachable common stock warrants and the issuance of preferred stock with detachable common stock warrants with features that are either i) not afforded equity classification, ii) embody risks not clearly and closely related to host contracts, or iii) may be net-cash settled by the counterparty. These instruments are required to be carried as derivative liabilities, at fair value.
     
    The Company estimates fair values of these derivatives (and related embedded beneficial conversion features) utilizing Level 3 inputs. The Company uses the Monte Carlo valuation technique for derivatives as it embodies all of the requisite assumptions (including trading volatility, remaining term to maturity, market price, strike price, risk free rates) necessary to fair value these instruments.
     
    Estimating fair values of derivative financial instruments, including Level 3 instruments, require the use of significant and subjective inputs that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are volatile and sensitive to changes in our trading market price, the trading market price of various peer companies and other key assumptions. Since derivative financial instruments are initially and subsequently carried at fair value, our income will reflect this sensitivity of internal and external factors.
    Revenue Recognition, Policy [Policy Text Block]
    Revenue Recognition
     
    The Company generates revenue from technology licenses, collaborative research arrangements, and agreements to provide research and development services. Revenue under technology licenses typically consists of nonrefundable, up-front license fees, technology access fees and various other payments. The Company recognizes revenue associated with performance milestones as earned, typically based upon the achievement of the specific milestones defined in the applicable agreements.
     
    The Company recognizes revenue under research and development contracts as the related costs are incurred. When contracts include multiple elements, the Company follows ASC 605-25, Multiple Element Arrangements, which requires the Company to satisfy the following before revenue can be recognized:
     
     
    •
    The delivered items have value to the customer on a stand-alone basis;
     
     
    •
    Any undelivered items have objective and reliable evidence of fair value; and
     
     
    •
    Delivery or performance is probable and within the Company’s control for any delivered items that have a right of return.
     
    The Company classifies advance payments received in excess of amounts earned as deferred revenue.
     
    Based upon the terms specified in its collaboration agreements, the Company receives advance payments from some of its collaboration partners before the project has been performed. These payments are deferred and recognized as revenue when the costs are incurred.
    Research and Development Expense, Policy [Policy Text Block]
    In Process Research and Development
     
    In Process Research & Development (IPR&D) assets represent capitalized incomplete research projects that the Company acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The fair value of the research projects is recorded as intangible assets on the consolidated balance sheet rather than expensed regardless of whether these assets have an alternative future use. The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company will make a determination as to the then remaining useful life of the intangible asset and begin amortization. The Company tests its indefinite-lived intangibles, including IPR&D assets, for impairment at least quarterly. 
     
    During the year ended December 31, 2012, the rights to SPH Holdings Pty Ltd’s IPR&D were acquired by the business combination. At December 31, 2012, IPR&D in the amount of $5,161,000 has been recorded. In management’s opinion, this IPR&D has not been impaired as of March 31, 2014 and December 31, 2013.
     
    During the year ended December 31, 2011, the rights to Biocontrol - IPR&D and patents were acquired by the business combination. At December 31, 2011, IPR&D in the amount of $7,285,000 has been recorded. In management’s opinion, this IPR&D has not been impaired as of March 31, 2014 and December 31, 2013. 
     
    Research and development costs include salaries, costs of outside collaborators and outside services, royalty and license costs and allocated facility, occupancy and utility expenses. The Company expenses research and development costs as incurred.
    Earnings Per Share, Policy [Policy Text Block]
    Net Loss per Common Share
     
    Net loss per common share is based on net loss divided by the weighted average number of common shares outstanding during the period. For each fiscal year reported, the diluted net loss per share is the same as the basic net loss per share because all stock options, warrants, contingent shares, and Series B redeemable convertible preferred stock shares are antidilutive with respect to computing the net loss per share and therefore are excluded from the calculation of diluted net loss per share. The total number of shares that the Company excluded from the calculations of net loss per share were 148,692,651 shares for the three month period ending March 31, 2014, 20,000,000 shares for the three month period ending March 31, 2013, and 77,490,242 shares for the year ending December 31, 2013.
    New Accounting Pronouncements, Policy [Policy Text Block]
    Recent Accounting Pronouncements
     
    On February 5, 2013, the FASB issued ASU no. 2013-02 which adds new disclosure requirements for items reclassified out of accumulated other comprehensive income (AOCI). The ASU is intended to help entities improve the transparency of changes in other comprehensive income (OCI) and items reclassified out of AOCI in their financial statements. It does not amend any existing requirements for reporting net income or OCI in the financial statements. For public entities, the new disclosure requirements are effective for fiscal years, and interim periods within those years, beginning after December 15, 2012. For nonpublic entities, the ASU is effective for fiscal years beginning after December 15, 2013, and interim and annual periods thereafter. The Company elected to early adopt this standard which did not result in any changes to the consolidated financial statements.
    XML 29 R11.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Correction of Errors
    		 3 Months Ended
    Mar. 31, 2014
    Accounting Changes and Error Corrections [Abstract]  
    Accounting Changes and Error Corrections [Text Block]
    5. Correction of Errors
     
    The Company’s previously issued March 31, 2014 financial statements were restated to remove deemed dividends which were accrued on its preferred shares and to recognize an increase in derivative expense due to adding several features to the valuation model used to measure the compound derivatives and changing from a Black-Scholes valuation model to a Monte Carlo valuation model. Additional paid in capital and accumulated deficit were reduced by $8,464,000 to reflect the elimination of deemed dividends. Loss on derivative liabilities increased by $1,870,000 to $9,428,000 due to the change in the valuation model.
     
    The Company also contracted a valuation team to review the purchase price allocation of Biocontrol. As a result, in process research and development (IPR&D) was restated and a new intangible asset, patents, was recognized. For the Biocontrol acquisition, $493,000 of IPR&D was reclassified to patents. In addition, amortization expense for patents was recognized in the three month period ending March 31, 2014 and the three month period ending March 31, 2013.
     
    As a result of these corrections, the Company’s net loss for the period ending March 31, 2014 increased by $1,885,000 to $12,029,000. The net loss per share decreased by $0.03 per share to $(0.07) per share which reflected both the increased net loss and the removal of the deemed dividends. The Company’s net loss for the period ending March 31, 2013 increased $7,000 to $1,619,000. The net loss per share remained the same.
     
    Amended Financial Statements
     
    The Company’s financial statements for the quarter ended March 31, 2014 have been further amended to:
     
    ⋅
    reclassify its Series B Redeemable Convertible Preferred Stock from Stockholders’ Equity (Deficit) to temporary equity due to the stock’s redemption features. This adjustment resulted in a reclassification at March 31, 2014 of $1,021,000 of Stockholders’ Equity (Deficit) to Series B Redeemable Convertible Preferred Stock, including the par value of these shares of $89,000 and the accretion of the stock’s redemption value of $932,000.
    ⋅
    recognize deferred revenue and deferred costs related to certain sub-licensing agreements. This change resulted in an increase in revenue of $104,000 and an increase in G&A expense of $33,000 in the first quarter of 2014.
    ⋅
    reclassify certain warrants issued in 2011 as liability instruments. These warrants were previously recorded in error as equity instruments. This adjustment resulted in the in the recording of a liability of $646,000 as of March 31, 2014.
    ⋅
    adjust goodwill for the acquisitions of Biocontrol and SPH for acquired deferred tax liabilities and errors in previous reporting. This change resulted in an increase of $1,685,000 in goodwill related to the Biocontrol acquisition and $1,548,000 in goodwill related to the acquisition of SPH.
    ⋅
    modify the key assumptions employed to value the compound derivative associated with the Series B Redeemable Convertible Preferred Stock and the Company’s 2013 warrants, under a Monte Carlo valuation model. The change in assumptions resulted in a $4,969,000 increase in the compound derivative liability and a $285,000 reduction in the warrant liability related to 2013 warrants. Loss on derivative liabilities declined by $655,000 in the first quarter of 2014.
     
    As a result of these corrections, the Company’s net loss attributable to common stockholders in the first quarter of 2014, as amended, was reduced by $408,000 to $11,621,000. The net loss per share attributable to common stockholders increased by $(0.01) per share to $(0.06) per share. The Company’s net loss attributable to common stockholders in the first quarter of 2013, as amended, was reduced by $26,000 to $1,645,000. The net loss per share in the attributable to common stockholders increased by $(0.01) to $(0.03) per share.
    XML 30 R23.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Correction of Errors (Details Textual) (USD $)
    		 3 Months Ended 12 Months Ended
    Mar. 31, 2014
    Mar. 31, 2013
    Dec. 31, 2013
    Dec. 31, 2012
    Dec. 31, 2011
    Net loss $ 11,307,000us-gaap_NetIncomeLoss $ 1,645,000us-gaap_NetIncomeLoss $ 64,583,000us-gaap_NetIncomeLoss    
    Earnings Per Share, Basic and Diluted, Total $ (0.06)us-gaap_EarningsPerShareBasicAndDiluted $ (0.03)us-gaap_EarningsPerShareBasicAndDiluted $ (0.64)us-gaap_EarningsPerShareBasicAndDiluted    
    Temporary Equity, Par Value 1,021,000us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital   707,000us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital    
    Derivative warrants liability 20,110,000aphb_DerivativeWarrantsLiability   16,871,000aphb_DerivativeWarrantsLiability    
    Sales Revenue, Services, Net, Total 104,000us-gaap_SalesRevenueServicesNet 22,000us-gaap_SalesRevenueServicesNet 81,000us-gaap_SalesRevenueServicesNet    
    General and Administrative Expense, Total 1,627,000us-gaap_GeneralAndAdministrativeExpense 714,000us-gaap_GeneralAndAdministrativeExpense 5,996,000us-gaap_GeneralAndAdministrativeExpense    
    Goodwill 7,562,000us-gaap_Goodwill   7,562,000us-gaap_Goodwill    
    Net Loss Available to Common Stockholders 11,621,000us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic 1,645,000us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic 65,201,000us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic    
    Derivative [Member]          
    Derivative, Loss on Derivative 9,428,000us-gaap_DerivativeLossOnDerivative
    / us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis
    = us-gaap_DerivativeMember    		        
    SPH Holdings Pty Ltd [Member]          
    Goodwill       3,929,000us-gaap_Goodwill
    / us-gaap_BusinessAcquisitionAxis
    = aphb_SphHoldingsPtyLtdMember    		  
    Biocontrol Limited [Member]          
    Derivative warrants liability 646,000aphb_DerivativeWarrantsLiability
    / us-gaap_BusinessAcquisitionAxis
    = aphb_BiocontrolLimitedMember    		        
    Goodwill         3,633,000us-gaap_Goodwill
    / us-gaap_BusinessAcquisitionAxis
    = aphb_BiocontrolLimitedMember
    First Amendment [Member]          
    Net loss 12,029,000us-gaap_NetIncomeLoss
    / aphb_AmendmentAxis
    = aphb_FirstAmendmentMember    		 (1,619,000)us-gaap_NetIncomeLoss
    / aphb_AmendmentAxis
    = aphb_FirstAmendmentMember    		      
    Earnings Per Share, Basic and Diluted, Total $ 0.07us-gaap_EarningsPerShareBasicAndDiluted
    / aphb_AmendmentAxis
    = aphb_FirstAmendmentMember    		        
    Restatement Adjustment [Member]          
    Additional Paid In Capital And Accumulated Deficit 8,464,000aphb_AdditionalPaidInCapitalAndAccumulatedDeficit
    / us-gaap_StatementScenarioAxis
    = us-gaap_RestatementAdjustmentMember    		        
    Derivative, Loss on Derivative 1,870,000us-gaap_DerivativeLossOnDerivative
    / us-gaap_StatementScenarioAxis
    = us-gaap_RestatementAdjustmentMember    		        
    Net loss   26,000us-gaap_NetIncomeLoss
    / us-gaap_StatementScenarioAxis
    = us-gaap_RestatementAdjustmentMember    		      
    Earnings Per Share, Basic and Diluted, Total $ (0.01)us-gaap_EarningsPerShareBasicAndDiluted
    / us-gaap_StatementScenarioAxis
    = us-gaap_RestatementAdjustmentMember    		 $ (0.01)us-gaap_EarningsPerShareBasicAndDiluted
    / us-gaap_StatementScenarioAxis
    = us-gaap_RestatementAdjustmentMember    		      
    Research and Development in Process 493,000us-gaap_ResearchAndDevelopmentInProcess
    / us-gaap_StatementScenarioAxis
    = us-gaap_RestatementAdjustmentMember    		        
    Temporary Equity Accretion To Par Value 89,000aphb_TemporaryEquityAccretionToParValue
    / us-gaap_StatementScenarioAxis
    = us-gaap_RestatementAdjustmentMember    		        
    Temporary Equity, Accretion to Redemption Value 932,000us-gaap_TemporaryEquityAccretionToRedemptionValue
    / us-gaap_StatementScenarioAxis
    = us-gaap_RestatementAdjustmentMember    		        
    Derivative warrants liability 646,000aphb_DerivativeWarrantsLiability
    / us-gaap_StatementScenarioAxis
    = us-gaap_RestatementAdjustmentMember    		        
    Sales Revenue, Services, Net, Total 104,000us-gaap_SalesRevenueServicesNet
    / us-gaap_StatementScenarioAxis
    = us-gaap_RestatementAdjustmentMember    		        
    General and Administrative Expense, Total 33,000us-gaap_GeneralAndAdministrativeExpense
    / us-gaap_StatementScenarioAxis
    = us-gaap_RestatementAdjustmentMember    		        
    Series B Redeemable Convertible Preferred Stock 4,969,000aphb_IncreaseInCompoundDerivativeLiability
    / us-gaap_StatementScenarioAxis
    = us-gaap_RestatementAdjustmentMember    		        
    Decrease In Warrant Liability 285,000aphb_DecreaseInWarrantLiability
    / us-gaap_StatementScenarioAxis
    = us-gaap_RestatementAdjustmentMember    		        
    Loss On Derivative Liabilities Declined 655,000aphb_LossOnDerivativeLiabilitiesDeclined
    / us-gaap_StatementScenarioAxis
    = us-gaap_RestatementAdjustmentMember    		        
    Net Loss Available to Common Stockholders 408,000us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic
    / us-gaap_StatementScenarioAxis
    = us-gaap_RestatementAdjustmentMember    		        
    Restatement Adjustment [Member] | SPH Holdings Pty Ltd [Member]          
    Goodwill 1,548,000us-gaap_Goodwill
    / us-gaap_BusinessAcquisitionAxis
    = aphb_SphHoldingsPtyLtdMember
    / us-gaap_StatementScenarioAxis
    = us-gaap_RestatementAdjustmentMember    		        
    Restatement Adjustment [Member] | Biocontrol Limited [Member]          
    Goodwill 1,685,000us-gaap_Goodwill
    / us-gaap_BusinessAcquisitionAxis
    = aphb_BiocontrolLimitedMember
    / us-gaap_StatementScenarioAxis
    = us-gaap_RestatementAdjustmentMember    		        
    Restatement Adjustment [Member] | First Amendment [Member]          
    Net loss $ 1,885,000us-gaap_NetIncomeLoss
    / aphb_AmendmentAxis
    = aphb_FirstAmendmentMember
    / us-gaap_StatementScenarioAxis
    = us-gaap_RestatementAdjustmentMember    		 $ (7,000)us-gaap_NetIncomeLoss
    / aphb_AmendmentAxis
    = aphb_FirstAmendmentMember
    / us-gaap_StatementScenarioAxis
    = us-gaap_RestatementAdjustmentMember    		      
    Earnings Per Share, Basic and Diluted, Total $ 0.03us-gaap_EarningsPerShareBasicAndDiluted
    / aphb_AmendmentAxis
    = aphb_FirstAmendmentMember
    / us-gaap_StatementScenarioAxis
    = us-gaap_RestatementAdjustmentMember    		        
    XML 31 R19.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Stock-Based Compensation (Details) (USD $)
    		 3 Months Ended 12 Months Ended
    Mar. 31, 2014
    Mar. 31, 2013
    Dec. 31, 2013
    Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]      
    Allocated Share-based Compensation Expense $ 234,000us-gaap_AllocatedShareBasedCompensationExpense $ 154,000us-gaap_AllocatedShareBasedCompensationExpense $ 1,437,000us-gaap_AllocatedShareBasedCompensationExpense
    General and administrative expense [Member]      
    Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]      
    Allocated Share-based Compensation Expense 196,000us-gaap_AllocatedShareBasedCompensationExpense
    / us-gaap_IncomeStatementLocationAxis
    = us-gaap_GeneralAndAdministrativeExpenseMember    		 112,000us-gaap_AllocatedShareBasedCompensationExpense
    / us-gaap_IncomeStatementLocationAxis
    = us-gaap_GeneralAndAdministrativeExpenseMember    		 191,000us-gaap_AllocatedShareBasedCompensationExpense
    / us-gaap_IncomeStatementLocationAxis
    = us-gaap_GeneralAndAdministrativeExpenseMember
    Research and development expense [Member]      
    Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]      
    Allocated Share-based Compensation Expense $ 38,000us-gaap_AllocatedShareBasedCompensationExpense
    / us-gaap_IncomeStatementLocationAxis
    = us-gaap_ResearchAndDevelopmentExpenseMember    		 $ 42,000us-gaap_AllocatedShareBasedCompensationExpense
    / us-gaap_IncomeStatementLocationAxis
    = us-gaap_ResearchAndDevelopmentExpenseMember    		 $ 1,246,000us-gaap_AllocatedShareBasedCompensationExpense
    / us-gaap_IncomeStatementLocationAxis
    = us-gaap_ResearchAndDevelopmentExpenseMember
    XML 32 R15.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Nature of Business and Significant Accounting Policies (Details Textual) (USD $)
    		 3 Months Ended 12 Months Ended
    Mar. 31, 2014
    Mar. 31, 2013
    Dec. 31, 2013
    Dec. 31, 2011
    Dec. 31, 2012
    Significant Policies [Line Items]          
    Goodwill $ 7,562,000us-gaap_Goodwill   $ 7,562,000us-gaap_Goodwill    
    In process research and development 12,446,000aphb_InProcessResearchAndDevelopment   12,446,000aphb_InProcessResearchAndDevelopment    
    Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 148,692,651us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount 20,000,000us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount 77,490,242us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount    
    Property, Plant and Equipment, Estimated Useful Lives three to seven years        
    Patents [Member]          
    Significant Policies [Line Items]          
    Finite-Lived Intangible Assets, Net       493,000us-gaap_FiniteLivedIntangibleAssetsNet
    / us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
    = us-gaap_PatentsMember    		  
    SPH Holdings Pty Ltd [Member]          
    Significant Policies [Line Items]          
    Goodwill         3,929,000us-gaap_Goodwill
    / us-gaap_BusinessAcquisitionAxis
    = aphb_SphHoldingsPtyLtdMember
    In process research and development         5,161,000aphb_InProcessResearchAndDevelopment
    / us-gaap_BusinessAcquisitionAxis
    = aphb_SphHoldingsPtyLtdMember
    Goodwill, Impairment Loss 0us-gaap_GoodwillImpairmentLoss
    / us-gaap_BusinessAcquisitionAxis
    = aphb_SphHoldingsPtyLtdMember    		 0us-gaap_GoodwillImpairmentLoss
    / us-gaap_BusinessAcquisitionAxis
    = aphb_SphHoldingsPtyLtdMember    		      
    Biocontrol Limited [Member]          
    Significant Policies [Line Items]          
    Goodwill       3,633,000us-gaap_Goodwill
    / us-gaap_BusinessAcquisitionAxis
    = aphb_BiocontrolLimitedMember    		  
    In process research and development       7,285,000aphb_InProcessResearchAndDevelopment
    / us-gaap_BusinessAcquisitionAxis
    = aphb_BiocontrolLimitedMember    		  
    Goodwill, Impairment Loss $ 0us-gaap_GoodwillImpairmentLoss
    / us-gaap_BusinessAcquisitionAxis
    = aphb_BiocontrolLimitedMember    		 0us-gaap_GoodwillImpairmentLoss
    / us-gaap_BusinessAcquisitionAxis
    = aphb_BiocontrolLimitedMember    		      
    XML 33 R13.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Stock Options and Warrants (Tables)
    		 3 Months Ended
    Mar. 31, 2014
    Stockholders Equity Note [Abstract]  
    Schedule of Stockholders Equity Note, Warrants or Rights [Table Text Block]
    The following warrants were issued in 2013 using the Monte Carlo valuation method with the key inputs as follows:
     
     
     
    June 26, 2013
     
     
    July 15, 2013
     
     
    December 23, 2013
     
    Warrants Issued
     
     
    28,394,834
     
     
     
    1,645,361
     
     
     
    4,320,420
     
    Risk free interest rate
     
     
    0.0109
     
     
     
    0.0109
     
     
     
    0.0167
     
    Volatility
     
     
    160.94
    %
     
     
    163.08
    %
     
     
    155.24
    %
    Expected term
     
     
    5 years
     
     
     
    5 years
     
     
     
    5 years
     
    Exercise price
     
    $
    0.14
     
     
    $
    0.14
     
     
    $
    0.25
     
    XML 34 R14.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Stock-Based Compensation (Tables)
    		 3 Months Ended
    Mar. 31, 2014
    Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
    Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]
    Following is a summary of the amount included as stock-based compensation expense in the accompanying consolidated statements of operations and comprehensive loss:
     
     
     
    Three Months Ended March 31,
     
    Year Ended
     
     
     
    2014
    (Unaudited)
     
    2013
    (Unaudited)
     
    December 31,
    2013
     
    Stock options:
     
     
     
     
     
     
     
     
     
     
    General and administrative expense
     
    $
    196,000
     
    $
    112,000
     
    $
    191,000
     
    Research and development expense
     
     
    38,000
     
     
    42,000
     
     
    1,246,000
     
    Total stock-based compensation expense
     
    $
    234,000
     
    $
    154,000
     
    $
    1,437,000
     
    Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]
    The following table summarizes Option activity:
      
     
     
    Shares
     
    Weighted Average Exercise
    Price
     
    Average Remaining
    Contractual Term
    (Years)
     
    Intrinsic Value
     
    Outstanding at December 31, 2013
     
     
    25,721,000
     
    $
    0.19
     
     
    9.15
     
    $
    6,451,441
     
    Granted
     
     
    —
     
     
    —
     
     
     
     
     
     
     
    Exercised
     
     
    —
     
     
    —
     
     
     
     
     
     
     
    Forfeited
     
     
    —
     
     
    —
     
     
     
     
     
     
     
    Expired
     
     
    —
     
     
    —
     
     
     
     
     
     
     
    Outstanding at March 31, 2014
     
     
    25,721,000
     
    $
    0.19
     
     
    8.88
     
    $
    8,416,233
     
    Exercisable at March 31, 2014
     
     
    10,089,662
     
    $
    0.19
     
     
    8.89
     
    $
    4,049,376
     
    Schedule of Common Stock, Capital Shares Reserved for Future Issuance [Table Text Block]
    As of March 31, 2013, the Company had reserved shares of its common stock for future issuance as follows:
     
     
     
    Shares Reserved
     
    Stock options outstanding
     
     
    25,721,000
     
    Available for future grants under the Stock Incentive Plan
     
     
    40,000,000
     
    Warrants
     
     
    38,425,745
     
    Total Shares reserved
     
     
    104,146,745
     
    XML 35 R16.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Preferred Shares (Details Textual) (USD $)
    		 0 Months Ended 1 Months Ended 3 Months Ended 12 Months Ended
    Oct. 17, 2013
    Jul. 25, 2013
    Mar. 31, 2014
    Mar. 31, 2013
    Dec. 31, 2013
    Class of Stock [Line Items]          
    Debt Instrument, Convertible, Beneficial Conversion Feature     $ 11,882,000us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature    
    Derivative Preferred Shares Conversion Liability     46,325,000aphb_DerivativePreferredSharesConversionLiability   40,791,000aphb_DerivativePreferredSharesConversionLiability
    Fair Value Adjustment of Warrants     (3,149,000)us-gaap_FairValueAdjustmentOfWarrants   9,929,000us-gaap_FairValueAdjustmentOfWarrants
    Reclassification From Derivative Liability To Equity 97,000aphb_ReclassificationFromDerivativeLiabilityToEquity       6,518,000aphb_ReclassificationFromDerivativeLiabilityToEquity
    Derivative, Gain (Loss) on Derivative, Net 5,000us-gaap_DerivativeGainLossOnDerivativeNet 5,035,000us-gaap_DerivativeGainLossOnDerivativeNet (8,773,000)us-gaap_DerivativeGainLossOnDerivativeNet 87,000us-gaap_DerivativeGainLossOnDerivativeNet (49,330,000)us-gaap_DerivativeGainLossOnDerivativeNet
    Warrant [Member]          
    Class of Stock [Line Items]          
    Derivative Liability         1,886,000us-gaap_DerivativeLiabilities
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_WarrantMember
    Preferred Stock [Member]          
    Class of Stock [Line Items]          
    Derivative Liability         5,064,000us-gaap_DerivativeLiabilities
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_PreferredStockMember
    Conversion of Stock, Shares Converted 23,227us-gaap_ConversionOfStockSharesConverted1
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_PreferredStockMember    		       1,132,875us-gaap_ConversionOfStockSharesConverted1
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_PreferredStockMember
    Common Stock [Member]          
    Class of Stock [Line Items]          
    Stock Issued During Period, Shares, New Issues One         0aphb_StockIssuedDuringPeriodSharesNewIssues1
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember
    Conversion of Stock, Shares Issued 232,270us-gaap_ConversionOfStockSharesIssued1
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		       11,328,750us-gaap_ConversionOfStockSharesIssued1
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember
    Convertible Notes Payable One [Member]          
    Class of Stock [Line Items]          
    Debt Conversion, Original Debt, Amount         5,491,000us-gaap_DebtConversionOriginalDebtAmount1
    / us-gaap_ShortTermDebtTypeAxis
    = aphb_ConvertibleNotesPayableOneMember
    Warrants Issued During Period Number Of Warrants One         4,999,999aphb_WarrantsIssuedDuringPeriodNumberOfWarrants1
    / us-gaap_ShortTermDebtTypeAxis
    = aphb_ConvertibleNotesPayableOneMember
    Warrants Issued During Period Exercise Price Of Warrants One         $ 0.14aphb_WarrantsIssuedDuringPeriodExercisePriceOfWarrants1
    / us-gaap_ShortTermDebtTypeAxis
    = aphb_ConvertibleNotesPayableOneMember
    Fair Value Adjustment of Warrants         759,000us-gaap_FairValueAdjustmentOfWarrants
    / us-gaap_ShortTermDebtTypeAxis
    = aphb_ConvertibleNotesPayableOneMember
    Payments of Stock Issuance Costs         350,000us-gaap_PaymentsOfStockIssuanceCosts
    / us-gaap_ShortTermDebtTypeAxis
    = aphb_ConvertibleNotesPayableOneMember
    Convertible Notes Payable One [Member] | Warrant [Member]          
    Class of Stock [Line Items]          
    Derivative Liability         1,644,000us-gaap_DerivativeLiabilities
    / us-gaap_ShortTermDebtTypeAxis
    = aphb_ConvertibleNotesPayableOneMember
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_WarrantMember
    Convertible Notes Payable One [Member] | Preferred Stock [Member]          
    Class of Stock [Line Items]          
    Derivative Liability         3,804,000us-gaap_DerivativeLiabilities
    / us-gaap_ShortTermDebtTypeAxis
    = aphb_ConvertibleNotesPayableOneMember
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_PreferredStockMember
    Convertible Notes Payable Two [Member]          
    Class of Stock [Line Items]          
    Warrants Issued During the Period, Number of Warrants         1,645,361aphb_WarrantsIssuedDuringPeriodNumberOfWarrants
    / us-gaap_ShortTermDebtTypeAxis
    = aphb_ConvertibleNotesPayableTwoMember
    Warrants Issued During the Period, Exercise Price of Warrants         $ 0.14aphb_WarrantsIssuedDuringPeriodExercisePriceOfWarrants
    / us-gaap_ShortTermDebtTypeAxis
    = aphb_ConvertibleNotesPayableTwoMember
    Debt Conversion, Original Debt, Amount         829,277us-gaap_DebtConversionOriginalDebtAmount1
    / us-gaap_ShortTermDebtTypeAxis
    = aphb_ConvertibleNotesPayableTwoMember
    Convertible Notes Payable Two [Member] | Warrant [Member]          
    Class of Stock [Line Items]          
    Derivative Liability         674,000us-gaap_DerivativeLiabilities
    / us-gaap_ShortTermDebtTypeAxis
    = aphb_ConvertibleNotesPayableTwoMember
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_WarrantMember
    Convertible Notes Payable Two [Member] | Preferred Stock [Member]          
    Class of Stock [Line Items]          
    Derivative Liability         155,000us-gaap_DerivativeLiabilities
    / us-gaap_ShortTermDebtTypeAxis
    = aphb_ConvertibleNotesPayableTwoMember
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_PreferredStockMember
    Series B redeemable convertible preferred stock [Member]          
    Class of Stock [Line Items]          
    Preferred Stock, Shares Authorized         10,016,080us-gaap_PreferredStockSharesAuthorized
    / us-gaap_StatementClassOfStockAxis
    = aphb_SeriesBRedeemableConvertiblePreferredStockMember
    Preferred Stock, Initial Stated Value Per Share         $ 1.40aphb_PreferredStockInitialStatedValuePerShare
    / us-gaap_StatementClassOfStockAxis
    = aphb_SeriesBRedeemableConvertiblePreferredStockMember
    Preferred Stock, Par or Stated Value Per Share         $ 0.01us-gaap_PreferredStockParOrStatedValuePerShare
    / us-gaap_StatementClassOfStockAxis
    = aphb_SeriesBRedeemableConvertiblePreferredStockMember
    Debt Instrument, Convertible, Number of Equity Instruments         10us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments
    / us-gaap_StatementClassOfStockAxis
    = aphb_SeriesBRedeemableConvertiblePreferredStockMember
    Preferred Stock, Dividend Rate, Percentage         10.00%us-gaap_PreferredStockDividendRatePercentage
    / us-gaap_StatementClassOfStockAxis
    = aphb_SeriesBRedeemableConvertiblePreferredStockMember
    Debt Instrument, Convertible, If-initial public offering proceeds meets Least amount         7,000,000aphb_DebtInstrumentConvertibleIfinitialPublicOfferingProceedsMeetsLeastAmount
    / us-gaap_StatementClassOfStockAxis
    = aphb_SeriesBRedeemableConvertiblePreferredStockMember
    Stock Issued During Period, Shares, New Issues One         4,999,999aphb_StockIssuedDuringPeriodSharesNewIssues1
    / us-gaap_StatementClassOfStockAxis
    = aphb_SeriesBRedeemableConvertiblePreferredStockMember
    Warrants Issued During the Period, Number of Warrants         12,499,996aphb_WarrantsIssuedDuringPeriodNumberOfWarrants
    / us-gaap_StatementClassOfStockAxis
    = aphb_SeriesBRedeemableConvertiblePreferredStockMember
    Warrants Issued During the Period, Exercise Price of Warrants         $ 0.14aphb_WarrantsIssuedDuringPeriodExercisePriceOfWarrants
    / us-gaap_StatementClassOfStockAxis
    = aphb_SeriesBRedeemableConvertiblePreferredStockMember
    Warrants Issued During the Period, Value of Warrants         $ 7,000,000aphb_WarrantsIssuedDuringPeriodValueOfWarrants
    / us-gaap_StatementClassOfStockAxis
    = aphb_SeriesBRedeemableConvertiblePreferredStockMember
    Series B redeemable convertible preferred stock [Member] | Convertible Notes Payable One [Member]          
    Class of Stock [Line Items]          
    Warrants Issued During the Period, Number of Warrants         10,894,839aphb_WarrantsIssuedDuringPeriodNumberOfWarrants
    / us-gaap_ShortTermDebtTypeAxis
    = aphb_ConvertibleNotesPayableOneMember
    / us-gaap_StatementClassOfStockAxis
    = aphb_SeriesBRedeemableConvertiblePreferredStockMember
    Warrants Issued During the Period, Exercise Price of Warrants         $ 0.14aphb_WarrantsIssuedDuringPeriodExercisePriceOfWarrants
    / us-gaap_ShortTermDebtTypeAxis
    = aphb_ConvertibleNotesPayableOneMember
    / us-gaap_StatementClassOfStockAxis
    = aphb_SeriesBRedeemableConvertiblePreferredStockMember
    Debt Conversion, Converted Instrument, Shares Issued         4,357,936us-gaap_DebtConversionConvertedInstrumentSharesIssued1
    / us-gaap_ShortTermDebtTypeAxis
    = aphb_ConvertibleNotesPayableOneMember
    / us-gaap_StatementClassOfStockAxis
    = aphb_SeriesBRedeemableConvertiblePreferredStockMember
    Series B redeemable convertible preferred stock [Member] | Convertible Notes Payable Two [Member]          
    Class of Stock [Line Items]          
    Debt Conversion, Converted Instrument, Shares Issued         658,145us-gaap_DebtConversionConvertedInstrumentSharesIssued1
    / us-gaap_ShortTermDebtTypeAxis
    = aphb_ConvertibleNotesPayableTwoMember
    / us-gaap_StatementClassOfStockAxis
    = aphb_SeriesBRedeemableConvertiblePreferredStockMember
    XML 36 R21.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Stock-Based Compensation (Details 2) (Employee Stock Option [Member])
    Mar. 31, 2014
    Dec. 31, 2013
    Employee Stock Option [Member]
    		    
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
    Stock options outstanding 25,721,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_EmployeeStockOptionMember    		 25,721,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_EmployeeStockOptionMember
    Available for future grants under the Stock Incentive Plan 40,000,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_EmployeeStockOptionMember    		  
    Warrants 38,425,745us-gaap_ClassOfWarrantOrRightOutstanding
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_EmployeeStockOptionMember    		  
    Total Shares reserved 104,146,745us-gaap_CommonStockCapitalSharesReservedForFutureIssuance
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_EmployeeStockOptionMember    		  
    XML 37 R5.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (USD $)
    Total
    Common Stock [Member]
    Additional Paid-in Capital [Member]
    Retained Earnings [Member]
    Redeemable Convertible Preferred Stock Series B [Member]
    Balances at Dec. 31, 2012 $ 12,943,000us-gaap_StockholdersEquity $ 669,000us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 $ 332,806,000us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 $ (320,532,000)us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 $ 0us-gaap_StockholdersEquity
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_RedeemableConvertiblePreferredStockMember
    Balances (in shares) at Dec. 31, 2012   66,908,810us-gaap_SharesOutstanding
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		     0us-gaap_SharesOutstanding
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_RedeemableConvertiblePreferredStockMember
    Net loss (64,583,000)us-gaap_NetIncomeLoss 0us-gaap_NetIncomeLoss
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 0us-gaap_NetIncomeLoss
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 (64,583,000)us-gaap_NetIncomeLoss
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 0us-gaap_NetIncomeLoss
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_RedeemableConvertiblePreferredStockMember
    Stock-based compensation 1,437,000us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue 0us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 1,437,000us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 0us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 0us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_RedeemableConvertiblePreferredStockMember
    Beneficial conversion feature and warrants associated with issuance of convertible loan notes 2,635,000us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature 0us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 2,635,000us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 0us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 0us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_RedeemableConvertiblePreferredStockMember
    Shares issued for Intrexon 3,000,000us-gaap_StockIssuedDuringPeriodValueNewIssues 240,000us-gaap_StockIssuedDuringPeriodValueNewIssues
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 2,760,000us-gaap_StockIssuedDuringPeriodValueNewIssues
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 0us-gaap_StockIssuedDuringPeriodValueNewIssues
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 0us-gaap_StockIssuedDuringPeriodValueNewIssues
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_RedeemableConvertiblePreferredStockMember
    Shares issued for Intrexon (in shares)   24,000,000us-gaap_StockIssuedDuringPeriodSharesNewIssues
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		     0us-gaap_StockIssuedDuringPeriodSharesNewIssues
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_RedeemableConvertiblePreferredStockMember
    Accretion of Series B convertible preferred stock to its redemption value (618,000)us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment 0us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 (618,000)us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 0us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 618,000us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_RedeemableConvertiblePreferredStockMember
    Issuance of preferred stock from conversion of convertible loan notes 0us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities 0us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 0us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 0us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 50,000us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_RedeemableConvertiblePreferredStockMember
    Issuance of preferred stock from conversion of convertible loan notes (in shares)   0us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		     5,016,081us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_RedeemableConvertiblePreferredStockMember
    Issuance of preferred stock 0aphb_StockIssuedDuringPeriodValueNewIssues1 0aphb_StockIssuedDuringPeriodValueNewIssues1
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 0aphb_StockIssuedDuringPeriodValueNewIssues1
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 0aphb_StockIssuedDuringPeriodValueNewIssues1
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 50,000aphb_StockIssuedDuringPeriodValueNewIssues1
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_RedeemableConvertiblePreferredStockMember
    Issuance of preferred stock (in shares)   0aphb_StockIssuedDuringPeriodSharesNewIssues1
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		     4,999,999aphb_StockIssuedDuringPeriodSharesNewIssues1
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_RedeemableConvertiblePreferredStockMember
    Preferred shares converted to common stock 7,084,000aphb_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities1 115,000aphb_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities1
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 6,969,000aphb_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities1
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 0aphb_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities1
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 (11,000)aphb_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities1
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_RedeemableConvertiblePreferredStockMember
    Preferred shares converted to common stock (in shares)   11,561,020aphb_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities1
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		     (1,156,102)aphb_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities1
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_RedeemableConvertiblePreferredStockMember
    Stock options exercised 13,000us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised 1,000us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 12,000us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 0us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 0us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_RedeemableConvertiblePreferredStockMember
    Stock options exercised (in shares)   61,018us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		     0us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_RedeemableConvertiblePreferredStockMember
    Shares released from escrow 0aphb_StockIssuedDuringPeriodValueSharesReleasedFromEscrow 80,000aphb_StockIssuedDuringPeriodValueSharesReleasedFromEscrow
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 (80,000)aphb_StockIssuedDuringPeriodValueSharesReleasedFromEscrow
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 0aphb_StockIssuedDuringPeriodValueSharesReleasedFromEscrow
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 0aphb_StockIssuedDuringPeriodValueSharesReleasedFromEscrow
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_RedeemableConvertiblePreferredStockMember
    Shares released from escrow (in shares)   8,000,000aphb_StockIssuedDuringPeriodSharesSharesReleasedFromEscrow
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		     0aphb_StockIssuedDuringPeriodSharesSharesReleasedFromEscrow
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_RedeemableConvertiblePreferredStockMember
    Issuance of common stock for December financing 15,464,000aphb_StockIssuedDuringPeriodValueNewIssues2 720,000aphb_StockIssuedDuringPeriodValueNewIssues2
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 14,744,000aphb_StockIssuedDuringPeriodValueNewIssues2
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 0aphb_StockIssuedDuringPeriodValueNewIssues2
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 0aphb_StockIssuedDuringPeriodValueNewIssues2
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_RedeemableConvertiblePreferredStockMember
    Issuance of common stock for December financing (in shares)   72,007,000aphb_StockIssuedDuringPeriodSharesNewIssues2
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		     0aphb_StockIssuedDuringPeriodSharesNewIssues2
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_RedeemableConvertiblePreferredStockMember
    Escheat shares 0us-gaap_StockRedeemedOrCalledDuringPeriodValue 0us-gaap_StockRedeemedOrCalledDuringPeriodValue
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 0us-gaap_StockRedeemedOrCalledDuringPeriodValue
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 0us-gaap_StockRedeemedOrCalledDuringPeriodValue
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 0us-gaap_StockRedeemedOrCalledDuringPeriodValue
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_RedeemableConvertiblePreferredStockMember
    Escheat shares (in shares)   (2,286)us-gaap_StockRedeemedOrCalledDuringPeriodShares
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		     0us-gaap_StockRedeemedOrCalledDuringPeriodShares
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_RedeemableConvertiblePreferredStockMember
    Balances at Dec. 31, 2013 (22,625,000)us-gaap_StockholdersEquity 1,825,000us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 360,665,000us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 (385,115,000)us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 707,000us-gaap_StockholdersEquity
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_RedeemableConvertiblePreferredStockMember
    Balances (in shares) at Dec. 31, 2013   182,535,562us-gaap_SharesOutstanding
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		     8,859,978us-gaap_SharesOutstanding
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_RedeemableConvertiblePreferredStockMember
    Net loss (11,307,000)us-gaap_NetIncomeLoss 0us-gaap_NetIncomeLoss
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 0us-gaap_NetIncomeLoss
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 (11,307,000)us-gaap_NetIncomeLoss
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 0us-gaap_NetIncomeLoss
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_RedeemableConvertiblePreferredStockMember
    Stock-based compensation 234,000us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue 0us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 234,000us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 0us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 0us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_RedeemableConvertiblePreferredStockMember
    Accretion of Series B convertible preferred stock to its redemption value (314,000)us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment 0us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 (314,000)us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 0us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 314,000us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_RedeemableConvertiblePreferredStockMember
    Balances at Mar. 31, 2014 $ (34,012,000)us-gaap_StockholdersEquity $ 1,825,000us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		 $ 360,585,000us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_AdditionalPaidInCapitalMember    		 $ (396,422,000)us-gaap_StockholdersEquity
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_RetainedEarningsMember    		 $ 1,021,000us-gaap_StockholdersEquity
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_RedeemableConvertiblePreferredStockMember
    Balances (in shares) at Mar. 31, 2014   182,535,562us-gaap_SharesOutstanding
    / us-gaap_StatementEquityComponentsAxis
    = us-gaap_CommonStockMember    		     8,859,978us-gaap_SharesOutstanding
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_RedeemableConvertiblePreferredStockMember
    XML 38 R10.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Stock-Based Compensation
    		 3 Months Ended
    Mar. 31, 2014
    Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
    Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
    4. Stock-Based Compensation
     
    The Company’s Stock Incentive Plan provides for the issuance of long-term incentive awards, or Awards, in the form of non-qualified and incentive stock options, or Options, stock appreciation rights, stock grants and restricted stock units. The awards may be granted by the Company’s Board of Directors to its employees, directors and officers and to consultants, agents, advisors and independent contractors who provide services to the Company. The exercise price for Options must not be less than the fair market value of the underlying shares on the date of grant. Options expire no later than ten years from the date of grant and generally vest and become exercisable over a four-year period following the date of grant. Every non-employee member of the Company’s Board of Directors receives an annual non-qualified Option or restricted stock unit grant. Upon the exercise of Options, the Company issues the resulting shares from shares reserved for issuance under the Company’s Incentive Plan.
     
    Under ASC 718 Stock Compensation, the Company is required to expense the fair value of share-based payments granted over the vesting period. The Company values Awards granted at their grant date fair value in accordance with the provisions of ASC 718 and recognizes stock-based compensation expense on a straight-line basis over the service period of each award.
     
    Stock-based compensation expense is reduced by an estimated forfeiture rate derived from historical employee termination behavior. If the actual number of forfeitures differs from the Company’s estimates, the Company may record adjustments to increase or decrease compensation expense in future periods. There were no significant adjustments related to changes in the Company’s estimates for the three months-ended March 31, 2014 and year ended December 31, 2013.
     
    Following is a summary of the amount included as stock-based compensation expense in the accompanying consolidated statements of operations and comprehensive loss:
     
     
     
    Three Months Ended March 31,
     
    Year Ended
     
     
     
    2014
    (Unaudited)
     
    2013
    (Unaudited)
     
    December 31,
    2013
     
    Stock options:
     
     
     
     
     
     
     
     
     
     
    General and administrative expense
     
    $
    196,000
     
    $
    112,000
     
    $
    191,000
     
    Research and development expense
     
     
    38,000
     
     
    42,000
     
     
    1,246,000
     
    Total stock-based compensation expense
     
    $
    234,000
     
    $
    154,000
     
    $
    1,437,000
     
     
    The following table summarizes Option activity:
      
     
     
    Shares
     
    Weighted Average Exercise
    Price
     
    Average Remaining
    Contractual Term
    (Years)
     
    Intrinsic Value
     
    Outstanding at December 31, 2013
     
     
    25,721,000
     
    $
    0.19
     
     
    9.15
     
    $
    6,451,441
     
    Granted
     
     
    —
     
     
    —
     
     
     
     
     
     
     
    Exercised
     
     
    —
     
     
    —
     
     
     
     
     
     
     
    Forfeited
     
     
    —
     
     
    —
     
     
     
     
     
     
     
    Expired
     
     
    —
     
     
    —
     
     
     
     
     
     
     
    Outstanding at March 31, 2014
     
     
    25,721,000
     
    $
    0.19
     
     
    8.88
     
    $
    8,416,233
     
    Exercisable at March 31, 2014
     
     
    10,089,662
     
    $
    0.19
     
     
    8.89
     
    $
    4,049,376
     
     
    The aggregate intrinsic value is determined using the closing price of the Company’s common stock of $0.58 on March 31, 2014.
     
    As of March 31, 2014, the Company had unrecognized compensation cost related to unvested Options of approximately $2,072,890 net of estimated forfeitures, which the Company expects to recognize over a weighted average period of approximately two and a half years
     
    As of March 31, 2013, the Company had reserved shares of its common stock for future issuance as follows:
     
     
     
    Shares Reserved
     
    Stock options outstanding
     
     
    25,721,000
     
    Available for future grants under the Stock Incentive Plan
     
     
    40,000,000
     
    Warrants
     
     
    38,425,745
     
    Total Shares reserved
     
     
    104,146,745
     
    XML 39 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.1.9 Html 88 189 1 false 23 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.ampliphibio.com/role/DocumentAndEntityInformation Document And Entity Information true false R2.htm 102 - Statement - Consolidated Balance Sheets Sheet http://www.ampliphibio.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets false false R3.htm 103 - Statement - Consolidated Balance Sheets [Parenthetical] Sheet http://www.ampliphibio.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets [Parenthetical] false false R4.htm 104 - Statement - Consolidated Statements of Operations Sheet http://www.ampliphibio.com/role/ConsolidatedStatementsOfOperations Consolidated Statements of Operations false false R5.htm 105 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) Sheet http://www.ampliphibio.com/role/ConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) false false R6.htm 106 - Statement - Consolidated Statement of Cash Flows Sheet http://www.ampliphibio.com/role/ConsolidatedStatementOfCashFlows Consolidated Statement of Cash Flows false false R7.htm 107 - Disclosure - Nature of Business and Significant Accounting Policies Sheet http://www.ampliphibio.com/role/NatureOfBusinessAndSignificantAccountingPolicies Nature of Business and Significant Accounting Policies false false R8.htm 108 - Disclosure - Preferred Shares Sheet http://www.ampliphibio.com/role/PreferredShares Preferred Shares false false R9.htm 109 - Disclosure - Stock Options and Warrants Sheet http://www.ampliphibio.com/role/StockOptionsAndWarrants Stock Options and Warrants false false R10.htm 110 - Disclosure - Stock-Based Compensation Sheet http://www.ampliphibio.com/role/StockbasedCompensation Stock-Based Compensation false false R11.htm 111 - Disclosure - Correction of Errors Sheet http://www.ampliphibio.com/role/CorrectionOfErrors Correction of Errors false false R12.htm 112 - Disclosure - Nature of Business and Significant Accounting Policies (Policies) Sheet http://www.ampliphibio.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies Nature of Business and Significant Accounting Policies (Policies) false false R13.htm 113 - Disclosure - Stock Options and Warrants (Tables) Sheet http://www.ampliphibio.com/role/StockOptionsAndWarrantsTables Stock Options and Warrants (Tables) false false R14.htm 114 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.ampliphibio.com/role/StockbasedCompensationTables Stock-Based Compensation (Tables) false false R15.htm 115 - Disclosure - Nature of Business and Significant Accounting Policies (Details Textual) Sheet http://www.ampliphibio.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsTextual Nature of Business and Significant Accounting Policies (Details Textual) false false R16.htm 116 - Disclosure - Preferred Shares (Details Textual) Sheet http://www.ampliphibio.com/role/PreferredSharesDetailsTextual Preferred Shares (Details Textual) false false R17.htm 117 - Disclosure - Stock Options and Warrants (Details) Sheet http://www.ampliphibio.com/role/StockOptionsAndWarrantsDetails Stock Options and Warrants (Details) false false R18.htm 118 - Disclosure - Stock Options and Warrants (Details Textual) Sheet http://www.ampliphibio.com/role/StockOptionsAndWarrantsDetailsTextual Stock Options and Warrants (Details Textual) false false R19.htm 119 - Disclosure - Stock-Based Compensation (Details) Sheet http://www.ampliphibio.com/role/StockbasedCompensationDetails Stock-Based Compensation (Details) false false R20.htm 120 - Disclosure - Stock-Based Compensation (Details 1) Sheet http://www.ampliphibio.com/role/StockbasedCompensationDetails1 Stock-Based Compensation (Details 1) false false R21.htm 121 - Disclosure - Stock-Based Compensation (Details 2) Sheet http://www.ampliphibio.com/role/StockbasedCompensationDetails2 Stock-Based Compensation (Details 2) false false R22.htm 122 - Disclosure - Stock-Based Compensation (Details Textual) Sheet http://www.ampliphibio.com/role/StockbasedCompensationDetailsTextual Stock-Based Compensation (Details Textual) false false R23.htm 123 - Disclosure - Correction of Errors (Details Textual) Sheet http://www.ampliphibio.com/role/CorrectionOfErrorsDetailsTextual Correction of Errors (Details Textual) false false All Reports Book All Reports Columns in Cash Flows statement 'Consolidated Statement of Cash Flows (USD $)' have maximum duration 364 days and at least 25 values. Shorter duration columns must have at least one fourth (6) as many values. Column '7/1/2013 - 7/25/2013' is shorter (24 days) and has only 1 values, so it is being removed. Columns in Cash Flows statement 'Consolidated Statement of Cash Flows (USD $)' have maximum duration 364 days and at least 25 values. Shorter duration columns must have at least one fourth (6) as many values. Column '10/2/2013 - 10/17/2013' is shorter (15 days) and has only 1 values, so it is being removed. Process Flow-Through: 102 - Statement - Consolidated Balance Sheets Process Flow-Through: Removing column 'Mar. 31, 2013' Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: 103 - Statement - Consolidated Balance Sheets [Parenthetical] Process Flow-Through: 104 - Statement - Consolidated Statements of Operations Process Flow-Through: Removing column '0 Months Ended Oct. 17, 2013' Process Flow-Through: Removing column '1 Months Ended Jul. 25, 2013' Process Flow-Through: 106 - Statement - Consolidated Statement of Cash Flows aphb-20140331.xml aphb-20140331.xsd aphb-20140331_cal.xml aphb-20140331_def.xml aphb-20140331_lab.xml aphb-20140331_pre.xml true true XML 40 R20.htm IDEA: XBRL DOCUMENT v2.4.1.9
    Stock-Based Compensation (Details 1) (Employee Stock Option [Member], USD $)
    		 3 Months Ended 12 Months Ended
    Mar. 31, 2014
    Dec. 31, 2013
    Employee Stock Option [Member]
    		    
    Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
    Shares, Outstanding at December 31, 2013 25,721,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_EmployeeStockOptionMember    		  
    Shares, Granted 0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_EmployeeStockOptionMember    		  
    Shares, Exercised 0us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_EmployeeStockOptionMember    		  
    Shares, Forfeited 0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_EmployeeStockOptionMember    		  
    Shares, Expired 0us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_EmployeeStockOptionMember    		  
    Shares, Outstanding at March 31, 2014 25,721,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_EmployeeStockOptionMember    		 25,721,000us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_EmployeeStockOptionMember
    Shares, Exercisable at March 31, 2014 10,089,662us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_EmployeeStockOptionMember    		  
    Weighted Average Exercise Price, Outstanding at December 31, 2013 $ 0.19us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_EmployeeStockOptionMember    		  
    Weighted Average Exercise Price, Granted $ 0us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_EmployeeStockOptionMember    		  
    Weighted Average Exercise Price, Exercised $ 0us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_EmployeeStockOptionMember    		  
    Weighted Average Exercise Price, Forfeited $ 0us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_EmployeeStockOptionMember    		  
    Weighted Average Exercise Price, Expired $ 0us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_EmployeeStockOptionMember    		  
    Weighted Average Exercise Price, Outstanding at March 31, 2014 $ 0.19us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_EmployeeStockOptionMember    		 $ 0.19us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_EmployeeStockOptionMember
    Weighted Average Exercise Price, Exercisable at March 31, 2014 $ 0.19us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_EmployeeStockOptionMember    		  
    Average Remaining Contractual Term (Years), Outstanding 8 years 10 months 17 days 9 years 1 month 24 days
    Average Remaining Contractual Term (Years), Exercisable at March 31, 2014 8 years 10 months 20 days  
    Intrinsic Value, Outstanding $ 8,416,233us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_EmployeeStockOptionMember    		 $ 6,451,441us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_EmployeeStockOptionMember
    Intrinsic Value, Exercisable at March 31, 2014 $ 4,049,376us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
    / us-gaap_StatementClassOfStockAxis
    = us-gaap_EmployeeStockOptionMember